From: (b)(6)
Sent: Tue, 12 Nov 2019 18:02:01 -0500
To: NIAID OD AM
Subject: Fwd: Please Confirm Plenary Session Speaker Details for CUGH 2020
Attachments: disclosure Content Validation Form 2.2018 (1).pdf, ATT00001.htm

Let us discuss.

Begin forwarded message:

From: 2020 CUGH Conference <>
Date: November 12, 2019 at 5:13:26 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" (b)(6)
Subject: Please Confirm Plenary Session Speaker Details for CUGH 2020

Dear Anthony Fauci,

On behalf of the Consortium of Universities for Global Health, we would like to welcome you as a plenary session speaker for the 2020 CUGH conference in Washington, D.C for the following panel:

TITLE: Global Security and Emerging Infectious Diseases

SHORT PANEL DESCRIPTION: (100 words maximum): In this area of emerging and re-emerging infectious diseases, global security for surveillance, detection, treatment and prevention of these diseases has never been more concerning. Ebola, Zika, MERS CoV, influenza, Dengue, antibiotic resistance, TB, HIV, Malaria and so forth are continual treats to humans. This topic should be discussed and experts in Global Security Agenda, One Health and Environmental Health can participate as well. Over recent decades, multiple epidemic events have underscored how highly vulnerable we are to viral threats. Our world is globally connected—and an "emerging threat" in one part of the world can pose a threat everywhere and to everyone. About 75 percent of new human diseases are caused by microbes that originate in animals. These include HIV, influenzas (including pandemic H1N1, H5N1, and H7N9), Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome-Coronavirus (MERS-CoV), Ebola, Marburg, and Nipah. Several of these have spread extensively in human populations, causing global epidemics (also known as pandemics).

We would like to collect your information for your plenary session for the 2020 CUGH conference in Washington, DC. We will need the following information:

1. Statement confirming your registration completion.
   Register at: https://cugh2020.org/registration
2. Attachment(s) – Disclosure of Commercial Interest Forms: required of *all* speakers and moderator(s) in order to be included in the scientific agenda. No exceptions. If no commercial

interests to declare the form takes ~2 minutes to complete. The “Faculty” box is pre-checked for all speakers. Moderators should also check the box for “Moderator.”

It is extremely important that you send your email to: 2020conference@cugh.org by **November 28, 2019**. Thank you again for your participation.

Best regards,

CUGH 2020 Conference Organizers

--

CUGH 2020 Events Team

www.cugh2020.org

2020conference@cugh.org

202-974-6291

Consortium of Universities for Global Health

1608 Rhode Island Avenue, Northwest, Suite 240

Washington DC, 20036, USA

CUGH's 2020 Annual Conference, April 18-20, Washington, DC
Satellite Sessions, April 17, 2020

Global Health in a Time of Worldwide Political Change

From: Barasch, Kimberly (NIH/NIAID) [C] [/O=EXCHANGELABS/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=EA5FAD4C52F64F80B7DAEE4982AE495F-BARASCHK]

Sent: 11/5/2019 8:30:26 PM

To: Fauci, Anthony (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=df38103d75134f658ae2d356f0396b94-afauci]; Dieffenbach, Carl (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=94acc37973d346fa98dfe16cd1bf7013-cdieffenba]; Read, Sarah (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=527b160038004a199ae6e0bac2226099-readsa]; Gehlhaus, Kristie (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=226e9558a5334bb6a18b93150624c2c1-gehlhauk]; Brewer, Teresa (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=c24a2179d06642ffacf3d8c2df1aeee0-knightt]; Hazell, Kimberly (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2b6c35473cec44f59c182eb364e2a4ec-khazell]; Gulakowski, Robert (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=89bac3e52fe54e468113d869c6d868df-rgulakow]; Auchincloss, Hugh (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=9304c753bb9e422c977dddab54da924b-auchincloss]; McGowan, John J. (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=fd4549a1a37c41c78410c7c29e3d3c00-jmcgowan]; Harper, Jill (NIH/NIAID) [E] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0bfd6dfb8e48482fb49a5f72abfcbac8-jharper]

CC: Robinson, Whitney (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=61415dec679b4802a894cabfc74f19ed-robinsonwhc]; Fowler, Karen (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=2c353f2ae5454d2fb88ed9bc9a71b8a9-fowlerk]; Sullivan, Fantasia (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=b0493ec476f94c10a78a1f3c6ba20bf2-sullivanfo]; Zografos, Olga (NIH/NIAID) [C] [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6240d4a4308f428faae36c673183f7aa-zografosoa]

Subject: FY 2020 Personnel Review - DAIDS
Location: 31/7A18

Start: 2/5/2020 5:00:00 PM
End: 2/5/2020 5:30:00 PM

Required Attendees: Dieffenbach, Carl (NIH/NIAID) [E]; Read, Sarah (NIH/NIAID) [E]; Gehlhaus, Kristie (NIH/NIAID) [E]; Brewer, Teresa (NIH/NIAID) [E]; Hazell, Kimberly (NIH/NIAID) [E]; Gulakowski, Robert (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Harper, Jill (NIH/NIAID) [E]
Optional Attendees: Robinson, Whitney (NIH/NIAID) [C]; Fowler, Karen (NIH/NIAID) [C]; Sullivan, Fantasia (NIH/NIAID) [C]; Zografos, Olga (NIH/NIAID) [C]

Due to the evolving Coronavirus epidemic we need to cancel the Personnel Review meeting scheduled for tomorrow. I will be in touch at a later date to reschedule.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 20:59:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - House Appropriations Committee with HHS and the relevant Operating Divisions to brief members on the situation with the coronavirus
Attachments: Please advise: Approps Heads up: HHS call on Friday Jan. 31st between 12:30-3:30pm

Hi everyone,

House Approps staff just let me know that they're working with HHS to set up a call on Friday January 31st between 12:30 and 3:30 for members of the House Appropriations Committee with HHS and the relevant Operating Divisions to brief members on the situation with the coronavirus.

You may have already, or should be hearing from HHS soon, regarding scheduling for Dr. Fauci, but I wanted to give you the heads up in case they hadn't reached out yet. They believe the White House will participate in this call as well. I'll share more details as soon as they're available.

Thanks.

MM

Michelle Mitchell, MSW
Office of Legislative Policy & Analysis
National Institutes of Health
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 10:42:47 +0000
Subject: Read: EXCLUSIVE! CDC Believes Coronavirus Has Broken Containment On The West Coast

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:49:58 +0000
To: pulmonary@heraldopenaccess.net
Subject: Read: Coronavirus updates: Acknowledging your impressive work " Coronavirus Infections-More Than Just the Common Cold"

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 11:13:01 +0000
Subject: Read: 1-29-20 from FOX FOX (A COMMENT, near Bottom of the Page) ... Coronavirus will have 'minimal impact' on US economy, Larry Kudlow says.

From: [redacted] (b) (6)
Sent: Thu, 30 Jan 2020 08:46:49 -0500
To: ROBERT FORD
Subject: Re: Coronavirus

Bob:
Thanks for the note. I hope that all is well with you.
Best regards,
Tony

> On Jan 30, 2020, at 7:33 AM, ROBERT FORD [redacted] (b) (6)> wrote:
>
> Thank you for once again explaining so clearly what the status is in the US with the virus.
>
> And it is good to see Paul Grady back on the golf course.
>
> Bob Ford.
>
> Sent from my iPhone

From: (b) (6)
Sent: Thu, 30 Jan 2020 08:48:02 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: Subject CoronaVirus China

Please handle.

Begin forwarded message:

From: DJ Donnelly < (b) (6)
Date: January 30, 2020 at 7:23:41 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)
Subject: Subject CoronaVirus China

To: Dr. Anthony Fauci, Whitehouse Health Doctor

1/30/2020

Dear Dr. Fauci,

Firstly, your office at The White House and for President Trump are doing a great job to combat this CoronaVirus from entering the USA from China. Dr. Fauci, your office and the CDC may have overlooked one venue this disease can enter the USA from China is from Chinese made products. as you know millions of products are imported from China that are not "sanitized" before America's open boxes from China. Case and point, I received a cd player from China, when I opened the box it had "hand prints" all over it. before I set it up Dr Fauci I "sanitized it with white vinegar" before use.

Dr Fauci, I know your offices are doing a great job with people coming in from China and is Pres Trump, the CDC etc, this may have been an "oversight" that "cargo" or "products" from China before American's open up the sealed boxes that shall release this disease to America via millions of un sanitized products could be massive for America.

Dr Fauci, do you think your office should have a" 5 min press conference" alerting America's 'before they open a product that is made in China once opened to "completely sanitize it with white vinegar or another form of product before use". Dr Fauci this will stop any residual disease from any "infected Chinese employee that made the products or packaged them in China, to combat this disease from spreading over America...

Dr Fauci, please confirm to my office you received this very important email.

Thank you Dr Fauci,

God bless
DJ Donnelly, Republican SC
CC: Pres Trump The White House

From: (b) (6)
Sent: Thu, 30 Jan 2020 09:17:13 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd:

Please handle

Begin forwarded message:

From: Bill Haines (b) (6)
Date: January 30, 2020 at 9:14:04 AM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)

Good Morning
I was watching you on Fox News this morning and have a question for you. I have worked in marine industry all my life and over the past several days I have been thinking about the container ships coming from China and coronavirus. Since I am not a medical expert my question is; can this virus survive in lets say clothing made in China or on card board boxes in a container for month or two while in transit.

This would also pertain to crew members on a ship whether picking up or discharging cargo in China or any other port. There is a web site I follow called "Gcaptian" and with in the past couple of days on their site the following article appeared "Coronavirus Scare on CMA _ CGA Container Ship". The ship was picking up containers in China when 6 crew members became sick. At first it was thought that the crew members might have contracted coronavis and were closely watched, but they are all well now, it might have been some other type of flue.

Air cargo carriers such as UPS and Fedx in which a package can be delivered in a matter of days; can the virus survive in this environment ?

So in your opinion, do you think that the virus can be transmitted from cargo. So far as crews they would have to be restricted to ships with no port leaves.

Your in put would be appreciated.
Thanks in advance;
Bill Haines
(b) (6)

From: [redacted] (b) (6)
Sent: Thu, 30 Jan 2020 09:22:03 -0500
To: Siegel, Marc
Subject: Re: Wuhan coronavirus isn't a threat to the United States. Flu is. - Los Angeles Times

Mark:
 Very nice OpEd.
Best,
Tony

> On Jan 30, 2020, at 8:29 AM, Siegel, Marc [redacted] (b) (6)> wrote:
>
>
> https://www.latimes.com/opinion/story/2020-01-29/coronavirus-no-threat-to-americans-but-flu-is
>
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:58:46 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD-Coronavirus interview with VOA
Attachments: RE: Interview request, RE: Interview request

From: Mariama Diallo Crandall <mdiallo@voanews.com>
Sent: Tuesday, January 21, 2020 12:15 PM
To: Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6) Stover, Kathy (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Interview request

Hello,
Hope this email finds you all well. Anyone available to do a quick skype interview (10 min or less) on the coronavirus in China. This is for today and I am on a very tight deadline. Please advise and thanks in advance!

Best regards,
Mariama
Voice of America, Washington, DC
202-203-4131

From: (b) (6)
Sent: Wed, 29 Jan 2020 12:20:58 -0500
To: Howard Bauchner
Cc: Annette Flanagin
Subject: Re: JAMA - Important quick read

No problem as far as I am concerned

On Jan 29, 2020, at 8:30 AM, Howard Bauchner <Howard.Bauchner@jamanetwork.org>wrote:

Tony this request came in from Shanghai Public Health Center – normally we would say no – provide a link – toll-free. But in this case we would like to say yes.

From your perspective any problem with that – they want to translate your VP into Chinese.

HCB

Hi Annissa:

Hope all is well. I received this request from the Shanghai Public Health Center to use a viewpoint published in JAMA. Although I informed them that they can link to the article, they want to post it in Chinese.

With the subject matter being 'Coronavirus Infections" and the fact that Shanghai Public Health Center has requested permission to use this viewpoint, I thought you might consider giving them permissions.
Let me know what you think.
Best regards,
Marsha

From: Annette Flanagin
Sent: Wednesday, January 29, 2020 12:11 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>; Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Subject: Re: Permission request of a viewpoint translating

Was thinking it would be good if we could translate into Chinese and host and make free for all - not sure if we have a way to that. But then others in China could link to it.

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Wednesday, January 29, 2020 12:06:51 AM
To: Annette Flanagin <Annette.Flanagin@jamanetwork.org>; Phil Fontanarosa

<Phil.Fontanarosa@jamanetwork.org>
Subject: Re: Permission request of a viewpoint translating

Thinking on this one – my instincts are to say yes – for public health –

What do the 2 of you think?

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: Annette Flanagin <Annette.Flanagin@jamanetwork.org>
Date: Tuesday, January 28, 2020 at 4:50 PM
To: Tiffany Jones <Tiffany.Jones@ama-assn.org>, Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Sean O'Donnell <Sean.O'Donnell@ama-assn.org>, Karen Adams-Taylor <Karen.Adams-Taylor@ama-assn.org>
Subject: Re: Permission request of a viewpoint translating

Howard

Please see below. Do you want to grant them permission to translate Fauci's nCoV VP into Chinese and post locally?

Thanks,

Annette

From: Tiffany Jones <Tiffany.Jones@ama-assn.org>
Date: Tuesday, January 28, 2020 at 4:02 PM
To: Annette Flanagin <Annette.Flanagin@jamanetwork.org>
Cc: Sean O'Donnell <Sean.O'Donnell@ama-assn.org>
Subject: FW: Permission request of a viewpoint translating

Hi Annette,
We received this request via our Reprints workflow, and we wanted to run this by you to see if there's any inclination to waive or adjust our rules in this case to allow the requester to translate/post a full article? https://jamanetwork.com/journals/jama/fullarticle/2759815?resultClick=1
Tiff

.....

Tiffany Jones
Manager, Journal Content Services

JAMA Network™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611
T 312-464-2596
jamanetwork.com

From: Marsha Fogler <Marsha.Fogler@jamanetwork.com>
Sent: Tuesday, January 28, 2020 10:17 AM
To: permissions <permissions@jamanetwork.com>
Subject: FW: Permission request of a viewpoint translating

Hi Annissa:

Hope all is well. I received this request from the Shanghai Public Health Center to use a viewpoint published in JAMA. Although I informed them that they can link to the article, they want to post it in Chinese.

With the subject matter being 'Coronavirus Infections" and the fact that Shanghai Public Health Center has requested permission to use this viewpoint, I thought you might consider giving them permissions.
Let me know what you think.
Best regards,
Marsha

From: nwu <wunannan@shphc.org.cn>
Sent: Saturday, January 25, 2020 4:09 AM
To: reprints <reprints@jamanetwork.com>
Subject: Permission request of a viewpoint translating

[Warning External Email]
To whom it may concern,

I am an assistant researcher in Shanghai Public Health Clinical Center, which is the 2019-nCoV-designated hospital in Shanghai. I write this email for the permission of translating and releasing the article "Coronavirus Infections—More Than Just the Common Cold"(doi:10.1001/jama.2020.0757). We would like to translate this article into Chinese and post the translating version on the WeChat official account of our hospital. This account is committed to science popularization and available to the public.
I am looking forward to your reply, we are glad to send you the Chinese version of this viewpoint before its release, if there is a need.

Best wishes,

Nannan WU
PhD, Assistant researcher,
Shanghai Institute of Phage, Shanghai Public Health Clinical Center
2901 Caolang Road, , Shanghai 201508, China

发送自 Windows 10 版邮件应用

From: [redacted] (b) (6)
Sent: Wed, 29 Jan 2020 20:51:59 -0500
To: Collins, Francis (NIH/OD) [E]
Cc: Tabak, Lawrence (NIH/OD) [E];Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: Re: ICs tomorrow AM

Francis:
I am so sorry, but I just found out(popped up on my calendar) that I have to go down to HHS tomorrow for an 8:15 AM meeting with the Secretary to prep him for a press appearance that he has tomorrow, and so I cannot do the IC Directors tomorrow. Again, I am very sorry.
Best,
Tony

On Jan 29, 2020, at 7:28 PM, Collins, Francis (NIH/OD) [E] <[redacted] (b) (6) wrote:

HI Tony,
Many thanks! I will plan to have you speak right at 8 AM unless that turns out to be impossible.
Francis

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) **On Behalf Of** Fauci, Anthony (NIH/NIAID) [E]
Sent: Wednesday, January 29, 2020 5:36 PM
To: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] <[redacted] (b) (6)
Subject: RE: ICs tomorrow AM

Dr. Collins –

Dr. Fauci asked that I respond to your email on his behalf as he just left an NSC meeting at the White house. Per your request, Dr. Fauci can brief the IC Directors tomorrow from 8:00 am – 8:15 am. He needs to depart the NIH at 8:30 am for a Congressional Briefing on the hill.

The only change he may have that we are waiting for confirmation from Secretary Azar's office is that they may schedule their daily Coronavirus conference call for 8:00 am – if that happens then he will not be able to participate in the IC Directors meeting.

Either way – we will confirm with you tonight. I hope this is helpful.

Best,
-patty

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)
Sent: Wednesday, January 29, 2020 4:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Tabak, Lawrence (NIH/OD) [E] <[redacted] (b) (6)
Subject: ICs tomorrow AM

Hi Tony,

I'm guessing you must be totally fried by the intensity of the 2019-nCoV situation. We are all fortunate that you are on the front lines, steering the US response in the most rational way, and responding to zillions of press calls. Your clear and accurate voice is the best channel we've got right now for the public to know the facts, and not panic.

I understand that you can't attend ICs tomorrow because of all these demands. But if you happened to have 15 minutes free anytime between 8 and 10 AM, I would very much like for you to call in and give our own leaders the updated intel about where this outbreaks stands.

Might that be possible?

Francis

From: [redacted] (b) (6)
Sent: Tue, 28 Jan 2020 20:10:14 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: 28 Jan. nCoV[redacted] (b) (5) Agenda
Attachments: nCoV [redacted] (b) (5)Agenda_28Jan.docx, ATT00001.htm

Sent from my iPhone

Begin forwarded message:

From: "Ferro, Phil J. EOP/NSC" <[redacted] (b) (6)
Date: January 27, 2020 at 7:07:16 PM EST
To: DL NSC Defense [redacted] (b) (6)>, DL NSC Legal [redacted] (b) (6)>, DL NSC NSA FO Staff [redacted] (b) (6)>, DL NSC STRATCOM <[redacted] (b) (6)>, "Droegemeier, Kelvin K. EOP/OSTP" <[redacted] (b) (6)>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6) "Daravi, Kamran S. EOP/WHO" [redacted] (b) (6)>, "Grewe, Brenda L. EOP/NSC" [redacted] (b) (6)>, "Deere, Judd P. EOP/WHO" [redacted] (b) (6)>, "Ditto, Jessica E. EOP/WHO" [redacted] (b) (6), "Yanick, Brittany M. EOP/WHO" [redacted] (b) (6)>, "Wilson, John Mark M. EOP/NSC" [redacted] (b) (6)>, "Martin, Michael E. EOP/NSC" [redacted] (b) (6)>, "Feddersen, Brett (FAA)" [redacted] (b) (6), "Sadat, Mir H. EOP/NSC" [redacted] (b) (6), "Gray, Alexander B. EOP/NSC" [redacted] (b) (6), "Rubini, Jeffrey H. EOP/NSC" [redacted] (b) (6) "Bonner, Maria K. EOP/WHO" [redacted] (b) (6), "Champagne, Joshua D. EOP/NSC" [redacted] (b) (6)>, "Ullyot, Jonathan L. EOP/NSC" [redacted] (b) (6) "Ruggiero, Anthony J. EOP/NSC" [redacted] (b) (6)>, "Stufft, Julie M. EOP/NSC" [redacted] (b) (6) "Hassell, David (Chris) (OS/ASPR/IO)" [redacted] (b) (6) [redacted] (b) (6) OSD OUSD POLICY (USA)" [redacted] (b) (6)>, "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6) "Costello, Kelly E" [redacted] (b) (6)>, "CAMPBELL, CARL S" [redacted] (b) (6) [redacted] (b) (6), "Baehr, James S. EOP/WHO" [redacted] (b) (6) "Doster, Kim M. EOP/OSTP" [redacted] (b) (6), "Lyons, Derek S. EOP/WHO" [redacted] (b) (6), "Hayes, Bradley F. EOP/OMB" [redacted] (b) (6)>, "Browne, Lisa Y. EOP/NSC" [redacted] (b) (6)>, "Smith, Gregory L. EOP/WHO" [redacted] (b) (6)>, "Grigsby, Garrett (HHS/OS/OGA)" <[redacted] (b) (6)"Ferrer Piran Basualdo, Austin G. EOP/WHO" <[redacted] (b) (6), "FORET, VERNON T"

[redacted] (b)(6)>, "Baum, Kristina R. EOP/OSTP"
[redacted] (b)(6), "Bicket, Mark C. EOP/OSTP"
[redacted] (b)(6)>, "Blair, Robert" < [redacted] (b)(6)>, "Bonyun,
Sean C. EOP/OSTP" [redacted] (b)(6), "Butterfield, Nicholas W. EOP/WHO"
[redacted] (b)(6), "Campana, Alexandra D. EOP/WHO"
< [redacted] (b)(6), "Grogan, Joseph" [redacted] (b)(6)
"Hudson, Renee R. EOP/WHO" [redacted] (b)(6) "Jack, Brian T. EOP/WHO"
[redacted] (b)(6)"Kan, Derek T. EOP/OMB" [redacted] (b)(6)>,
"Kratsios, Michael J. EOP/OSTP" [redacted] (b)(6), "Lattimore, Tracie B.
EOP/OSTP" [redacted] (b)(6), "Lin, Merry S. EOP/WHO"
[redacted] (b)(6), "McKenna, Michael A. EOP/WHO"
[redacted] (b)(6)>, "Merkel, Theo W. EOP/WHO"
[redacted] (b)(6), "Miles, Aaron R. EOP/OSTP"
[redacted] (b)(6), "Olmem, Andrew J. EOP/WHO"
[redacted] (b)(6) "Pataki, Tim A. EOP/WHO"
[redacted] (b)(6) "Ray, Paul J. EOP/OMB" [redacted] (b)(6)
"Wong, Anna W. EOP/CEA" [redacted] (b)(6)>, [redacted] (b)(6)"
[redacted] (b)(6), "Sinclair, Michael R. EOP/NSC"
[redacted] (b)(6)>, DL NSC WMD [redacted] (b)(6), "Cetron, Marty
(CDC/DDID/NCEZID/DGMQ)" [redacted] (b)(6)
[redacted] (b)(6), "Naar, Alex (FAA)" [redacted] (b)(6), "Firoved, Aaron"
[redacted] (b)(6)"Limage, Julia" [redacted] (b)(6)>, "Seffel, Gary A.
EOP/NSC" [redacted] (b)(6), "Waterman, Paige E. EOP/OSTP"
[redacted] (b)(6), "Waterman, Elijah J. EOP/NSC"
[redacted] (b)(6)>, "Watson, Ian D. EOP/OSTP"
[redacted] (b)(6), [redacted] (b)(6) OSD OUSD POLICY (USA)"
[redacted] (b)(6) "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b)(6)
"Marks, Peter (FDA/CBER)" [redacted] (b)(6), "Mair, Michael (FDA/OC)"
[redacted] (b)(6), "Kadlec, Robert (OS/ASPR/IO)" [redacted] (b)(6)>,
[redacted] (b)(6) "Disbrow, Gary (OS/ASPR/BARDA)"
[redacted] (b)(6) [redacted] (b)(6) [redacted] (b)(6), " [redacted] (b)(6)
[redacted] (b)(6) DL NSC IO [redacted] (b)(6), DL NSC Asia
[redacted] (b)(6)>, DL NSC Press [redacted] (b)(6)>, DL NSC Resilience
[redacted] (b)(6), DL NSC HSA FO Staff < [redacted] (b)(6)>,
DL NSC Legislative [redacted] (b)(6)>, DL NSC BATS [redacted] (b)(6)
"Redd, John (OS/ASPR/SPPR)" [redacted] (b)(6), [redacted] (b)(6) CIV (USA)"
[redacted] (b)(6), " [redacted] (b)(6)OSD OUSD POLICY
(USA)" [redacted] (b)(6) [redacted] (b)(6) [redacted] (b)(6)>, "Liebschutz,
Jennifer E. EOP/OMB" [redacted] (b)(6), "Farquharson, Christine E.
EOP/OMB" [redacted] (b)(6)
[redacted] Kendra Chittenden
[redacted] (b)(6) "Boney, Virginia M. EOP/WHO"
[redacted] (b)(6), "Tully, Ryan M. EOP/NSC"
[redacted] (b)(6)"Frater, Eric M" [redacted] (b)(6), "Christ, Katelyn E.
EOP/NSC" < [redacted] (b)(6)>, "Weinberger, Collin (OS/OGA)"
[redacted] (b)(6), "Gastfriend, Daniel Z. EOP/OMB"

[redacted] (b) (6), "Landrum, Ryan P. EOP/NSC"
[redacted] (b) (6)>, "Rault, Nick M. EOP/NSC"
[redacted] (b) (6)>, "Hanna, Cory M. EOP/NSC"
[redacted] (b) (6)>, "Burton, Nicholas S. EOP/OMB"
[redacted] (b) (6)>, "Garufi, Marc A. EOP/OMB"
[redacted] (b) (6), "Mroz, Sara K. EOP/NSC" < [redacted] (b) (6)>,
"Wade, Dave S. EOP/NSC" [redacted] (b) (6), "Troye, Olivia EOP/NSC"
[redacted] (b) (6), [redacted] (b) (6) [redacted] (b) (6), "McGowan, Robert
(Kyle) (CDC/OD/OCS)" [redacted] (b) (6), "Lowry, Patrick J. EOP/NSC"
[redacted] (b) (6), "Cartin, Josh M. EOP/NSC" [redacted] (b) (6),
"Kanapathy, Ivan J. EOP/NSC" [redacted] (b) (6)>, "Elvander, Erika (OS/OGA)"
[redacted] (b) (6), "Cavanaugh, Brian J. EOP/NSC"
[redacted] (b) (6), [redacted] (b) (6) < [redacted] (b) (6)>,
"Thomas, Gloria (HHS/OS/OGA)" < [redacted] (b) (6), "Butler, Jay C.
(CDC/DDID/OD)" [redacted] (b) (6)"Bright, Rick (OS/ASPR/BARDA)"
[redacted] (b) (6), Brett Armstrong - D1R < [redacted] (b) (6),
[redacted] (b) (6), [redacted] (b) (6)
[redacted] (b) (6), [redacted] (b) (6) [redacted] (b) (6) "McMillin,
Virginia D. EOP/WHO" [redacted] (b) (6)>, "Telle, Adam R. EOP/WHO"
[redacted] (b) (6), "Sugarman, AJ J. EOP/WHO"
[redacted] (b) (6), "Planning, David M. EOP/WHO"
[redacted] (b) (6)" [redacted] (b) (6) [redacted] (b) (6), "Greene
Richard S. (GH/HIDN) [USAID] [redacted] (b) (6)>, "Magrino,
Christopher" [redacted] (b) (6)
[redacted]
[redacted], "Tobin, Elizabeth D. EOP/NSC"
[redacted] (b) (6), "Jonas, Seth H. EOP/NSC" [redacted] (b) (6)>,
[redacted] (b) (6) [redacted] (b) (6) "Music, Chris G. EOP/OMB"
< [redacted] (b) (6), [redacted] (b) (6) [redacted] (b) (6), "Burris, Meghan K.
EOP/WHO" [redacted] (b) (6), "Henning, Alexa A. EOP/WHO"
[redacted] (b) (6), "Daravi, Roma S. EOP/WHO"
[redacted] (b) (6), "Horstman, John H. EOP/WHO"
[redacted] (b) (6)
[redacted] (b) (6)OSD OUSD POLICY
(USA)" [redacted] (b) (6), "Stimson, Brian (HHS/OGC)"
[redacted] (b) (6) "Davis, May M. EOP/WHO" [redacted] (b) (6), "Lekan,
Scott (ACF)" [redacted] (b) (6)>, "Chafin, Kelly B. EOP/NSC"
[redacted] (b) (6)>, "Bailey, Drew M. EOP/OMB"
[redacted] (b) (6)>
Subject: 28 Jan. nCoV (b) (5) Agenda

Dear Colleagues,

Please find attached the agenda for the (b) (5) SAP Ruggiero will convene tomorrow regarding the response to the nCoV epidemic. As a reminder Principles located in the Washington Metropolitan Area are expected to attend in person, while SVTC available for D/A staff. Please come prepared to discuss and propose solutions to the agenda items as this meeting will in preparation for a (b)(5) meeting that will take place tomorrow afternoon.

Thank you for your continued focus on this important and urgent matter.

Best Regards,

Phil

Philip J. Ferro, PhD, MS
Director for Countering Biological Threats
National Security Council
(b)(6) (O) (b)(6) (cell)
(b)(6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 16:02:08 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Times Corona virus interviw
Attachments: RE: Interview request: Wuhan coronavirus, Washington Times

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 15:13:22 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD Radio Free Asia Interview (taped)
Attachments: RE: Dr Fauci interview

Thank you. Would like to film for both our radio and social media (Facebook and Youtube).
Looking forward to hearing from you.

Carmen Wu
Broadcaster
Cantonese Service

Radio Free Asia
2025 M Street NW Ste. 300
Washington, DC 20036
Telephone - (202) 530-4016

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 17:38:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- ABC local news Corona on Camera (Taped)
Attachments: RE: Media Request: Wuhan coronavirus/ABC7 TV (in office, on camera)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 14:17:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - NPR's daily news show, 1A (Live Hit 10:20 am ET)
Attachments: RE: Radio interview request (NPR/1A): Tuesday, January 28, 10:30 - 11am ET

My name is Stacia Brown, and I'm a producer for NPR's daily news show, 1A. I'm writing to see if you might be able to join us for an on-air discussion about the coronavirus tomorrow. We're planning a "latest updates" and fact-check conversation for a 10:30 - 11am segment tomorrow, January 28. If you'd be able to join us in studio at WAMU on American University's campus, we'd be honored to have you back as a guest.

Thank you for considering this request!

Sincerely,

Stacia Brown
Producer, 1A
WAMU 88.5 | 4401 Connecticut Ave NW, Washington, DC 20008
202.885.1296 (o)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:54:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Pre-Brief: GPMB Mtg w/ Nicki Lurie & Jerry Keusch
Attachments: RE: time to discuss GPMB, RE: time to discuss GPMB

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 18:26:54 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CBS Evening News Nora ODonnell (taped on Camera at 5:00 pm ET)
Attachments: Fwd: Adam Verdugo, Adam Verdugo.vcf, ATT00001.txt

Andrew Verdugo -on site contact Cell is [redacted] (b)(6) – CALL ANDREW UPON ARRIVAL AND HE WILL MEET IN LOBBY

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 18:13:03 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: NewsMax Live Hit 7:20 pm ET - 7:30 pm ET
Attachments: RE: Wuhan interview with Dr. Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 14:33:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: -Interview with WIRED re Corona virus
Attachments: FW: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, RE: Wired article on Wuhan coronavirus, FW: Wired article on Wuhan coronavirus

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:51:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD CNBC Taped or Live on Camera
Attachments: RE: CNBC

From: Conrad, Patricia (NIH/NIAID) [E] on behalf of Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 19:29:14 +0000
To: Jeremy Farrar;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Is there a cell number to reach you? or best number?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar <[redacted] (b) (6)
Sent: Wednesday, January 29, 2020 2:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

I could not make it until 5pm CET today. But next few days also OK.

From: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)> on behalf of "Fauci, Anthony (NIH/NIAID) [E]" <[redacted] (b) (6)
Date: Wednesday, 29 January 2020 at 18:54
To: Jeremy Farrar [redacted] (b) (6)
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Dr Fauci is in back to back meetings but hopes to be able to step out and call you between 3:00 pm ET – 4:00 pm ET. Is that time ok and what is the best number to reach you at that time?

Best,

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jeremy Farrar [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 1:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: Informal coronavirus teleconference, 29 January, 19.00 CET

Tony - Would be very keen to hear your personal views on n-CoV. If you have 5 mins for a phone call.
Best wishes Jeremy

From: "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)
Date: Wednesday, 29 January 2020 at 16:44
To: Michael RYAN [redacted] (b) (6) "Redfield, Robert R. (CDC/OD)" [redacted] (b) (6) (b) (6) [redacted] (b) (6), David Heymann [redacted] (b) (6) [redacted] "Chris.Elias" [redacted] (b) (6), Richard Hatchett [redacted] (b) (6) Jeremy Farrar [redacted] (b) (6) [redacted] "COX, Paul Michael" [redacted] (b) (6) SHOC <shoc@who.int>, "GREIN, Thomas" [redacted] (b) (6)"Conrad, Patricia (NIH/NIAID) [E]" < [redacted] (b) (6) "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6)
Cc: "GHEBREYESUS, Tedros Adhanom" [redacted] (b) (6), Bernhard Schwartländer [redacted] (b) (6)>, "MINHAS, Raman" [redacted] (b) (6)
Subject: RE: Informal coronavirus teleconference, 29 January, 19.00 CET

Mike:

I am sorry but I have an important meeting with Secretary Azar that is a prep meeting for another important meeting at the White House. These overlap with the 19:00 CET time frame of your call. Unless something changes I cannot be on the call. If that is the case, I will ask Hilary Marston from my staff to fill in for me and report back to me. Please send the call in information to my Special Assistant, Patty Conrad, and me just in case something changes.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. < [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) [redacted] (b) (6) ; David Heymann [redacted] (b) (6) Chris.Elias < [redacted] (b) (6) ; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) [redacted] (b) (6) COX, Paul Michael [redacted] (b) (6); SHOC <shoc@who.int>; GREIN, Thomas [redacted] (b) (6)
Cc: GHEBREYESUS, Tedros Adhanom [redacted] (b) (6)>; SCHWARTLANDER, Bernhard F. [redacted] (b) (6); MINHAS, Raman [redacted] (b) (6)
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 18:47:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Daily Caller Skype interview
Attachments: RE: FW: Interview request: The Daily Caller, Wuhan coronavirus, RE: FW: Interview request: The Daily Caller, Wuhan coronavirus

My cell number is (b) (6). We will add you on Skype tomorrow and contact you with via the username below. Thank you!

The Skype username is (b) (6)

Maranda Finney
The Daily Caller
(b) (6)
maranda@dailycaller.com
Topic: Wuhan coronavirus
Deadline: Thursday

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 17:51:03 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CSPAN Podcast Taped 20 minutes Corona virus w/ Steve Scully
Attachments: RE: C-SPAN Interview Request , RE: C-SPAN Interview Request , RE: C-SPAN Interview Request

Yes, we can confirm for 12:30pmET for the interview. This will be done by landline and taped on our end.
If you need to reach me the best number is (b) (6)

My name is Shannon Rice, I'm a producer at C-SPAN. Jenn Ruff from Washington Journal passed me on your contact info and says hello! We were hoping that Dr. Facui might have some time this week to do TAPED podcast on the Coronavirus & disease outbreaks in general. It would be for our podcast The Weekly. It would be 20-25 minutes in length. No calls, just a conversation between him and our host Steve Scully.

We can either do it on the phone or if he is available we can arrange a car for him to come to the studio here on Capitol Hill. Might he have any time this week?

Thank you so much.

Shannon Rice
C-SPAN Radio
Producer, Washington Today & The Weekly Podcast
202-626-4841

From: [redacted] (b) (6)
Sent: Thu, 23 Jan 2020 08:55:11 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Coronavirus and Davos

Thanks, Francis.

> On Jan 23, 2020, at 8:51 AM, Collins, Francis (NIH/OD) [E] < [redacted] (b) (6) wrote:
>
> Thanks for all this updated info, Tony. I had a premonition that Lally Weymouth would call on me at the Washington Post luncheon (in front of numerous US Cabinet members, Ivanka, and several heads of state). Sure enough, she did. I think I did a decent job of relating what we currently know about coronavirus, and what we don't know yet.
>
> If there are press calls about what the US is doing, I will refer them to you. I'm ccing John.
>
> FC
>
> -----Original Message-----
> From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
> Sent: Thursday, January 23, 2020 6:56 AM
> To: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
> Subject: RE: Coronavirus and Davos
>
> Anecdotal data suggest that most transmissions occur when transmitter is late in the infection, i.e. clinically ill. However, some anecdotal data suggest that early transmission does occur to some degree. The man in Seattle who travelled to Wuhan cannot remember coming into contact with anyone who appeared ill. Regarding mAbs, we have them against SARS and MERS and are hoping that there is some cross-reactivity of the anti-SARS Abs with nCov. However, it is difficult at this time to test since we do not yet have isolates of nCov; we only have sequence. As soon as we get isolated we can test.
>
> -----Original Message-----
> From: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
> Sent: Thursday, January 23, 2020 5:50 AM
> To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
> Subject: Coronavirus and Davos
>
> Hi again,
> Was just part of a discussion with Hatchett, Farrar, WHO rep (Tedros not here), Berkley, Stoffels. Big issue seems to be whether transmissibility happens early or late in the course of infection. Obviously late would be much better for public health measures. Your read on current data?
> Any effort on developing MAb at NIH?
> FC
>
> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 15:26:13 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD TENATIVE - CNN New Day (Live Hit: 6 am hour)
Attachments: RE: Request from CNN's New Day

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 13:55:09 +0000
To: Secretary Scheduler (OS/IOS)
Subject: Accepted: HOLD: AMA updates on Coronavirus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 20:19:37 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - WTOP Live hit at 12:10 pm ET
Attachments: RE: WTOP Request

Hoping Dr. Fauci can is available is join us tomorrow morning or early afternoon to discuss the WHO declaring a public emergency for the coronavirus.

We could pretape the interview at 8:30am or he could join us live at 10:40a, 11:10a, or 12:10p.

Thanks!

Joslyn Chesson
Editor
WTOP News
(202) 895-5060

From: [redacted] (b) (6)
Sent: Sat, 25 Jan 2020 15:16:59 -0500
To: Anderson, Jennifer (NIH/NIAID) [E]
Subject: Fwd: Prospective Intern, Interested in Your Research

Please handle
Sent from my iPhone

Begin forwarded message:

From: [redacted] (b) (6)
Date: January 25, 2020 at 1:39:13 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" < [redacted] (b) (6)
Subject: Prospective Intern, Interested in Your Research

Howdy Dr. Anthony S. Fauci,

I have recently completed the SIP application to be considered for a summer internship through the NIH. Upon searching for potential labs to contact I quickly found your name and was intrigued by your work and the potential to be considered as an intern in your research group. I apologize if this is not standard protocol, I definitely feel some apprehension towards reaching out to such esteemed scientists but the recommendation given upon submission of the application was that I reach out to researchers, as you-all are the deciding factor in the placement of interns.

I am a senior Animal Science, Entomology, and Public Health student at [redacted] (b) (6) who will be attending [redacted] (b) (6) as a Masters Student, studying Epidemiology, in the Fall of 2020.

I am very interested in the research interests listed under your profile, specifically concerning your work on understanding the molecular mechanisms of immune dysfunction caused by HIV infection as well as the references to your work, in the news, concerning the Wuhan Coronavirus. [redacted] (b) (6) I believe a lab such as yours could be beneficial in preparing me for success in these endeavors!

I have spent my undergraduate career working in a CDC Excellence Center lab under [redacted] (b) (6)

I would love to get in contact with you concerning the potential to be involved in your research!

I appreciate your time,

(b) (6)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 16:48:49 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Podcast with Newt Gingrich
Attachments: RE: Guest for Coronavirus podcast episode, RE: Guest for Coronavirus podcast episode

Hello Dr. Fauci -- My name is Tamera, I handle the booking for Newt Gingrich's Podcast, Newt's World. It is a non-partisan show where Newt gives historical context behind people and events. We launched last February and have 2.5 millions downloads to date with new episodes each Sunday. We are working on an episode of the podcast centered around "The Coronavirus" where you might discuss **The Global viruses** [Novel Coronavirus 2019 (nCoV-2019),SARS,MERS,Bird Flu] and **What Can Be Done to Prevent the Next Epidemic?**

If interested, Newt would interview you on Thursday, February 6th, where you would call in to the studio. The podcast would air Sunday, February 9th.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:57:18 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Masur, Henry (NIH/CC/CCMD) [E];Burton, Deborah (NIH/CC/CCMD) [E];Shyamasundaran Kottilil [redacted] (b) (6);Barasch, Kimberly (NIH/NIAID) [C];Lerner, Andrea (NIH/NIAID) [E];Eisinger, Robert (NIH/NIAID) [E]
Subject: Update on HIV, HBV, OUD with Drs Masur and kottillil
Attachments: RE: Update on HIV, HBV, OUD, Update on HIV, HBV, OUD with Drs Masur and kottillil

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 19:23:55 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: AFP On Camera Interview Corona virus (taped)
Attachments: RE: Interview request: AFP, Wuhan coronavirus

From: [redacted] (b) (6)
Sent: Sun, 26 Jan 2020 15:19:59 -0500
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Wuhan coronavirus

[redacted] (b) (5)

On Jan 26, 2020, at 3:08 PM, Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6) wrote:

ASF: [redacted] (b) (5)

From: "Buchholz, Ulla (NIH/NIAID) [E]" <[redacted] (b) (6)>
Date: Sunday, January 26, 2020 at 1:25 PM
To: Hilary Marston [redacted] (b) (6)
Cc: "Cohen, Jeffrey (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Wuhan coronavirus

Dear Hilary,

In 2003/2004, a small group in the lab of Peter Collins rapidly generated parainfluenza virus vaccine candidates expressing SARS S, please see attached publications. We used a bovine/human parainfluenza virus type 3 vector (B/HPIV3) which contains internal proteins of bovine PIV3; its surface glycoproteins F and HN are derived from human PIV3. In the African green monkey model, a single intranasal dose of B/HPIV3 expressing the S protein of SARS CoV S induced high levels of SARS CoV neutralizing antibodies. After SARS CoV challenge, all control animals shed SARS CoV, while no SARS CoV shedding was detected in the B/HPIV3/SARS-S immunized NHPs.

This vector is also being used to express versions of the respiratory syncytial virus fusion protein. The RSV F expressing version of B/HPIV3 has been evaluated in Phase 1 studies, and shown to be safe in PIV3-seronegative infants and children.

[redacted] (b) (5)

[redacted] (b) (5)

Thank you,
Ulla

--

Ursula Buchholz, PhD
Senior Associate Scientist
RNA Viruses Section
Laboratory of Infectious Diseases
NIAID, NIH
Bldg. 50, Rm. 6503
50 South Drive, MSC 8007
Bethesda, MD 20892

Phone: [redacted] (b) (6)
Fax: (301) 480-1268
email: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<>
<>

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Fri, 31 Jan 2020 20:13:56 +0000
To:	Fauci, Anthony (NIH/NIAID) [E]
Subject:	RAI Italy TV Coronavirus interview (taped on camera)
Attachments:	RE: ON AIR: Interview request: coronavirus/profile | RAI Italy

Erika Esposito (Producer)
RAI Italy
(b)(6) | booking@gvqusa.com
Reporter: Claudio Paglira
Subject: coronavirus, ASF profile

Hi Patty,

Italy's national TV network would like to produce a segment on their evening news broadcast profiling Dr. Fauci's work on coronavirus and infectious disease control generally. The crew is based in NYC and can come to campus at Dr. Fauci's earliest convenience anytime after Feb 5. They anticipate needing 30 min for an interview with 20 min for set-up in his office.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 17:55:17 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E]
Subject: HOLD Hill.TV Corona Interview - taped via Skype 1:00 -1:15pm
Attachments: RE: Hill.TV Interview Request, RE: Hill.TV Interview Request

From: (b) (6)
Sent: Sun, 26 Jan 2020 16:56:42 -0500
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: Fwd: Ayesha from FOX 5

Sent from my iPhone

Begin forwarded message:

From: Ayesha Khan <Aisha.Khan@FOXTV.COM>
Date: January 26, 2020 at 4:53:10 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" < (b) (6)
Subject: Ayesha from FOX 5

Hello Dr. Fauci,

Reporter Ayesha Khan from FOX 5. Are you by any chance available for another on camera interview regarding three people who are currently being investigated for possibly showing signs of the Coronavirus in Virginia? Two in Central and one in No. Va.

I can be reached on my cell at (b) (6).
Thanks so much!
Ayesha

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 13:53:30 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CNN New Day (Live Hit: 6:28 am ET)
Attachments: Fwd: Request from CNN's New Day, RE: Request from CNN's New Day

From: (b) (6)
Sent: Tue, 28 Jan 2020 12:41:40 -0500
To: Howard Bauchner
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: Re: Quick follow-up.

Wonderful! Thanks for sending.

On Jan 28, 2020, at 11:10 AM, Howard Bauchner <Howard.Bauchner@jamanetwork.org>wrote:

Tony – see belowl

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

Late yesterday I had the privilege of interviewing Tony Fauci about the coronavirus epidemic. A follow-up of his VP that we published.

Had 1000 folks listening in while we live streamed it (Mike tells me that is good).

More exciting it has had 70,000 views on the various outlets – see below.

Not sure there is anyone in the world who could provide as erudite a description of SARs, MER, and this new outbreak than Tony.

HCB

From: Eman Aly
Sent: Tuesday, January 28, 2020 9:19 AM
To: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Cc: Michael Berkwits <Michael.Berkwits@jamanetwork.org>
Subject: Links to Livestream

Twitter: https://www.pscp.tv/w/1vOGwolpLBbGB
Youtube: https://www.youtube.com/watch?v=3qlagdc_luM
Facebook: https://business.facebook.com/jamajournal/videos/179944506555011/

.....

Eman H. Aly
Manager – Social Communications &Digital Channel Strategy
JAMA Network™
330 N Wabash Ave, Ste 39300, Chicago, IL 60611
T 312-464-4259 M (b) (6)
eman.aly@jamanetwork.org
jamanetwork.com
Skype: eman.aly
Twitter: @EmanMSW
Twitter: @JAMANetwork

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:59:40 +0000
To: NIAID OD AM
Subject: FW: Coronavirus Preparedness Summit & Workshop- Call for Speakers

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: events@cov-s.com <events@cov-s.com>
Sent: Wednesday, January 29, 2020 10:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Coronavirus Preparedness Summit & Workshop- Call for Speakers

Dear Dr. Fauci,

It is my sincere pleasure to invite you to speak at the upcoming Coronavirus Preparedness Summit & Workshop planned for this June 17th to 19th in Washington, DC.

With expected 300 delegates from local, state, federal, and abroad, the 3-day event will bring together Public Health Officials, Emergency Preparedness Leaders, Academia, Business, Public and Private Sector Partners.

The 2019-nCoV Summit will provide a platform for public health officials and community stakeholders to come together, to network and exchange preparedness and response efforts.
Special emphasis will be placed on identifying the responsibilities of various stakeholders in order to improve global communication coordination and collaboration.

Topics include:

- Delivery of Vaccine and Antiviral Medication
- Mass Fatality Management Planning
- Preparing Communities Strategies; Local Partnership and Participation
- Benefit-Risk Assessment: Public Health, Industry and Regulatory Perspectives
- Prevention Education Efforts and Risk Communication
- Command, Control and Management

- Emergency Response Management
- Business-Based Planning
- Community-Based Planning

I greatly appreciate your consideration of this request.

Best Regards,

Edna Santos
(703) 651-2092
events@cov-s.com
Events Coordinator

CORONAVIRUS
PREPAREDNESS
SUMMIT & WORKSHOP
WASHINGTON, DC JUNE 17-19, 2020
Syllabusx
11250 Roger Bacon Drive #10, Reston, VA 20190

From: [redacted] (b) (6)
Sent: Tue, 28 Jan 2020 13:23:05 -0500
To: Corey MD, Larry
Subject: Re: [EXTERNAL] FW: Patient with coronavirus

Thanks

On Jan 28, 2020, at 10:21 AM, Corey MD, Larry <[redacted] (b) (6)>wrote:

Interesting email from Davide Corti [redacted] (b) (4)

Helen how is the patient doing ?

Sent from my iPhone

Begin forwarded message:

From: Davide Corti [redacted] (b) (6)
Date: January 28, 2020 at 7:00:05 AM PST
To: Skip Virgin [redacted] (b) (6)>
Cc: "Corey MD, Larry" [redacted] (b) (6)>
Subject: Re: [EXTERNAL] FW: Patient with coronavirus

Hi!
Thanks for sharing these infos.

[redacted] (b) (4)

Best,
Davide
<PastedGraphic-8.tiff>

Davide Corti, PhD
SVP, Antibody Research
Humabs BioMed SA | a subsidiary of Vir Biotechnology
Via dei Gaggini 3 | 6500 Bellinzona | Switzerland

On Jan 28, 2020, at 5:23 AM, Skip Virgin [redacted] (b) (6)>wrote:

Larry

[redacted] (b) (4)

Davide please cmment

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Corey MD, Larry [redacted] (b) (6)>
Sent: Monday, January 27, 2020 4:49 PM
To: Skip Virgin [redacted] (b) (6)
Subject: RE: [EXTERNAL] FW: Patient with coronavirus

[redacted] (b) (4), (b) (6)

From: Skip Virgin [redacted] (b) (6)
Sent: Monday, January 27, 2020 3:26 PM
To: Corey MD, Larry [redacted] (b) (6)
Subject: RE: [EXTERNAL] FW: Patient with coronavirus

You are a god

[redacted] (b) (6), (b) (4)

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158

he/him/his

From: Corey MD, Larry [redacted] (b) (6)
Sent: Monday, January 27, 2020 1:13 PM
To: Skip Virgin [redacted] (b) (6); George Scangos [redacted] (b) (6)
Subject: [EXTERNAL] FW: Patient with coronavirus

[redacted] (b) (4), (b) (6)

From: Helen Y Chu [redacted] (b) (6)
Sent: Sunday, January 26, 2020 9:11 PM
To: Corey MD, Larry [redacted] (b) (6)
Cc: Boeckh, Michael [redacted] (b) (6)
Subject: Re: Patient with coronavirus

Thank you, Larry, understood. [redacted] (b) (6), (b) (4)
(b) (6), (b) (4)

Helen Y. Chu, MD MPH
Division of Allergy &Infectious Diseases
chulab.org
__Our lab has moved to a new location in South Lake Union__

From: "Corey MD, Larry" <[redacted] (b) (6)>
Date: Sunday, January 26, 2020 at 1:42 PM
To: Helen Y Chu [redacted] (b) (6)
Cc: "Boeckh, Michael" [redacted] (b) (6)>
Subject: RE: Patient with coronavirus

Helen

[redacted] (b) (4)

[redacted] (b) (4)

From: Helen Y Chu [redacted] (b) (6)>
Sent: Sunday, January 26, 2020 10:27 AM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>; Anna Wald [redacted] (b) (6); Suhana, Tina (NIH/VRC) [E] [redacted] (b) (6)>
Cc: Corey MD, Larry [redacted] (b) (6)>; McElrath, Julie [redacted] (b) (6)>; Kathleen Neuzil [redacted] (b) (6) >; Wesley C. Van Voorhis < [redacted] (b) (6); Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>; Corbett, Kizzmekia (NIH/VRC) [E] [redacted] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] [redacted] (b) (6)>; Bok, Karin (NIH/VRC) [E] [redacted] (b) (6)>; Stein, Judy (NIH/VRC) [C] [redacted] (b) (6)>; Ledgerwood, Julie (NIH/NIAID) [E] [redacted] (b) (6)>; Chen, Grace (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>; Austin, Sarah (NIH/NIAID) [E] < [redacted] (b) (6)>; Jay A. Shendure [redacted] (b) (6)
Subject: Re: Patient with coronavirus

Dear John,
That sounds perfect. We will wait to hear from you about setting up a call as soon as possible.

Helen

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Sent: Sunday, January 26, 2020 10:18 AM
To: Anna Wald; Suhana, Tina (NIH/VRC) [E]
Cc: Corey MD, Larry; Helen Y Chu; Julie McElrath; Kathleen Neuzil; Wesley C. Van Voorhis; Graham, Barney (NIH/VRC) [E]; Corbett, Kizzmekia (NIH/VRC) [E]; Morabito, Kaitlyn (NIH/VRC) [E]; Bok, Karin (NIH/VRC) [E]; Stein, Judy (NIH/VRC) [C]; Ledgerwood, Julie (NIH/NIAID) [E]; Chen, Grace (NIH/NIAID) [E]; Marston, Hilary (NIH/NIAID) [E]; Austin, Sarah (NIH/NIAID) [E]
Subject: RE: Patient with coronavirus

Great.

Helen – I just talked to Barney who will be out of town next week, but suggested we proceed with a call. Kaitlyn Morabito is coordinating efforts for his lab and our clinical staff now also copied.

So lets wait to get confirmation for Hilary Marson from Tony's office – and then Tina can find time for a call.

[redacted] (b) (4)

John

From: Anna Wald [redacted] (b) (6)
Sent: Sunday, January 26, 2020 12:56 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Cc: Corey MD, Larry < [redacted] (b) (6)>; Helen Y Chu [redacted] (b) (6) Julie McElrath [redacted] (b) (6); Kathleen Neuzil [redacted] (b) (6); Wesley C. Van Voorhis [redacted] (b) (6); Graham, Barney (NIH/VRC) [E] [redacted] (b) (6); Corbett, Kizzmekia (NIH/VRC) [E] [redacted] (b) (6)>; Morabito, Kaitlyn (NIH/VRC) [E] [redacted] (b) (6)>; Bok, Karin (NIH/VRC) [E] [redacted] (b) (6); Stein, Judy (NIH/VRC) [C] [redacted] (b) (6)>
Subject: Re: Patient with coronavirus

Dear John,

That sounds perfect. While I would like to remain in the loop, I am teaching in subSaharan Africa for the next 2 weeks so calls may be hard to coordinate with my schedule and I don't want to delay the discussions. Please go ahead and work with Helen directly- I know she is excited to collaborate. Helen and I will talk so she can update me.

Please don't hesitate to call my cell if there is anything we should discuss.

Best, Anna

Anna Wald, MD, MPH

Head of Allergy and Infectious Diseases Division
Professor of Medicine, Laboratory Medicine &Epidemiology, University of Washington

tel. [redacted] (b) (6)
fax. 206/520-4371
University of Washington Virology Research Clinic
http://depts.washington.edu/herpes/

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:

Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error, do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Sent: Sunday, January 26, 2020 9:49:31 AM
To: Anna Wald [redacted] (b) (6)
Cc: Corey MD, Larry [redacted] (b) (6); Helen Y Chu [redacted] (b) (6)>; Julie McElrath [redacted] (b) (6)>; Kathleen Neuzil [redacted] (b) (6); Wesley C. Van Voorhis [redacted] (b) (6)>; Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>; Corbett, Kizzmekia (NIH/VRC) [E] [redacted] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] [redacted] (b) (6)>; Bok, Karin (NIH/VRC) [E] [redacted] (b) (6)>; Stein, Judy (NIH/VRC) [C] [redacted] (b) (6)
Subject: RE: Patient with coronavirus

Dear Anna,

Thank you for this important email. We have had discussion with CDC leadership that NIAID/NIH should be primarily involved here. I'm copying the NIH POC, Dr. Hillary Marston, special assistant to Dr. Fauci.

[redacted] (b) (4)

Of note, Dr. Barney Graham and several of his lab are leading our CoV vaccine and antibody efforts. Barney's lab has been working for several years on CoV spike protein and can produce stabilized versions that can be used as vaccine immunogens and protein probes to isolate antibodies. He is making these available to CDC and others.

Hilary, with help from Karin Bock on our end, can help set up a call, which I suggest would first be between your group and our NIH staff.

Thank you,

John R. Mascola, M.D.
Director, Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
email: [redacted] (b) (6)
office tel: [redacted] (b) (6)

From: Anna Wald [redacted] (b) (6) >
Sent: Sunday, January 26, 2020 12:02 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Cc: Corey MD, Larry [redacted] (b) (6)>; Helen Y Chu [redacted] (b) (6); Julie McElrath [redacted] (b) (6); Kathleen Neuzil <[redacted] (b) (6)>; Wesley C. Van Voorhis [redacted] (b) (6)
Subject: Patient with coronavirus

Dear Dr. Mascola,

[redacted] (b) (4), (b) (6)

I am heading to the airport in few hours for a trip to Kenya so will not be on email. However, if anyone is trying to reach me, my cell phone is [redacted] (b) (6).

Thank you, Anna

Anna Wald, MD, MPH

Head of Allergy and Infectious Diseases Division,
Professor of Medicine, Laboratory Medicine &Epidemiology,
University of Washington

tel. 206/520-4340
fax. 206/520-4371
University of Washington Virology Research Clinic
http://depts.washington.edu/herpes/
pronouns: she/her/hers

PHYSICAL LOCATION:
908 Jefferson St, Suite 11NJ-1166, Seattle, WA 98104

MAILING ADDRESS:
Harborview Medical Center, 325 9th Ave, Box #359928, Seattle, WA 98104

Privileged, confidential or patient identifiable information may be contained in this message. This information is meant only for the use of the intended recipients. If you are not the intended recipients. If you are not the intended recipient, or if the message has been addressed to you in error,
do not read, disclose, reproduce, distribute, disseminate or otherwise use this transmission. Instead, please notify the sender by reply e-mail, and then destroy all copies of the message and any attachments.

<PastedGraphic-8.tiff>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 12:45:05 +0000
To: NIAID OD AM
Subject: FW: Question

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: Question

Just quoted you on Fox and Friends.
We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.
Grand Rounds are Wednesday mornings at 8 AM
It would be a great honor and pleasure to have you here.
We would of course cover all expenses and your fee.
Hope you will consider.
Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6) wrote:

[EXTERNAL]

Marc:
  You certainly can quote me.
Best regards,
Tony

From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:
  Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.
Best regards,
Tony

-----Original Message-----
From: Siegel, Marc <Marc.Siegel@nyulangone.org>
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Question

Tony
Any chance of a vaccine for this coronavirus?
I believe they were testing one in dogs.
Marc

Sent from my iPhone

From: [redacted] (b) (6)
Sent: Tue, 28 Jan 2020 13:26:48 -0500
To: Collins, Francis (NIH/OD) [E]
Subject: Re: Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

No down side in re-affirming statement

On Jan 28, 2020, at 1:22 PM, Collins, Francis (NIH/OD) [E] <[redacted] (b) (6) wrote:

Hi Tony,

See below. NIH signed the 2016 statement. Do you see any negatives in re-affirming this?

Francis

From: Jeremy Farrar <[redacted] (b) (6)
Sent: Tuesday, January 28, 2020 1:17 PM
To: [redacted] (b) (6)
[redacted] (b) (6)
[redacted] (b) (6); Casey, Christine G. (CDC/DDPHSS/CSELS/OD) [redacted] (b) (6);
[redacted] (b) (6)
[redacted]
[redacted] (b) (6) Mark J Walport [redacted] (b) (6)
[redacted] Charlotte Watts [redacted] (b) (6)
Collins, Francis (NIH/OD) [E] <[redacted] (b) (6) [redacted] (b) (6)
[redacted] Dzau, Victor J. [redacted] (b) (6)
[redacted]; Paul Stoffels
[redacted] (b) (6)>; George Gao [redacted] (b) (6); Maria Van kerkhove [redacted] (b) (6);
Redfield, Robert R. (CDC/OD) [redacted] (b) (6) Fiona Watt - UKRI MRC [redacted] (b) (6);
[redacted] (b) (6) Barbara Kerstiens [redacted] (b) (6);
[redacted] (b) (6); Mercedes TATAY [redacted] (b) (6) Rebecca GRAIS
[redacted] (b) (6) Julie Gerberding
[redacted] (b) (6) Venkayya, Rajeev [redacted] (b) (6)
Cc: Josie Golding [redacted] (b) (6); Teresa Miller de Vega
[redacted] (b) (6); David Carr [redacted] (b) (6); Jeremy Farrar
[redacted] (b) (6)>
Subject: Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

Dear All,

Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

I am writing to ask your organisation to recommit to a joint statement to rapid and open sharing of research data and findings relevant to the coronavirus (2019-nCoV) outbreak in China. The text of the joint statement follows below. Please do also share with others who may not be on this list.

This statement updates the 2016 joint statement on data sharing in public health emergencies, to which your organisation was a signatory.

In light of the urgent global health threat presented by this outbreak, we are asking signatories to reaffirm their commitment to these principles and pledge to also ensure research findings of relevance are shared rapidly with WHO. This statement reflects the public commitments already made by several leading journals over the last few days. It is aimed at researchers globally, and is necessary because of the unprecedented speed and number of research papers in response to the outbreak.

We plan to publish this statement before the end of the day on Thursday 30 January, so please let us know by 14:00 GMT on Thursday if you would like to sign.

Please reply to my colleague David Carr at Wellcome (d.carr@wellcome.ac.uk), who will also be happy to answer any questions you have.

With best wishes,

Jeremy Farrar

PROPOSED JOINT STATEMENT

Sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak

The outbreak of the novel coronavirus in China (2019-nCoV) represents a significant and urgent threat to global health.

We call on researchers, journals and funders to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.

We affirm our commitment to the principles set out in the 2016 Statement on data sharing in public health emergencies, and pledge to ensure that the World Health Organization has rapid access to emerging findings that could aid the global response.

Specifically, we commit to work together to ensure:

- all peer-reviewed research publications relevant to the outbreak are made immediately open access

- research findings relevant to the outbreak are shared immediately with the WHO upon journal submission, with author approval
- research findings are made available via preprint servers at or before journal submission, or via platforms that make papers openly accessible before peer review – with clear statements regarding the availability of underlying data
- interim and final research data relating to the outbreak are shared as rapidly and widely as possible, including with public health and research communities and the WHO
- journals are clear that data or preprints shared ahead of submission will not pre-empt its publication in these journals

We will apply the principles of this statement to similar outbreaks in the future where there is a significant public health benefit to ensuring data is shared widely and rapidly. We urge others to make the same commitments. If your organisation is committed to supporting these principles, please contact us (d.carr@wellcome.ac.uk) and we will add your organisation to the list of signatories

SIGNATORIES TO THE STATEMENT ON EBOLA

- Academy of Finland
- Academy of Medical Sciences, UK
- Bernhard Nocht Institute for Tropical Medicine
- Bill and Melinda Gates Foundation
- Biotechnology and Biological Sciences Research Council (BBSRC)
- The British Medical Journal (BMJ)
- Bulletin of the World Health Organization
- Calouste Gulbenkian Foundation – Gulbenkian Science Institute
- Canadian Institutes of Health Research
- The Centers for Disease Control and Prevention (to include Morbidity and Mortality Weekly Report [MMWR])
- Chinese Academy of Sciences
- Chinese Centre for Disease Control and Prevention
- The Department of Biotechnology, Government of India
- The Department for International Development (DFID)
- Deutsche Forschungsgemeinschaft (DFG)
- eLife
- EcoHealth Alliance
- The Economic and Social Research Council (ESRC)
- EMBO Press
- F1000
- Fondation Mérieux
- Fundação Oswaldo Cruz (Fiocruz)
- The Global Health Network
- Global Virus Network
- GlaxoSmithKline (GSK)
- The Institut Pasteur

- Instituto Butantan, Brazil
- Instituto Nacional de Salud, Peru
- International Severe Respiratory and emerging Infection Consortium (ISARIC)
- International Society for Infectious Diseases
- Japan Agency for Medical Research and Development (AMED)
- The JAMA Network
- The Lancet
- Médecins du Monde/Doctors of the World (MdM/DoW)
- Médecins Sans Frontières/Doctors Without Borders (MSF)
- Microbide Limited
- National Academy of Medicine
- National Institutes of Health, USA
- National Institute for Infectious Diseases Lazzaro Spallanzani (INMI), Italy
- National Science Foundation, USA
- The New England Journal of Medicine (NEJM)
- PLOS
- ProMED
- Research Ideas and Outcomes (RIO) Journal
- The Rockefeller University Press
- The Royal Society
- SAB Biotherapeutics
- Science Journals
- ScienceOpen
- South African Medical Research Council
- Springer Nature
- Thieme Publishers
- UK Medical Research Council
- Universidade Jean Piaget de Capo Verde
- USAID
- Wellcome Trust
- ZonMw – The Netherlands Organisation for Health Research and Development

Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation.

The Wellcome Trust is a charity registered in England and Wales, no. 210183. Its sole trustee is The Wellcome Trust Limited, a company registered in England and Wales, no. 2711000 (whose registered office is at 215 Euston Road, London NW1 2BE, UK)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 16:24:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Washington Post on camera interview re Wuhan
Attachments: Media Request: Wuhan coronavirus/WashPost VIDEO, RE: Media Request: Wuhan coronavirus/WashPost VIDEO

Reporter: Amber Ferguson, video editor

Organization: Washington Post, video

Phone #(s): 202-334-4194 (Desk) (b)(6) (cell) amber.ferguson@washpost.com

Subject: Coronavirus, how to control outbreaks, how they have been controlled in past

Deadline: Loose—early week of Feb. 3

Spokesperson: NIAID Director Dr. Anthony S. Fauci

Expected place of publication (print, online, broadcast): online video story on WashPost.com

Expected date of publication/airing: unknown

Expected prominence (e.g. front page, Sunday, evening/morning show, etc.):

Key messages/talking points:

Additional information:

Patty,
She wants to come with camera to ASF office later this week or early next to film a video story. Please see her message to me below.
Hello Anne,

My name is Amber Ferguson and I'm a video producer/editor at The Washington Post. We are working on a video about how infectious diseases spread and if containment practices work. We would like to interview Dr. Fauci on-camera about the coronavirus and get his thoughts on past infectious outbreaks. We would be able to come to NIH. Could we schedule this for this Wednesday or Thursday or anytime early next week? Please let me know if you have any questions and if we can set up an interview.

Thank you,
Amber

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 19:37:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - Radio Free Asia Coronoavirus Taped on Camera
Attachments: RE: Dr Fauci interview

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 15:27:41 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FOX Corona Interview Neal Cavuto (LIVE HIT 10:25 am ET)
Attachments: Media Request: Wuhan coronavirus/Fox Cavuto LIVE weekend show, Corona virus interview with Dr Fauci for Saturday

Yes, we're confirmed for 10:25AM ET tomorrow.
The on-site contact is: Bryan McCarthy who can be reached at (b) (6)
We are on floor 5 at 400 North Capitol NW

I'll be in NYC, but can also be reached with any questions at (b) (6)

From: Ciniglio, Brianna <brianna.ciniglio@FOXNEWS.COM>
Sent: Thursday, January 23, 2020 9:50 AM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Fox News Cavuto Saturday Request

Good morning,

I work on Neil Cavuto's weekend show on Fox News. I am reaching out to see if Director Fauci would be available to join our show this Saturday at any point between 10AM-12PM ET to discuss the coronavirus. We will be live from NYC, but can arrange a remote interview. Please let me know if there's any way we can make something work.

Thank you,

Brianna Ciniglio
Booker, "Cavuto LIVE"
Fox News Channel
Office: (212)-301-5051
Cell: (b) (6)

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Wed, 29 Jan 2020 22:55:05 +0000
To:	Fauci, Anthony (NIH/NIAID) [E]
Subject:	CORONAVIRUS UPDATE TO IC DIRECTORS (8 am -8:15 am)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 17:50:10 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Shanghai Media Skype interview re Coronoavirus
Attachments: Coronavirus interview with Dr. Fauci, Interview request: Wuhan coronavirus, Shanghai Media Group

Marat Sadana
Shanghai Media Group
(b) (6)
(b) (6)
Topic: Wuhan pneumonia
Deadline: Wednesday 1/22 COB

Hi Patty,

This is a student reporter who is working for Shanghai Media Group's video division, PearVideo. (See attached earlier email exchange—their info checks out, and the video will likely be broadcast here: https://www.pearvideo.com/) They'd like to set up a 20-minute Skype interview with Dr. Fauci, which will be taped for later broadcast. They'd like to do this ASAP (no solid deadline, but would need to do today or tomorrow). They sent the following questions:

1. Could you briefly introduce for us about what's special about 2019-nCoronavirus?
2. any possible speculation about the source of infection 2019-nCoronavirus?(animals?)
3. How transmissible 2019-nCoronavirus could be? What are the possible routes of infection?
4. 2019-nCoronavirus is confirmed to possibly transmit from people to people. What does this mean? Any further possible serious effect?
5. It is said NIH has begun to develop vaccine. How soon we could have it?
6.Any suggestion for public? How can we protect ourselves from 2019-nCoronavirus so far?

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Wed, 22 Jan 2020 12:37:20 +0000
To:	Fauci, Anthony (NIH/NIAID) [E]
Subject:	HOLD - FOX Business Coronavirus Interview (LIVE HIT: 5:10 pm ET)
Attachments:	Re: [EXTERNAL] FW: Fox Business Interview Request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 15:45:36 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- Fox Business News - Corona virus Interview (LIVE HIT TBD)
Attachments: Fauci interview request

Hope all is well.
We've worked together when I was at AJE and CGTN AMERICA. I moved to FBN in NYC!

I am reaching out to you to check the availability of Dr Fauci for an interview tomorrow 01/23 sometime between 10a-12pmET to talk about the coronavirus. This is a 5min LIVE hit for our show, Varney & CO. The name of the anchor is Stuart. We can book NIH TV studios.

Can he accommodate?
https://www.foxbusiness.com/technology/china-coronavirus-vaccine-outbreak-wuhan-virus-in-china

Please let me know.

Joana

Joana Godinho | Fox Business Network
Coordinating Booker, Varney & Co.

1211 Avenue of the Americas New York, NY 10036
E: joana.godinho@foxbusiness.com 0: 212-601-2941 C: (b) (6) (work) | C: (b) (6)
(personal)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 20:37:06 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Akinso, Woleola (NIH/OD) [E];Akinso, Woleola (NIH/OD) [E];Akinso, Woleola (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: PRe-Tape with Brett Baer Corona)Taped on camera)
Attachments: RE: Bret Baier Request for Anthony Fauci, PRe-Tape with Brett Baer Corona)Taped on camera)

My name is Ashley Moir and I'm the booker for "Special Report w/ Bret Baier" at Fox News Channel in Washington, DC.

Bret was wondering if Dr. Fauci would be available to join us on the show in the 6pm hour this coming Monday, January 27 to discuss the latest with the Coronavirus.

Please get back to me at your earliest convenience. Thank you for considering!

Best,
Ashley

Ashley Koerber Moir
Booking Producer
Special Report w/ Bret Baier
Fox News Channel – DC Bureau
(b) (6) (cell)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 14:07:31 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: House E&C Member briefing on coronavirus
Attachments: RE: Please advise: E&C full committee briefing

E&C staff would like to have the full committee, Member-level briefing on Coronavirus on Thursday morning (Jan. 30) starting at 9:45am

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Fri, 24 Jan 2020 23:13:44 +0000
To:	Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject:	Yahoo online skype interview (Live hit 2:00 pm - 2:15 pm ET)
Attachments:	FW: (Monday, 2-3 p.m.?) Yahoo Finance TV interview request -- Dr. Anthony Fauci

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 14:21:53 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Fox Bus NEws w/ David Asman Live Hit: TBD
Attachments: RE: [EXTERNAL] FW: Fox Business Interview Request, RE: [EXTERNAL] FW: Fox Business Interview Request, ON-CAMERA -- Interview request: Wuhan virus

Haley.Gillman@FOXNEWS.COM

Subject: Wuhan coronavirus

Organization: Fox News Channel Fox Business Network

Specific Outlet Show: Bulls and Bears

Taped or live: Live at 5:12 p.m. Jan. 30

Deadline: Today Jan. 30

Reporter: David Asman (program host, doing interview)

Producer: Haley Gillman

Phone #(s) or e-mail: 646-468-1720 haley.gillman@foxnews.com

Agency spokesperson: NIAID Director Dr. Anthony S. Fauci

Expected place of publication: Fox News program Bulls and Bears

Expected date of publication/airing: Jan. 30 at 5:12 pm ET

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 00:07:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6));Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Science Vs New Coronavirus

Let us discuss whether we can do this during the coming week.

From: Wendy Zukerman <wzukerman@spotify.com>
Sent: Saturday, January 25, 2020 12:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Science Vs New Coronavirus

Dear Anthony, This is Wendy from Science Vs - we interviewed you last year about our episode on Pandemics, thank you so much. More than 500,000 people heard the episode.

With the new Wuhan coronavirus - we'd like to do a quick, follow up interview. What's happening? Where did this come from? (Snakes?) How worried should we be?

Is there any chance you're available early next week? We'd need around 30 minutes.

Thank you

Wendy

Sent from my iPhone

On Oct 8, 2019, at 1:17 PM, Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) wrote:

Some flu vaccines (relatively small proportion) are grown in cells as opposed to eggs. This is somewhat more reliable but not really faster. A very small percentage are developed through recombinant DNA technology and this is faster. We are trying to convert much more to the recombinant vaccine platforms but we are not there yet

On Oct 8, 2019, at 6:21 PM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Thanks - regarding the question about growing vaccine in chicken eggs. Do we have alternate (non-chicken egg/ faster) technology available right now, but it hasn't been rolled out? Or, do we need to develop better vaccine making technology?

thank you so much.

On Tue, Oct 8, 2019 at 2:02 AM Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) wrote:
Rough estimate assuming a conservative 20% infection rate and a 2% mortality I would estimate 1.5 million deaths in the USA and ~35 million global.

On Oct 8, 2019, at 12:53 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Thank you!! And if we've been going back and forth on what our final "death toll" should be. We're assuming highly contagious, with a 2% mortality rate, vaccine arrives around 6 months in, episode ends at 7 months. Do you think 2 million in the US would make sense? And worldwide, 33, 35 million or 40 million?

On Mon, Oct 7, 2019 at 4:04 PM Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) wrote:
Pandemics will occur and we cannot "prevent" them, but we can mitigate their impact and prevent worst case scenarios. There are several ways to do this. Three of the most important are: 1) improve global surveillance so that we can get a head start on response such as development of a vaccine. 2) improve vaccine platform technology and manufacturing capabilities to allow rapid development of vaccines. 3) stockpile readily deliverable interventions such as respirators, antivirals and antibiotics for bacterial complications.

On Oct 7, 2019, at 9:35 AM, Wendy Zukerman <wendyz@gimletmedia.com> wrote:

Hi Tony, We're almost out of the woodwork with all the fact checking! Thank you for your time. Quick question. **What are the top three things can we do now to help prevent a worst case scenario flu pandemic?**

Best, Wendy

--
Wendy Zukerman
Host and Executive Producer
Science Vs podcast
wzukerman@spotify.com
[redacted] (b) (6)

--
Wendy Zukerman
Host and Executive Producer
Science Vs podcast
wzukerman@spotify.com
[redacted] (b) (6)

--

Wendy Zukerman
Host and Executive Producer
[Science Vs podcast]()
wzukerman@spotify.com
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 01:15:46 +0000
To: Lipkin, Ian W.
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: 2020 [redacted] Foreign Language

Great! I am anxious to learn of your impression.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. [redacted] (b) (6)
Sent: Thursday, January 23, 2020 7:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: 2020 [redacted] Foreign Language

Tony,
I've been invited to China by the central govt. details to follow

On Jan 23, 2020, at 6:05 PM, Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) wrote:

Thanks, Ian.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)

FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lipkin, Ian W. [redacted] (b) (6)
Sent: Wednesday, January 22, 2020 10:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: 2020 [redacted] Foreign Language

Tony,
See translation of Mandarin text regarding age and baseline medical status in the 17 Wuhan CoV fatalities.

Ian

As of 24:00 on January 22, our committee had received a total of 571 confirmed cases of pneumonia of new coronavirus infection in 25 provinces (autonomous regions, municipalities) in China, including 95 severe cases and 17 deaths (all from Hubei Province). A total of 393 suspected cases were reported in 13 provinces (autonomous regions and municipalities).

At 00:00 on the 22nd, 24 provinces (autonomous regions and municipalities) reported 131 new confirmed cases and 8 new deaths, including 5 males and 3 females. 13 provinces (autonomous regions and municipalities) reported 257 new suspected cases. A total of 25 provinces (autonomous regions and municipalities) reported the epidemic.

Confirmed cases reported overseas: 1 case in Hong Kong, China, 1 case in Macau, 1 case in Taiwan, China; 1 case in the United States, 1 case in Japan, 3 cases in Thailand, and 1 case in South Korea.

At present, 5897 close contacts have been traced, 969 people have been released from medical observation, and 4928 people are still receiving medical observation.

Introduction of 17 deaths

[redacted] (b) (6)

(b)(6)

[redacted]

(b) (6)

[redacted]

(b)(6)

Foreign language

[redacted]

foreign language

[redacted]

Foreign language

[redacted]

foreign language

[redacted]

foreign language

[redacted]

W. Ian Lipkin, MD
John Snow Professor of Epidemiology and Director
Center for Infection and Immunity
Mailman School of Public Health

Professor of Pathology and Neurology
College of Physicians & Surgeons
Columbia University
722 West 168th Street, 17th Floor
New York, NY 10032
Voice: [redacted] (b) (6)
Fax: (212) 342-9044
Email: [redacted] (b) (6)

Administrative Coordinator
[redacted] (b) (6)
Voice: [redacted] (b) (6)
Email: [redacted] (b) (6)

www.cii.columbia.edu
Follow CII on Twitter: CII_Columbia | Facebook: CII.Columbia

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 23:22:59 +0000
To: Paules, Catharine;Marston, Hilary (NIH/NIAID) [E]
Subject: n-CoV manuscript
Attachments: Coronavirus manuscript-first draft 1-20-2020 - with Fauci tracked changes.docx, Coronavirus manuscript-first draft 1-20-2020 - Clean copy.docx

I am attaching 2 copies of the manuscript with my tracked changes showing and a clean copy

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:36:40 +0000
To: Dzau, Victor J.;'GPMB Secretariat';As Sy Elhadj;Brundtland Gro Harlem;Chris.Elias;Farrar Jeremy;Fore Henrietta;Gao Fu;Gashumba Diane;Kaag Sigrid;Ilona Kickbusch;Suzuki Yasuhiro;Vega Morales Jeanette;Vega Morales Jeanette;VijayRaghavan Krishnaswamy;'Skvortsova Veronika'
Cc: MAHJOUR, Jaouad;MINHAS, Raman;Toomas Palu;Pate Muhamed;RYAN, Michael J.;SCHWARTLANDER, Bernhard F.;Alex Harris;Alveberg, Benedikte Louise;Chiaki NOGUCHI;Esveld Marja;Esveld Marja;Esveld Marja;Gonggrijp Mette;Julie.HALL;Kanarek, Morgan;Marston, Hilary (NIH/NIAID) [E];Omar Abdi;Amelie RIOUX;Tore Godal;GABEDAVA, Tsira;ROSS, Alex;Banks Lynn;Block, Bruce;Conrad Jane;Conrad, Patricia (NIH/NIAID) [E];Del Sol Dinia;Diao Fay;Gahungu Zacharie;Harikumar M K;Harikumar M K;Kabagire Christine;KITA Yosuke;Steven T. Smith;Miller de Vega Teresa;MURIUKI, Hilda Wairimu;Muzenda Sindiso;Sarah Belmir;YU Bai;Kirsi Madi [redacted] (b) (6);'Oleg Sonin ';Marston, Hilary (NIH/NIAID) [E]
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Attachments: Draft GPMB Statement_nCOV_28Jan_for Bd member review NIAID.docx

Looks fine. Please see my comments in attached document.
Thanks,
Tony

From: Dzau, Victor J. <[redacted] (b) (6)
Sent: Tuesday, January 28, 2020 11:46 PM
To: 'GPMB Secretariat' <gpmbsecretariat@who.int>; As Sy Elhadj [redacted] (b) (6); Brundtland Gro Harlem <[redacted] (b) (6); Chris.Elias [redacted] (b) (6) Farrar Jeremy [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) Fore Henrietta [redacted] (b) (6) Gao Fu [redacted] (b) (6); Gashumba Diane [redacted] (b) (6) Kaag Sigrid [redacted] (b) (6) Ilona Kickbusch [redacted] (b) (6)>; Suzuki Yasuhiro (b) (6) [redacted]; Vega Morales Jeanette [redacted] (b) (6); Vega Morales Jeanette [redacted] (b) (6); VijayRaghavan Krishnaswamy [redacted] (b) (6); 'Skvortsova Veronika' [redacted] (b) (6)
Cc: MAHJOUR, Jaouad <[redacted] (b) (6); MINHAS, Raman [redacted] (b) (6)>; Toomas Palu [redacted] (b) (6); Pate Muhamed [redacted] (b) (6); RYAN, Michael J. [redacted] (b) (6) SCHWARTLANDER, Bernhard F. [redacted] (b) (6) Alex Harris [redacted] (b) (6); Alveberg, Benedikte Louise [redacted] (b) (6); Chiaki NOGUCHI [redacted] (b) (6)>; Esveld Marja <[redacted] (b) (6); Esveld Marja [redacted] (b) (6)>; Esveld Marja [redacted] (b) (6)>; Gonggrijp Mette [redacted] (b) (6) Julie.HALL <[redacted] (b) (6); Kanarek, Morgan [redacted] (b) (6); Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6) Omar Abdi [redacted] (b) (6); Amelie RIOUX [redacted] (b) (6); Tore Godal [redacted] (b) (6)>; GABEDAVA, Tsira [redacted] (b) (6); ROSS, Alex [redacted] (b) (6)>; Banks Lynn [redacted] (b) (6)>; Block, Bruce [redacted] (b) (6); Conrad Jane [redacted] (b) (6) Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Del Sol Dinia [redacted] (b) (6) Diao Fay [redacted] (b) (6) Gahungu Zacharie [redacted] (b) (6); Harikumar M K [redacted] (b) (6) Harikumar M K [redacted] (b) (6); Kabagire Christine <[redacted] (b) (6) KITA Yosuke

[redacted] (b)(6) Steven T. Smith [redacted] (b)(6)>; Miller de Vega Teresa [redacted] (b)(6); MURIUKI, Hilda Wairimu [redacted] (b)(6)>; Muzenda Sindiso [redacted] (b)(6) Sarah Belmir [redacted] (b)(6)>; YU Bai [redacted] (b)(6)>; Kirsi Madi [redacted] (b)(6); 'Oleg Sonin ' [redacted] (b)(6)
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

The message is clear and appropriate. I support it.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Tuesday, January 28, 2020 7:09 AM
To: As Sy Elhadj [redacted] (b)(6)>; Brundtland Gro Harlem [redacted] (b)(6)>; Dzau, Victor J. < [redacted] (b)(6)>; Chris.Elias [redacted] (b)(6); Farrar Jeremy [redacted] (b)(6)>; Fauci Anthony < [redacted] (b)(6) Fore Henrietta [redacted] (b)(6) Gao Fu [redacted] (b)(6)>; Gashumba Diane [redacted] (b)(6); Kaag Sigrid [redacted] (b)(6); Ilona Kickbusch [redacted] (b)(6)>; Suzuki Yasuhiro [redacted] (b)(6)>; Vega Morales Jeanette [redacted] (b)(6)>; Vega Morales Jeanette [redacted] (b)(6); VijayRaghavan Krishnaswamy [redacted] (b)(6)>; 'Skvortsova Veronika' [redacted] (b)(6)
Cc: MAHJOUR, Jaouad [redacted] (b)(6)>; MINHAS, Raman [redacted] (b)(6)>; Toomas Palu [redacted] (b)(6); Pate Muhamed [redacted] (b)(6)>; RYAN, Michael J. [redacted] (b)(6)>; SCHWARTLANDER, Bernhard F. [redacted] (b)(6)>; Alex Harris [redacted] (b)(6)>; Alveberg, Benedikte Louise [redacted] (b)(6); Chiaki NOGUCHI [redacted] (b)(6)>; Esveld Marja [redacted] (b)(6)>; Esveld Marja [redacted] (b)(6) Esveld Marja [redacted] (b)(6)>; Gonggrijp Mette [redacted] (b)(6)>; Julie.HALL < [redacted] (b)(6)>; Kanarek, Morgan [redacted] (b)(6)>; Marston Hilary [redacted] (b)(6) Omar Abdi [redacted] (b)(6)>; Amelie RIOUX [redacted] (b)(6)>; Tore Godal [redacted] (b)(6)>; GABEDAVA, Tsira [redacted] (b)(6)>; ROSS, Alex [redacted] (b)(6)>; Banks Lynn [redacted] (b)(6)>; Block, Bruce [redacted] (b)(6)>; Conrad Jane [redacted] (b)(6); Conrad Patricia < [redacted] (b)(6) Del Sol Dinia [redacted] (b)(6)>; Diao Fay [redacted] (b)(6); Gahungu Zacharie [redacted] (b)(6)>; Harikumar M K [redacted] (b)(6)>; Harikumar M K [redacted] (b)(6) [redacted] >; Kabagire Christine [redacted] (b)(6)>; KITA Yosuke [redacted] (b)(6) [redacted]; 'Steve Smith' < [redacted] (b)(6)>; Miller de Vega Teresa [redacted] (b)(6)>; MURIUKI, Hilda Wairimu < [redacted] (b)(6)>; Muzenda Sindiso [redacted] (b)(6); Sarah Belmir [redacted] (b)(6)>; YU Bai [redacted] (b)(6); Kirsi Madi [redacted] (b)(6); 'Oleg Sonin ' [redacted] (b)(6)>
Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 01:10:59 +0000
To: Redfield, Robert R. (CDC/OD)
Subject: FW: CNN: Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data https://cnn.it/36pifVH

FYI

From: Folkers, Greg (NIH/NIAID) [E] (b)(6)>
Sent: Sunday, January 26, 2020 8:04 PM
Subject: CNN: Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data https://cnn.it/36pifVH

7 hr 26 min ago

Top NIH doctor wants China to invite US disease detectives to inspect Wuhan coronavirus data

From CNN Health's Elizabeth Cohen

Tom Williams/CQ-Roll Call/Getty Images

The United States' top infectious disease doctor wants a team of disease detectives from the US Centers for Disease Control and Prevention to go to China and check on crucial questions about how the Wuhan coronavirus is spreading.

But there's one problem: China first has to invite the CDC.

"Up to now, to my knowledge, we have not been invited," said Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases at the US National Institutes of Health.

A CDC spokesperson was not immediately available to comment on Sunday. NIH and CDC are separate divisions of the US Department of Health and Human Services.

On Sunday, Ma Xiaowei, China's health minister, told reporters that the virus could spread before someone develops symptoms. If so, that means the virus will spread much more quickly than expected. Ma did not explain how Chinese authorities arrived at this conclusion.

"The implications for this are so important that in my mind it's absolutely critical that we ourselves see the data, because what goes on over there has implications for what happens here," Fauci said.

Fauci said that CDC disease detectives would need to see precisely how Chinese health authorities have gathered their data.

"To my knowledge, we have not seen the precise minute, granular data and how they collected it," he said. "We need to get to the real bottom line of how they collected their data and see if it's valid."

"The Chinese have good people. I don't want to impugn their capabilities," Fauci added. "But when it's something as important as this, our people who are trained epidemiologists need to go over their data and the best way to do that is go there and see how they're collecting it."

He added that to his knowledge, the Chinese did not tell US health authorities that the virus could spread before someone is symptomatic, a crucial aspect of any disease investigation. He said he learned about it after reading a CNN reporter's email.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 02:02:08 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Our NIAID supported SARS receptor binding domain vaccine (from China)
Attachments: hvi-10-648.pdf, nihms436421.pdf, nihms906599.pdf, Shi ZL_Cross-neutraliz SL-CoV by anti-SARS-CoV antibodies_Sci China_Life Sci_2017.pdf

As per prior e-mail. See attachments.

From: Hotez, Peter Jay [redacted] (b) (6) >
Sent: Monday, January 20, 2020 8:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) Stemmy, Erik (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Bottazzi, Maria Elena [redacted] (b) (6); Hotez, Peter Jay [redacted] (b) (6) >
Subject: Re: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise. [redacted] (b) (4)

(b) (4) [redacted]

Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine

Health Policy Scholar

Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children's Hospital Center for Vaccine Development

University Professor

Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study

Senior Fellow, Scowcroft Institute of International Affairs

Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University

Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: [redacted] (b) (6)
Twitter: [redacted] (b) (6)

Skype: [redacted] (b) (6)

Website: [redacted] (b) (6)

Amazon Author Center: https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48

Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/

Executive Assistant: [redacted] (b) (6)

[redacted] (b) (6)

Phone [redacted] (b) (6)

Baylor College of Medicine
National School of Tropical Medicine
Texas Children's Hospital
BAYLOR UNIVERSITY

From: Hotez, Peter Jay [redacted] (b) (6)>
Sent: Monday, January 20, 2020 7:17 PM
To: Anthony (NIH/NIAID) [E] Fauci <[redacted] (b) (6)
[redacted] (b) (6)>
Cc: Bottazzi, Maria Elena [redacted] (b) (6)>; Hotez, Peter Jay <[redacted] (b) (6)>
Subject: Our NIAID supported SARS receptor binding domain vaccine (from China)

Dear Tony and Erik, I hope it's OK I'm emailing you directly, but given the emerging situation I thought it would be wise. [redacted] (b) (4)

(b) (4)

Warm regards, Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine

Health Policy Scholar

Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children's Hospital Center for Vaccine Development

University Professor

Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study

Senior Fellow, Scowcroft Institute of International Affairs

Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University

Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: [redacted] (b) (6)
Twitter: [redacted] (b) (6)

Skype: [redacted] (b) (6)

Website: [redacted] (b) (6)

Amazon Author Center: https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48

Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/

Executive Assistant: [redacted] (b) (6)

[redacted] (b) (6)

Phone: [redacted] (b) (6)

Baylor
College of
Medicine

TROPICAL
MEDICINE

Texas Children's
Hospital

BAYLOR

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 01:17:29 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: question from a reporter about Dx mention in JAMA article

Please respond for me. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Thursday, January 23, 2020 6:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: RE: question from a reporter about Dx mention in JAMA article

As I mentioned, I would just say a number of diagnostic developers are exploring use in their platform. Since none have publicly announced their plans, we would not want to get ahead of their planning.

From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Sent: Thursday, January 23, 2020 1:09 PM
To: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Subject: FW: question from a reporter about Dx mention in JAMA article

See question below.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)

FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Madeleine Johnson <madeleine.johnson@genomeweb.com>
Sent: Thursday, January 23, 2020 12:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: question from a reporter about Dx mention in JAMA article

Dear Dr. Fauci, My name is Madeleine Johnson and I am a reporter at GenomeWeb.com and 360Dx.com covering diagnostic technologies.

I'm writing a short feature story on companies and agencies developing diagnostic tests for 2019-nCoV. I noted in your *JAMA* Viewpoint article today that you and your co-authors refer to this as well.*

So far, I am aware of RT-qPCR tests developed by CDC, a lab in Germany, Co-Diagnostics, and BGI, and the possibility of rapid sequencing-based testing being developed by Oxford Nanopore. Are you aware of any others that you can disclose, on or off the record?

Also, I imagine that a rapid, near-patient diagnostic test would be the ideal in outbreak control. Are you aware of any pan-coronavirus tests that could be adapted for screening, or any sign that specific point of care molecular diagnostic platform developers are working on rapid MDx for use in airports or ERs, etc?

I am sure you are extremely busy, but even a few brief comments via email would be amazing! I am hoping to run a story later this afternoon (~3PM Eastern) but can also add to it once it is published online, if needed.

Thanks so much! Madeleine

*"For example, platform diagnostic modalities are being rapidly adapted to include 2019-nCoV, allowing early recognition and isolation of cases."

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:37:15 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Thanks!

From: Marston, Hilary (NIH/NIAID) [E] (b)(6)>
Sent: Tuesday, January 28, 2020 6:56 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E] < (b)(6) Folkers, Greg (NIH/NIAID) [E] (b)(6)>; Steven T. Smith (b)(6) Handley, Gray (NIH/NIAID) [E] (b)(6)
Subject: RE: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus

Consolidated comments from me and from Steve Smith.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: martes, 28 de enero de 2020 9:09
To: As Sy Elhadj < (b)(6)>; Brundtland Gro Harlem (b)(6); Dzau Victor (b)(6)>; Chris.Elias (b)(6)>; Farrar Jeremy < (b)(6); Fauci Anthony < (b)(6) Fore Henrietta (b)(6)>; Gao Fu (b)(6)>; Gashumba Diane (b)(6)>; Kaag Sigrid (b)(6); Ilona Kickbusch (b)(6)>; Suzuki Yasuhiro (b)(6)>; Vega Morales Jeanette (b)(6) Vega Morales Jeanette (b)(6); VijayRaghavan Krishnaswamy (b)(6); 'Skvortsova Veronika' (b)(6)>
Cc: MAHJOUR, Jaouad (b)(6)>; MINHAS, Raman (b)(6); Toomas Palu (b)(6)>; Pate Muhamed (b)(6)>; RYAN, Michael J. (b)(6); SCHWARTLANDER, Bernhard F. (b)(6); Alex Harris (b)(6); Alveberg, Benedikte Louise (b)(6) Chiaki NOGUCHI (b)(6)Esveld Marja (b)(6)>; Esveld Marja (b)(6)>; Esveld Marja (b)(6); Gonggrijp Mette (b)(6)>; Julie.HALL (b)(6); Kanarek Morgan (b)(6)>; Marston Hilary (b)(6); Omar Abdi (b)(6)>; Amelie RIOUX (b)(6)>; Tore Godal (b)(6)>; GABEDAVA, Tsira (b)(6)>; ROSS, Alex (b)(6)>; Banks Lynn (b)(6)>; Block Bruce (b)(6)>; Conrad Jane (b)(6); Conrad Patricia < (b)(6) Del Sol Dinia (b)(6); Diao Fay (b)(6); Gahungu Zacharie (b)(6)>; Harikumar M K (b)(6)>; Harikumar M K (b)(6) [redacted]; Kabagire Christine (b)(6)>; KITA Yosuke (b)(6) [redacted]>; 'Steve Smith' (b)(6)>; Miller de Vega Teresa

[redacted] (b) (6)>; MURIUKI, Hilda Wairimu [redacted] (b) (6)>; Muzenda Sindiso [redacted] (b) (6)>; Sarah Belmir [redacted] (b) (6)>; YU Bai [redacted] (b) (6)>; Kirsi Madi [redacted] (b) (6); 'Oleg Sonin ' [redacted] (b) (6)>
Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:41:34 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wuhan coronavirus treatment candidate

Please respond to this person. Thanks.

From: Beitler, Jeremy R. (b) (6)
Sent: Wednesday, January 29, 2020 12:17 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Wuhan coronavirus treatment candidate

Dear Dr. Fauci:

I am a physician-scientist at Columbia University and study human acute respiratory distress syndrome (ARDS). I am not a virologist. However, I read with interest your JAMA viewpoint on Wuhan 2019 nCoV and noted a potential prophylaxis/treatment that was not mentioned but that may be of interest.

From my ARDS research, I am familiar with a recent GSK study of recombinant human angiotensin-converting enzyme-2 (rhACE2) for ARDS (NCT01597635), for which it showed some promise. Regardless, it may be an effective treatment for Wuhan coronavirus.

As you noted, ACE2 is a main binding site for SARS. In lab models, soluble ACE2 appears effective at inhibiting propagation of SARS. Early published data for Wuhan CoV suggest it also may bind to ACE2 (Xu et al. Science China Life Sciences 2020:63). If Wuhan CoV indeed binds to ACE2, then rhACE2 might be effective at attenuating illness severity or blocking transmission. Given the established safety profile of rhACE2 from the prior GSK human trials, it seems to me an excellent candidate therapy for prophylaxis (not ideal in the studied iv formulation) or treatment if the Wuhan nCoV outbreak continues to grow.

I imagine you and others have already thought of this. Since I do not recall seeing it in the JAMA paper, I thought it worth sharing only because it is a treatment potentially immediately ready for testing.

Thank you for considering,
Jeremy
Cell: (b) (6)

Jeremy R. Beitler, MD, MPH
Assistant Professor
Director of Clinical Research
Center for Acute Respiratory Failure

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Tue, 21 Jan 2020 11:07:14 +0000
To:	Conrad, Patricia (NIH/NIAID) [E]
Cc:	Barasch, Kimberly (NIH/NIAID) [C]
Subject:	FW: Interview Invitation on coronavirus outbreak in China

They will send a crew.

From: [redacted] (b) (6)
Sent: Monday, January 20, 2020 11:34 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Subject: Interview Invitation on coronavirus outbreak in China

Dear Dr. Fauci,

I'm Youyou Wang from Hong Kong Phoenix TV, Washington DC bureau. I would like to invite you for a TV interview on coronavirus outbreak in China.

The situation in China is very fluid. We would really appreciate if you could share some insights on coronavirus. Your expertise in this area would be extremely valuable for our audience at this critical moment.

Please kindly let us know if you could accept our invitation, and your earliest availability. We could come to NIH earlier to set up for the interview.

Looking forward to hearing back from you!

Best regards,

--
王又又 | Youyou WANG

Correspondent
Washington D.C. Bureau | Phoenix Satellite Television

Phone: +1(202)715-0352 | Fax: +1(202)715-1374
Mobile: [redacted] (b) (6) | E-mail: wangyouyou@phoenixtv.com
101 Constitution Ave NW | Suite 920 EAST | Washington DC 20001

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:23:31 +0000
To: Janet Tobias;Conrad, Patricia (NIH/NIAID) [E]
Cc: Rancourt, Anne (NIH/NIAID) [E]
Subject: RE: Coronavirus and interview for the film

Patty:
Please set something up for me to have a conversation with Janet.
Thanks,
Tony

From: Janet Tobias <janet@ikanamedia.com>
Sent: Sunday, January 26, 2020 9:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b)(6) Conrad, Patricia (NIH/NIAID) [E]
<[redacted] (b)(6)
Cc: Rancourt, Anne (NIH/NIAID) [E] [redacted] (b)(6)
Subject: Coronavirus and interview for the film

Dear Tony and Patty: I know you must be extremely busy. I talked to Anne last week and told her I was going to write to you both to put in place an interview in

(b)(4)

[redacted]

Janet

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:42:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Possible Coronavirus cure

Please respond to this person.

From: Austin Avino (b) (6)
Sent: Wednesday, January 29, 2020 12:20 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Possible Coronavirus cure

My name is austin avino. I am not a dr. Or a med student. I have been doing research on coronavirus and know it can be in both animals and humans. Through furthere research i found out that there is one animal in particular that has almost an immunity to all deseases some professionals have discovered. The shark. They have squalimine that years ago was tested against cancer but was not sucessful. Coronavirus is a respitory desease and i have been thinking whats the best way to get medicine in the lungs. There is a squalamine inhalant that has been tested on rats to treat sertain strands of pneumonia. After several days of being applied 2 doses of the inhalant daily the percentage of the pneumonia bacteria droped. I do not know if this would work or not but it would be worth finding a cure for a disease without a cure at the moment. Lab testing a coronavirus strand to see if squalamine can fight back against it would be worth a shot and could save thousands of people. If you have any questions feel free to email me

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 11:09:55 +0000
To: Cohen, Elizabeth
Subject: RE: Vaccine for new Chinese coronavirus in the works - CNN

I have not heard anything definite about the dynamics of the infection of the 14 healthcare workers.

-----Original Message-----
From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Tuesday, January 21, 2020 6:01 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: Vaccine for new Chinese coronavirus in the works - CNN

Tony –
Many thanks. Please let me know if there's anything else in particular you think we ought to be reporting today. We're trying to learn more about these 14 healthcare workers. Have you heard whether it was just one patient who infected all of them?
Cheers,
Elizabeth

> On Jan 21, 2020, at 12:51 PM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6) wrote:
>
> Elizabeth:
> Nice piece!
> Best,
> Tony
>
> -----Original Message-----
> From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
> Sent: Tuesday, January 21, 2020 12:21 AM
> To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
> Subject: Vaccine for new Chinese coronavirus in the works - CNN
>
> Tony - thank you for your help with this. Looking forward to speaking today to see if we've learned more about this virus.
>
> https://www.cnn.com/2020/01/20/health/coronavirus-nih-vaccine-development/index.html

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:28:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: From Italy

Please set this up **IF** it is possible.

From: Michele Bocci <m.bocci@repubblica.it>
Sent: Saturday, January 25, 2020 8:21 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: From Italy

Hello, I'm a journalist from the Italian national newspaper La Repubblica and I'd like to have an interview with you about the new coronavirus. Just some question about it's nature and it's dangerousness.
Is it possible?

Thank you,
Michele Bocci

Il presente messaggio (inclusi gli allegati) contiene informazioni riservate esclusivamente al destinatario/ai destinatari indicato/i nel messaggio, ed è protetto dalla legge. La diffusione, distribuzione e/o la copia del contenuto del presente messaggio da parte di qualsiasi soggetto diverso dal destinatario è severamente vietata ai sensi dell'art. 616 c.p. e delle vigenti normative in materia di protezione dei dati personali. Se non siete i destinatari del presente messaggio, vi preghiamo di distruggerlo e di darcene immediata comunicazione inviando un messaggio di ritorno all'indirizzo e-mail del mittente.

This message (including any attachments) contains confidential information intended only for the recipient(s) named above, and is protected by law. Any disclosure, distribution and/or copying of this message by any subject different from the named recipient(s) is strictly prohibited according to art. 616 c.p. and to the applicable data protection laws. If you are not the intended recipient, please delete this message and inform us immediately about the deletion by sending a message to the sender's e-mail address.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 15:54:54 +0000
To: Wayne Holman
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: 2019-nCOR: Could anti-IL6 be helpful if cytokine storm is driving the pathology in the sickest patients?

Thanks, Wayne.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Wayne Holman (b) (6)
Sent: Wednesday, January 29, 2020 9:16 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: 2019-nCOR: Could anti-IL6 be helpful if cytokine storm is driving the pathology in the sickest patients?

Hi Tony,
I share Wendy's view of the amazing work you and your team. Many thanks from a grateful nation.

> The literature suggests that those who are asymptomatic have lower levels of cytokines and those who are highly symptomatic have something of a cytokine storm. In the CART field uses anti-IL6 monoclonals to treat the CRS. I wonder if anti-IL6 would work for these patients. The literature describes steroid use but perhaps IL-6 is more targeted, less immunosuppressive and more effective. I see literature describing IL-6 as key in SARS but not anti-IL6 use. The Lancet paper showed some modest change in the IL-6 levels in the 2019-nCoV patients relative to other cytokines however it could be a central mediator none-the-less. I know there is no easy answer.

Best Wishes,

Wayne

Wayne Holman, MD
Founder & CEO
Ridgeback Capital
Co-Founder
Ridgeback Biotherapeutics
www.ridgebackcap.com
(b) (6)
(b) (6)

Cytokine. 2019 Mar;115:13-23. doi: 10.1016/j.cyto.2018.12.008. Epub 2019 Jan 4.

Decoding the enigma of antiviral crisis: Does one target molecule regulate all?

Mahmud-Al-Rafat A[1], Majumder A[2], Taufiqur Rahman KM[3], Mahedi Hasan AM[4], Didarul Islam KM[5], Taylor-Robinson AW[6], Billah MM[7].
Author information

Abstract

Disease fatality associated with Ebola, SARS-CoV and dengue infections in humans is attributed to a cytokine storm that is triggered by excessive pro-inflammatory responses. Interleukin (IL)-6 acts as a mediator between pro- and anti-inflammatory reactivity by initiating trans- and classical-signaling, respectively. Hence, IL-6 is assumed to provide a target for a broad range of antiviral agents. Available immunosuppressive antivirals are directed to control an often exaggerated pro-inflammatory response that gives rise to complex clinical conditions such as lymphocytopenia. It is known that IL-6, via its soluble receptor (sIL-6R), initiates a pro-inflammatory response while an anti-inflammatory response is triggered by the membrane-bound IL-6 receptor (IL-6R). Future antivirals should thus aim to target the mechanism that regulates switching between IL-6 trans- and classical-signaling. In this review, we propose that the tumour necrosis factor-α converting enzyme ADAM-17 could be the master molecule involved in regulating IL-6 class switching and through this in controlling pro- and anti-inflammatory responses to viral antigenic stimuli. Therefore, ADAM-17 should be considered as a potential target molecule for novel antiviral drug discovery that would regulate host reactivity to infection and thereby limit or prevent fatal outcomes.

Copyright © 2018 Elsevier Ltd. All rights reserved.

KEYWORDS:
ADAM-17; Antiviral; Cytokine storm; Dengue; Ebola; IL-6; Pro-inflammatory response; SARS-CoV; Virus

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the individual or entity to which it is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this message and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:00:26 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: coronavirus vaccine
Attachments: Codagenix-NewCoV.pptx

FYI

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 10:00 PM
To: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: FW: coronavirus vaccine

Please take a look at this and respond to this person one way or another.

-----Original Message-----
From: J. Robert Coleman [redacted] (b) (6)
Sent: Thursday, January 23, 2020 9:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: coronavirus vaccine

Dear Dr. Fauci

Thank you for responding to Dr. Norton, I am sure you are being pulled in many different directions.

[redacted] (b) (4)

Thank you for your time and I look forward to hearing from NIAID. Best Regards, Robert Coleman

On Thu, Jan 23, 2020 at 7:08 PM [redacted] (b) (6)> wrote:
>
> Thank you so much! We need all the smartest minds (like yours) we can focus on this issue, I suspect with trepidation.
>
> I am fine but working too hard. I know you know that syndrome too!
>
> I trust all is well with you too.
>

> All my best.
>
> Larry
>
>
>
> From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
> Sent: Thursday, January 23, 2020 6:04 PM
> To: Norton, Larry/President's Office (b) (6)>
> Cc: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
> Cassetti, Cristina (NIH/NIAID) [E] (b) (6)>
> Subject: [EXTERNAL] RE: coronavirus vaccine
>
>
>
> Larry:
>
> Thanks for the note. Have them send me some material and I will forward it to the appropriate people here at NIAID. I hope that all is well with you.
>
> Best regards,
>
> Tony
>
>
>
> Anthony S. Fauci, MD
> Director
> National Institute of Allergy and Infectious Diseases Building 31,
> Room 7A-03
> 31 Center Drive, MSC 2520
> National Institutes of Health
> Bethesda, MD 20892-2520
> Phone: (b) (6)
> FAX: (301) 496-4409
> E-mail: (b) (6)
>
> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.
>
>
>
> ==
>
> Please note that this e-mail and any files transmitted from Memorial
> Sloan Kettering Cancer Center may be privileged, confidential, and
> protected from disclosure under applicable law. If the reader of this
> message is not the intended recipient, or an employee or agent
> responsible for delivering this message to the intended recipient, you
> are hereby notified that any reading, dissemination, distribution,
> copying, or other use of this communication or any of its attachments
> is strictly prohibited. If you have received this communication in
> error, please notify the sender immediately by replying to this

> message and deleting this message, any attachments, and all copies and
> backups from your computer.

--

J. Robert Coleman, PhD, MBA
Chief Executive Officer
Co-founder, Codagenix, Inc.
3 Bioscience Park Drive
Farmingdale, NY 11735-0176
Phone: (b) (6)
(b) (6)

This e-mail (and any attachment) is intended solely for the use of the individual or entity to which it is addressed, and may contain proprietary, confidential or privileged information of Codagenix, Inc.
and/or its subsidiaries. If you are not the intended recipient of this e-mail, or responsible for delivering this e-mail to the intended recipient, you are hereby notified that any dissemination, distribution, copying or other action taken with respect to this e-mail is strictly prohibited. If you have received this e-mail in error, please notify the sender immediately and permanently delete the original and any copy.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:41:56 +0000
To: [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: from Dame Jillian Sackler

Dear Dame Sackler:
Thank you for your note. As you have probably already heard, the Chinese authorities have closed down the wet markets that sell exotic animals for consumption and are encouraging the population to avoid such consumption.
Best regards,
Tony

From: [redacted] (b) (6)
Sent: Friday, January 24, 2020 2:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: from Dame Jillian Sackler

Dear Dr. Fauci,

We met when you delivered the inaugural opening of The DJS Distinguished Lecture on Global Health Issues at the Foreign Policy Association. Thank you again. Of course the Sackler name has been completely destroyed - due to fake news: I have no opioid money, my husband Arthur had nothing to do with this scandal or any other nefarious behavior, he was a magnificent man.

Anyway, I have been involved with China for years, and have wondered why pathogens such as the Wuhan Coronavirus all seem to begin in China, considering India and other countries maintain unhygienic practices. I just read that Chinese health officials believe it originated at a market selling exotic live animals for food, such as crocodiles, rats, peacocks (more than 100 kinds of wildlife), they think the culprits may be snakes or bats. Perhaps your or another US health leader can pressure China to ban the merchandising and eating of wild animals.

Kind regards and happy Chinese Lunar New Year.

Dame Jillian Sackler

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 15:55:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Assistance/Guidance

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Hank Safferstein [redacted] (b) (6)>
Sent: Wednesday, January 29, 2020 9:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Assistance/Guidance

Dear Dr. Fauci,

I hope this email finds you well.

[redacted] (b) (4)

I was hoping to schedule a call with the appropriate person at NIAID to discuss in further detail.

Appreciate your help and thank you

Hank

--
Hank Safferstein, Ph.D., J.D., M.B.A.

CEO
Generian
Executive in Residence
Pittsburgh Life Sciences Greenhouse
2425 Sidney Street
Pittsburgh, PA 15203

[redacted] (b) (6) Direct
(b) (6) Mobile
412-770-1276 Fax
[redacted] (b) (6) *Email*
www.plsg.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 15:34:31 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Attachments: JAMA - Viewpoint on 2019 n-CoV - Paules, Marston and Fauci - 01-21-2020.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 02:55:37 +0000
To: Ali, Imran X. -ND
Subject: RE: Coronavirus..... Holy Cross Grad....

Imran:

Unfortunately, I am too swamped to do this right now. Sorry.

Best,
Tony

From: Ali, Imran X. -ND <Imran.X.Ali.-ND@abc.com>
Sent: Friday, January 24, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b)(6)
Subject: Coronavirus..... Holy Cross Grad....

Greetings Dr. Fauci,

I hope you remember me. This is Imran Ali the Holy Crow Graduate who has been inspired by your work throughout the years. We met on several occasions and you were interviewed for my podcast. We have been in touch ever since you gave me your autographed photo way back in 1999.

I know that you are extremely busy right now doing what you do best informing the public and our lawmakers in the Senate today. As you can see I am a contributor to ABC News as a freelancer. I was wondering if you could reply briefly to the following questions that I could include in an article that I can send to my editor for consideration next week:

1. SO FAR WE HAVE 63 PATIENTS UNDER INVESTIGATION FROM 22 STATES WITH 2 TESTING POSITIVE AS OG FRIDAY JAN 24TH, 11 ARE NEGATIVE, HOW WORRIED SHOULD THE AMERICAN PUBLIC BE?

2. CORONAVIRUS HAS BEEN AROUND FOR MANY YEARS BUT WHAT MAKES THIS STRAIN DIFFERENT?

3. DURING THE EBOLA OUTBREAK WE ONLY HAD ABOUT 700 PEOPLE ARRIVING TO THE US EVERY DAY BUT NOW WE HAVE ALMOST 10,000 PEOPLE COMING FROM CHINA EVERY DAY.... IS THERE ANY USE IN CURTAILING FLIGHTS?

4. JUST LAST YEAR USAID HAS CUT FUNDING TO THE "PREDICT" PROGRAM THAT WAS INSPIRED BY THE 2005 H5N1 BIRD FLU SCARE, WOULD THIS PROGRAM BE HELPFUL IN BETTER UNDERSTANDING THE CORONA VIRUS?

5. FINALLY, IN A RECENT ARTICLE IN THE JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION IT WAS MENTIONED THAT BACK WHEN THE SARS VIRUS OUTBREAK A DNA VACCINE TOOK ABOUT 20 MONTHS TO DEVELOP BUT SINCE THEN WE HAVE MRNA VACCINE TECHNOLOGY, HOW QUICKLY COULD WE POTENTIALLY SEE A VACCINE FOR THIS CORONAVIRUS STRAIN?

Thank you very Dr. Fauci for your time if you are able to answer these questions.... I totally understand if you are busy and need to defer this as this is an article that I am volunteering not necessarily assigned at the moment

Sincerely,

Imran

Imran Ali MD MS MPH

Physician Fellow ABC News Medical Unit

Office 212-456-2632

Cell [redacted] (b) (6)

Email Imran.X.Ali.-ND@abc.com

Personal Email: [redacted] (b) (6).

abc NEWS medical unit
Precise. Swift. Relevant.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 16:06:12 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Informal coronavirus teleconference, 29 January, 19.00 CET

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: RYAN, Michael J. [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 10:45 AM
To: Redfield, Robert R. (CDC/OD) <[redacted] (b) (6) [redacted] (b) (6) [redacted] ; David Heymann <[redacted] (b) (6) ; [redacted] (b) (6) ; Chris.Elias [redacted] (b) (6) [redacted] ; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) [redacted] (b) (6) [redacted] ; COX, Paul Michael [redacted] (b) (6) >; SHOC [redacted] (b) (6) ; GREIN, Thomas [redacted] (b) (6) >
Cc: GHEBREYESUS, Tedros Adhanom [redacted] (b) (6) >; SCHWARTLANDER, Bernhard F. [redacted] (b) (6) >; MINHAS, Raman [redacted] (b) (6)
Subject: Informal coronavirus teleconference, 29 January, 19.00 CET

Dear colleagues,

Dr Tedros would like to take the opportunity to informally discuss with you the ongoing 2019 novel coronavirus.

We are planning to host a teleconference today at 19.00 CET and will provide a dial-in number with a passcode.

If you face any difficulties with the dial-in number, please provide us with a contact number and we will attempt to dial you in.

Best,

Mike

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 15:42:16 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Speak with Dr. Fauci on the coronavirus?

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Sent: Tuesday, January 21, 2020 5:41 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Fwd: Speak with Dr. Fauci on the coronavirus?

Sent from my iPhone

Begin forwarded message:

From: Eileen O'Reilly <eileen@axios.com>
Date: January 20, 2020 at 8:17:07 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" < (b) (6)
Subject: Speak with Dr. Fauci on the coronavirus?

Hi Patricia:

Hope you had a nice holiday weekend.

Would Dr. Fauci have 10 minutes on Tuesday to speak about what we now know about the coronavirus linked to Wuhan?

Thanks,

Eileen O'Reilly, Axios
(b) (6)
eileen@axios.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:18:43 +0000
To: Gallo, Robert
Subject: FW: GVN

Sorry. Pressed "send" too soon. Let us discuss this next time we get together.
Best,
Tony

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thursday, January 23, 2020 10:17 PM
To: Gallo, Robert [redacted] (b) (6)
Subject: RE: GVN

Bob:
Thanks for the note.

From: Gallo, Robert <[redacted] (b) (6)>
Sent: Thursday, January 23, 2020 4:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: GVN

Hi Tony,

I want you to know GVN is very active internationally in the new coronavirus problem via its respiratory Watch Group.

[redacted] (b) (4)

Please let me know if you wish to discuss further.

Thanks and with my very best wishes,

Bob

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:19:56 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Wired article on Wuhan coronavirus

Please set up a call with this person. It can wait until next week.

From: Michele Cohen Marill [redacted] (b) (6)
Sent: Thursday, January 23, 2020 3:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Wired article on Wuhan coronavirus

Dr. Fauci,
I'm a writer with Wired, and I'm interested in writing about the Wuhan coronavirus and particularly about the issue of super spreaders and the potential they pose to greatly increase transmission. (I know that both SARS and MERS had important incidents of super spreading.) I would love to get your perspective on this issue. A key question is how to detect super spreaders—yet it seems like that is still not well-understood. I was also intrigued with a couple of points raised in your JAMA article—particularly, why are most coronaviruses so benign that we call them "the common cold" but then in recent years we are having outbreaks of much more serious disease? And how quickly could a vaccine be produced—and how effective would it likely be?

Would you be available to talk in the next few days? (This afternoon would be awesome, if that's possible. Or perhaps tomorrow late morning (10:30 or 11-ish?) or midday? Or please let me know if a different time would work.)

Here's a bit of my background: I'm a health and medical writer based in Atlanta and a regular contributor to Wired, Health Affairs, and Medscape. I have also written for Stat, Nature Medicine, and WebMD magazine, among other publications. Here are a couple of recent articles for Wired: https://www.wired.com/story/new-tests-use-epigenetics-to-guess-how-fast-youre-aging/ and https://www.wired.com/story/why-a-promising-potent-cancer-therapy-isnt-used-in-the-us/. More info about me is available on my website, www.michelemarill.com.

Thanks so much for your help!
-Michele

Michele Cohen Marill
Journalist/Writer
(404) 636-6021 (office)
[redacted] (b) (6) (cell)
[redacted] (b) (6)
www.michelemarill.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:01:02 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Attachments: WHO Bridge Calling Information.docx

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj (b) (6)>; Brundtland Gro Harlem (b) (6)>; Dzau Victor (b) (6); Chris.Elias (b) (6); Farrar Jeremy (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Fore Henrietta (b) (6)>; Gao Fu (b) (6); Gashumba Diane (b) (6)>; Kaag Sigrid (b) (6); Ilona Kickbusch (b) (6)>; Skvortsova Veronika (b) (6); Suzuki Yasuhiro (b) (6)>; Vega Morales Jeanette (b) (6)>; Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6) Toomas Palu (b) (6)>; Pate Muhamed (b) (6)>; RYAN, Michael J. (b) (6)>; SCHWARTLANDER, Bernhard (b) (6); Alex Harris (b) (6)>; Alveberg, Benedikte Louise (b) (6); Chiaki NOGUCHI (b) (6)>; Esveld Marja (b) (6) Esveld Marja (b) (6)>; Esveld Marja (b) (6)>; Gonggrijp Mette (b) (6) Julie.HALL < (b) (6)>; Kanarek Morgan (b) (6); Marston, Hilary (NIH/NIAID) [E] < (b) (6) Oleg Sonin (b) (6); Omar Abdi (b) (6); Amelie RIOUX (b) (6); Tore Godal < (b) (6)>; GABEDAVA, Tsira (b) (6)>; ROSS, Alex (b) (6); Banks Lynn (b) (6); Block Bruce (b) (6) Conrad Jane (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < (b) (6) Del Sol Dinia (b) (6)>; Diao Fay (b) (6)>; Elena Kirsanova (b) (6)>; Gahungu Zacharie (b) (6)>; Harikumar M K (b) (6); Harikumar M K (b) (6); Kabagire Christine (b) (6)>; KITA Yosuke (b) (6); Miller de Vega Teresa (b) (6)>; MURIUKI, Hilda Wairimu (b) (6)>; Muzenda Sindiso (b) (6); Sarah Belmir (b) (6); YU Bai (b) (6)
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 18:30:52 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: update on coronavirus?

Indeed, it happened 15 minutes after I sent you the e-mail. Embargoed until 3:00 PM ET

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: ([redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
Sent: Tuesday, January 21, 2020 1:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: update on coronavirus?

Thanks. Larry just gave me a heads up that your last sentence may have come true in WA.

Sent from my iPhone

On Jan 21, 2020, at 5:13 PM, Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) wrote:

Francsi:

Thanks for the note. There is definite person-to-person transmission. 15 heath care workers were infected in a Wuhan Hospital. We do not know about the degree of "sustained" person-to-person transmission. There have been 298 cases reported as of this AM with 6 deaths. The number is likely larger and is growing by the hour. We have already started working on a vaccine for the 2019 n-CoV. We are partnering with the Moderna Company using their mRNA vaccine platform. We should be in Phase 1 trials (unless there are unforeseen issues) within 3 months. We are also pursuing any cross-reactivity of mAbs that we developed for SARS to see if they could be used as therapeutics for n-CoV. Other drugs such as remdesivir and ritonavir have been tried with MERS and may be useful. We would however, need the isolates (we just have sequence) to test these. We are already screening entries from China at JFK, LAX and SFO. I would not be surprised if just like SARS and MERS we ultimately see an imported case in the USA.

Hope that this is helpful.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] < (b) (6)
Sent: Tuesday, January 21, 2020 10:59 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: update on coronavirus?

HI Tony,

I will be in a Davos session on Thursday where response to the coronavirus outbreak will be a topic. Paul Stoffels will be there, as will Tedros.

What's now the best information about person-to-person transmission and mortality risk? Can you give me a quick precis of what the US is doing about risks of the illness coming to our shores? What do we know about possible therapies? And what is the plan to utilize the fastest possible platform to work on a vaccine?

Thanks, and sorry to hit you with this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:28:35 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Interview on coronavirus

Please have me call him tomorrow.

From: John Lauerman (BLOOMBERG/ NEWSROOM:) <jlauerman@bloomberg.net>
Sent: Thursday, January 23, 2020 12:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Interview on coronavirus

Hi Dr. Fauci: How are you? I have a few more questions that I think you could really help with. WHO has been saying this is a much quicker, more thorough and more transparent reaction than with SARS. We're trying to put together some early information about when the coronavirus first came to light, what the responses were, and what kinds of action were taken. Would you have some time to talk about this today or tomorrow? I'd just want to get some details about what you heard and when; I'm sure you've been on the case for a while. Thanks and regards, JL

John Lauerman, Bloomberg News
3 Queen Victoria Street, London, UK
tel. +44 (0) 2035 251028 cell [redacted] (b) (6)
http://www.bloomberg.com
http://www.bloomberg.com/prognosis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:03:10 +0000
To: Paules, Catharine
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review （Chinese）

Please respond to this person.

From: Tao Sun (b) (6)
Sent: Friday, January 24, 2020 2:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Dear Prof. Anthony Fauci, here is a request from MIT Technology Review （Chinese）

Dear Prof. Anthony Fauci,

I am Tao Sun, a reporter from Beijing. I am currently writing reports for the MIT Technology Review （Chinese） .

JAMA published your article Coronavirus Infections—More Than Just the Common Cold, and Xinhua News Agency reported this article. Here are some questions I would like to ask you.

1 Some people think that it is not necessary to develop a new vaccine against SARS or coronavirus in Wuhan. The reason is that, firstly, there is no commercial interest to pharmaceutical manufacturers, and secondly, such outbreaks may not return after the extinction.
What do you think of these views?

2 For the Wuhan virus vaccine being developed, the epidemic is likely to be eliminated after three months, so is it still necessary to develop a vaccine?

3 You can talk about SARS. How much does a vaccine against SARS actually play?

Looking forward to your reply.

--
TAO SUN

DEEPTECH MIT Technology Review

(b) (6)

suntao@mittrchina.com

7th FL, Tower AB Office Park, 10 Jintong West Road, Chaoyang District, Beijing

http://www.mittrchina.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 23:58:30 +0000
To: Routh, Jennifer (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E]
Subject: RE: Media Inquiry

Looks fine. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Sent: Monday, January 27, 2020 10:45 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Billet, Courtney (NIH/NIAID) [E] < (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] < (b) (6) Folkers, Greg (NIH/NIAID) [E] (b) (6); Stover, Kathy (NIH/NIAID) [E] < (b) (6)
Subject: RE: Media Inquiry

Dr. Fauci –

I have drafted responses to Radio Free Asia for your review. Please let me know if you have edits. I will share the final version with the reporter on your behalf and I will note the responses are attributed to you.

Can we make medicine and vaccine against that virus? And if so, how long do you think is it going to take?
NIAID, part of the U.S. biomedical research agency NIH, has mobilized a research response to 2019-nCoV that builds on experience with SARS-CoV, MERS-CoV and other emerging pathogens. Scientists are continuing basic research to characterize the novel virus and understand how it causes disease, as well as developing diagnostics, vaccines and treatments.

We have begun early stage development of an mRNA (messenger RNA) vaccine for 2019-nCoV. mRNA vaccines direct the body's cells to express a protein to elicit a broad immune response including high levels of neutralizing antibodies. The expressed protein is designed based on knowledge of the virus structure, but the platform does not contain live or inactivated virus. The mRNA platform can be quickly adapted and manufactured efficiently. NIAID and its industry partner Moderna anticipate the 2019-nCoV vaccine will be ready for the first stage of clinical testing in the coming months.

Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?
At this stage it is difficult to predict how the virus will spread and cause disease in different regions. Experts around the globe are working to understand key epidemiological transmission features of 2019-nCoV and to characterize the severity and spectrum of disease. Certainly, a robust public health system that can effectively diagnose, isolate and care for patients and trace contacts is critical to controlling an emerging infectious disease.

Thanks,
Jen

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Sent: Sunday, January 26, 2020 9:57 PM
To: Billet, Courtney (NIH/NIAID) [E] < (b) (6)
Cc: Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: FW: Media Inquiry

Please have Jen prepare a response for me.

From: Albert Hong <honga@rfa.org>
Sent: Friday, January 24, 2020 10:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Media Inquiry

Hi,

I'm Albert Hong a reporter of the Radio Free Asia in Washington DC. I'm writing about new virus, called 2019 novel coronavirus (2019-nCoV). I want to ask you..

1)Can we make medicine and vaccine against that virus?
2)And if so, how long do you think is it going to take?
3)Do you think It will be even more lethal if that virus spread in a country with poor health environment such as North Korea?

Thank you and I'll be looking forward your comment.

Best,
Albert

Albert Hong
Broadcaster
Radio Free Asia- Korean Service
2025 M Street, NW., Washington DC 20036
Office (202) 266-4091

CONFIDENTIAL COMMUNICATION
This e-mail message is intended only for the use of the addressee and may contain information that is privileged and confidential. Any unauthorized dissemination, distribution, or copying is strictly prohibited.
If you receive this transmission in error, please contact network@rfa.org.

Visit us at www.rfa.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 21:48:41 +0000
To: Alice Park
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Time request

I called and left voice mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Alice Park <alice.park@time.com>
Sent: Tuesday, January 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Time request

Hi Dr. Fauci -- hope all is well, and happy new year!

I'm writing, as you can imagine, about the emerging coronavirus cases, w/the first reported case in the US (brought from Wuhan). I wanted to speak to you more generally about coronaviruses, what we know and how it typically transmits, what we've learned since SARS and MERS, and what if any specific challenges these viruses pose in terms of developing treatments or vaccines against them. Happy to talk whenever you have a few minutes, today or tomorrow. Best, Alice

PLEASE NOTE NEW PHONE NUMBER
Alice Park
TIME
(b) (6)
alice.park@time.com
@aliceparkny

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 03:32:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Hi Dr. Fauci - JAMA piece

Please set up a call.

From: Michelle Cortez (Cortez,Michelle) <mcortez@bloomberg.net>
Sent: Thursday, January 23, 2020 11:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Hi Dr. Fauci - JAMA piece

Hi Dr. Fauci -

I just read your JAMA piece on the importance of preparedness given the new coronavirus.

I'm wondering if you have a moment to discuss the effort, both before and since the latest outbreak. We are working on a Tick Tock of the situation and I think that effort - done before the latest virus emerged - would be a key piece.

Thanks so much -
Michelle
(b) (6)

Michelle Fay Cortez | Health-Science-Medical Technology | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:05:09 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Wuhan accelerated vaccine development- Codagenix

Please handle this. Thanks.

From: Wayne Koff [redacted] (b) (6)>
Sent: Thursday, January 23, 2020 10:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6) Steffen Mueller [redacted] (b) (6)
Subject: Wuhan accelerated vaccine development- Codagenix

Tony, Emily

[redacted] (b) (4)

All the best,

WK

Wayne C. Koff, PhD
President and CEO
Human Vaccines Project
One Penn Plaza, Suite 6178
New York, NY 10119

Phone: [redacted] (b) (6)
Email: [redacted] (b) (6)
Website: www.humanvaccinesproject.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:48:07 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Continuous Temperature Monitoring

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Ruth Phillips (b) (6)>
Sent: Tuesday, January 28, 2020 4:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Continuous Temperature Monitoring

Dear Dr. Fauci,

Blue Spark Technologies is the inventor of a wearable patient temperature monitoring patch called TempTraq (www.temptraq.healthcare). TempTraq is a soft, comfortable patch worn under the arm that provides a continuous patient temperature feed to a smart device or directly to a hospital's monitoring station and/or EHR via Bluetooth.

We currently partner with Doctors Without Borders to support their Ebola clinic in Butembo, DRC and Malaria clinics in Tanzania. University of Rochester Medical Center has also begun to use TempTraq in their Malaria clinics in Zambia and Malawi.

Several clinical trials were conducted that show that TempTraq can:

- Accurately monitor patient temperature
- Detect neutropenic fevers in oncology patients **up to three hours earlier than the standard of care**
- Enable remote patient fever monitoring that can enable earlier discharge for BMT Patients

With the recent Coronavirus outbreak, we were interested in getting your thoughts about the use of TempTraq for those patients that need remote monitoring. I would love to set up a call to discuss further. Please let me know if there is a good time to connect.

Sincerely,
Ruth

Ruth Phillips BSN, MS, OCN, BCMAS
Director, Medical Affairs
(b) (6)
(b) (6)
https://temptraq.healthcare/

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 23:13:09 +0000
To: Siegel, Marc
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Question

Marc:

Thanks for the note. Am stuck for a while in DC with the coronavirus situation. I will let you know about any future possibility of my coming up there.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Siegel, Marc [redacted] (b) (6)
Sent: Wednesday, January 22, 2020 7:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: Question

Just quoted you on Fox and Friends.
We want to know if you might be interested in coming to NYU to give Grand Rounds sometime over the next several weeks - on this coronavirus and vaccine candidate.
Grand Rounds are Wednesday mornings at 8 AM
It would be a great honor and pleasure to have you here.
We would of course cover all expenses and your fee.
Hope you will consider.
Marc

Sent from my iPhone

On Jan 22, 2020, at 5:52 AM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) wrote:

[EXTERNAL]

Marc:
You certainly can quote me.
Best regards,
Tony

From: Siegel, Marc [redacted] (b) (6)>
Sent: Tuesday, January 21, 2020 10:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: Question

thanks Tony!

hope I can quote you!

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Tuesday, January 21, 2020 10:00:21 PM
To: Siegel, Marc
Subject: RE: Question

[EXTERNAL]

Marc:
Thanks for the note. We are already working on a vaccine for the 2019 n-CoV. We have the sequence of the virus and are employing an mRNA vaccine platform in collaboration with the Moderna Company. We hope to have the candidate in Phase 1 trials within 3 months. You might remember that we actually developed a DNA vaccine for SARS (another coronavirus pathogen) several years ago and brought it through Phase 1 trials showing safety and immunogenicity. We never developed it further since the SARS outbreak was completely stopped by good public health measures. Bottom line is that there is a good chance that over time, we will develop a vaccine for this virus.
Best regards,
Tony

-----Original Message-----
From: Siegel, Marc [redacted] (b) (6)>
Sent: Tuesday, January 21, 2020 4:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Question

Tony
Any chance of a vaccine for this coronavirus?
I believe they were testing one in dogs.
Marc

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 03:09:30 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

OK. Have Steve sit in for us and de-brief us. You do the Moderna meeting.

From: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Sunday, January 26, 2020 10:08 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

It looks like it overlaps with the Moderna meeting. I will participate in whichever you tell me to (of course), but Steve Smith can listen into GPMB (and has been following/meeting with secretariat etc).

From: Anthony Fauci < [redacted] (b) (6)
Date: Sunday, January 26, 2020 at 10:01 PM
To: Hilary Marston < [redacted] (b) (6)
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY

Can you listen in on this? It overlaps with an AMA call.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Friday, January 24, 2020 9:39 AM
To: As Sy Elhadj [redacted] (b) (6)>; Brundtland Gro Harlem [redacted] (b) (6)>; Dzau Victor [redacted] (b) (6)>; Chris.Elias [redacted] (b) (6) Farrar Jeremy [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) Fore Henrietta [redacted] (b) (6) Gao Fu < [redacted] (b) (6)>; Gashumba Diane [redacted] (b) (6); Kaag Sigrid [redacted] (b) (6)>; Ilona Kickbusch [redacted] (b) (6) Skvortsova Veronika [redacted] (b) (6)>; Suzuki Yasuhiro [redacted] (b) (6)>; Vega Morales Jeanette [redacted] (b) (6)>; Vega Morales Jeanette < [redacted] (b) (6); VijayRaghavan Krishnaswamy < [redacted] (b) (6)
Cc: MAHJOUR, Jaouad [redacted] (b) (6)>; MINHAS, Raman [redacted] (b) (6); Toomas Palu [redacted] (b) (6)>; Pate Muhamed < [redacted] (b) (6)>; RYAN, Michael J. [redacted] (b) (6)>; SCHWARTLANDER, Bernhard F. < [redacted] (b) (6)>; Alex Harris [redacted] (b) (6)>; Alveberg, Benedikte Louise [redacted] (b) (6) Chiaki NOGUCHI [redacted] (b) (6)>; Esveld Marja [redacted] (b) (6); Esveld Marja [redacted] (b) (6)>; Esveld Marja [redacted] (b) (6)>; Gonggrijp Mette [redacted] (b) (6)>; Julie.HALL [redacted] (b) (6)>; Kanarek Morgan [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6) Oleg Sonin [redacted] (b) (6)>; Omar Abdi [redacted] (b) (6)>; Amelie RIOUX [redacted] (b) (6)>; Tore Godal [redacted] (b) (6)

GABEDAVA, Tsira <[redacted] (b) (6); ROSS, Alex [redacted] (b) (6)>; Banks Lynn
[redacted] (b) (6); Block Bruce [redacted] (b) (6); Conrad Jane
[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Del Sol Dinia
[redacted] (b) (6)>; Diao Fay [redacted] (b) (6) Elena Kirsanova
[redacted] (b) (6)>; Gahungu Zacharie [redacted] (b) (6)>; Harikumar M K
[redacted] (b) (6)>; Harikumar M K [redacted] (b) (6)>; Kabagire Christine
[redacted] (b) (6); KITA Yosuke [redacted] (b) (6)>; Miller de Vega Teresa
[redacted] (b) (6); MURIUKI, Hilda Wairimu [redacted] (b) (6)>; Muzenda Sindiso
[redacted] (b) (6); Sarah Belmir [redacted] (b) (6)YU Bai [redacted] (b) (6)
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:49:52 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: accelerated pathway to a coronavirus vaccine development
Attachments: career highlights.docx, CV GIM 2019.doc

Please handle. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: George Moonsammy [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 8:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: accelerated pathway to a coronavirus vaccine development

Dear Dr. Fauci:

I am writing you for two reasons;

a. Congrats to you and your team for the recent publication of the corona virus, very clear and concise.

[redacted] (b) (4)

[redacted] (b) (4)

George Moonsammy, PhD

M: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 02:46:58 +0000
To: Burklow, John (NIH/OD) [E]
Subject: RE: Press interviews

John:
Thank you for your kind note. It is much appreciated.
Best regards,
Tony

From: Burklow, John (NIH/OD) [E] (b) (6)>
Sent: Friday, January 24, 2020 2:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Press interviews

Hi, Dr. Fauci—

I know it goes without saying, but you do such a great job in your TV interviews on the Wuhan coronavirus! You deftly handle any question they throw at you, and they run the gamut!

John

John Burklow
Associate Director for Communications and Public Liaison
National Institutes of Health
1 Center Drive/Building 1
Room 344
9000 Rockville Pike
Bethesda, MD 20892
Phone (b) (6)
Cell: (b) (6)
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 10:46:12 +0000
To: Corey MD, Larry
Subject: RE: 702 / confidential

[redacted] (b) (5), (b) (4)

From: Corey MD, Larry [redacted] (b) (6)
Sent: Sunday, January 26, 2020 10:24 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: RE: 702 / confidential

[redacted] (b) (5), (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Sunday, January 26, 2020 7:16 PM
To: Corey MD, Larry [redacted] (b) (6)
Subject: RE: 702 / confidential

[redacted] (b) (5)

From: Corey MD, Larry < [redacted] (b) (6)
Sent: Sunday, January 26, 2020 5:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: 702 / confidential

Tony

[redacted] (b) (5), (b) (4)

(b) (3), (b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 15:32:26 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- BBC News - Taped on camera - Corona virus
Attachments: RE: Interview request: BBC News, Wuhan coronavirus

Producer: Lindle Markwell
Organization: BBC News
lindle.markwell@bbc.co.uk, Tel: (b) (6)
Subject: Wuhan coronavirus
Deadline: 1/31

Hi Patty,

If Dr. Fauci has free time on Friday, the BBC would like to send a small crew to do a 30-minute interview in his office. This would be taped for a TV segment. Is there a time when he could make this work?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:53:42 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Bloomberg TV Asia Daybreak (Live Skype hit at 6:30 pm ET)
Attachments: FW: Interview request: Wuhan Coronavirus, RE: Interview request: Wuhan Coronavirus, RE: Interview request: Wuhan Coronavirus

Jonah Davis
Bloomberg TV—Bloomberg Daybreak Asia
(b) (6)
Topic: Wuhan Coronavirus
jdavis57@bloomberg.net

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Jan 2020 16:19:25 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: Meeting with Nicki Lurie and Jerry Keusch re GPMB
Attachments: RE: time to discuss GPMB, RE: time to discuss GPMB, RE: time to discuss GPMB, Re: time to discuss GPMB

Jerry cell phone is [redacted] (b) (6)

From: Nicole Lurie [redacted] (b) (6)
Sent: Thursday, January 16, 2020 1:54 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Keusch, Gerald T < [redacted] (b) (6) >; Dzau, Victor J. [redacted] (b) (6)
Subject: time to discuss GPMB

Hi Tony and Hilary-
As you know from Victor, Jerry and I have been asked to write the chapter on the R&D ecosystem for the GPMB. We're in the process of putting together an early framing of this. But, its clear that our first stop needs to be to talk with you both, to get your input about any draft framing, issues you think need to be highlighted for the Board, progress, gaps, etc. We'd love to come out to NIAID sometime in the next two weeks and sit down with you. Might you be able to suggest some potential times--Jerry will try to fly down for the day. For me, other than Wednesday mornings when I have clinic, I can be pretty flexible.
Many thanks, in advance, and we very much look forward to seeing you both.

With warmest regards,
Nicki and Jerry

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:06:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - FOX Sean Hannity
Attachments: RE: [EXTERNAL] Fwd: Fox News request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 20:27:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: KPBS San Diego Public Radio & TV (taped via zoom with awwad)
Attachments: RE: ON AIR: Interview request: coronavirus outbreak

Shalina Chatlani
Science and Technology Reporter, KPBS
Work: 619-594-8142 **Cell**: (b) (6)

Shalina Chatlani
KPBS San Diego Public Radio & TV
(b) (6) | schatlani@kpbs.org
Subject: coronavirus vaccine research
Deadline: 6pm ET

Hi Patty,

This science reporter is asking for an update on NIAID coronavirus vaccine research in the form of a taped video conference to take 20 min max. The video would broadcast on KPBS Evening Edition, and the audio would broadcast on the local radio station as well. She has a tight deadline of 6pm ET tonight, but if a spokesperson is only available tomorrow, she is open to taping an interview then.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 21:16:04 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: i24 news - israeli news corona virus interview - (LIVE HIT BY LANDLINE PHONE 7:05 pm ET)
Attachments: Corona virus interview with Dr. Fauci

Interview is with Michelle Mikori

Adriana Guzman (booking agent)
i24NEWS Live Tonight
(b) (6)
(b) (6)
Topic: Wuhan coronavirus
Deadline: 7:00 or 9:00 EST

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 13:52:22 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- Call with Richard Hatchett CEPI re Coronavirus (B. Graham)
Attachments: RE: My notes from WHO SAG call this morning

Belated best wishes for 2020 and I hope this finds you well. In case helpful, I just wanted to share my notes from the WHO call this morning, which was convened on short notice and before US working hours, in light of the dramatic increase of cases and new cases in Beijing and South Korea over the weekend. On the call we also heard about new cases in Shanghai. I joined a bit late so am not sure if Hilary was on that call.

(b) (4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 20:53:19 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLd - Print Interviews - several calls
Attachments: RE: Interview request: Washingtonian Magazine, Wuhan coronavirus

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 19:12:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: The TODAY SHOW - pre tape 7:00 am - 7:15 am ET
Attachments: RE: TODAY Request Tomorrow 1/31, RE: TODAY Request Tomorrow 1/31, RE: TODAY Request Tomorrow 1/31, image001.png

I'm adding my colleagues here, Jane Marie and Tracy. They will handle the logistics of this!

Our contact number will be our control room, (b) (6)

Thank you!
Clare

CLARE E. HILER | NBC NEWS | 212-664-3639 | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:22:46 +0000
To: Howard Bauchner
Cc: Phil Fontanarosa;Paules, Catharine;Marston, Hilary (NIH/NIAID) [E];Fauci, Anthony (NIH/NIAID) [E]
Subject: Viewpoint
Attachments: Viewpoint on 2019 n-CoV - Paules, Marston and Fauci - 01-21-2020.docx

Howard:

As you may have noticed, I am in the middle of the activity associated with the 2019 novel CoV that has hit China and now (yesterday) has reached the United States. Even though the situation is evolving rapidly and is a moving target, I believe that we need to comment on this. I know that others are sending commentaries into other journals including the *New England Journal of Medicine*. My first choice is you guys and so I am sending this to you to see if you feel that we should do a Viewpoint at this time even though it is early in the game. I would hate to see us get scooped by others who are not involved, as we are knee-deep in this. What do you think? Many thanks.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 03:07:58 +0000
To: NIAID OD AM
Subject: FW: Tin-cupping for the 2020 International Summit in Genetics and Genomics
Attachments: ISHGG 2019_Agenda[1].pdf, ISHGG 2019_DIR report_Final[1][1].pdf, Annual Report 2018 10072019_Final[1].pdf
Importance: High

Let us discuss and obviously do this.

From: Kastner, Daniel (NIH/NHGRI) [E] (b) (6)>
Sent: Tuesday, January 21, 2020 9:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Kaur, Manjit (NIH/NHGRI) [E] (b) (6)>; Solomon, Ben (NIH/NHGRI) [E] (b) (6)
Subject: Tin-cupping for the 2020 International Summit in Genetics and Genomics
Importance: High

Hi Tony,

I hope all is well with you. I'm writing in my capacity as Scientific Director of the NHGRI to thank you for your generous support of the 2019 International Summit in Genetics and Genomics. Last year we hosted 34 participants from low to middle-income countries (LMICs, as defined by the World Bank in 2019) for this month-long program. To date, we have trained 105 healthcare professionals from 43 different countries. Please see attached details, including the most recent report and last year's agenda.

In short, the purpose of this trans-NIH initiative is to advance the field of Genetics and Genomics in resource-poor countries. The Summit also helps extend the reach of the NIH to the global community.

To continue the program in 2020, I'm hoping that you will extend your previous support of $20,000/year, and would appreciate if you would let us know if this is something that you are able and willing to do, so that we can work on documentation and logistics. In 2020 we hope to host 40 trainees. Each selected participant costs $20,000 to cover expenses such as travel, housing, and meals. We appreciate any amount we receive from you; sponsoring at least one full participant would be ideal.

Please let us know if you have any questions or if we can help in any way. I am cc'ing Manjit Kaur, who administers the program, and Ben Solomon, the new Clinical Director of NHGRI.

With my very best wishes,

Dan

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 18:18:44 +0000
To: Stacy Christiansen
Cc: Marston, Hilary (NIH/NIAID) [E];Paules, Catharine;Fauci, Anthony (NIH/NIAID) [E]
Subject: RE: Urgent: JAMA Viewpoint on HCoV
Attachments: JAMA - VP - Coronavirus - Paules, Martson, Fauci.pdf

Stacy:

Here it is. Very minor edits.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stacy Christiansen <Stacy.Christiansen@jamanetwork.org>
Sent: Wednesday, January 22, 2020 12:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Urgent: JAMA Viewpoint on HCoV
Importance: High

Hi Dr Fauci and Dr Marston.

Attached is your Viewpoint on the n-CoV. We would really like to publish it tomorrow morning.

Is it possible for you to review very quickly today? In the next hour or 2?

Thanks so much
Stacy

Stacy L. Christiansen, MA
Managing Editor, *JAMA*
Chair, *AMA Manual of Style*

New Edition

AMA MANUAL OF STYLE
A Guide for Authors and Editors

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:08:42 +0000
To: NIAID OD AM
Subject: FW: Invitation to present at the SD/CD meeting on Feb. 5
Attachments: SD-CDAgenda2-5-2020.docx

Let us discuss.

From: Wyatt, Richard G (NIH/OD) [E] [redacted] (b) (6)
Sent: Thursday, January 30, 2020 9:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Gottesman, Michael (NIH/OD) [E] [redacted] (b) (6); Holland, Steven (NIH/NIAID) [E] [redacted] (b) (6)>; Kleinman, Joe (NIH/OD) [E] [redacted] (b) (6)
Subject: Invitation to present at the SD/CD meeting on Feb. 5

Tony:

The Scientific Directors have asked if you could possibly give a brief scientific update on the new coronavirus and the status of the outbreak at their meeting with the Clinical Directors next Wednesday, Feb. 5 (draft agenda attached). They will be meeting in Wilson Hall, 9 -11 AM, and we are flexible on timing.

[redacted] (b) (5)

It would be frankly great if you had a few minutes to brief the SDs and CDs, but I know your schedule is overly full right now. If you can't do this, would you please recommend a colleague who might be able to fill in?

Thanks.

Richard

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:22:56 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: CONFIRMNNG GPMB Board Teleconference, Monday, 27 January, re: novel coronovirus
Attachments: WHO Bridge Calling Information.docx, GPMB Teleconference Agenda 27 January.pdf

Let us discuss.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Sunday, January 26, 2020 6:13 PM
To: As Sy Elhadj (b) (6)>; Brundtland Gro Harlem (b) (6)>; Dzau Victor (b) (6)>; Chris.Elias (b) (6); Farrar Jeremy (b) (6); Fauci, Anthony (NIH/NIAID) [E] < (b) (6) Fore Henrietta (b) (6)>; Gao Fu (b) (6) Gashumba Diane (b) (6) Kaag Sigrid (b) (6) Ilona Kickbusch (b) (6); Suzuki Yasuhiro (b) (6) ; Vega Morales Jeanette (b) (6); Vega Morales Jeanette (b) (6); VijayRaghavan Krishnaswamy (b) (6)>
Cc: MAHJOUR, Jaouad (b) (6); MINHAS, Raman (b) (6); Toomas Palu (b) (6)>; Pate Muhamed (b) (6)>; RYAN, Michael J. (b) (6)>; SCHWARTLANDER, Bernhard F. (b) (6)>; Alex Harris < (b) (6); Alveberg, Benedikte Louise (b) (6)>; Chiaki NOGUCHI < (b) (6)>; Esveld Marja (b) (6); Esveld Marja (b) (6)>; Esveld Marja (b) (6); Gonggrijp Mette (b) (6) Julie.HALL (b) (6); Kanarek Morgan (b) (6) Marston, Hilary (NIH/NIAID) [E] < (b) (6) Omar Abdi (b) (6); Amelie RIOUX (b) (6)>; Tore Godal (b) (6) GABEDAVA, Tsira (b) (6) ROSS, Alex (b) (6); Banks Lynn (b) (6)>; Block Bruce (b) (6); Conrad Jane (b) (6); Conrad, Patricia (NIH/NIAID) [E] < (b) (6) Del Sol Dinia < (b) (6)>; Diao Fay (b) (6) Gahungu Zacharie (b) (6)>; Harikumar M K (b) (6) Harikumar M K (b) (6); Kabagire Christine (b) (6) KITA Yosuke (b) (6); Miller de Vega Teresa (b) (6) MURIUKI, Hilda Wairimu < (b) (6); Muzenda Sindiso (b) (6); Sarah Belmir (b) (6); YU Bai (b) (6)
Subject: CONFIRMNNG GPMB Board Teleconference, Monday, 27 January, re: novel coronovirus
Importance: High

Dear GPMB Board Members,

We are confirming the teleconference tomorrow, **Monday 27 January 2020, 1500-1600 Geneva Time.**

Please find attached the agenda (replicated below) and for ease of reference the call-in numbers and participant code.

Please let us know if you have any questions

Thank you very much
GPMB Secretariat (on behalf of the co-Chairs)

GPMB Teleconference on the 2019-novel Coronavirus outbreak

Monday, 27 January 2020
15.00-16.00 Geneva time[i]

15.00 – 15.10 **1. Welcome and Roll call**

15.10 – 15.30 **Updates on the Novel 2019-Coronavirus outbreak**
2. Prof George Gao, Director, China CDC (10 min)
3. Dr. Mike Ryan, Executive Director, WHO/WHE (10 minutes)

15.30 – 16.00 **4. Discussion/Actions from the Board (30 minutes)**
- **Possible statement**

16.00 **Adjourn**

From: GPMB Secretariat
Sent: Friday, January 24, 2020 4:44 PM
Subject: RE: URGENT TIME CORRRECTION -- GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Importance: High

Dear GPMB Board members

We apologize -- please note there is a TIME CORRECTION for the call this **Monday 27 January. The call is at 1500-1600 Geneva time**

The call in details remain the same.

Thank you very much
GPMB Secretariat

From: GPMB Secretariat
Sent: Friday, January 24, 2020 3:39 PM
To: 'As Sy Elhadj' [redacted] (b) (6); 'Brundtland Gro Harlem' [redacted] (b) (6); 'Dzau Victor'

[redacted] (b) (6)>; 'Elias Chris' <[redacted] (b) (6) 'Farrar Jeremy'
[redacted] (b) (6) 'Fauci Anthony' <[redacted] (b) (6) 'Fore Henrietta'
[redacted] (b) (6)>; 'Gao Fu' [redacted] (b) (6); 'Gashumba Diane' [redacted] (b) (6)>; 'Kaag
Sigrid' [redacted] (b) (6); 'Kickbusch Ilona' [redacted] (b) (6)>; 'Skvortsova Veronika'
[redacted] (b) (6); 'Suzuki Yasuhiro' [redacted] (b) (6)>; 'Vega Morales Jeanette'
[redacted] (b) (6)>; 'Vega Morales Jeanette' [redacted] (b) (6); 'VijayRaghavan
Krishnaswamy' [redacted] (b) (6)
Cc: MAHJOUR, Jaouad <[redacted] (b) (6)>; 'Minhas Raman' [redacted] (b) (6)>; 'Palu Toomas'
[redacted] (b) (6)>; 'Pate Muhamed' [redacted] (b) (6)>; RYAN, Michael J.
[redacted] (b) (6); 'Schwartlander Bernhard' [redacted] (b) (6)>; 'Alex Harris'
[redacted] (b) (6) 'Alveberg Benedikte L.' [redacted] (b) (6)>; 'Chiaki
NOGUCHI' [redacted] (b) (6)>; 'Esveld Marja' [redacted] (b) (6); 'Esveld Marja'
[redacted] (b) (6)>; 'Esveld Marja ' [redacted] (b) (6) 'Gonggrijp Mette '
[redacted] (b) (6); 'Hall Julie' [redacted] (b) (6) 'Kanarek Morgan'
[redacted] (b) (6); 'Marston Hilary' [redacted] (b) (6) 'Oleg Sonin '
[redacted] (b) (6)>; 'Omar Abdi' [redacted] (b) (6); 'Rioux Amelie'
[redacted] (b) (6)>; 'Tore Godal' [redacted] (b) (6)>; GABEDAVA, Tsira [redacted] (b) (6)
'ROSS, Alex' <[redacted] (b) (6)>; 'Banks Lynn' [redacted] (b) (6)>; 'Block Bruce'
[redacted] (b) (6)>; 'Conrad Jane' [redacted] (b) (6)>; 'Conrad Patricia' <[redacted] (b) (6)
'Del Sol Dinia' [redacted] (b) (6)>; 'Diao Fay' <[redacted] (b) (6) 'Elena Kirsanova '
[redacted] (b) (6)>; 'Gahungu Zacharie' [redacted] (b) (6)>; 'Harikumar M K'
[redacted] (b) (6); 'Harikumar M K' [redacted] (b) (6)>; 'Kabagire Christine'
[redacted] (b) (6)>; 'KITA Yosuke' [redacted] (b) (6)>; 'Miller de Vega Teresa'
[redacted] (b) (6)>; 'Muriuki Hilda Wairimu' [redacted] (b) (6)>; 'Muzenda Sindiso'
[redacted] (b) (6)'Sarah Belmir' [redacted] (b) (6); 'YU Bai' <[redacted] (b) (6)>
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Proposed Board teleconference THIS MONDAY
Importance: High

Dear Board members,

As many of you, we are concerned about the Novel 2019-Coronavirus outbreak. We believe the Board has a role to play in supporting the response and encouraging countries to step up their preparedness activities, as well as to support WHO in their efforts.

As co-chairs of the GPMB we therefore suggest to hold a **teleconference** of the Board to discuss the outbreak.

An outcome of the call could be a GPMB statement supporting the response and highlighting crucial preparedness activities that should be undertaken, or other suggestions to be discussed.

We would suggest to hold the teleconference call on **Monday 27 January at 1400-1500 Geneva time**. This is the only time next week the Co-Chairs are available.

Attached is information for a telephone bridge for the call. We would appreciate it if you could please confirm your participation.

We will share with you shortly a more detailed agenda.

We look forward to hearing from you on this and thank you for your continued engagement.

Kinds regards,

Gro and As

---

[i] Please refer to email planning for the call to find call-in information.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 23:04:22 +0000
To: [redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: coronavirus vaccine

Larry:

Thanks for the note. Have them send me some material and I will forward it to the appropriate people here at NIAID. I hope that all is well with you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6)>
Sent: Thursday, January 23, 2020 11:24 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: [redacted] (b) (6)
Subject: coronavirus vaccine

I know you must be bombarded with stuff right now. [redacted] (b) (4)

Larry

Larry Norton, MD, FASCO, FAACR
Senior Vice President, Office of the President
Medical Director, Evelyn H. Lauder Breast Center
Norna S. Sarofim Chair of Clinical Oncology
Department of Medicine

Memorial Sloan Kettering Cancer Center
300 E. 66th Street, New York, NY 10065
T [redacted] (b) (6) (Admin) T [redacted] (b) (6)(Clinical) F 646.888.4924
[redacted] (b) (6)

www.mskcc.org

Please note that this e-mail and any files transmitted from Memorial Sloan Kettering Cancer Center may be privileged, confidential, and protected from disclosure under applicable law. If the reader of this message is not the intended recipient, or an employee or agent responsible for delivering this message to the intended recipient, you are hereby notified that any reading, dissemination, distribution, copying, or other use of this communication or any of its attachments is strictly prohibited. If you have received this communication in error, please notify the sender immediately by replying to this message and deleting this message, any attachments, and all copies and backups from your computer.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:49:18 +0000
To: Corey MD, Larry
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Talk today

Please handle this. I am literally drowning in coronavirus stuff. I was in the Situation Room of the White House for about 4 – 5 hours today.

-----Original Message-----
From: Corey MD, Larry [redacted] (b) (6)>
Sent: Tuesday, January 28, 2020 10:45 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: RE: Talk today

Ok understand ; looks like this Coronavirus has traction and is likely to stay around ; if they report 4500 there must be 20,000 at least and almost all person to person. Is the virus stable genetically therefore maximally adapted ?

(b) (4), (b) (5)

[redacted]

Ok that's my 3 cents worth.

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Tuesday, January 28, 2020 7:27 PM
To: Corey MD, Larry [redacted] (b) (6)>

Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: RE: Talk today

I will be tied up tomorrow as I was today with coronavirus. Please work with Patty about squeezing something in later in the day.

-----Original Message-----
From: Corey MD, Larry [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 1:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Talk today

[redacted] (b) (4), (b) (5)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 00:05:57 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Coronavirus talk work

The Tuesday afternoon before the talk on Wednesday, we need to make a slide showing the total number of cases and deaths.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, January 25, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Coronavirus talk work

Dear Dr. Fauci,

Spoke with Hilary, who told me you are looking at the coronavirus talk currently and let her know of a few edits. FYI, I also asked the Weddles to make slides of (just for consideration):

[redacted] (b) (5)

I won't add/change slides to the talk without talking to you first because I don't want to mess things up!

[redacted] (b) (6) fully wired, [redacted] (b) (6) but otherwise available. Should we touch base this afternoon to discuss additional edits/thoughts? Phone or email, whatever you prefer.

Sincerely

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892
Cell: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 22:14:02 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Coronavirus: Oy vey

John:
Can you call me at [redacted] (b) (6). It will take only a minute.
Thanks,
Tony

-----Original Message-----
From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Monday, January 20, 2020 5:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Graham, Barney (NIH/VRC) [E] <[redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E]
<[redacted] (b) (6)
Subject: FW: Coronavirus: Oy vey

Tony,

One item to point out is that while this falls exactly into Barneys predicted framework for pandemic response; i.e. a new Betacoronavirus - there are some risks to success.

Barney and team know how to express MERS and SARS viral spikes - using structural information to introduce a key stabilizing mutation. We think the same mutation will apply here - but we need to express the protein and test.

We think the likelihood of success is high enough - that we should move full speed ahead to make the mRNA.

We can stop by to update you in more scientific detail if useful

John

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Monday, January 20, 2020 1:32 PM
To: Jon LaPook [redacted] (b) (6)>
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>; Angelica Fusco <fuscoa@cbsnews.com>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Mascola, John (NIH/VRC) [E] <[redacted] (b) (6)>; Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: Coronavirus: Oy vey

Jon:
We are working with the Moderna company to put the gene for the spike protein of the 2019 n-CoV into an mRNA platform to develop a vaccine to go into Phase 1 trials. We did it with Zika with DNA in 3.25 months. We can probably go from sequence to Phase 1 with the mRNA platform in about 2 months. We are doing this at the Vaccine Research Center that you have previously visited. We can certainly arrange for you to visit some time and see directly what we are doing.
Best regards,
Tony

-----Original Message-----
From: Jon LaPook <[redacted] (b) (6)
Sent: Monday, January 20, 2020 1:21 PM

To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: amb@cbsnews.com; Kevin Finnegan <kpf@cbsnews.com>; Leigh Winick <WinickL@cbsnews.com>; Angelica Fusco <fuscoa@cbsnews.com>
Subject: Coronavirus: Oy vey

Hi Tony,
Deja vu all over again.
Of course, I'm following along closely. If there is an opportunity for me to get an inside look at what you and your team are doing, please let me know.

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:50:07 +0000
To: Jon LaPook
Subject: RE: All Fauci, all the time! Thanks again.

Will do.

-----Original Message-----
From: Jon LaPook (b) (6)
Sent: Tuesday, January 28, 2020 10:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: All Fauci, all the time! Thanks again.

Thanks so much, Tony. That means a lot coming from you! PLEASE ping me when you are next in NYC with time for a meal.

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 28, 2020, at 10:46 PM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6) wrote:

You did a great job on the interview with your colleagues on CBS This Morning.

-----Original Message-----
From: Jon LaPook (b) (6)>
Sent: Tuesday, January 28, 2020 8:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: All Fauci, all the time! Thanks again.

[https://pbs.twimg.com/profile_images/1147114353679843329/W3nIPg4K_normal.png] CBS This Morning (@CBSThisMorning<https://twitter.com/cbsthismorning?s=11>)
1/28/20, 8:25 AM<https://twitter.com/cbsthismorning/status/1222148703126982657?s=11>
The □@CDCgov□<https://twitter.com/@CDCgov□> has issued its strongest travel warning, urging Americans to avoid all nonessential travel to China.

□@CBSNews□<https://twitter.com/@CBSNews□> Chief Medical Correspondent Dr. Jon Lapook (□@DrLaPook□<https://twitter.com/@DrLaPook□>) joins us to discuss the ongoing research of the coronavirus. pic.twitter.com/Tl0GEjnrSA<https://t.co/Tl0GEjnrSA>

Download<https://twitter.com/download?ref_src=MailTweet-iOS> the Twitter app

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 23:03:19 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: ASM Biothreats session

Let us discuss this tomorrow.

From: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Monday, January 20, 2020 3:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Subject: FW: ASM Biothreats session

For discussion. Next Wednesday (the 29th), you are scheduled to give a 20 min/5 q&a talk at ASM Biothreats as part of a session entitled "Biothreats: How Prepared are We?" We had planned to do an Ebola Tale of Two Outbreaks talk. The organizers are asking if you can include the Wuhan virus in your talk. A few options here, [redacted] (b) (5).

[redacted] (b) (5)

As you consider, here are the recent talks you have given at ASM BioD. Despite the title, the 2017 talk was actually more of five prez talk, not the usual pandemic preparedness talk.

2015-02-11 ASM Biodefense and EID Mtg - Ebola in 2014-2015, perfect storm
2016-02-10 ASM Biodefense Meeting -- Zika Virus, a Pandemic in Progress
2017-02-07 ASM Biothreats Pandemic Preparedness - Learning from Experience
2019-01-31 ASM Biothreats Conference - Chasing Influenza

From: "Bloom, Marshall (NIH/NIAID) [E]" [redacted] (b) (6)
Date: Monday, January 20, 2020 at 12:47 PM
To: Patricia Conrad < [redacted] (b) (6) Hilary Marston < [redacted] (b) (6)

Cc: "Bloom, Marshall (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: ASM Biothreats session

Patty and Hilary,
The organizers of the conference would like ASF to devote part of his talk next Wednesday morning to the emerging Wuhan coronavirus and what NIAID is doing to respond even at this early date. Is this a possibility?
I saw the CNN interview from his office and it looked very nice.
Thanks very much.
Marshall
Division of Intramural Research
Chief, Biology of Vector-borne Viruses Section
Laboratory of Virology
Rocky Mountain Laboratories
National Institute of Allergy and Infectious Diseases
National Institutes of Health
903 South 4th Street
Hamilton, MT 59840
PHO: [redacted] (b) (6)
Cell: [redacted] (b) (6)
email: [redacted] (b) (6)
****

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 11:20:25 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus antibodies

Please handle.

From: Andrew Bradbury [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 11:22 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Coronavirus antibodies

Dear Dr. Fauci

I read your recent viewpoint in JAMA with great interest.

(b) (4)
[redacted]

Best wishes

Andrew

Andrew Bradbury, CSO | Specifica Inc.

Land [redacted] (b) (6)
Cell

Office:
1512 Pacheco Street, Suite A203
Santa Fe NM 87505

Laboratory:
NMC Biological Laboratory
100 Entrada Drive
Los Alamos NM 87544

www.Specifica.bio

The information contained in this e-mail is for the exclusive use of the intended recipient(s) and may be confidential, proprietary, and/or legally privileged. Inadvertent disclosure of this message does not constitute a waiver of any privilege. If you receive this message in error, please do not directly or indirectly use, print, copy, forward, or disclose any part of this message. Please also delete this e-mail and all copies and notify the sender.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 00:54:05 +0000
To: (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus concerns on campus

Kent:

Thanks for the note. The students will almost certainly go through enhanced screening at a USA airport upon entry . They will receive educational material telling them what they should be doing. If you want the details of this, you should contact the CDC. The key person in charge of this at CDC is Dr. Martin Cetron.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: (b) (6)
Sent: Wednesday, January 29, 2020 9:49 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Coronavirus concerns on campus

Tony,

It was reassuring hearing you on NPR and other news programs.

With students from American, Georgetown and George Washington University being told to return from China due to Coronavirus, what protocols should be in place on campus and in the neighborhood?

An article in today's Washington Post said some students have been quarantined for two weeks before starting classes in China. Should they do the same before they join their classmates here? Most of the Georgetown, GW and AU students probably live on campus, but some live in the neighborhood.

https://www.washingtonpost.com/world/asia_pacific/coronavirus-china-live-updates/2020/01/29/d49b9194-423b-11ea-b503-2b077c436617_story.html#link-SRBFEVBXQM6MXN24FB2MVDQF5E

What are the appropriate quarantine protocols? Who is responsible for setting up the protocols? Should we start wearing masks? Are we prepared for this?

Keep up the good work.

Kent Slowinski

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:28:40 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: update on coronavirus?

Embargoes are becoming a joke. CNN and NY Times both broke it.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] <(b) (6)
Sent: Tuesday, January 21, 2020 2:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Re: update on coronavirus?

And that embargo clearly didn't hold!

Sent from my iPhone

> On Jan 21, 2020, at 7:30 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6) wrote:
>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 03:01:39 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: coronavirus

NIAID inquiries, please.

From: Randy Cron, M.D. [redacted] (b) (6)>
Sent: Friday, January 24, 2020 4:31 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: coronavirus

Hi Dr. Fauci:

I wonder if therapy (anti-interferon-gamma, rhIL-1R antagonist) for cytokine storm syndromes will benefit patients with the current coronavirus outbreak.

An interferon-gamma-related **cytokine storm** in SARS patients.
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY.
J Med Virol. 2005 Feb;75(2):185-94.
Delayed induction of proinflammatory **cytokines** and suppression of innate antiviral response by the novel Middle East respiratory syndrome **coronavirus**: implications for pathogenesis and treatment.
Lau SK, Lau CC, Chan KH, Li CP, Chen H, Jin DY, Chan JF, Woo PC, Yuen KY.
J Gen Virol. 2013 Dec;94(Pt 12):2679-90.
Current and future developments in the treatment of virus-induced hypercytokinemia.
Wong JP, Viswanathan S, Wang M, Sun LQ, Clark GC, D'Elia RV.
Future Med Chem. 2017 Feb;9(2):169-178.
Pathogenic human **coronavirus** infections: causes and consequences of **cytokine storm** and immunopathology.
Channappanavar R, Perlman S.
Semin Immunopathol. 2017 Jul;39(5):529-539.
Severe acute respiratory syndrome **coronavirus** ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3-dependent ubiquitination of ASC.
Siu KL, Yuen KS, Castaño-Rodriguez C, Ye ZW, Yeung ML, Fung SY, Yuan S, Chan CP, Yuen KY, Enjuanes L, Jin DY.
FASEB J. 2019 Aug;33(8):8865-8877.

Sincerely,

Randy

Randy Q. Cron, MD, PhD
Professor of Pediatrics & Medicine
Arthritis Foundation, Alabama Chapter, Endowed Chair
Director, Division of Pediatric Rheumatology
Children's Hospital of Alabama/
University of Alabama at Birmingham
Children's Park Place N., Ste. G10
1601 4th Avenue South
Birmingham, AL 35233

Tel.: (b) (6)
Email: (b) (6)
FAX: (205) 638-2875

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 23:42:59 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Billet, Courtney (NIH/NIAID) [E];Stover, Kathy (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: RE: For review (due to HHS for White House by 8:30 tonight): press conference talking points
Attachments: Talking Points for NIAID Director Dr. Fauci - press conference - 01-28-2020.docx

Here it is with my minor edits. Thanks!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, January 27, 2020 6:14 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6) Stover, Kathy (NIH/NIAID) [E] < [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: For review (due to HHS for White House by 8:30 tonight): press conference talking points

Dr. Fauci –

You will be making brief remarks at the HHS press conference tomorrow. HHS has requested your talking points by 8:30 tonight. (They are really just a placeholder for the White House to have something and so they are not surprised by any news). I have attached proposed points and pasted them below.

Please let me know if you have edits. I will send the final version to HHS tonight.

Thanks,
Jen

Talking Points for NIAID Director Anthony S. Fauci, M.D.

HHS Press Conference on Coordinated Public Health Response to 2019 Novel Coronavirus

(b) (5)

[redacted]

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:10:15 +0000
To: Billet, Courtney (NIH/NIAID) [E]
Subject: FW: Coronavirus Expert Needed For Romper Article

NIAID inquiries, please.

From: Lindsay Mack (b) (6)>
Sent: Friday, January 24, 2020 2:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Coronavirus Expert Needed For Romper Article

Hello Dr. Anthony S. Fauci,

I'm writing an article for Romper about the coronavirus, and I need some input from an expert. Would you respond to the following questions via email by the end of day this Monday, Jan 27? I will be happy to include info about your work in the piece as well.

What exactly is the coronavirus, and why has it been such a news story lately?

Are there any precautions against coronavirus that people in the US should take now? For the most part, is coronavirus not worth stressing about, or should people be on alert about this virus?

What do you wish more people knew about coronavirus in general?

Thank you,

Lindsay Mack

www.romper.com

Romper is a part of theBustle Media Group, the largest premium publisher reaching millennial women. Nearly 80 million readers a month rely on the Bustle Media Group for info about everything from pop culture to relevant social interests.

--
Lindsay Mack
Freelance Writer
(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:09:44 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Routh, Jennifer (NIH/NIAID) [E]
Subject: RE: interview request: LA Times Emily Baumgaertner

Done!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Monday, January 27, 2020 7:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Fwd: interview request: LA Times Emily Baumgaertner

Sent from my iPhone

Begin forwarded message:

From: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: January 27, 2020 at 6:58:01 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" < [redacted] (b) (6) NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: LA Times Emily Baumgaertner

This is a different LA Times request—please send this one for ASF consideration rather than prior Melissa Healy request. Emily said she will patch in Melissa to the same line if they need to. Emily said she is available on her cell below tonigh.

Emily Baumgaertner, MPH

Los Angeles Times
Cell: [redacted] (b) (6)

Her note: I hope you're well. I'd love to speak briefly by phone with Dr. Fauci regarding what would need to be done in the event that coronavirus isn't quickly contained. Lots of experts discussing what it would look like to accelerate vaccine development and scale up protective work quickly -- but it would be excellent to ask the expert! Around the rest of the day.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct: [redacted] (b) (6)
[redacted] (b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 00:47:25 +0000
To: Mascola, John (NIH/VRC) [E]
Subject: RE: Wuhan sample

You and Barney should initiate and if there is any resistance, let me know and I will speak with Bob. I will also mention casually to Bob that you guys are trying to work with his people to accomplish this, just to give him a heads-up.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)
Sent: Tuesday, January 21, 2020 7:43 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>
Subject: RE: Wuhan sample

Agree. Do you want me an Barney to initiate or do you want to involve Bob Redfield?

From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Tuesday, January 21, 2020 7:32 PM
To: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Subject: RE: Wuhan sample

We should talk with the CDC about [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520

National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Mascola, John (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Tuesday, January 21, 2020 2:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>
Subject: Wuhan sample

https://www.nytimes.com/2020/01/21/health/cdc-coronavirus.html

Tony,

[redacted] (b) (5)

John

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:11:25 +0000
To: Arnold Vera
Subject: RE: Coronavirus infections (CoVs)

At least 14 days.

-----Original Message-----
From: Arnold Vera <[redacted] (b) (6)>
Sent: Friday, January 24, 2020 6:30 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Coronavirus infections (CoVs)

Dear Dr.Faucy,
Thank you for the excellent information regarding CoVs. Do you recommend for a quarantines time of person expose and arriving at USA from epidemic areas .Thank you , very much. Arnold Vera, MD., MSc.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:39:34 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: [EXTERNAL] Fwd: Fox News request

Done

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 7:28 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6) Woloshin, Stephanie <stephanie.woloshin@FOXNEWS.COM>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Hi Patricia!

Copying my colleague Stephanie.

We wanted to confirm Dr. Fauci's titles for his name banners. Also would you mind sending over a few talking points about the virus/treatment etc?

Thanks,
Hayley

From: Caronia, Hayley
Sent: Monday, January 27, 2020 6:21 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: RE: [EXTERNAL] Fwd: Fox News request

Yes! I have all of that info. Thanks!!

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Monday, January 27, 2020 6:19 PM
To: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: RE: [EXTERNAL] Fwd: Fox News request

Great- Dr. Fauci will be ready at 9:40 pm ET for the hit - thank you – reconfirming address is [redacted] (b) (6) Dr. Fauci's home phone is [redacted] (b) (6) and cell is [redacted] (b) (6)

Also adding him here on email.

Thank you

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 6:15 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: [EXTERNAL] Fwd: Fox News request

All confirmed for tonight. I spoke with the truck operator and he knows to call upon arrival. Thanks so much!

HAYLEY CARONIA "HANNITY"
C: (b) (6) ◦ O: 212.301.3275

On Jan 27, 2020, at 4:58 PM, Caronia, Hayley <hayley.caronia@foxnews.com> wrote:

Yes! If anything changes I will let you know. It's 95% firm. Just have to have Sean confirm after radio. Thanks for your patience!!

Sent from my iPhone

On Jan 27, 2020, at 4:56 PM, Conrad, Patricia (NIH/NIAID) [E] < (b) (6) wrote:

Thank you – still 9:40 pm ET live hit with Sean Hannity?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 4:49 PM
To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] (b) (6)
Subject: Re: [EXTERNAL] Fwd: Fox News request

The truck operator is named Oran: (b) (6)

HAYLEY CARONIA "HANNITY"
C: (b) (6) ◦ O: 212.301.3275

On Jan 27, 2020, at 4:18 PM, Caronia, Hayley <hayley.caronia@foxnews.com> wrote:

Sure, I'll have them call upon arrival. Thanks!

HAYLEY CARONIA "HANNITY"
C: [redacted] (b) (6) ◦ O: 212.301.3275

On Jan 27, 2020, at 4:10 PM, Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
wrote:

Ok Thank you

Dr. Fauci's home phone is [redacted] (b) (6) and cell is [redacted] (b) (6). Will you call when the truck is outside?

My cell in case you need me is [redacted] (b) (6)

Thank you.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Caronia, Hayley <hayley.caronia@FOXNEWS.COM>
Sent: Monday, January 27, 2020 4:03 PM

To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] < (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C]
(b) (6)>
Subject: RE: [EXTERNAL] Fwd: Fox News request

Hi!

As of right now, Dr. Fauci will be in the D block at 9:40 PM ET. There will be a quick one minute reporter hit before the interview.

D BLOCK - CORONAVIRUS SCARE // HOW TO CONTAIN THE CORONAVIRUS?
FOX NEWS: CDC: 110 SUSPECTED CORONAVIRUS CASES IN US UNDER INVESTIGATION, NUMBER 'WILL ONLY INCREASE'
https://www.foxnews.com/health/cdc-110-suspected-coronavirus-cases-in-us-under-investigation-number-will-only-increase

NY TIMES: AS CORONAVIRUS FEARS INTENSIFY, EFFECTIVENESS OF QUARANTINES IS QUESTIONED
https://www.nytimes.com/2020/01/26/world/asia/coronavirus-wuhan-china-hubei.html

FOX NEWS: CORONAVIRUS CAN BE SPREAD DURING INCUBATION PERIOD, CHINESE OFFICIAL CLAIMS
https://www.foxnews.com/health/coronavirus-spread-during-incubation-period-chinese-official-claims

TRACE GALLAGHER REPORTER HIT ((LA BUREAU))
THEN...
GUEST: DR. ANTHONY FAUCI, DIRECTOR OF THE NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES ((DC BUREAU))

From: Caronia, Hayley
Sent: Monday, January 27, 2020 2:54 PM
To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Deatrick, Elizabeth (NIH/NIAID) [C]
(b) (6)
Subject: Re: [EXTERNAL] Fwd: Fox News request

Amazing. Booking it now. Thank you!

Will send over hit time as soon as I can.

HAYLEY CARONIA "HANNITY"
C: (b) (6) ◦ O: 212.301.3275

On Jan 27, 2020, at 2:48 PM, Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
wrote:

Wow...ok that would be great.

Address is [redacted] (b) (6)
[redacted] (b) (6)

Please send us your crew name and cell numbers and hit time as soon as possible.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.
without defect.

This message and its attachments may contain legally privileged or confidential information. It is intended solely for the named addressee. If you are not the addressee indicated in this message (or responsible for delivery of the message to the addressee), you may not copy or deliver this message or its attachments to anyone. Rather, you should permanently delete this message and its attachments and kindly notify the sender by reply e-mail. Any content of this message and its attachments that does not relate to the official business of Fox News or Fox Business must not be taken to have been sent or endorsed by either of them. No representation is made that this email or its attachments are without defect.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 04:14:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus epidemic in China
Attachments: Viruses Presentation 012220.pdf

Please handle. Thanks.

From: Kucuk, Omer [redacted] (b) (6)
Sent: Friday, January 24, 2020 9:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: omer kucuk [redacted] (b) (6)
Subject: coronavirus epidemic in China

Dear Dr. Fauci,

My friend Kieu Hoang is a business man with companies in Los Angeles and Shanghai. Kieu has a nutritional product that has remarkable anti-viral activity (see attached) and could potentially benefit people with coronavirus infection. He is willing to provide the product which is produced at his FDA approved GMP facility in Los Angeles.

If you are interested, I would be happy to give you Kieu's contact information.

All the best,

Omer

Ömer Küçük, MD
Professor of Hematology-Oncology and Urology
Correll Chair in Genitourinary Cancer
Director, Emory Integrative Health and Medicine Center
Director, Multidisciplinary Genitourinary Oncology Group
Chief, Genitourinary Medical Oncology Service
Leader, Prostate Cancer Research Program
Georgia Research Alliance Distinguished Scientist
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Atlanta, GA 30322
Email: [redacted] (b) (6)
Mobile: [redacted] (b) (6)

This e-mail message (including any attachments) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. If the reader of this message is not the intended recipient, you are hereby notified that any dissemination, distribution or copying of this message (including any attachments) is strictly prohibited.

If you have received this message in error, please contact
the sender by reply e-mail message and destroy all copies of the
original message (including attachments).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 00:40:25 +0000
To: Johnson, Richard Allen,M.D.
Subject: RE: 01.27 Monday

Dick:

Very busy. I hope that you are well.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Johnson, Richard Allen,M.D. (b) (6)
Sent: Monday, January 27, 2020 6:37 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6) (b) (6)
Subject: 01.27 Monday

Hi, Tony,

You must be busy. I am expecting to see you on the news discussing coronavirus outbreak.

Best wishes,
Dick

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 03:02:28 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: interview request: coronavirus AND HIV

Done.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Tuesday, January 21, 2020 1:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: FW: interview request: coronavirus AND HIV

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, January 21, 2020 1:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) NIAID FOG <fog@niaid.nih.gov>
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: interview request: coronavirus AND HIV

Betsy McKay
Wall Street Journal
[redacted] (b) (6)
betsy.mckay@wsj.com

Betsy would like to speak with ASF after 3 p.m. today about

1. Novel coronavirus (she is aware of CDC call)
2. HIV papers coming out in Nature tomorrow (see attached)

Laura Leifman can provide additional information on the Nature papers as requested – I believe we are issuing a news release about this research tomorrow.

For awareness, if ASF would like to speak with Betsy, we're going to send this as two separate clearance requests for organizational purposes.

Jennifer Routh [E]
News and Science Writing Branch
Office of Communications and Government Relations
National Institute of Allergy and Infectious Diseases (NIAID)
NIH/HHS
31 Center Drive Room 7A17C
Bethesda, MD 20892
Direct (b) (6)
(b) (6)

Disclaimer: The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 03:36:28 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: News - Germ/Virus Containment

Please handle.

From: [redacted] (b) (6)>
Sent: Wednesday, January 29, 2020 1:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: News - Germ/Virus Containment

Hi Dr. Fauci,

I have been following the news and some interviews with yourself. I was hoping you would be willing to speak with me about our technology?

We have the only GERM CONTAINMENT TECHNOLOGY of it's kind.

The ongoing Coronavirus and FLU viruses pose a significant threat to public health globally and here in the US.
We have the most powerful solution to minimize infection and maximize protection against SARS, EBOLA, FLU, and all types of germs and viruses.

With local 3rd party tested efficacy of 100%, no other technology anywhere can yield this result or sustainable 24/7/365 protection.

XTIO2 is a world exclusive containment technology with self-cleaning functions that can help minimize the risk of cross-contamination in hospitals, planes, public transportation, elevators, and public places.

XTIO2 technology works by forming an invisible protective layer on mostly ALL material surfaces (plastic, steel, glass, fabric, paper, walls, etc...). It is green, sustainable, and has yielded up to 100% efficacy proven by SGS LABS (US).

I look forward to hearing from you and sending you an information file for your review.

Thank you,

Michael Holbert

Cleancoating LLC
2522 State Rd., BLDG ISPBC
Bensalem, PA 19020
http://www.cleancoating.us
Email: (b) (6)
Direct: (b) (6)
Mobile: (b) (6)

DISCLAIMER
This e-mail message is intended for sole use of the above named recipient(s). If you are not the intended recipient, you may not review, copy or forward this e-mail message. If you have received this communication incorrectly, please notify Clean Coating Technologies LLC immediately via e-mail or phone and delete the message accordingly.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 13:08:59 +0000
To: Howard Bauchner
Subject: RE: Thank You

Howard:
Thank you for your kind note. Much appreciated.
Best regards,
Tony

From: Howard Bauchner <Howard.Bauchner@jamanetwork.org>
Sent: Saturday, January 25, 2020 5:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Phil Fontanarosa <Phil.Fontanarosa@jamanetwork.org>
Subject: Thank You

Tony

Can't thank you enough for getting in touch and submitting the coronavirus piece.

60,000 views in less than 2 days. Suspect will pass 100,000 views this week.

NYT and others doing a great job on the quarantine, deaths, etc – but this piece provides the science.

Again, many thanks – not sure any one else could have written it with such clarity.

HCB

Howard Bauchner, MD
Editor in Chief of JAMA and the JAMA Network

Please respect the confidentiality of this email

Listen to my chats with authors

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 03:38:28 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: ASM Biothreats 2019-nCoV

Please handle. Thanks.

From: Boltz David [redacted] (b) (6)>
Sent: Wednesday, January 29, 2020 2:23 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: ASM Biothreats 2019-nCoV

Dear Dr. Fauci,

My is David Boltz and I am a virologist at IIT Research Institute. I am attending the ASM Biothreats conference and want to thank you for the informative and up to date talk this morning about the novel coronavirus (2019-nCoV). I agree that the number of cases is likely 10-100X what has been reported.

Your presentation reminded me of a game my son plays called Plague Inc as the outbreak of the 2019-nCoV appears to be playing out like the game. If you are not familiar with the game, in the game the player is pathogen trying to infect the world's population. To achieve your goal, you make the pathogen more transmissible and increase the types and severity of clinical symptoms while the governments of the world shut down airports and perform research to study the pathogen and make a vaccine. Once the vaccine is made, the pathogen/player loses. Thus far, the current real life efforts to contain the spread of the virus and develop the vaccine would ultimately stop the pathogen in the game.

(b) (3) (A), (b) (4)

[redacted]

Thank you for time.

Best Regards,

David A. Boltz, Ph.D

Senior Virologist

IIT Research Institute

10 West 35th Street

Chicago, IL 60616

Ph: (b) (6)

(b) (6)

The information contained in this e-mail and any attached documents are confidential, may be privileged, and are intended solely for the persons or entities to whom the e-mail is addressed. Unauthorized review, use, disclosure, or copying of this communication, or any part thereof, is strictly prohibited and may be unlawful. If you have received this e-mail in error, please return the e-mail and attachments to the sender and delete the e-mail and attachments and any copy from your system.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 18:51:42 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Interview with Dr. Fauci about novel coronavirus spreading in China

I called and left voice mail

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Saturday, January 25, 2020 1:35 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Fwd: Interview with Dr. Fauci about novel coronavirus spreading in China

Sent from my iPhone

Begin forwarded message:

From: "Oplinger, Anne (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: January 25, 2020 at 1:08:09 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <[redacted] (b) (6)
Cc: NIAID COGCORE <COGCORE@mail.nih.gov>, NIAID Media Inquiries <mediainquiries@niaid.nih.gov>
Subject: Fwd: Interview with Dr. Fauci about novel coronavirus spreading in China

Patty. See below for asf. Wants phone call before Monday if possible.

Anne A. Oplinger
NIAID News Branch
National Institutes of Health
Sent from my iPhone
Any typos are yours to keep.

Begin forwarded message:

From: "Sheikh, Knvul" <knvul.sheikh@nytimes.com>
Date: January 25, 2020 at 12:52:47 PM EST
To: (b) (6)
Subject: Interview with Dr. Fauci about novel coronavirus spreading in China

Hi Anne,

My name is Knvul Sheikh and I'm a science reporter at The New York Times. I was hoping to speak with Dr. Anthony Fauci about the coronavirus currently spreading in China and a few other countries.

I'm interested in understanding the human backstory of how U.S. scientists got involved in ID'ing the virus and/or developing a test to diagnose the new virus. I understand Chinese scientists posted the genetic sequence of the virus on an NIH database sometime on Friday night, Jan. 17, so I wanted to ask Dr. Fauci about the next steps that his team took to understand the nature of the new virus.

Please let me know if he has time to speak over the phone tomorrow or early Monday morning. I'm on a tight deadline, trying to get some context for a story by Monday morning, Jan. 27.

Thanks and best regards,
Knvul

—

Knvul Sheikh
(Pronunciation: kah-vl shake)
Science & Health Reporter

620 Eighth Avenue
New York, NY 10018
(b) (6)
knvul.sheikh@nytimes.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:08:57 +0000
To: Grady, Christine (NIH/CC/BEP) [E]
Subject: FW: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.

With the POTUS.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b)(6)>
Sent: Wednesday, January 29, 2020 11:05 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.



Donald J. Trump
@realDonaldTrump

Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China. We will continue to monitor the ongoing developments. We have the best experts anywhere in the world, and they are on top of it 24/7!

7:06 PM · Jan 29, 2020 · Twitter for iPhone

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 02:26:08 +0000
To: Daniel Bednarik
Cc: Cassetti, Cristina (NIH/NIAID) [E]
Subject: RE: Hello and Idea

Dan:

Thanks for the note. I will pass this on to our program people. All is well here. I hope the same for you.
Best regards,
Tony

From: Daniel Bednarik (b) (6) >
Sent: Monday, January 27, 2020 1:21 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Hello and Idea

Dear Tony:

It has been a long time since we last communicated. I listened carefully to your NPR interview this morning which was very clear and I think understandable by the lay public. This triggered a thought, which might be a long shot. The coronaviruses typically express a viroporin or pH-sensitive ion channel that is required for budding of new particles and sometimes for de novo infection. There is evidence that the SARS-CoV is inhibited by amantadine, that age old drug used to block the M2 channel in flu. By analogy, could one also consider amantadine prophylactically for this virus?

I hope you are well; I often interact with (b) (6)

Best,

Dan Bednarik

--
Daniel Bednarik, Ph.D.
Senior Vice President
Molecular Engineering & Protein Design
NexImmune, Inc.
9119 Gaither Road
Gaithersburg, MD 20877
Phone: (b) (6)
Email: (b) (6)
Web: www.neximmune.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 20:09:24 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Coronavirus talk work

OK. I just saw this. I have 650 e-mails in my in box. I will connect with you later today or sometime tomorrow. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Lerner, Andrea (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, January 25, 2020 1:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Coronavirus talk work

Dear Dr. Fauci,

Spoke with Hilary, who told me you are looking at the coronavirus talk currently and let her know of a few edits. FYI, I also asked the Weddles to make slides of (just for consideration):

[redacted] (b) (5)

I won't add/change slides to the talk without talking to you first because I don't want to mess things up!

[redacted] (b) (6), fully wired, [redacted] (b) (6) but otherwise available. Should we touch base this afternoon to discuss additional edits/thoughts? Phone or email, whatever you prefer.

Sincerely

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892
Cell: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:10:06 +0000
To: Aaron Weddle
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers ((b)(6))
Subject: FW: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.

Please call me or Greg about what we can do with these pictures to make slides and prints for framing. Thanks.

From: Folkers, Greg (NIH/NIAID) [E] (b)(6)
Sent: Wednesday, January 29, 2020 11:05 PM
To: NIAID COGCORE <COGCORE@mail.nih.gov>; NIAID OD AM <NIAIDODAM@niaid.nih.gov>; NIAID OCGR Leg <NIAIDOCGRLeg@mail.nih.gov>
Subject: POTUS: Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China.



Donald J. Trump
@realDonaldTrump

Just received a briefing on the Coronavirus in China from all of our GREAT agencies, who are also working closely with China. We will continue to monitor the ongoing developments. We have the best experts anywhere in the world, and they are on top of it 24/7!

7:06 PM · Jan 29, 2020 · Twitter for iPhone

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 4 Nov 2019 20:32:29 +0000
To: vince@leavittpartners.com
Cc: mike@leavittpartners.com;Greg Folkers (GFOLKERS@niaid.nih.gov);Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Insight
Attachments: jama_marston_2017_vp_170145.pdf

Vince:

Thanks for the note. I am attaching a pdf of a paper that I wrote in the *Journal of the American Medical Association* that addresses the role of biomedical research in pandemic preparedness. In addition, I have inserted into this e-mail a few graphics that describe the relationship between NIH, FDA, and industry in developing countermeasures such as drugs and vaccines. Finally, I include a link below of some of my recent testimonies on this precise subject. I believe that these will supply you with all of the information that you need. If you would still like to chat after you go through this material, please let me know.

Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

JAMA. 2017;318(18):1757-1758. doi:10.1001/jama.2017.15033

The Critical Role of Biomedical Research in Pandemic Preparedness

Hilary D. Marston, MD, MPH[1]; Catharine I. Paules, MD[1]; Anthony S. Fauci, MD[1]

And some of my recent testimony https://www.niaid.nih.gov/news-events/congressional-testimony

These graphics might be helpful


Early concept and product development
Advanced development
Commercial manufacturing
Regulatory review
NIH
BARDA
Industry
FDA
Industry
FDA consultation and interim review


Industry
Basic Research
Pathogen Biology
Host Response
Target Identification
Preclinical Development
Clinical Evaluation
Vaccines
Therapies
Diagnostics
Research Resources
Academia

From: Vince Ventimiglia <vince@leavittpartners.com>
Sent: Monday, November 4, 2019 11:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Mike Leavitt <mike@leavittpartners.com>
Subject: Insight

Doctor, good morning.

The Governor has been asked to consider writing a short oped or paper describing the drug/vaccine development ecosystem, and the respective roles of NIH, industry, academia, and other players in that enterprise. Would you or a designee have a few moments to elaborate on your view of the appropriate role of NIH, or to point us toward statements you have made to this effect?

As we address biodefense product development, and efforts to expand NIH work in this area, we'd value your sense of the optimal collaboration.

Thanks for your time,

Vince Ventimiglia
Leavitt Partners

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 6 Nov 2019 19:09:06 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Attachments: Letter of invitation to WHO DG Tedros to write Introductory Chapter.doc, Draft Introduction to Emergency Response Research Book - with Fauci tracked changes.docx

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 04:22:42 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Hi, potential off-label for the Coronavirus (Resveratrol)

Please handle.

From: David Lee (b)(6)
Sent: Wednesday, January 29, 2020 7:48 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b)(6)
Subject: Hi, potential off-label for the Coronavirus (Resveratrol)

Hi Dr Anthony Fauci

I won't take up too much of your time. I'm David, a general science enthusiast and I want to let you know something regarding the Coronavirus in case interested (and if not readily known)

There are some papers floating around where Resveratrol (molecule from wine), that has been shown to be effective against the 2001 SARS and 2012 Mers, but in vitro.

Resveratrol and sars:

https://www.sciencedirect.com/science/article/pii/S0223523406001437?via%3Dihub

And a paper where it was good against Mers:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307780/#!po=0.877193

It has also been noted by a biologist and Professor in Genetics David Sinclair

https://twitter.com/davidasinclair/status/1221177622157307904?s=21

whether it can work against the 2019 version of SARs (as it is 75% similar to the 2001 version), and in vivo, not sure.

But letting you know in case, because Resveratrol is readily available in Chemists over the counter and is safe to use already, so if wanted to test it with humans with the latest Coronavirus, conceptually could be quite fast.

But understand could be a niche, non-standard approach

Also If you are already aware if this, my bad

Thanks for your time

Regards,

David

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:07:51 +0000
To: Rebecca Harris
Subject: RE: NPR today; [redacted] (b) (6)

Pneumonia vaccines should be given to everyone over 65 years of age or older should receive the pneumococcus vaccine no matter where they are o where they travel.

From: Rebecca Harris [redacted] (b) (6) >
Sent: Monday, January 27, 2020 10:16 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: NPR today; [redacted] (b) (6)

Tony,

Thank you so much! I can't tell you how appreciative I am. [redacted] (b) (6) was in China last time he basically described it as a huge "outdoor spittoon!" He said the sanitary conditions, street food vendors, and intense crowds were not to be believed. And Hangzhou is a 'small city'...only 8 million people!

I just looked at the CDC website - have they increased the level to 3 now?
https://wwwnc.cdc.gov/travel/notices/warning/novel-coronavirus-china

[redacted] (b) (6)

In closing, thank you again. I hope the work to find a vaccine is moving along. Are you all recommending pneumonia vaccines as a precautionary matter for people who travel even if not to China? Keep up the great work!

Warm regards,
Rebecca

Rebecca U. Harris
[redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Monday, January 27, 2020 9:21:48 PM
To: Rebecca Harris [redacted] (b) (6)
Subject: RE: NPR today; [redacted] (b) (6)

Rebecca:

Thanks for the note. The CDC has a Level 2 alert for all of China (such as Hangzhou) which means enhanced precautions and a level 3 for Wuhan, which means only essential travel. However, the State department is evacuating all of their staff from Wuhan, which tells you something. Given the evolving nature of the situation and the possibility of an explosive outbreak, [redacted] (b) (6) I would recommend that he not go. I hope that this is helpful.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rebecca Harris [redacted] (b) (6)
Sent: Monday, January 27, 2020 4:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: NPR today; [redacted] (b) (6)

Dear Dr. Fauci:

I heard you on NPR this morning and was so very impressed with your knowledge of the coronavirus, the work being done to contain the disease, and your astute comment that the CDC has not been 'invited' to assess the situation.

[redacted] (b) (6)

(b) (6)

[redacted]

I would so value your input.

My sincere thanks - keep up the great work.

Rebecca Harris

Rebecca U. Harris

(b) (6)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 13:00:39 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

See my edits in **red.** You can forward these to her.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Sent: Tuesday, January 21, 2020 4:50 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Do you want to edit this?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it

from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Tuesday, January 21, 2020 4:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: FW: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Patty,

See below—Tanya Lewis, at Scientific American, has asked if ASF can review the transcript of their convo. Let me know if there's anything I can do to help.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>
Sent: Tuesday, January 21, 2020 4:43 PM
To: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)
Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

I just spoke with Dr. Fauci—thanks for arranging the call on short notice! I don't usually do this, but I had some problems with my recording software, so I wondered if I could run the transcript of my interview by Dr. Fauci to make sure I copied everything correctly. Can you ask Dr. Fauci to review it for accuracy only? (We may edit the conversation slightly for length and clarity, but it will be pretty close to this):

Do we know how the U.S. patient contracted the virus? The earliest cases appeared to be people who had been to a seafood market in Wuhan, but there have since been documented cases of human-to-human transmission.
He [the patient] was not in any market where there may have been an animal reservoir, and he does not recall coming into contact with someone who was ill. That's not surprising— **often people contract respiratory infections without knowing the definite exposure source**. But he was in Wuhan.

Do you suspect the virus is transmitted via a respiratory route?
A respiratory infection is almost certainly transmitted through droplets. Respiratory spread is a very good guess. We have **definitively proven that the virus entered through the respiratory tract,** but it is highly likely. When you have symptoms of fever, cough, infiltrates in the lung, and respiratory [symptoms]... historically, respiratory is the route.

How similar or different is the virus from other Coronaviruses such as SARS and MERS?
First of all, it's a Coronavirus, the same family as SARS. It has some of the same molecular homology as SARS. It's closer to SARS than it is to MERS. But it isn't overwhelmingly close.

Do we know the mortality rate of the new virus?

It's a moving target. It's a rough estimate. If you look at the number of cases, it's around 300. There have been six deaths so far. That's about 2 percent mortality. But we have not identified all the cases. We're only seeing the ones who are hospitalized. If there are asymptomatic infections, the mortality rate would be much less. Among symptomatic people, the mortality rate is around 2 percent. It was 10 percent with SARS, and 30-35 percent with MERS. It may be less virulent than those two, or it may evolve. It's too early to know.

Aren't the symptoms of this viral infection similar to many other types of respiratory infection? How can you tell them apart?
It's a syndromic and epidemiological association. If somebody comes into an emergency room in Washington with a respiratory illness and they haven't been to china, they probably have the flu or some other virus. But if they came from Wuhan, [it's likely to be the new Coronavirus]. The symptoms are very common to a number of viruses, though, so it's [based on] epidemiology.

How are the patients with this virus being treated?
It's mostly symptomatic treatment. There are experimental antivirals that have been used *in vitro* and *in vivo*. If [the patients] need antibiotics **for complicating bacterial infections**, you give them antibiotics. If they need to be put on a respirator, they're put on a respirator. Most [patients] in China are doing well. But a proportion of them are very ill, and are on respirators.

How long will it be before we have a vaccine for this virus?
We've already started to develop a vaccine. We got the [genetic] sequence from the Chinese. We're partnering with a company called Moderna to develop a messenger RNA-based platform for a vaccine. We will likely have a candidate in **early phase 1 trials for safety in** about three months. That doesn't mean we will have **a** vaccine **ready for use** in three months**; even in an emergency, that would take a year or more.**

Is the most likely source of this virus an animal market in Wuhan?
It almost certainly came from an animal. Almost certainly.

How common are Coronaviruses, and how often do they jump from animals to humans?
Coronviruses represent 10-30 percent of common colds. Over the last 18 years, we've had three coronaviruses from animal reservoirs: SARS, MERS, and now this. There could be several intermediary hosts, but at least with SARS and MERS, the primary host is thought to be a bat. [We don't know what the primary host is for this virus yet.]

Thanks very much,

Tanya

--
Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell # (b) (6)

From: Administrator <tlewis@sciam.com>
Date: Tuesday, January 21, 2020 at 1:25 PM
To: "Deatrick, Elizabeth (NIH/NIAID) [C]" [redacted] (b) (6)
Subject: Re: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Elizabeth,

Thanks for getting back to me. I don't have a hard deadline, but as this is a quickly evolving topic, I'd like to file something fairly soon. I am aware of the CDC telecom this afternoon, and plan on listening in. But I'm still interested in speaking with Dr. Fauci if he's available.

Best,
Tanya

--
Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: [redacted] (b) (6)

From: "Deatrick, Elizabeth (NIH/NIAID) [C]" < [redacted] (b) (6)
Date: Tuesday, January 21, 2020 at 1:01 PM
To: Administrator <tlewis@sciam.com>
Subject: RE: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Hi Tanya,

Thank you for reaching out to NIAID. I'll be checking with Dr. Fauci to see if he's available for an interview tomorrow morning, or late this afternoon. Do you have a hard deadline tomorrow you're working to meet?

Also, in case you're unaware, the CDC is having a telebriefing on this topic later this afternoon—it may answer some of your questions (see attachment for details). If you're still interested in a call afterwards, we'd be happy to work on that for you.

Best,
Elizabeth

From: Tanya Lewis <tlewis@sciam.com>
Sent: Tuesday, January 21, 2020 12:41 PM
To: NIAID NEWS (NIH/NIAID) <NIAIDNEWS@niaid.nih.gov>
Cc: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Time-Sensitive Media Request from Scientific American: Chinese Coronavirus

Dear NIAID press officers,

I'm a news editor at Scientific American, and I'm reporting a story on the ongoing outbreak of a new coronavirus from China. I'm writing to request an interview with Dr. Fauci, or someone else in your agency who is an expert on this topic, or coronaviruses in general. I'm hoping to file my story no later than noon ET tomorrow. Let me know if you can set something up for this afternoon (anytime except 2-3 ET), or first thing tomorrow morning. Thanks!

Best regards,

Tanya

--

Tanya Lewis
Associate Editor, Health and Medicine
Scientific American
New York, NY
Office #: 212-451-8419
Cell #: (b) (6)

DISCLAIMER: This e-mail is confidential and should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage mechanism. Springer Nature America, Inc. does not accept liability for any statements made which are clearly the sender's own and not expressly made on behalf of Springer Nature America, Inc. or one of their agents.
Please note that neither Springer Nature America, Inc. or any of its agents accept any responsibility for viruses that may be contained in this e-mail or its attachments and it is your responsibility to scan the e-mail and attachments (if any).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 8 Nov 2019 21:22:42 +0000
To: STEWART SIMONSON
Cc: Marston, Hilary (NIH/NIAID) [E];Higgs, Elizabeth (NIH/NIAID) [E];Sorenson, Robert (NIH/NIAID) [C];Conrad, Patricia (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: Request for Tedros
Attachments: Draft Introduction to Emergency Response Research Book- 11.08.2019.docx, Letter to DG Tedros - 11-08-2019.pdf

Stewart:

I am hoping you can help gauge Tedros' interest in co-authoring with me an introduction for a new textbook on response research. NIAID staff are spearheading this effort, having recognized the growing global interest in the topic and the need for practical standards to guide the field. Given his leadership in this area, I can think of no one better suited to introduce the volume.

Recognizing the many demands on his time, he should of course feel free to decline – that is why I wanted to route through you and not send to him directly. If he does accept, I tried to make it as straightforward a task as possible and took the liberty of drafting text (attached). Should he decide to co-author this with me, he should feel free to send any edits or comments over email.

Best regards,
Tony
Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 25 Jan 2020 20:45:32 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: ASM Biothreats - Coronavirus talk for 1/29

It is now marked as "1st FINAL" in the OD folder. Hilary is in the loop.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)>
Sent: Saturday, January 25, 2020 3:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: ASM Biothreats - Coronavirus talk for 1/29

Dr Fauci,

Sounds good. (b) (6) but otherwise available to assist. As I said in other email, I will wait to hear further from you.

Andrea

Sent from my iPhone

> On Jan 25, 2020, at 3:07 PM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6) wrote:
>
> I understand that you are (b) (6) and so I do not want to bother you. I will get to the talk later in the day or tomorrow AM and then I will e-mail you about the way forward. Thanks.
>
> Anthony S. Fauci, MD
> Director
> National Institute of Allergy and Infectious Diseases Building 31,
> Room 7A-03
> 31 Center Drive, MSC 2520
> National Institutes of Health
> Bethesda, MD 20892-2520
> Phone: (b) (6)
> FAX: (301) 496-4409

> E-mail: (b) (6)

> The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

>

> -----Original Message-----
> From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
> Sent: Friday, January 24, 2020 6:22 PM
> To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
> Subject: ASM Biothreats - Coronavirus talk for 1/29

>

> Dear Dr. Fauci,

>

> I know you will need a little bit more time over the weekend to look at the talk. Let me know what edits or thoughts you have and I will be available over the weekend to discuss things with you!

>

> Sincerely
> Andrea

>

> Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:55:58 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: URGENT GPMB: Message on behalf of the Co-Chairs: Statement on 2019-nCoV
Attachments: GPMB Statement on 2019 nCoV.pdf

FYI and let us discuss.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Thursday, January 30, 2020 4:43 AM
To: [redacted] (b) (6)>; Gro [redacted] (b) (6)>; Dzau Victor < [redacted] (b) (6); Chris.Elias [redacted] (b) (6)>; Farrar Jeremy [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) Fore Henrietta [redacted] (b) (6) Gao Fu [redacted] (b) (6)>; Gashumba Diane [redacted] (b) (6)>; Kaag Sigrid [redacted] (b) (6)>; Ilona Kickbusch [redacted] (b) (6); Skvortsova Veronika [redacted] (b) (6) Suzuki Yasuhiro [redacted] (b) (6); Vega Morales Jeanette [redacted] (b) (6)>; Vega Morales Jeanette [redacted] (b) (6); VijayRaghavan Krishnaswamy [redacted] (b) (6)
Cc: SCHWARTLANDER, Bernhard F. [redacted] (b) (6)>; FALL, Ibrahima Soce [redacted] (b) (6) MAHJOUR, Jaouad [redacted] (b) (6) MINHAS, Raman [redacted] (b) (6)>; Toomas Palu [redacted] (b) (6); 'Pate Muhamed' [redacted] (b) (6); RYAN, Michael J. [redacted] (b) (6); 'Alex Harris' [redacted] (b) (6); Alveberg, Benedikte Louise [redacted] (b) (6)>; 'Chiaki NOGUCHI' [redacted] (b) (6) 'Esveld Marja' [redacted] (b) (6)>; 'Gonggrijp Mette ' [redacted] (b) (6)>; Julie.HALL [redacted] (b) (6) 'Kanarek Morgan' [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6) 'Oleg Sonin ' [redacted] (b) (6)>; 'Omar Abdi' [redacted] (b) (6); Amelie RIOUX [redacted] (b) (6) Tore Godal' < [redacted] (b) (6) GABEDAVA, Tsira [redacted] (b) (6)>; ROSS, Alex [redacted] (b) (6) 'Banks Lynn' [redacted] (b) (6)>; 'Block Bruce' [redacted] (b) (6) 'Conrad Jane' [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) 'Del Sol Dinia' [redacted] (b) (6); 'Diao Fay' [redacted] (b) (6); 'Elena Kirsanova ' [redacted] (b) (6) 'Gahungu Zacharie' [redacted] (b) (6)>; 'Harikumar M K' [redacted] (b) (6); 'Harikumar M K' [redacted] (b) (6); 'Kabagire Christine' [redacted] (b) (6); 'KITA Yosuke' [redacted] (b) (6); 'Miller de Vega Teresa' [redacted] (b) (6)>; MURIUKI, Hilda Wairimu [redacted] (b) (6)>; 'Muzenda Sindiso' [redacted] (b) (6)>; 'Sarah Belmir' [redacted] (b) (6) 'YU Bai' [redacted] (b) (6); Scott Dowell [redacted] (b) (6); 'Kanarek Morgan' [redacted] (b) (6) STERN, Gabriella [redacted] (b) (6); LOEWENBERG, Samuel Richard < [redacted] (b) (6)>
Subject: URGENT GPMB: Message on behalf of the Co-Chairs: Statement on 2019-nCoV
Importance: High

Dear Board members,

Thank you for your rapid response and participation in the teleconference call and feedback to the draft statement on the 2019 n-CoV outbreak.

Please find attached the final statement which reflects all of your comments. It is supportive of countries' and WHO's critical efforts for further immediate preparedness and response, and calls for urgent actions to strengthen global preparedness and response to this outbreak.

We encourage you to circulate the Statement through your channels.

The Statement will be uploaded to the GPMB website, and the Secretariat is circulating to various media. You may wish to use the original hashtag from our report #AWorldatRisk in social media posts.

As media will reach out to the Secretariat, please let the Secretariat know of your willingness to be interviewed in the coming days (the Secretariat will screen requests and coordinate with you/your staff).

Please also note that WHO is convening the IHR Emergency Committee later this afternoon.

Thank you for your continued engagement.

Kinds regards,

Gro and As

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:08:58 +0000
To: Paules, Catharine
Subject: RE: Reply regarding email sent to Dr. Fauci

Very little ☹

From: Paules, Catharine [redacted] (b) (6)
Sent: Monday, January 27, 2020 9:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: RE: Reply regarding email sent to Dr. Fauci

Just saw you on the news. Hope you are getting some sleep in all this.

From: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Date: January 27, 2020 at 9:16:45 PM EST
To: Paules, Catharine [redacted] (b) (6)
Subject: RE: Reply regarding email sent to Dr. Fauci

== CAUTION: External Sender ==
This message came from outside of Penn State Health & College of Medicine.
Please use caution when opening attachments or links.

Thanks, Cat

From: Paules, Catharine < [redacted] (b) (6)
Sent: Monday, January 27, 2020 4:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E]
< [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: FW: Reply regarding email sent to Dr. Fauci

Just FYI—this was the gentleman you asked me to respond to and here is the response below. Thanks much, Cat

From: Paules, Catharine
Sent: Monday, January 27, 2020 4:54 PM
To: [redacted] (b) (6)
Subject: Reply regarding email sent to Dr. Fauci

Hello Mr. Sun,

Thank you very much for reaching out to Dr. Fauci with your questions and for reading the manuscript in JAMA. Please see the links below to two publications that I think will help address some of your questions and highlight the importance of vaccine development (and other countermeasure development) in response to emerging viral pathogens.

https://jamanetwork.com/journals/jama/fullarticle/2676502
https://jamanetwork.com/journals/jama/fullarticle/2656224

In regard to the novel coronavirus, this situation is evolving rapidly so it is difficult to make predictions regarding the scope and duration of this outbreak. Vaccine development remains a key priority at this time.

Thank you very much for reaching out,

Catharine

Catharine I. Paules MD
Assistant Professor, Infectious Diseases
Penn State University College of Medicine, Milton S. Hershey Medical Center
500 university drive Hershey PA 17033

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:21:23 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Any coronavirus update?

Francis:

You can use any of the information in my 01/21/2020 e-mail. There are close to 500 cases (440 at last count) and 9 deaths. Mortality remains at around 2% for people who are recognized with sxs. No evidence at present regarding asymptomatic infections. In addition to the ORD and ATL airports plus JFK, LAX and SFO, DHS will work out funneling people coming from China to USA through these 5 airports. Also, CDC has elevated their Travel Alert to Level 2, which means enhanced precaution. Level 1 is business as usual and Level 3 is only essential travel.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
Sent: Wednesday, January 22, 2020 8:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Burklow, John (NIH/OD) [E] [redacted] (b) (6); Myles, Renate (NIH/OD) [E] [redacted] (b) (6)>; Tabak, Lawrence (NIH/OD) [E] < [redacted] (b) (6)
Subject: Any coronavirus update?

Hi Tony,

I'm doing a Swiss Radio interview at 4 pm in Davos (10 am EST). It's supposed to be wide-ranging about many issues in biomedical research, but I'd be surprised if they don't bring up the coronavirus situation.

Stephane Bancel sent me a heads up (just forwarded to you) that Moderna was announcing their collaboration with NIH on an RNA based vaccine development, as you told me yesterday. Just so I'm clear, is there anything in your message from 1/21 11:13 AM that I should NOT mention? And is there anything new in the last 24 hours other than screening at Chicago and Atlanta airports?

Thanks for all your help on this!

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:57:45 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Skype Interview requests of Arirang TV in Seoul

Please handle.

From: 김효선 [redacted] (b) (6)>
Sent: Thursday, January 30, 2020 3:06 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Skype Interview requests of Arirang TV in Seoul

Hello. My name is Hyosun kim and I'm a writer at Arirang TV, based in Seoul, Korea.

I am writing to you because I'd love to have you as a guest on my show.
The show, titled <Peace & Prosperity>, is a 30-minute pre-recorded segment that focuses on inter-Korean issues and denuclearization negotiations on the Korean Peninsula.

Below is our program site link.

http://www.arirang.com/Tv2/Tv_Home.asp?PROG_CODE=TVCR0863&MENU_CODE=102722

This week's topic is the new coronavirus.

I would like to say the importance of cooperation between the Korean and Chinese governments.

And I contacted you because I needed medical explanation for the new coronavirus.

Would you be free for a 10-minute Skype interview on

February 3 (monday) or February 4 (tuesday) ?

I look forward to hearing from you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:14:38 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers (GFOLKERS@niaid.nih.gov)
Subject: FW: Invitation to write a Perspective for Cell

Let us discuss.

From: Narasimhan, Sri Devi (ELS-CMA) <srnarasimhan@cell.com>
Sent: Monday, January 27, 2020 4:00 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Invitation to write a Perspective for Cell

Dear Tony,

I hope all is well. I had the great pleasure of meeting you in person when you were the keynote speaker at our Cell Symposium on Emerging and Re-emerging Viruses in 2017. You then gave a wonderful talk that covered AIDS to Zika and your experiences across different outbreaks, administrations and the challenges you encountered.

I realize I am writing to you in the middle of a yet another outbreak but you have such a broad, unique and valuable perspective on the complexity and multifaceted nature of dealing with these situations that I think would be of very broad interest and value to the scientific community. I'd love Cell to be the platform for this communication - it could be focused more on the Wuhan coronavirus or a broader perspective on outbreak to management and everything in between where you focus on common threads as well as unique challenges.

This could be a more long-term article for Cell if your hands are full right now but I'd love to know if you would be interested in writing for us.

My best wishes,
Sri.

Sri Devi Narasimhan, PhD
Deputy Editor, Cell
Cell Press/Reed Elsevier

50 Hampshire St., Cambridge, MA 02139
srnarasimhan@cell.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:46:51 +0000
To: Phil.Fontanarosa@jamanetwork.org
Subject: RE: JAMA20-0602 Decision Letter - Please Confirm Receipt

Received!

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms
Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:
Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 10:58:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Interview Request on Novel Coronavirus

Please handle.

From: 박현영 <park.hyunyoung@joongang.co.kr>
Sent: Thursday, January 30, 2020 3:29 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Interview Request on Novel Coronavirus

Dear Dr. Fauci,

I am Senior Washington Correspondent with The JoongAng Ilbo and JTBC news network, the largest media group in South Korea.

I would like to schedule an interview regarding Novel Coronavirus 2019, how it spreads and how to fight it.

Topics I would like to discuss are how dangerous this virus is, what is the best way to prevent it in local communities and whether patients without symptoms can transmit the disease.

Yesterday CDC announced it won't quarantine 200 Americans flown home from Wuhan, China. Japan has followed the same path. However, South Korea, Australia, France and UK governments decided to quarantine evacuees for 14 days in independent facilities. Why are governments' responses different and what is the optimal choice?

Currently S. Korea has 4 confirmed cases which is not very many, but the nation is split on where evacuees should be quarantined after they're airlifted later this week. Nobody wants them closeby.

I hope this interview could be an informative reference to our readers who seek scientific inormation on the new virus.

I am based in Washington DC. When scheduled our team can visit NIH. I hope to hear from you soon. Thank you.

Best regards,
Hyun Young

Hyun Young PARK
Washington Correspondent
The Joongang Ilbo & JTBC Broadcasting Network
Mobile: (b) (6)
Office: (202) 347-0122

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:35:01 +0000
To: Lusso, Paolo (NIH/NIAID) [E]
Subject: RE: Statement on new coronavirus

Paolo:

The JAMA article is still the best summary of what is going on.

Best,
Tony

From: Lusso, Paolo (NIH/NIAID) [E] (b) (6)
Sent: Monday, January 27, 2020 9:26 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Statement on new coronavirus

Dear Tony,

I am sorry we haven't been able to meet recently, but I can imagine how busy you must be with the Wuhan virus. In this respect, I have received a request from the Italian Ambassador through the scientific attache', Dr. Gilli, who was enquiring if NIH has released any official statement on the new coronavirus situation. Is there any such statement or other material I can send them other than your JAMA article? Please, let me know. Thanks!

All the best,

Paolo

Paolo Lusso, M.D., Ph.D.
Chief, Section of Viral Pathogenesis
Laboratory of Immunoregulation
Bldg. 10, Rm. 6A11
NIAID, NIH
Bethesda, MD 20892

Phone: (b) (6) (personal)
(b) (6) (lab)
Fax: (301) 480-5291
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious

Diseases (NIAID) shall not accept liability for any statement made that are the sender’s own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:48:00 +0000
To: Paules, Catharine;Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: JAMA20-0602 Decision Letter - Please Confirm Receipt

FYI

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (301) 496-2263
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms
Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:

Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 18 Dec 2019 18:21:00 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CSIS Health Security Commission Final Report Released
Attachments: CSIS Ending The Cycle of Crisis and Complacency_11.22.pdf

Let us discuss. I may need to take a look at the report as well as attend the dinner. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b)(6)
FAX: (301) 496-4409
E-mail: [redacted] (b)(6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stephen Morrison <SMorriso@csis.org>
Sent: Wednesday, December 18, 2019 12:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b)(6)
Cc: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b)(6) Anna Carroll <ACarroll@csis.org>; Samantha Stroman <SStroman@csis.org>
Subject: CSIS Health Security Commission Final Report Released

Hi Tony,

I hope this email finds you well. I am pleased to share that, in late November, the CSIS Commission on Strengthening America's Health Security released its final report, *Ending the Cycle of Crisis and Complacency in U.S. Global Health Security*. We are extremely grateful for all of the time and input you have given to the Commission over the past year and a half.

The report proposes seven strategic recommendations to replace the cycle of crisis and complacency that has long plagued health security preparedness with a doctrine of continuous prevention, protection, and resilience. The Commission settled on what it believes to be cost-effective, proven, commonsense recommendations that can draw support from across the political divide.

The report calls on Congress and the administration to adopt the following integrated package of critical actions:

1. Restore health security leadership at the White House Security Council.
2. Commit to full and sustained multi-year funding for the Global Health Security Agenda to build partner capacity.
3. Establish a Pandemic Preparedness Challenge at the World Bank to incentivize countries to invest in their own preparedness.
4. Ensure rapid access to resources for health emergencies.
5. Establish a U.S. Global Health Crises Response Corps.
6. Strengthen the delivery of critical health services in disordered settings.
7. Systematically confront two urgent technology challenges: the need for new vaccines and therapeutics and the public health communications crisis.

We would welcome the opportunity to brief you on the report, should that be of interest to you. In particular, we would be interested in meeting to discuss the recently established National Influenza Vaccine Task Force and its forthcoming five-year plan. The Commission report includes a recommendation to increase investment in universal flu vaccine development, and we plan to write a follow-up policy brief on the issue of pandemic and seasonal influenza. We are eager to align this policy brief with the work of the Task Force.

Lastly, on Tuesday, February 4, we will host a by-invitation dinner discussion following the fourth and final private meeting of the Commission. The dinner will be a high-level dialogue between the Commission and executive branch leaders on advancing the recommendations of the Commission's final report. Dr. John J. Hamre, President and CEO of CSIS, will attend the dinner, along with Commission Co-Chairs Kelly Ayotte and Julie Gerberding. We expect many members of the Commission to join as well, including Members of Congress. We would be delighted to have you participate, and we hope you can join us.

Best Steve

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 02:07:20 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E]
Subject: FW: AlphC: Medical Modelling/Historical Travel Modelling and (2019-nCoV) spread

Please take a look and respond if appropriate.

From: Shafin Valla <shafin@alphc.com>
Sent: Saturday, January 25, 2020 2:46 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Stephen Baruch (b) (6) >
Subject: AlphC: Medical Modelling/Historical Travel Modelling and (2019-nCoV) spread

Dr. Anthony Fauci,

Please see below and we can talk. I have also left a voicemail at (b) (6)

We reach out to you based on the current issues with nCov. Our medical modelling is new knowledge to the field and we share this with you.

Alphabet Communication (AlphC) creates an email for every physical address in the world. A message sent to the email of the address connects you to all occupants. You have the unique ability to map the global population. Every email created is unique and cannot be duplicated (similar to a fingerprint/DNA). We are at the cusp and new age for the Internet. Travel patterns can now be mapped providing medical models and instant connectivity based on needs. Historical and current locations of travellers (places of visit, neighbours, etc), we can provide vast opportunities and fill gaps current technologies have not addressed.

Here is a quick illustration below.



An email is auto generated for the address of each passenger. This shows where they came from, destination, flight connections, for ease or tracking and who may possible infected

123abcSt@thailand.who.com
367kingSt@hongkong.who.com
anySt@malaysia.who.org.com
anyRuralPlace@africa.who.com
Persons at Risk
123 2ndStNewYork@who.com
anyAdressWorld@who.com
We can map any street anywhere
Shows location of infected passenger on plane

Based on the addresses for each person on the flight. Person at risk and there location can be identified and at risk population easy tracked and advised of possible infections.
NOTE: An email sent to the address@ connects you to the passenger

In summary:

- Every Passenger has an address
- These can be graphically mapped instantly to exact address in the world (travel itinerary)
- There destinations mapped
- Passengers that sat in their vicinity, possible infections can be mapped
- Authorities can then have a graphic-mapped-areas of possible areas of infection
- The infection can be mapped to the origin (exact-address) and at-risk neighbors identified
- At risk population at the new addresses can also be identified
- Graphic display of each address with infection, quarantined areas, suspect sites of infection
- Rural addresses can also mapped and high-rise building to the unit number.
- 80% of the population has a cell. This is where the message gets sent as text with 100% penetration.
- All this information is captured before we board a flight.
- Hence everything auto populates and can be activated by CDC or NIH or designated authority

Feel free to connect ...

Shafin Valla
Alphabet Communication (AlphC)
shafin@alphc.com
1.647.836.7867
https://www.linkedin.com/in/shafin-valla-b99ba6181/

On Fri, Jan 24, 2020 at 11:58 PM Stephen Baruch [redacted] (b) (6) > wrote:

Shafin, please consider reaching out to Dr. Anthony Fauci. He is the US point person for the 2019 novel coronavirus . Your company's capability to efficiently track and communicate with people who may have been exposed could be a real interest to him and his colleagues.
Stephen

Dr. Stephen B. Baruch, MBCI, CBCP
The Baruch Group, Disaster Preparedness....Business Continuity
Tel: 650-279-2556
Twitter: http://twitter.com/bcpexpert
LinkedIn: http://www.linkedin.com/in/stephenbaruch
Facebook:http://www.facebook.com/TheBaruchGroup

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:36:11 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Level of interest @ NIAID: Chemo-prophylaxis/treatment by drug reprofiling for coronavirus.

Please handle.

From: Dr. Farhan Subhani [redacted] (b) (6)
Sent: Monday, January 27, 2020 9:04 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Level of interest @ NIAID: Chemo-prophylaxis/treatment by drug reprofiling for coronavirus.

Dear Dr. Fauci,

I am drug discovery/reprofiling consultant with clinical medicine background. I'm aware that NIAID is interested for vaccine of cornavirus new strain but vaccine will take years. So, at this time, chemo-prophylaxis is best option [redacted] (b) (4)

[redacted] (b) (4)

Looking forward for your response.

Kind regards

Dr. Farhan Ul Haq Subhani (M.B.,B.S)
Independent Drug Discovery/Reprofiling Consultant
email: [redacted] (b) (6)
Cell/WhatsApp: [redacted] (b) (6)
Lahore, Pakistan.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:59:05 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: Authorship Form Needed for JAMA20-0602

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Cheryl.Sykes@jamanetwork.org <Cheryl.Sykes@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Authorship Form Needed for JAMA20-0602

January 22, 2020

Dear Dr Fauci:

Your manuscript, Coronavirus Infections: More Than Just the Common Cold, is being considered for possible publication in JAMA. Meanwhile, please complete the Authorship Form.

Click on the link below to access the electronic authorship form. You will be required to enter your password. If you are unable to locate your password please click the "Unknown/Forgotten password" link.

Please do not share this email with anyone.

https://manuscripts.jama.com/cgi-bin/main.plex?el=A6e5BMng1A4BtRQ3w6A3E1F7A4A9ftdszp7SLUBygn9I47YfWJZAZ

This form must be completed online. Each author needs to complete Section 1: Author Responsibility, Criteria, and Contributions; Section 2: Disclosure of Potential Conflicts of Interest, Section 3: Publishing Agreement, and Section 4: Confirmation. The corresponding author also needs to complete Section 1A.

Acknowledgement.

After completing the sections online, type your name as it appears on the top of the form and date into Section 4: Confirmation. A digital signature is not required. Click the submit button on the form display screen to save the authorship form in the manuscript submission system.

Instructions for Authors are available online at:

http://jamanetwork.com/journals/jama/pages/instructions-for-authors

Sincerely yours,

Cheryl R. Sykes
Supervisor, JAMA
Phone: 312.464.4416
Email: Cheryl.Sykes@jamanetwork.org

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 02:13:08 +0000
To: Lerner, Andrea (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: ASM Biothreats coronavirus talk, 20 min, 1/29

I would like to include slides 3.4, and 5. Thanks.

From: Lerner, Andrea (NIH/NIAID) [E] (b) (6)
Sent: Saturday, January 25, 2020 7:59 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Folkers, Greg (NIH/NIAID) [E] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] < (b) (6) Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Subject: ASM Biothreats coronavirus talk, 20 min, 1/29

Dear Dr. Fauci,

I have gone through the slides labeled "1st FINAL" in the OD drive and made the noted edits. I will also update the map slides as we see what happens over the weekend,.

Regarding demographics, there is a Lancet paper detailing demographics and clinical information for 41 patients, and 2 reports (1 from the Hubei Province Health Commission, 1 from the Chinese Health Commission) reviewing demographics and limited clinical information for a total of 24 patients who died. I could not find an age range for all severe cases, or for all deaths reported.

Slides 1-4 in this deck are possibilities for the demographics and clinical information. Slide 5 in this attachment can possibly update slide #61 on cities quarantined in the presentation. Cc'ing Greg and Hilary as well for ideas and input, and in case they are aware of sources that I didn't find!

Let me know what you think,

Andrea

Andrea Lerner, MD
Medical Officer
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health
31 Center Drive, Room 7A10A
Bethesda, MD 20892

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:36:50 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Disinfecting Against NovoCorona Virus
Attachments: ncnovoviruspaper, danolyte200126.pptx

Please handle.

From: Robert Jackson (b) (6)
Sent: Monday, January 27, 2020 8:53 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Don Peterson (b) (6)
Subject: Fwd: Disinfecting Against NovoCorona Virus

Dr Anthony Fauci Director of National Institute of Allergy and Infectious Diseases

Dr. Fauci,

Please note the forwarded email and the attachments. I believe we have an effective, economical and environmentally safe technology that can be a first line of defense against the coronavirus outbreak. You are well aware infected individuals may remain asymptomatic for days and it will be months before an effective vaccine can be found and dispensed. This technology can disinfect contaminated environments
effectively covering all surfaces and is hypoallergenic. It also includes a solar powered system so that power outages and remote regions of the world can use the unit.

We hope to hear from you soon so that we can join with your current plan of action against this epidemic.

Highest Regards,

Dr. Jackson
Clinical Consultant Danolyte Global

Robert Wayne Jackson, **DO, FACOI**
President & Founder
Premier Specialty Network
3610 Buttonwood Drive, Suite 200
Columbia, MO 65201
Office :(573) 231-9022
Office Fax: (573) 886-8901
Cell: (b) (6)
(b) (6)

'If the purpose of your heart is pure then anything is possible'

+PSN Premier Specialty Network
Improving Access to Healthcare

This electronic communication is from **PSN** (Premier Specialty Network) and is confidential, privileged and intended only for the use of the recipient named above. If you are not the intended recipient or the employee or agent responsible for delivering this information to the intended recipient, unauthorized disclosure, copying, distribution, or use of the contents of this transmission is strictly prohibited.

If you have received this message in error, please notify the sender immediately at the following email address: administrator@psnmo.net or by calling **573-886-8904** or **573-231-9022**. Emails originating from psnmo.net are **HIPAA** compliant. Documentation on file. Additional documentation encryption may be included.

---------- Forwarded message ---------
From: **Don Peterson** [redacted] (b) (6)>
Date: Sun, Jan 26, 2020 at 11:00 AM
Subject: Disinfecting Against NovoCorona Virus
To: <[redacted] (b) (6)>
Cc: Bob Jackson MD <[redacted] (b) (6)

Dear Dr. Van-Kerhove,

Attached please find a few slides that explain the capabilities of hypochlorous acid in eliminating pathogens on various surfaces. Hypochlorous acid sprayed using our electrostatic spraying technology could help contain the corona virus. The virtue of electrostatic spraying is that every surface with a negative charge would be uniformly coated with HOCl insuring complete coverage and improving efficacy throughout the sprayed environment.

We would propose shipping several HOCl generators to key sites where large amounts of 500ppm HOCl could be deployed. We also propose shipping drums of HOCl to port cities to spray inbound and outbound passenger aircraft and other sites where people gather who may have been exposed to the virus.

My colleague, Dr. Robert Jackson is copied here and could serve as a clinical consultant on this effort.

We hope to hear from you soon.

Sincerely,
Don Peterson

Don Peterson
[redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:59:35 +0000
To: Eisinger, Robert (NIH/NIAID) [E]
Subject: FW: JAMA20-0602 Decision Letter - Please Confirm Receipt

Read carefully

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Phil.Fontanarosa@jamanetwork.org <Phil.Fontanarosa@jamanetwork.org>
Sent: Wednesday, January 22, 2020 8:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Lupe.Morales@jamanetwork.org
Subject: JAMA20-0602 Decision Letter - Please Confirm Receipt

PLEASE REPLY TO CONFIRM RECEIPT OF THIS LETTER

January 22, 2020

Dr Anthony S Fauci
Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
Bethesda, MD 20892-2520

RE: Coronavirus Infections: More Than Just the Common Cold

Dear Dr Fauci:

We have completed our review of your manuscript and are considering accepting it for publication in JAMA. However, acceptance will not be final until we receive all of the items described in this letter.

Do NOT send a revised version of your manuscript at this time.

After receipt of all of the items, your manuscript is accepted with the understanding that its contents, all or in part, have not been published elsewhere and will not be published elsewhere in print or electronic format without the consent of the editor.

We are planning to publish your article online ahead of print. Any information you may receive about the proposed publication date of your article is tentative and should be kept confidential. Shortly before publication, the publication date can be confirmed. Prepublication distribution of the accepted manuscript without permission is prohibited.

Please note that the news media should not release any information about your article until it is published. If you need help in coordinating press conferences or releases, please contact the JAMA Network Media Relations Department at mediarelations@jamanetwork.org or 312-464-JAMA (312-464-5262).

We sincerely appreciate your submitting the manuscript for our consideration and look forward to seeing it in JAMA.

Sincerely yours,

Phil B Fontanarosa, MD, MBA
Executive Editor, JAMA
Email: Phil.Fontanarosa@jamanetwork.org
Phone: (312) 464-2457
Fax: (312) 464-5824

Lupe Morales
Editorial Assistant, JAMA
Email: Lupe.Morales@jamanetwork.org
Phone: 312.464.2457
Fax: 866.460.7052

Confidentiality Note: This communication, including any attachments, is solely for the use of the addressee, may contain privileged, confidential, or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

EDITOR'S REQUIREMENTS

Authorship Forms
Each author will be sent an email with instructions for submitting the Authorship Forms, with information about authorship responsibility, funding and conflicts of interests, and a publishing agreement.

Author Conflict of Interest Disclosures

Please verify and confirm that all conflict of interest disclosure information for you and all coauthors is accurate, complete, up-to-date, and reported in the Acknowledgment section of the manuscript in a manner that is consistent with that reported in the disclosures of potential conflicts of interest section of the JAMA's Authorship Form.

Our policy requires that all authors disclose:
Any potential conflicts of interest involving the work under consideration for publication (during the time involving the work, from initial conception and planning to present);

Any relevant financial activities outside the submitted work (during the 3 years prior to submission);

And any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what is written in the submitted work (based on all relationships that were present during the 3 years prior to submission).

Potential conflicts of interest include but are not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers' bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. For example, authors of a manuscript about hypertension should report all financial relationships they have with all manufacturers of products used in the management of hypertension, not only those relationships with companies whose specific products are mentioned in the manuscript.

Authors without potential conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests. If you are uncertain about what constitutes a relevant financial interest or relationship, please let me know. Each author will be sent an email with further instructions for submitting the Authorship Form, which includes the ICMJE Disclosure of Potential Conflicts of Interest section.

All financial and material support for the research and/or the work reported in the manuscript should be clearly and completely identified in the Acknowledgment.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 03:29:22 +0000
To: Awwad, David (NIH/NIAID) [C]
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Thanks.

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)
Sent: Saturday, January 25, 2020 9:28 PM
To: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: CTV NEWS CHANNEL INTERVIEW REQUEST

Here is the clip from today.

https://mobile.twitter.com/RobynCurnowCNN/status/1221236930576297984?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet

Sent from my iPhone

On Jan 25, 2020, at 9:21 PM, Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

Thx

Sent from my iPhone

On Jan 25, 2020, at 9:13 PM, Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)> wrote:

I will be onsite by 7:25am for 7:30am test.

David

Sent from my iPhone

On Jan 25, 2020, at 8:09 PM, Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) wrote:

Firm for 8 am tomorrow. See below.

Sent from my iPhone

Begin forwarded message:

From: "Taylor, Brooke" <brooke.taylor@bellmedia.ca>
Date: January 25, 2020 at 7:57:59 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" <[redacted] (b) (6) "Awwad, David (NIH/NIAID) [C]" [redacted] (b) (6)v>
Cc: "Lautenschlager, Tyson" <tyson.lautenschlager@bellmedia.ca>, "Pekoc, Ken (NIH/NIAID) [E]" [redacted] (b) (6)"Oplinger, Anne (NIH/NIAID) [E]" [redacted] (b) (6)>, "Lalonde, Jared" <Jared.Lalonde@bellmedia.ca>
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Patricia,
The live hit will be at 8:00 a.m. ET. Our morning producer should do a connection test around 7:30 a.m. ET, our control room will connect around 7:55 a.m. ET.
Correct, Andrea Bain is the anchor doing the interview.
I have a pronouncer in the script for his last name ☺

Thanks!
Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [mailto:[redacted] (b) (6)]
Sent: Saturday, January 25, 2020 7:41 PM
To: Taylor, Brooke; Awwad, David (NIH/NIAID) [C]
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Good evening:

Just touching base to reconfirm:

1) Live hit will be at 8:00 am ET – when will you connect via skype?
2) Andrea Bain will do the interview
3) Pronunciation of Fauci is Fow-chee – rhymes with grouchy
4) Will you test connection in advance and what time?

Thank you
-patty

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:47 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Will do, thank you!

From: Conrad, Patricia (NIH/NIAID) [E] [mailto:[redacted] (b) (6)
Sent: Friday, January 24, 2020 5:30 PM
To: Taylor, Brooke; Awwad, David (NIH/NIAID) [C]
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

If there are any changes over the weekend please email all here and my cell is [redacted] (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:16 PM
To: Awwad, David (NIH/NIAID) [C] <[redacted] (b) (6)>; Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Great, thank you so much!

Best,

Brooke

From: Awwad, David (NIH/NIAID) [C] [[redacted] (b) (6)
Sent: Friday, January 24, 2020 5:15 PM
To: Taylor, Brooke; Conrad, Patricia (NIH/NIAID) [E]
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Skype ID: Live:niaidithelp or niaidithelp@outlook.com

My cell is [redacted] (b) (6)

David Awwad, Contractor
Customer Services Branch, NIH\NIAID\OCICB
NTT DATA Services Federal, LLC
Phone: ([redacted]
[redacted] (b) (6)

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 5:12 PM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>; Pekoc, Ken (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Great, let's confirm this for Sunday, January 26 at 8:00 a.m. ET.
Dr. Fauci will be on with our anchor Andrea Bain.

Thanks!
Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [mailto:[redacted] (b) (6)
Sent: Friday, January 24, 2020 5:06 PM
To: Taylor, Brooke
Cc: Lautenschlager, Tyson; Pekoc, Ken (NIH/NIAID) [E]; Oplinger, Anne (NIH/NIAID) [E]; Awwad, David

(NIH/NIAID) [C]
Subject: [EXT]RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Dr. Fauci can be available on Sunday 1/26 at 8:00 am ET for your skype interview. IF this works – please confirm asap and we will send you the connection info.

Thanks.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 2:51 PM
To: Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>
Subject: RE: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Patricia,
This would be done via FaceTime or Skype, whichever you prefer.
I have lots of time available on Sunday, 8:00 a.m., 9:00 a.m., 10:00 a.m., 12:00 p.m., 4:00 p.m. or 6:00 p.m..
Let me know if any of those times work!
The interview will be between three and five minutes long.

Thanks!
Brooke

From: Conrad, Patricia (NIH/NIAID) [E] [mailto: (b) (6)
Sent: Friday, January 24, 2020 2:50 PM
To: Taylor, Brooke
Subject: [EXT]FW: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Brooke

What is the timing for this? how long would the interview be and what is the location of your studio? Or is this something that can be done by skype – please provide more details. Thanks.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Taylor, Brooke <brooke.taylor@bellmedia.ca>
Sent: Friday, January 24, 2020 2:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Cc: Lautenschlager, Tyson <tyson.lautenschlager@bellmedia.ca>
Subject: CTV NEWS CHANNEL INTERVIEW REQUEST

Hi Dr. Fauci,
I hope you're well!

I'm reaching out to see if you might have any availability **this Sunday, January 26th** to join us on air to talk about the coronavirus.

Let me know if you're available and we can set up a time!

Best,
Brooke

Brooke Taylor | Chase Producer | CTV News Channel

t 416-384-7400 brooke.taylor@bellmedia.ca 9 Channel Nine Court
Toronto, ON M1S 4B5

<image001.jpg>
CTV is Canada's largest private broadcaster. CTV News Channel is the network's 24-hour, all news, specialty channel.

External Email: *Please use caution when opening links and attachments /* ***Courriel externe:*** *Soyez prudent avec les liens et documents joints*

External Email: *Please use caution when opening links and attachments /* ***Courriel externe:*** *Soyez prudent avec les liens et documents joints*

External Email: *Please use caution when opening links and attachments /* ***Courriel externe:*** *Soyez prudent avec les liens et documents joints*

External Email: *Please use caution when opening links and attachments /* ***Courriel externe:*** *Soyez prudent avec les liens et documents joints*

External Email: *Please use caution when opening links and attachments /* ***Courriel externe:*** *Soyez prudent avec les liens et documents joints*

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Jan 2020 21:48:24 +0000
To: Holland, Steven (NIH/NIAID) [E]
Cc: Lane, Cliff (NIH/NIAID) [E]
Subject: FW: Qiastat-DX

Steve:

Please take a look at this. It is very interesting and something that we might want to have.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Altan-Bonnet, Nihal (NIH/NHLBI) [E] (b) (6)
Sent: Wednesday, January 8, 2020 12:34 PM
To: Gallin, John (OD) [E] < (b) (6); Glass, Roger (NIH/FIC) [E] (b) (6) Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Qiastat-DX

Hi John, Roger and Tony

It was very nice meeting you last night.

I am just following up regarding that machine I mentioned that does quantitative multiplex QPCR on a number of pathogens in < 1hour.

Here is a link to a brief video regarding the machine:

https://www.youtube.com/watch?v=5KrNgq1vNds

I've listed all the pathogens that can be tested from a single sample below. The machine is in my lab on the 2nd floor of Bldg 50 (Room 2537), you or someone from your lab is welcome to come and play with it. It is incredibly simple to use.

The GI panel and Respiratory panel cassettes (though they were initially approved for stool and respiratory expectorates respectfully) work with really any biological fluid we've tested (cell culture materials, breast milk, diluted blood etc).

It’s a great tool to quickly get a quantitative and qualitative snap shot of pathogen in your samples.
If you have any questions or like to try it out, just contact me.
Best
Nihal

GI Panel

14 bacteria

- Clostridium difficile toxin A/B
- Enteroaggregative E.coli (EAEC)
- Enteroinvasive E.coli (EIEC)/Shigella
- Enteropathogenic E.coli (EPEC)
- Enterotoxigenic E.coli (ETEC) lt/st
- Pathogenic Campylobacter spp. (C.jejuni, C.upsaliensis, C.coli)
- Plesiomonas shigelloides
- Salmonella
- Shiga-like toxin producing E.coli (STEC) stx1/stx2
- Shiga-like toxin producing E.coli (STEC) O157:H7
- Vibrio cholerae
- Vibrio parahaemolyticus
- Vibrio vulnificus
- Yersinia enterocolitica

4 parasites

- Cyclospora cayetanensis
- Cryptosporidium spp.
- Entamoeba histolytica
- Giardia lamblia

6 viruses

- Adenovirus F40/41
- Astrovirus
- Norovirus GI
- Norovirus GII
- Rotavirus A

Respiratory Panel

18 viruses

- Adenovirus
- Bocavirus
- Coronavirus 229E

- Coronavirus HKU1
- Coronavirus NL63
- Coronavirus OC43
- human Metapneumovirus A/B
- Influenza A
- Influenza A subtype H1N1/2009
- Influenza A subtype H1
- Influenza A subtype H3
- Influenza B
- Parainfluenza virus 1
- Parainfluenza virus 2
- Parainfluenza virus 3
- Parainfluenza virus 4
- Respiratory Syncytial virus A/B
- Rhinovirus/Enterovirus

3 Bacteria

- Bordetella pertussis
- Legionella pneumophila
- Mycoplasma pneumoniae

Nihal Altan-Bonnet Ph.D
Senior Investigator
Head, Laboratory of Host-Pathogen Dynamics
National Heart Lung and Blood Institute
National Institutes of Health
9000 Rockville Pike
Bldg 50 Room 2537
Bethesda MD 20892 USA

phone : [redacted] (b) (6)
email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 15:28:47 +0000
To: Carmina Conley
Subject: RE: JAMA article JVP200006 ready for editing

My office phone is [redacted] (b) (6) and my cell phone is [redacted] (b) (6).

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: jnjournals@jamanetwork.org <jnjournals@jamanetwork.org>
Sent: Wednesday, January 22, 2020 9:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: JAMA article JVP200006 ready for editing

01-22-2020

Dear Dr Fauci,

Please confirm receipt of this email as soon as possible.

Your manuscript, "Coronavirus Infections: More Than Just the Common Cold" (JVP200006), is entering the editing process. You will receive an edited typescript, including editors' queries, from a JAMA manuscript editor very soon. Responses to the manuscript editor will be due 24 hours from contact. A few days after that, a proof will be sent to you for final review and approval.

If you have a mobile phone number that we can use to reach you, please send that to me. Please do your best to respond as thoroughly and quickly as possible.

Should you plan to be traveling during the next couple of weeks and not able to access email, please let me know immediately and please identify the name and contact information (email address and phone number) of your backup. We look forward to working with you.

Sincerely,

Carmina Conley
JAMA

Confidentiality Note: This communication, including any attachment, is solely for the use of the addressee(s), may contain privileged, confidential or proprietary information, and may not be redistributed in any way without the sender's consent. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 04:37:47 +0000
To: Graham, Barney (NIH/VRC) [E]
Subject: FW: updated CoV slides
Attachments: Updated CoV for ASF 27Jan2020.pptx

Sorry. Here they are. This is what happens when you have 600 e-mails in your in box

---

From: Graham, Barney (NIH/VRC) [E] [redacted] (b) (6)>
Sent: Monday, January 27, 2020 8:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Corbett, Kizzmekia (NIH/VRC) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) Mascola, John (NIH/VRC) [E] [redacted] (b) (6); Morabito, Kaitlyn (NIH/VRC) [E] [redacted] (b) (6)>
Subject: updated CoV slides

Updated CoV

BG

****

Barney S. Graham, MD, PhD
Senior Investigator
Deputy Director, Vaccine Research Center
Chief, Viral Pathogenesis Laboratory
National Institute of Allergy and Infectious Diseases, NIH
40 Convent Drive, MSC 3017
Bldg 40, Room 2502
Bethesda, MD 20892-3017
Phone: [redacted] (b) (6)
URL: https://www.niaid.nih.gov/research/barney-graham-md-phd

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases shall not accept liability for any statements made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 03:33:41 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavaccine
Attachments: Evaluation of master project 2011.pdf

Please handle. Thanks.

From: Petra Lernö Hagaskolan [redacted] (b) (6)
Sent: Saturday, January 25, 2020 3:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Coronavaccine

Hi!
I saw that you are working with a coronavirus vaccine. I studied Masters in Infection biology and tried a new non toxic adjuvant for mucosal immunisation as my Masters thesis. I
delivered plasmids into the cell with a non toxic adjuvant and it had full access to the nucleus. It gave antibodies both in serum and in the mucosa.
It was my own project but I was not allowed to continue with my research.
[redacted] (b) (6)

Best regards

Petra Lernö,
Lärare åk 7-9
Biologi
Matematik

Hagaskolan
Dals- Eds kommun
Besöksadress
Gamla Edsvägen 46
668 30 Ed

Postadress;
Box 30
668 21 Ed

E- post
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 10 Jan 2020 21:39:23 +0000
To: Graham, Barney (NIH/VRC) [E]
Subject: FW: Wuhan coronavirus

Barney:

As per Jon Cohen's questions, have you officially requested the virus? If not, you should so that we can say that we did indeed try to obtain it. Will you answer Jon Cohen's question?

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Jon Cohen <jcohen@aaas.org>
Sent: Friday, January 10, 2020 4:33 PM
To: Graham, Barney (NIH/VRC) [E] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Wuhan coronavirus

Hi Barney and Tony,

Has the NIH requested the Wuhan coronavirus sequence from China?

If so, when, and what has been the response?

Thanks,

Jon

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 17:10:33 +0000
To: Paules, Catharine
Subject: FW: Urgent: JAMA Viewpoint on HCoV
Attachments: JVP200006.pdf

As discussed.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Stacy Christiansen <Stacy.Christiansen@jamanetwork.org>
Sent: Wednesday, January 22, 2020 12:02 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Urgent: JAMA Viewpoint on HCoV
Importance: High

Hi Dr Fauci and Dr Marston.
Attached is your Viewpoint on the n-CoV. We would really like to publish it tomorrow morning.
Is it possible for you to review very quickly today? In the next hour or 2?

Thanks so much
Stacy

Stacy L. Christiansen, MA
Managing Editor, *JAMA*
Chair, *AMA Manual of Style*

AMA MANUAL OF STYLE
A Guide for Authors and Editors

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 12:27:42 +0000
To: Corey MD, Larry
Subject: RE: Coronavirus

Thanks.

-----Original Message-----
From: Corey MD, Larry [redacted] (b) (6)
Sent: Sunday, January 26, 2020 3:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6) Conrad, Patricia (NIH/NIAID) [E]
<[redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (4), (b) (6)

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Saturday, January 25, 2020 5:55 PM
To: Corey MD, Larry [redacted] (b) (6)>
Cc: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6) Conrad, Patricia (NIH/NIAID) [E]
<[redacted] (b) (6)
Subject: RE: Coronavirus

[redacted] (b) (6), (b) (4)

-----Original Message-----
From: Corey MD, Larry <[redacted] (b) (6)
Sent: Saturday, January 25, 2020 8:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Coronavirus

[redacted] (b) (6), (b) (4)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 12 Jan 2020 17:25:16 +0000
To: Paules, Catharine
Cc: Marston, Hilary (NIH/NIAID) [E];Folkers, Greg (NIH/NIAID) [E]
Subject: RE: Coronaviruses are cool

The outline looks good – [redacted] (b) (5)

From: Paules, Catharine [redacted] (b) (6) >
Sent: Saturday, January 11, 2020 11:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronaviruses are cool

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 00:01:04 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

I have not responded. Please take care of this. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Thursday, January 30, 2020 6:41 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Cc: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] <[redacted] (b) (6) Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Thanks a million.

May Dr. Ashton and I come to DC Monday afternoon to record some development of the potential vaccine and interview you?
What might we be able to capture on camera?

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
www.ericmstrauss.com
Phone: 212-456-2016
Connect on Social: T/I/F = @ericMstrauss

From: Fauci, Anthony (NIH/NIAID) [E] [mailto: [redacted] (b) (6)
Sent: Wednesday, January 29, 2020 10:45 PM
To: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] < [redacted] (b) (6) Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6) Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Eric:

The CDC is holding people for 3 days since that will give them the opportunity to question the level of risk to which they were exposed and also, their nasal passages will be tested for virus. If they have symptoms they go to tertiary follow-up of a closer medical exam. If they have no symptoms and their medical exam is negative they will be go home with instructions to monitor themselves carefully. There is reluctance to keep people for 15 days when they have a negative diagnostic test and they are in the loop of being self-monitored.

I am sure that we can arrange to have Dr. Ashton come to our vaccine research center to witness the actual research of the vaccine.

Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Wednesday, January 29, 2020 3:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Fwd: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Hello Dr Fauci. I thought the joint press conference yesterday was great. Very clear information.

Especially your guidance in asymptomatic spread in relation to previous outbreaks and it's minor impact.

[redacted] (b) (6), (b) (4)

- please see my colleagues questions below. Why are they keeping the US citizens isolated for only 3 days if the incubation period has been reported between a day and 14? May I quote your answer or just for my background knowledge?

- I have a standing request with HHS and CDC about bringing Dr Ashton and a crew to see the preparedness / on going response... do you have any visual ideas what we can do to educate and reassure the US public? Anything about diagnostic, therapy or vaccine development?

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
212-456-2016
@ericMstrauss

Begin forwarded message:

From: "Finnegan, Conor J." <Conor.J.Finnegan@abc.com>
Date: January 29, 2020 at 2:15:37 PM EST
To: "Strauss, Eric M." <Eric.M.Strauss@abc.com>
Subject: Re: UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Random medical Q... if the incubation period is 14 days, why aren't they holding everyone from the flight for 14 days? If they're infected, they wouldn't necessarily show signs after 3 days— so they could potentially be releasing infected people right?

Conor Finnegan | ABC News State Dept Reporter-Producer | Cell: [redacted] (b)(6) | Sent from my iPhone

On Jan 29, 2020, at 2:08 PM, Strauss, Eric M. <Eric.M.Strauss@abc.com> wrote:

UPDATED: HHS and CDC receive flight carrying repatriated US citizens

Media Statement

For Immediate Release
Wednesday, January 29, 2020

Contact: CDC Media Relations
(404) 639-3286

UPDATED: HHS and CDC receive flight carrying repatriated US citizens

This morning, the Department of Health and Human Services (HHS) and Centers for Disease Control and Prevention (CDC) in collaboration with the Department of State received the flight carrying approximately 210 U.S. citizens from Wuhan at March Air Reserve Base in California.

The plane was met by a team of CDC medical officers deployed there to assess the health of the passengers. The passengers have been screened, monitored and evaluated by medical personnel every step of the way, including before takeoff, during the flight, during a refueling in Anchorage, Alaska, and now post-arrival. CDC staff have conducted risk assessments to ensure the health of each traveler, including temperature checks and observing for respiratory symptoms.

CDC will work with the California Department of Public Health and Riverside County Public Health to transport any passenger exhibiting symptoms to a hospital for further evaluation. Passengers not exhibiting symptoms of exposure, will be asked to stay on the base in housing to allow CDC medical officers to perform more thorough screening and to better understand each individual's exposure.

CDC is committed to protecting the health and safety of Americans. At this time, we continue to believe the risk of coronavirus exposure to the general public is low. CDC is taking these measures to assess and care for these returning Americans to protect them, their loved ones, and their communities.

Visit 2019 novel coronavirus for the latest updates on CDC's response.

###

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

CDC works 24/7 protecting America's health, safety and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, or from human activity or deliberate attack, CDC responds to America's most pressing health threats. CDC is headquartered in Atlanta and has experts located throughout the United States and the world.

If

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 12:32:02 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Request for Interview Regarding Novel Coronavirus

Let us discuss. Doubt if I have time for this.

From: Anjana Nair <(b) (6)>
Sent: Sunday, January 26, 2020 3:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)
Subject: Request for Interview Regarding Novel Coronavirus

Sir,

My name is Anjana Jayakrishnan Nair and I am currently a student of Journalism and Mass Communication at Kerala University in South India.

We are doing a semester-wise lab journal and I am in charge of the science page. One of articles is on the coronavirus epidemic. Reuters reported talk of a vaccine for it. If it is not an inconvenience, could you give us some details on that? It would be a great honour to quote you directly in an article.

Thanking you,

Anjana J Nair

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Jan 2020 12:39:33 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: GloPID-R call

Thanks. Very helpful.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] < [redacted] (b) (6)
Sent: Monday, January 13, 2020 7:00 AM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Handley, Gray (NIH/NIAID) [E] [redacted] (b) (6)
Subject: GloPID-R call

The Global Research Collaboration for Infectious Diseases (GloPID-R) convened to discuss the Wuhan coronavirus situation this morning. GloPID-R is a consortium of funders for EID research; we are not permanent members [redacted] (b) (5) [redacted]. Call was held this morning to accommodate global time zones.

Participants: WHO R&D Blueprint, NIH, EC, BMGF, INSERM, Institut Pasteur, ISARIC, GOARN China is not part of GloPID-R (though they have been invited). South Korea and Thailand are, and were invited but were unable to join.

Situation update (from WHO):

- Wuhan cluster information unchanged – 41 cases, 1 death; investigations ongoing for a zoonotic source. Based on sequencing info, it appears to be a single source (with some minor variation based on sequencing methodology). Importantly, when market was closed live animals were moved and likely not carefully tracked.

- Confirmed case in Thailand, identified by sequencing. Patient resides in Wuhan and traveled to Thailand. Exposure history is being investigated – whether in market or not. She was identified and isolated January 8 and is doing well.
- Sequences deposited in GenBank, apparently NOT to be used for countermeasure development as stipulated when submitted.

Research priorities (from WHO):

1. Diagnostics: WHO held an expert call on Saturday (I believe Vincent participated?). Discussing development of diagnostics outside of China, which is critical for preparedness. Marion Kaufmann convened group.
2. Therapeutics and vaccines – similar to prior report. Preparing landscape analysis; prioritizing products to be tested; adjusting existing clinical protocols used for MERS.
3. WHO will present funders with a research plan. Clearly an expectation that funders would support (we often do "in kind"/noting research we fund as contributions). Also need staff support.

Data sharing: a key priority; group thankful that sequences are being deposited, even with those restrictions.

Reorienting existing projects: EC, IHR, NIH all reaching out to coronavirus investigators regarding potential interest in work on this virus.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 00:04:36 +0000
To: NIAID OD AM
Subject: FW: Invitation to join USGLC nationwide call on coronavirus Week of February 10

Let us discuss.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jason Gross [redacted] (b) (6)
Sent: Thursday, January 30, 2020 12:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Invitation to join USGLC nationwide call on coronavirus Week of February 10
Importance: High

Dr. Fauci,
I hope you are well. You regaled the leadership of the business-ngo U.S. Global Leadership Coalition over dinner in July of 2017, and we are requesting your expertise again at a time of deep concern for the country and the world.

Our nationwide network of veterans, returned Peace Corps volunteers, Rotary Club members, global health professionals, faith leaders, state and local Chamber presidents, and elected officials are obviously concerned about reports of the Coronavirus from China. They have been asking us for the latest on the virus and how our civilian international capabilities are up to the task on this matter and on other global health security issues to come.

Would you be able to join us from your office for a nationwide conference call on the Coronavirus for 30-45 minutes for any of these windows during the week of February 10:

- February 10 | 2:30pm – 3:30pm EST
- February 11 | 2:00pm – 5:00 pm EST
- February 12 | 2:00pm – 6:00pm EST

- February 13 | 4:00pm – 6:00pm EST

We'll build our call around your availability! We know how much your time is in demand, but you can reach thousands of influential community leaders – deeply interested in global affairs – during our call. We would be so grateful if you could find 45 minutes in two weeks to join us.

Thank you so much and don't hesitate to contact me with any questions,
Jason
Jason J. Gross| Executive Director | (b) (6)| p: (b) (6)
U.S. Global Leadership Coalition | 1129 20th Street NW, Suite 600, Washington, DC 20036 | @USGLC

From: Jason Gross (b) (6)
Sent: Thursday, July 20, 2017 4:44 PM
To: (b) (6)
Cc: Lindsay Lee Plack (b) (6)>
Subject: Thank you for joining us last evening

Dr. Fauci,

On behalf of the entire U.S. Global Leadership Coalition, Lindsay and I want to thank you for anchoring our dinner last night with key members of our leadership. Immediately after the dinner last night and spilling into today, we have received heartfelt, positive feedback from your remarks last night. Our members are not only wiser after sitting down with you for an evening, but they were also reassured and proud that you worked at the fulcrum of so many public health challenges our nation has faced over the past decades.

Equally importantly, the conversation last night served to reinforce our coalition's determination to educate and advocate for the resources for pro-active American leadership in global health and related initiatives. Whether it was your recounting of the unforeseen resilience of Nigeria's Ebola resistance after PEPFAR investments a decade earlier, the remarkable story of advances in AIDS treatment due to private sector research and development, or the residual challenges in multilateral coordination for global health challenges we must address, your words rang true with our participants and provided them with ideas and arguments to press forward.

Please do not hesitate to call on us if we can provide any assistance to you in the future, and thank you again for your remarkable service to our country. We hope our paths cross again soon in the future.

Yours,
Jason Gross
Executive Director
U.S. Global Leadership Coalition

Lindsay Lee Plack
Government Relations Director
U.S. Global Leadership Coalition

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 11:34:51 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Corona Virus Vacccine

Please take a look at this.

From: Dr.Hugo Manly <[redacted] (b) (6)>
Sent: Tuesday, January 28, 2020 1:26 AM
To: Bolan, Gail (CDC/DDID/NCHHSTP/DSTDP) [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Corona Virus Vacccine

Doctors in France believe a vaccine can be made with CD 21 and CD83, combined with the DPT vaccine,since most of the Orientals in that region, lack that,at least those who have fallen victim to the Coronavirus.

The Wuhan Dept of Health is very lax and will not respond to this data, but,Xi Jinping's assistants,are eager to have more data from us, which your offices have reviewed and followed up on with supportive, technical information,since they have no DPT formulatioin dats now, and they do not make up CD83 correctly and he knows it..

Dr.Hu Manly

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 12:33:11 +0000
To: Jack Magan
Subject: RE: ANTHONY S. FAUCI, M.D., January 26, 2020

Jack:

Thank you for your kind note. I hope that all is well with you.

Best regards,
Tony

From: Jack Magan [redacted] (b) (6)
Sent: Sunday, January 26, 2020 3:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: ANTHONY S. FAUCI, M.D., January 26, 2020

Tony:

Just reading the latest coronavirus-news out of China, and it looks as if you could be the most-important man in the world within the foreseeable future.

If so, mankind couldn't be in better hands.

I don't think I ever mentioned it, [redacted] (b) (6) The two of you could possibly wind-up in the forefront of any pandemic that might evolve, should the virus elude the PRC's exceptional effort at containment.

Nobleheartedly,

Jack

---

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 13 Jan 2020 20:43:25 +0000
To: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Wuhan coronavirus overview
Attachments: Wuhan Coronavirus Update 1.10.2020.docx

Print out for PCC folder. Thanks.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Friday, January 10, 2020 5:16 PM
To: NIAID OD AM <NIAIDODAM@niaid.nih.gov>
Cc: Bushar, Nicholas (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Wuhan coronavirus overview

With input from divisions and budget, Nick and I put together the attached brief overview of our *existing* (mainly MERS) coronavirus work. I will also put in disease info.

Hilary D. Marston, MD, MPH
Medical Officer and Policy Advisor for Global Health
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
Cell: [redacted] (b) (6)
Email: [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 00:54:04 +0000
To: Barry Albertson
Subject: RE: Hi from Ore

Barry:

A travel history is the best way to go. The Chinese had person-to-person spread in the first week of December and did not realize that they had any infections with a new virus until Dec. 31, 2019. Then then thought that it was all animal to human. We they finally figured out that the virus spread human to human, the horse was already out of the barn.

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barry Albertson [redacted] (b) (6)>
Sent: Monday, January 27, 2020 1:11 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: RE: Hi from Ore
Importance: High

Hi Tony.....
Question for you,

...my clinic just put out a note to all Nursing & Front Desk staff about the period of time that person can be infected with the Coronavirus ... be potentially contagious, and yet exhibit no symptoms ...as being 1-14 days. I think that's pretty close to accurate, ...but we didn't talk much about stuff like this during Lynn's bedside patient rounds in Bldg. 10.

I see from the major news channel coverage that airport officials (and others) seem to be making initial screenings of large numbers of people (at airports, etc.) using infrared forehead temp guns.

What do you think the false negative rates might be with these infrared guns for head temps measurements, especially for asymptomatic yet coronavirus infected people,...and should we, at our Clinic (being on the West Coast), be a bit more inquisitive and pro-active ....re: asking where patients coming into our clinic have been and if they have been in the company of others who have been traveling to and from China, ...or other SE Asian countries?

Then, ...what exactly happened in Wuhan that started all of this?

I pay top-dollar for answers like this !
Barry

From: Fauci, Anthony (NIH/NIAID) [E] [mailto: (b) (6)]
Sent: Friday, January 17, 2020 1:50 PM
To: Barry Albertson
Subject: RE: Hi from Ore

Barry:

Thanks for the note. All is well here. I hope the same for you. Great photo! Thanks for sending it.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Barry Albertson (b) (6)
Sent: Friday, January 17, 2020 4:42 PM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Hi from Ore
Importance: High

Hi Tony,
... saw you last night on our local PBS station talking about Ebola, ..nicely done as usual.
Do you ever get any rest?
Hope you're well and holding up. DC (i.e. the Capitol building) seems to be a really happening place these days!!
Note sure if I send this to you, but attached is the group photo of the 1970-1990 ERRB/DEB group at our reunion last March...Lynn is seated front/center...probably didn't need to tell you that,...I'm in the back row near center.
Barry
Ps - Lynn turns (b)(6) in a few months, but still hospital bedside rounding with Medicine/Endocrinology med students, Residents & Fellows !! You and he seem to be cut from the same cloth!

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 11:43:27 +0000
To: Billet, Courtney (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E];Greg Folkers
[redacted] (b) (6))
Subject: FW: urgent news overnight

Done!

From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Tuesday, January 28, 2020 6:35 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: urgent news overnight

Good morning, Tony,
These both published in the past hour.
Can you talk right away?
Many thanks.
Elizabeth

From: https://edition.cnn.com/asia/live-news/coronavirus-outbreak-01-28-20-intl-hnk/index.html

Coronavirus patient in Germany is a 33-year-old German citizen

From CNN's Stephanie Halasz

The coronavirus patient in Germany has been identified as a 33-year-old German man who works in Starnberg, south of Munich. He had not been to China but was in a meeting with a Chinese national last week, who has since been identified with the coronavirus, Dr. Andreas Zapf, the head of the Bavarian State Office for Health and Food safety said Tuesday.

Zapf said at a news conference that the patient had attended a company meeting in Starnberg last week, where the training manager -- a female Chinese citizen -- was leading the meeting. The Chinese staff member is originally from Shanghai, but her parents had visited her there a few days prior to the meeting in Germany, Zapf said.

The Chinese citizen has since flown back to China. She felt ill on the flight back and tested positive for the coronavirus after her return to Shanghai. She notified the German office upon this discovery, Zapf said.

The first three European cases of Wuhan coronavirus were identified in France on Friday.

First suspected case of human-to-human transmission of novel coronavirus in Japan

From CNN's Junko Ogura and Yoko Wakatsuki in Tokyo

Customers buy face masks from a drugstore in Tokyo's Akihabara district. Charly Triballeau/AFP/Getty Images

Japan's health ministry confirmed two additional cases of the novel coronavirus on Tuesday, bringing the total number of confirmed cases in the country to six.

The sixth patient -- a man in his 60s in western Japan -- has no history of visiting Wuhan, but is a bus driver who drove tour groups from the central Chinese city for nine days, according to the health ministry.

This is the first case of suspected human-to-human transmission in Japan from someone who did not travel to Wuhan.

On Sunday, China announced a ban on outbound group travel as part of measures to stop the spread of the Wuhan coronavirus.

Elizabeth Cohen, MPH
CNN Senior Medical Correspondent

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 13:59:01 +0000
To: Cohen, Elizabeth
Subject: RE: To discuss

Am tied up right now. Will call a little later.

From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Sunday, January 26, 2020 4:51 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: To discuss

Has to do with this - copy and paste of the pertinent paragraph below. Ma is the Chinese health minister. This reporting appears to be accurate – CNN has it as well

Ma said the incubation period for the coronavirus can range from one to 14 days, and that the virus is infectious during incubation, which was not the case with Severe Acute Respiratory Syndrome (SARS), a coronavirus that originated in China and killed nearly 800 people globally in 2002 and 2003.

https://www.reuters.com/article/us-china-health-transmission-idUSKBN1ZP09G

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 22:28:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: (b) (6);Marston, Hilary (NIH/NIAID) [E]
Subject: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma
Attachments: Clover_Intro-Vaccines_2020.01_NonConfidential_v2.pdf

Cristina:

I am drowning here with coronavirus stuff and I am starting to get these types of e-mails. I do not have time to respond to them and so I will be forwarding them to you. Use your judgment in your response, try to help if appropriate, and as always in the spirit of NIAID, be sensitive, polite and your usual charming self. ☺

Thanks,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Steven GONG (b) (6)
Sent: Wednesday, January 22, 2020 5:57 AM
To: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma
Importance: High

Dear Professor Fauci,

This is Steven GONG from Clover Biopharma. I am writing to inform you that Clover has started development of a **recombinant coronavirus (2019-nCoV) S-protein subunit-trimer vaccine** using our globally-patented Trimer-Tag platform, and we would like to seek your advice and see if there are any potential collaboration opportunities with NIAID.

Clover is a global, clinical-stage and VC-backed biopharmaceutical company, and our novel & proprietary ***Trimer-Tag***$^{©}$ **Technology** platform can be used produce covalently-trimerized fusion proteins to target trimerization-dependent pathways. [redacted] (b) (4) As you are aware, the **Spike (S) glycoprotein of 2019-nCoV from WUHAN CHINA forms a trimer on the viral envelope**.

We have completed gene-synthesis of our 2019-nCoV subunit-trimer vaccine, and plan to have the vaccine material ready for further preclinical evaluation in **February 2020**. Given that Clover has [redacted] (b) (4)

(b) (4) [redacted]

I have attached a brief introduction to Clover, Trimer-Tag, and our Subunit-Trimer Vaccines. Let us know if any further questions.

I hope that Clover's innovative subunit-trimer vaccines platform could be of some help in assisting CDC/NIAID in rapidly developing a viable coronavirus vaccines. We will keep you posted on our progress on this as more data will be come out in next couple of weeks, and we appreciate your comments on our approach and [redacted] (b) (4)

Steven GONG | 龚东屹
Clover Biopharmaceuticals | 三叶草生物制药
[redacted] (b) (6)

VP, BD & Strategy | 副总裁、业务发展和战略
M: (b) (6)
www.cloverbiopharma.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 01:24:59 +0000
To: Rafe Sagalyn
Subject: RE: --

Rafe:

Great to hear from you. I hope that you are well. This very intense. [redacted] (b) (6) [redacted] (b) (6) should touch bases again some time when things settle down. I will fill you in on where I am.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Rafe Sagalyn [redacted] (b) (6)
Sent: Thursday, January 30, 2020 9:36 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: --

Hello Tony - What a time this must be for you.

A new client [redacted] (b) (6) told me about [redacted] (b) (6) George Scangos who, like you, is appearing on news programs to explain how serious this virus is. I figure you know Scangos and his new company VIR

Thank you for doing what you do.

P.S. [redacted] (b) (6) have had the best possible news of late — not one but two grandchildren. They're in Seattle this weekend seeing baby [redacted] (b) (6)

P.P.S. Those WHO stats below are fascinating how they put things into context

On Jan 30, 2020, at 12:45 AM, [redacted] (b) (6) wrote:

Had no idea that the infection rates were so high for measles. Yikes. Thanks for sending along.

[redacted] (b) (6) George Scangos on the coronavirus outbreak from CNBC this morning:

https://www.cnbc.com/video/2020/01/29/vir-biotechnology-ceo-on-fighting-the-coronavirus-outbreak.html

[redacted] (b) (6)

vg # of people infected by an individual w/ the following Measles 12-18 infected Smallpox 5-7 Polio 5-7 Mumps 4-7 HIV/AIDS 2-5 SARS-CoV 2-5 Influenza 2-3 *Coronavirus 1.4-2.5 (current outbreak) Ebola 1.5-2.5

via WHO

Raphael Sagalyn
ICM
PARTNERS
1500 K Street NW
Washington DC 20005
(P) [redacted] (b) (6)
(C) [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 12:06:42 +0000
To: ZHANG SHENG
Cc: Greg Folkers ([redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Questions to your new article "Coronavirus Infections more than just the common cold"

See responses in **red** below

From: ZHANG SHENG <z[redacted] (b) (6)>
Sent: Tuesday, January 28, 2020 4:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Questions to your new article "Coronavirus Infections more than just the common cold"

Dear Prof. Anthony S. Fauci: Hi.

My name is Sheng Zhang, a research fellow at a Chinese University.
I just read your article about the new type Coronavirus infections, and have some questions.
Sincerely appreciate that if you can answer them to clear some of my doubts.

The questions are:

(1) Is the vaccine ready and approved by FDA? [redacted] (b) (5)

(2) Did you get the virus sample? [redacted] (b) (5)

(3) What do you think about this outbreak of Coronavirus infections in China? And based on which judgement? [redacted] (b) (5)

I sincerely appreciate that if you can briefly answer these questions. Looking forwards to your reply.

Best regards,

--
Sheng (Shawn) Zhang

Tsinghua University

State Key Laborotory of Tribology

Beijing 100084, China

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 15:33:50 +0000
To: Jon LaPook
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Greg Folkers (b)(6);Billet, Courtney (NIH/NIAID) [E]
Subject: RE: Thanks so much, Tony. Two more questions.

John:

Thanks for the note. As you said, I will be in town tomorrow. I have my NIAID Advisory Council from 10:30 to 11:45 AM and some other things that I need to do during the day, but I am sure that Patty Conrad can do her magic and figure out a way that we can do an interview. In that regard, please make sure that you copy her on all communications (she is copied here). You have my cell number. Her office number is (b)(6) and her cell in (b)(6). I look forward to speaking with you.
Best regards,
Tony

-----Original Message-----
From: Jon LaPook <(b)(6)>
Sent: Sunday, January 26, 2020 10:10 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Re: Thanks so much, Tony. Two more questions.

Thanks, Tony.
I'm in LA and coming back a day early so I can do a piece on coronavirus tomorrow (Monday). Now that you will be in town, I wonder if I should fly to DC today rather than NYC, and interview you Monday morning or early afternoon. Are you available?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 26, 2020, at 4:30 AM, Fauci, Anthony (NIH/NIAID) [E] <(b)(6)> wrote:

Jon:

They are still trying to figure out the R0. I have heard 1.5 to 2.5, but I have not seen data. If asked, I would say that we just do not know at this point. At first we were saying 2 to 14 days and now the Chinese Health Minister is saying 14 days. I think that this is still an evolving question.
Best,
Tony

-----Original Message-----
From: Jon LaPook (b)(6)
Sent: Saturday, January 25, 2020 10:55 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b)(6)
Subject: Thanks so much, Tony. Two more questions.

1) Any sense of the R0?

2) Do you think the incubation period is 2-14 days?

Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 23:45:50 +0000
To: Reddy, Sumathi
Subject: RE: Kids and flu

I am sorry that I did not get back to you. I am swimming in coronavirus stuff.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Reddy, Sumathi <sumathi.reddy@wsj.com>
Sent: Tuesday, January 21, 2020 6:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Kids and flu

Hi Dr Fauci

I'm working on a story on the flu's impact on children this year. Do you have a few minutes to talk tomorrow? Let me know best # and time. Thanks. I'm free 9 am to 1:30 pm.
Best,
Sumathi

--
Sumathi Reddy
The Wall Street Journal
"Your Health" columnist

M: [redacted] (b) (6) O: +1 212 416 2945
E: sumathi.reddy@wsj.com
T: @rddysum
A: 1211 Avenue of the Americas, New York, NY 10036

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 15 Jan 2020 23:53:35 +0000
To: Paules, Catharine;Marston, Hilary (NIH/NIAID) [E]
Subject: RE: International Journal of Infectious Diseases: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China http://bit.ly/30mm2lt

I think that we will be OK.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Paules, Catharine [redacted] (b) (6)>
Sent: Wednesday, January 15, 2020 6:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: International Journal of Infectious Diseases: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China http://bit.ly/30mm2lt

Is it too similiar to ours? I just read it and there are similarities for sure but if the focus is more on the need for prototype pathogens I think we may be ok?

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Date: January 15, 2020 at 6:34:50 PM EST
To: Paules, Catharine < [redacted] (b) (6)>, Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: International Journal of Infectious Diseases: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China http://bit.ly/30mm2lt

== CAUTION: External Sender ==
This message came from outside of Penn State Health & College of Medicine.
Please use caution when opening attachments or links.

As per our plans for a commentary

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Wednesday, January 15, 2020 6:16 PM
Subject: International Journal of Infectious Diseases: The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China
http://bit.ly/30mm2lt

International Journal of Infectious Diseases

Available online 14 January 2020
In Press, Journal Pre-proof
What are Journal Pre-proof articles?

Editorial

The continuing epidemic threat of novel coronaviruses to global health - the latest novel coronavirus outbreak in Wuhan, China

Author links open overlay panelDavid S.Hui
EsamEl AzharTariq A.MadaniFrancineNtoumiRichardKock[1]OsmanDarGiuseppeIppolitoTimothy D.Mchugh[1]Ziad A.Memish[ab]ChristianDrosten[abc]AlimuddinZumla[1]EskildPetersen[ab]

https://doi.org/10.1016/j.ijid.2020.01.009Get rights and content

Under a Creative Commons license
open access

The city of Wuhan in China is the focus of global attention due to an outbreak of a febrile respiratory illness due to a novel coronavirus. In December 2019, there was an outbreak of pneumonia of unknown cause in Wuhan, Hubei province in China, with an epidemiological link to the Huanan Seafood Wholesale Market where there was also sale of live animals. Notification of the WHO on 31 Dec 2019 by the Chinese Health Authorities has prompted health authorities in Hong Kong, Macau, and Taiwan to step up border surveillance, and generated concern and fears that it could mark the emergence of a novel and serious threat to public health (WHO, 2020a, Parr, 2020).

The Chinese health authorities have taken prompt public health measures including intensive surveillance, epidemiological investigations, and closure of the market on 1 Jan 2020. SARS-CoV, MERS-CoV, avian influenza, influenza and other common respiratory viruses were ruled out. The Chinese scientists were able to isolate a novel CoV from a patient within a short time on 7 Jan 2020 and perform genome sequencing of the novel CoV. The genetic sequence of the novel CoV has become available to the WHO on 12 Jan 2020 and this has facilitated the laboratories in different countries to produce specific diagnostic PCR tests for detecting the novel infection (WHO, 2020b). The novel CoV is a β CoV of group 2B with at least 70% similarity in genetic sequence to SARS-CoV.

SARS is a zoonosis caused by SARS-CoV, which first emerged in China in 2002 before spreading to 29 countries/regions in 2003 through a travel-related global outbreak with 8,098 cases with a case fatality rate of 9.6%. Nosocomial transmission of SARS-CoV was common while the primary reservoir was bats and the intermediary source was civet cats in the wet markets in Guangdong (Hui and Zumla, 2019).

MERS is a novel lethal zoonotic disease of humans endemic to the Middle East, caused by MERS-CoV. Humans are thought to acquire MERS-CoV infection though contact with camels or camel products with a case fatality rate close to 35% while nosocomial transmission is also a hallmark (Azhar et al., 2019).

The recent outbreak of clusters of viral pneumonia due to a novel CoV in the Wuhan market poses significant threats to international health and may be related to sale of wild animal as game food at the seafood market.

As of 10 Jan 2020, 41 patients have been diagnosed to have infection by the novel CoV. The onset of illness of the 41 cases ranges from 8 December 2019 to 2 January 2020. Symptoms include fever (>90% cases), malaise, dry cough (80%), shortness of breath (20%) and respiratory distress (15%). The vital signs were stable in most of the cases while leucopenia and lymphopenia were common. Among the 41 cases, six patients have been discharged, seven patients are in critical care and one died, while the remaining patients are in stable condition. The fatal case involved a 61 year-old man with an abdominal tumour and cirrhosis who was admitted to a hospital due to respiratory failure and severe pneumonia. The diagnoses included severe pneumonia, acute respiratory distress syndrome, septic shock and multi-organ failure. The novel CoV infection in Wuhan appears clinically milder than SARS or MERS overall in terms of severity, case fatality rate and transmissibility. There is currently no clear evidence of human to human transmission. At present, 739 close contacts including 419 healthcare workers are being quarantined and monitored for any development of symptoms (WHO, 2020b, Center for Health Protection and HKSAR, 2020). No new cases have been detected in Wahung since 3 January 2020.

However the first case outside China has been reported today, 13th January 2020 in a Chinese tourist visiting Thailand, who is being treated in hospital.

The Chinese Health Authorities have carried out very appropriate and prompt response measures including active case finding, and retrospective investigations of the current cluster of patients which have been completed; The Huanan Seafood Wholesale Market has been temporarily closed to carry out investigation, environmental sanitation and disinfection; Public risk communication activities have been carried out to improve public awareness and adoption of self-protection measures. Technical guidance on novel coronavirus has been developed and will continue to be updated as additional information becomes available.

However, many questions about the new coronavirus remain. While it appears to be transmitted to humans via animals, the specific animals and other reservoirs need to be identified, the transmission route, the incubation period and characteristics of the susceptible population and survival rates. At present, there is however very limited clinical information of the novel CoV infection and data are missing in regard to the age range, animal source of the virus, incubation period, epidemic curve, viral kinetics, transmission route, pathogenesis, autopsy findings and any treatment response to antivirals among the severe cases. Once there is any clue to the source of animals being responsible for this outbreak, global public health authorities should examine the trading route and source of movement of wild animals from other parts to Wuhan and prevent further such trade which is posing risk to human health. The rapid identification and containment of a novel coronavirus virus rapidly in a short period of time (phylogenetic tree Archive Number: 20200112.6885385) is a re-assuring and a commendable achievement by China's public health authorities and reflects the increasing global capacity to detect, identify, define and contain new outbreaks.

This outbreak brings back memories of of the novel coronavirus outbreak in China, the severe acute respiratory syndrome (SARS) in China in 2003, caused by a novel SARS-CoV-coronavirus (World Health Organization, 2019a). SARS-CoV rapidly spread from southern China in 2003 and infected more than 3,000 people, killing 774 by 2004, and then disappeared - never to be seen again.

However, The Middle East Respiratory Syndrome (MERS) Coronavirus (MERS-CoV) (World Health Organization, 2019b), a lethal zoonotic pathogen that was first identified in humans in the Kingdom of Saudi Arabia (KSA) in 2012 continues to show up through intermittent sporadic cases, community clusters and nosocomial outbreaks. Between 2012 and December 2019, a total of 2465 laboratory-confirmed cases of MERS-CoV infection, including 850 deaths (34.4% mortality) were reported from 27 countries to WHO, the majority of which were reported by KSA (2073 cases, 772 deaths. Whilst several important aspects of MERS-CoV epidemiology, virology, mode of transmission, pathogenesis, diagnosis, clinical features, have been defined, there remain many unanswered questions, including source, transmission and epidemic potential. The Wuhang outbreak is a stark reminder of the continuing threat of zoonotic diseases to global health security. More funder and governmental investments are required for a more concerted and collaborative global effort, learning from experiences from all geographical regions, through a 'ONE-HUMAN-ENIVRONMENTAL-ANIMAL-HEALTH' global consortium to reduce the global threat of zoonotic diseases (Zumla et al., 2016).

Author declarations

All authors have a specialist interest in emerging and re-emerging pathogens. FN, OD, GI, CD are members of the Pan-African Network on Emerging and Re-emerging Infections (PANDORA-ID-NET) funded by the European and Developing Countries Clinical Trials Partnership the EU Horizon 2020

Framework Programme for Research and Innovation. AZ has received a National Institutes of Health Research senior investigator award. All authors declare no conflicts of interest.

References

WHO, 2020a

WHO**Emergencies preparedness, response. Pneumonia of unknown origin – China**
Disease outbreak news (2020)
5 January, Accessed 12 Jan 2020. Available at:
https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/
Google Scholar

Parr, 2020

J. Parr**Pneumonia in China: lack of information raises concerns among Hong Kong health workers**
BMJ, 368 (2020), p. m56, 10.1136/bmj.m56
Published 8 January 2020
Google Scholar

WHO, 2020b

WHO**Emergencies preparedness, response. Pneumonia of unknown origin – China**
Disease outbreak news (2020)
12 January, Accessed 12 Jan 2020. Available at:
https://www.who.int/csr/don/12-january-2020-novel-coronavirus-china/en/
Google Scholar

Hui and Zumla, 2019

DSC Hui, A Zumla**Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features**
Infect Dis Clin North Am., 33 (4) (2019), pp. 869-889
Article
Download PDFView Record in ScopusGoogle Scholar

Azhar et al., 2019

EI Azhar, DSC Hui, ZA Memish, C Drosten, A. Zumla**The Middle East Respiratory Syndrome (MERS)**
Infect Dis Clin North Am., 33 (4) (2019), pp. 891-905
Article
Download PDFView Record in ScopusGoogle Scholar

Center for Health Protection and HKSAR, 2020

Center for Health Protection, HKSAR**Press Release**
11 Jan Accessed 12 Jan 2020. Available at:
https://www.info.gov.hk/gia/general/202001/11/P2020011100233.htm (2020)
Google Scholar

World Health Organization, 2019a

World Health Organization**SARS (Severe Acute Respiratory Syndrome)**
https://www.who.int/ith/diseases/sars/en/ (2019)
-accessed 12th January, 2020
Google Scholar

World Health Organization, 2019b

World Health Organization**MERS situation update**
http://applications.emro.who.int/docs/EMROPub_2019_MERA_apr_EN_23513.pdf?ua=1
(2019)

(accessed August 20, 2019)
Google Scholar

Zumla et al., 2016
A Zumla, O Dar, R Kock, *et al.* **Taking forward a' One Health' approach for turning the tide against the Middle East respiratory syndrome coronavirus and other zoonotic pathogens with epidemic potential**
Int J Infect Dis, 47 (2016), pp. 5-9
Article
Download PDFView Record in ScopusGoogle Scholar

[1] Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

[1] Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

[1] Richard Kock, Alimuddin Zumla and Timothy D Mchugh are PANDORA members.

View Abstract

© 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 12:20:58 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Attachments: Draft GPMB Statement_nCOV_28Jan_for Bd member review.docx

Please take care of this as you have done in the past. Thanks.

From: GPMB Secretariat <gpmbsecretariat@who.int>
Sent: Tuesday, January 28, 2020 7:09 AM
To: As Sy Elhadj (b)(6)>; Brundtland Gro Harlem (b)(6) Dzau Victor (b)(6)>; Chris.Elias (b)(6); Farrar Jeremy (b)(6)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6); Fore Henrietta (b)(6)>; Gao Fu (b)(6) Gashumba Diane (b)(6); Kaag Sigrid (b)(6)>; Ilona Kickbusch (b)(6); Suzuki Yasuhiro (b)(6); Vega Morales Jeanette (b)(6)>; Vega Morales Jeanette (b)(6)>; VijayRaghavan Krishnaswamy (b)(6)>; 'Skvortsova Veronika' (b)(6)
Cc: MAHJOUR, Jaouad (b)(6)>; MINHAS, Raman (b)(6) Toomas Palu (b)(6)>; Pate Muhamed (b)(6)>; RYAN, Michael J. (b)(6); SCHWARTLANDER, Bernhard (b)(6)>; Alex Harris (b)(6)>; Alveberg, Benedikte Louise (b)(6); Chiaki NOGUCHI <(b)(6)>; Esveld Marja (b)(6); Esveld Marja (b)(6)>; Esveld Marja (b)(6) Gonggrijp Mette (b)(6); Julie.HALL (b)(6)>; Kanarek Morgan (b)(6)>; Marston, Hilary (NIH/NIAID) [E] (b)(6); Omar Abdi (b)(6)>; Amelie RIOUX (b)(6); Tore Godal (b)(6); GABEDAVA, Tsira (b)(6); ROSS, Alex (b)(6)>; Banks Lynr (b)(6) Block Bruce (b)(6); Conrad Jane (b)(6)>; Conrad, Patricia (NIH/NIAID) [E] (b)(6)>; Del Sol Dinia (b)(6); Diao Fay (b)(6); Gahungu Zacharie <(b)(6)>; Harikumar M K (b)(6); Harikumar M K (b)(6); Kabagire Christine (b)(6); KITA Yosuke (b)(6)>; Steven T. Smith (b)(6)>; Miller de Vega Teresa (b)(6); MURIUKI, Hilda Wairimu (b)(6); Muzenda Sindiso (b)(6); Sarah Belmir <(b)(6) YU Bai (b)(6)>; Kirsi Madi (b)(6); 'Oleg Sonin ' (b)(6)
Subject: TIME SENSITIVE Message from GPMB Co-Chairs: review of draft GPMB Statement on 2019-novel coronavirus
Importance: High

Dear Board members,

Thank you to all who participated in yesterday's teleconference call regarding the novel 2019-Coronavirus outbreak.

We received excellent updates from WHO and from Professor Gao.

There was consensus for the GPMB to issue a statement supportive of countries' (especially China) and WHO response efforts, and to call for urgent actions to further strengthen global preparedness and response to this outbreak.

Please find attached a draft GPMB Statement.

We ask that you please send us any feedback (preferably in track change mode) no later than 1700 Wednesday 29 January, Geneva time

Thank you very much.

Kinds regards,

Gro and As

From: [redacted] (b) (6)
Sent: Thu, 30 Jan 2020 20:45:42 -0500
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: Fwd: The Coronavirus & Peptide BioScineces' Immune Complex Inhibitor
Attachments: Final_Peptide BioSciences Overview_12-1-2019_LMD.pdf, ATT00001.htm, Final_ICI_MOAScience_12-1-2019.pdf, ATT00002.htm, Final PBI Alzheimer's Presentation_12-1-2019_LMD.pdf, ATT00003.htm, Final_PBI_PPP_1-3-2020_LMD.pdf, ATT00004.htm

Please handle

Begin forwarded message:

From: Lisa [redacted] (b) (6)>
Date: January 30, 2020 at 7:16:15 PM EST
To: "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: [redacted] (b) (6)>
Subject: The Coronavirus & Peptide BioScineces' Immune Complex Inhibitor

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 15:45:23 +0000
To: Strauss, Eric M.
Subject: RE: Returning Home Safety

Eric:

Thanks for the note. [redacted] (b) (6), (b) (4) The reports from China that it can spread from asymptomatic people are troubling. I have not seen the data and so I really cannot figure out how strong the science is. We really need to have our own CDC be allowed to go to China to see the data. The drugs that have shown in pre-clinical studies to "possibly" have some activity against corona viruses are remdesivir, which is a drug that we tested in DRC against Ebola. It did not work very well against Ebola, but people are considering using it for nCoV. This is not an anti-HIV drug. The other drug, which is an anti-HIV drug, is Kaletra. It is a combination of two drugs: lopinavir and ritonavir. Given the fact that there are no proven drugs to treat this coronavirus, it is understandable that they are using Kaletra on a compassionate basis. If someone is seriously ill with the virus, there is little down-side to using it. It may not help, but it unlikely will hurt. My cell number is [redacted] (b) (6).

Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Sunday, January 26, 2020 9:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: Returning Home Safety

Thx for checking back in.

[redacted] (b) (6), (b) (4)

Do you think the reports from Chinese that it can spread in asymptomatic is based in science?

What do you make of using HIV meds?

Would you pls trust us with your cell? Dr Ashton wanted to ask you something private and didn't save your number from last week. Promise not to bother you too often.

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
212-456-2016
@ericMstrauss

On Jan 25, 2020, at 9:04 PM, Fauci, Anthony (NIH/NIAID) [E] (b) (6)> wrote:

The Lancet paper established that people who are infected can have no symptoms. They made the implication without evidence that people without symptoms (asymptomatic) can transmit the infection despite the fact that they are not clinically ill. There is no solid evidence at this time that this is the case

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Saturday, January 25, 2020 7:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: Returning Home Safety

That's exactly what I'm asking! Thank you so much. And thanks for answering on a Sat night!

Dr Ashton and I and ABC News have been aggressively trying to keep everyone calm in our reporting.

Especially unless there is any human to human spread discovered in the US.

What do you make of the early Lancet studies showing a few of the people didn't have respiratory symptoms? Just GI.... probably more about poor reporting but Chinese clinicians than true on-set right?

-EMS
C: (b) (6)

Eric M. Strauss, ABC News
Managing Editor, Medical Unit
212-456-2016
Connect online: @ericMstrauss

On Jan 25, 2020, at 6:48 PM, Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:

Eric:
Thanks for the note. [redacted] (b) (6), (b) (4) (b) (6), (b) (4)
I hope that this is helpful.
Best regards,
Tony

From: Strauss, Eric M. <Eric.M.Strauss@abc.com>
Sent: Saturday, January 25, 2020 11:46 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Returning Home Safety

Dear Dr. Fauci:

Thank you as always for your reasonable perspective in putting ID in context. The important precautions you recommend and pointing out that this is a travers disease was so important for our coverage at ABC News!

[redacted] (b) (6), (b) (4)

(b) (6), (b) (4)

[redacted]

Eric M. Strauss, Managing Editor
ABC News, Medical Unit
@ericMstrauss
212-456-2016
eric.m.strauss@abc.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 03:03:52 +0000
To: Erbelding, Emily (NIH/NIAID) [E]
Subject: FW: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma

Emily:
We need to chat about your email address.
Tony

From: Microsoft Outlook <MicrosoftExchange329e71ec88ae4615bbc36ab6ce41109e@mail.nih.gov>
Sent: Wednesday, January 22, 2020 5:29 PM
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Undeliverable: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine development @ Clover Biopharma

Delivery has failed to these recipients or groups:

(b) (6)
The email address you entered couldn't be found. Please check the recipient's email address and try to resend the message. If the problem continues, please contact your helpdesk.

Diagnostic information for administrators:

Generating server: uccbX03.nih.gov

(b) (6)
Remote Server returned '550 5.1.1 RESOLVER.ADR.RecipNotFound; not found'

Original message headers:

```
Received: from uccbX02.nih.gov (156.40.79.152) by uccbX03.nih.gov
 (156.40.79.153) with Microsoft SMTP Server (TLS) id 15.0.1473.3; Wed, 22
Jan
 2020 17:28:59 -0500
Received: from GCC02-DM3-obe.outbound.protection.outlook.com (156.40.79.134)
 by uccbX02.nih.gov (156.40.79.152) with Microsoft SMTP Server (TLS) id
 15.0.1473.3 via Frontend Transport; Wed, 22 Jan 2020 17:28:59 -0500
Received: from SN6PR09MB3758.namprd09.prod.outlook.com (52.132.113.14) by
 SN6PR09MB3664.namprd09.prod.outlook.com (20.177.252.29) with Microsoft SMTP
 Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id
 15.20.2644.19; Wed, 22 Jan 2020 22:28:58 +0000
Received: from SN6PR09MB3758.namprd09.prod.outlook.com
 ([fe80::fd99:99b9:cbfc:73b7]) by SN6PR09MB3758.namprd09.prod.outlook.com
 ([fe80::fd99:99b9:cbfc:73b7%3]) with mapi id 15.20.2644.027; Wed, 22 Jan
2020
 22:28:58 +0000
From: "Fauci, Anthony (NIH/NIAID) [E]" (b) (6) >
To: "Cassetti, Cristina (NIH/NIAID) [E]" (b) (6)
CC: " (b) (6), "Marston, Hilary
 (NIH/NIAID) [E]" (b) (6)
Subject: FW: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine
 development @ Clover Biopharma
Thread-Topic: Recombinant 2019 Novel Coronavirus (2019-nCoV) Subunit Vaccine
 development @ Clover Biopharma
Thread-Index: AdXREhaegnqIYTGTRSSmaYfapfq9/gAYNX9A
Importance: high
X-Priority: 1
Date: Wed, 22 Jan 2020 22:28:57 +0000
Message-ID:
<SN6PR09MB3758A5BFC141F79C88EE045B990C0@SN6PR09MB3758.namprd09.prod.outlook.c
om>
References: <007701d5d112$b46d34d0$1d479e70$@cloverbiopharma.com>
In-Reply-To: <007701d5d112$b46d34d0$1d479e70$@cloverbiopharma.com>
Accept-Language: en-US
Content-Language: en-US
X-MS-Has-Attach: yes
X-MS-TNEF-Correlator:
authentication-results: niaid.nih.gov; dkim=none (message not signed)
 header.d=none;niaid.nih.gov; dmarc=none action=none
 header.from=niaid.nih.gov;
x-originating-ip: [156.40.216.11]
x-ms-publictraffictype: Email
x-ms-office365-filtering-correlation-id: 8ed60c23-4feb-49f6-c22e-
08d79f8a7901
x-ms-traffictypediagnostic: SN6PR09MB3664:
x-ms-oob-tlc-oobclassifiers: OLM:10000;
x-forefront-antispam-report: SFV:SKI;SFS:;DIR:INB;SFP:;SCL:-
1;SRVR:SN6PR09MB3664;H:SN6PR09MB3758.namprd09.prod.outlook.com;FPR:;SPF:None;
LANG:en;
x-microsoft-antispam: BCL:0;
x-microsoft-antispam-message-info:
83aFRBd72BcZrD+oWBXxtRtxtmlbhym4eGl14PizAWH4PajLlPbt5Cc2F8tilvCN0WEohvIGL8DfT
z2iJC3VFp/H4xWTXdbSsgzS32fcZTWP/pIvdMlQr+qlYPl3xui8gW+5VDJ4RlPTyxsnHyYlgHCLV+
785x0WgT97GiZKECEag6YfavwRYKPLFTStSkX0jrKlAAhiwtMhGnGd0zZj193DamqAu/8E+pe0bQO
efIb/vZA9bpPA+jp6S0i0UZfYEmg9QT39oBDDk4GLIxvUWv6BLfGzCyy3p21mXuXaQ4IGSgJ9jt+b
Ek65o0rIeJ+hnfTYCIkLAXAGSfu+C2K54vGLYrNbvmPD/q2bTf8BB47+6kjx7GSOe0aEUVov0Meyy
k6tAfUfAbnq8dHwj1gReTza5krRmhxBalfkRBskSGgMk02Fcoj9Ula2gKa3s9R3
x-ms-exchange-transport-forked: True
Content-Type: multipart/mixed;

boundary="_004_SN6PR09MB3758A5BFC141F79C88EE045B990C0SN6PR09MB3758namp_"
MIME-Version: 1.0
X-MS-Exchange-CrossTenant-Network-Message-Id: 8ed60c23-4feb-49f6-c22e-
08d79f8a7901
X-MS-Exchange-CrossTenant-originalarrivaltime: 22 Jan 2020 22:28:57.8517
 (UTC)
```

```
X-MS-Exchange-CrossTenant-fromentityheader: Hosted
X-MS-Exchange-CrossTenant-id: 14b77578-9773-42d5-8507-251ca2dc2b06
X-MS-Exchange-CrossTenant-mailboxtype: HOSTED
X-MS-Exchange-CrossTenant-userprincipalname:
K0vjajfvAEIJzu0pPk1OQNrMYauIJykWrGilFYbfoIghkvghuM1tpLdj1P+D9KWh
X-MS-Exchange-Transport-CrossTenantHeadersStamped: SN6PR09MB3664
X-OrganizationHeadersPreserved: SN6PR09MB3664.namprd09.prod.outlook.com
Return-Path: (b) (6)
X-CrossPremisesHeadersPromoted: uccbX02.nih.gov
X-CrossPremisesHeadersFiltered: uccbX02.nih.gov
X-OriginatorOrg: niaid.nih.gov
```

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 17 Jan 2020 22:16:16 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: FW: intro chapter - response research
Attachments: Draft Introduction to Emergency Response Research Book 11082019_master edit_WHO_rev2_track.docx, ATT00001.htm, Draft Introduction to Emergency Response Research Book 11082019_master edit_WHO_rev_clean.docx, ATT00002.htm

As per our discussion.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: SIMONSON, Stewart [redacted] (b) (6)
Sent: Friday, January 17, 2020 5:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: intro chapter - response research

See below. I honestly thought I had sent this back—but it got hung up. Sorry about that.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 16:30:26 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus: Potential treatment options

Please handle. Thanks.

-----Original Message-----
From: Al Abed, Yousef <(b) (6)
Sent: Sunday, January 26, 2020 10:39 AM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Coronavirus: Potential treatment options

Dear Dr Anthony,
I have been involved in the field of drug discovery and sepsis for many years and I have two ideas that could be of interest to treat symptoms of coronavirus.

I am available to discuss it by phone or send it to you by an email.

Best,
Yousef
(b) (6)
—
Yousef Al-Abed, PhD
The Feinstein Institute for Medical Research Northwell Health Manhasset, NY

The information contained in this electronic e-mail transmission and any attachments are intended only for the use of the individual or entity to whom or to which it is addressed, and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient, or the employee or agent responsible for delivering this communication to the intended recipient, you are hereby notified that any dissemination, distribution, copying or disclosure of this communication and any attachment is strictly prohibited. If you have received this transmission in error, please notify the sender immediately by telephone and electronic mail, and delete the original communication and any attachment from any computer, server or other electronic recording or storage device or medium. Receipt by anyone other than the intended recipient is not a waiver of any attorney-client, physician-patient or other privilege.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 03:06:50 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Speakers for 2020 Novel Coronavirus DLG - January 23, 2020

OK. Take those out. Thanks.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)
Sent: Wednesday, January 22, 2020 9:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: Speakers for 2020 Novel Coronavirus DLG - January 23, 2020

They have now – looks like 15 mins for CDC, NIH and BARDA to do diagnostics, therapeutics and vaccines. I can take out the basic research and natural history slides. The others should work.

From: Hilary Marston (b) (6)>
Date: Wednesday, January 22, 2020 at 9:47 PM
To: Anthony Fauci (b) (6)>
Subject: Re: Speakers for 2020 Novel Coronavirus DLG - January 23, 2020

Just FYI they have not sent an agenda. I'm getting the slides weddle-ized, but it's possible you won't even present them.

From: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>
Date: Wednesday, January 22, 2020 at 5:03 PM
To: Anthony Fauci (b) (6)>, Hilary Marston < (b) (6)
Cc: "DLGDESK (HHS/ASPR/OPP)" <DLGDESK@hhs.gov>, "DeBord, Kristin (OS/ASPR/SPPR)" < (b) (6)>, "Moody, Robin (OS/ASPR/SPPR)" (b) (6)
Subject: Speakers for 2020 Novel Coronavirus DLG - January 23, 2020

Dear NIH Colleagues,

The agenda for tomorrow's Novel Coronavirus Disaster Leadership Group includes one topic for NIH to speak to, therapeutics. Can you please confirm that at least one representative from NIH will participate in this DLG to speak to this issue? Please confirm attendance by emailing DLGDESK@hhs.gov.

Respectfully,

Kelsey Donnelly (CTR)
Jr. Management Analyst, Aveshka Inc.
Office of the Assistant Secretary for Preparedness and Response
Office of Strategy, Policy, Planning, and Requirements

HEALTH AND HUMAN SERVICES (DHHS) | O'Neill House Office Building | 200 C Street SW | Washington, DC
o: (b) (6) m: (b) (6)

(b) (6) | www.phe.gov

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sat, 18 Jan 2020 21:02:50 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Greg Folkers [redacted] (b) (6);Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Wuhan 2019-NCoV perspective

[redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Saturday, January 18, 2020 1:12 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Fwd: Wuhan 2019-NCoV perspective

[redacted] (b) (5)

[redacted] (b) (6)

Begin forwarded message:

From: "Munster, Vincent (NIH/NIAID) [E]" [redacted] (b) (6)
Date: January 18, 2020 at 11:18:37 AM EST
To: "Marston, Hilary (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: "De wit, Emmie (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: FW: Wuhan 2019-NCoV perspective

Hi Hilary,

[redacted] (b) (5)

Let me know what you think,

Vincent Munster, PhD
Chief, Virus Ecology Section
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH

From: "Baden, Lindsey, M.D." <lbaden@nejm.org>
Date: Friday, January 17, 2020 at 6:14 PM
To: "[redacted] (b) (6) NEJM Presubmission inquiries <presubmissioninquiries@nejm.org>
Subject: Re: Wuhan 2019-NCoV perspective

Vincent,
This could be of interest. Since you already have a draft, do you mind sharing as this will help me more rapidly assess the potential?

Lindsey

From: "Munster, Vincent (NIH/NIAID) [E]" <vincent.munster@nih.gov>
Date: Friday, January 17, 2020 at 3:40 PM
To: "Baden, Lindsey, M.D." <lbaden@nejm.org>, NEJM Presubmission inquiries <presubmissioninquiries@nejm.org>
Subject: Wuhan 2019-NCoV perspective

Dear Dr. Baden

We would like to ask whether you think a perspective on Wuhan novel coronavirus (2019-NCoV)is of interest for NEJM.
Given the current situation in China (and Thailand, Japan and potentially Singapore), we think this contribution is very timely.

The contribution will give a perspective on emerging coronavirus outbreaks, with an emphasis on the novel coronavirus 2019-NCoV. Global public health communities are on high alert after the emergence of a novel coronavirus in Wuhan, China. The third novel emerging coronavirus in two decades, after SARS-CoV and MERS-CoV. So far, 48 cases have been reported in 3 countries (China, Thailand and Japan), including 2 fatalities and clear indications of human-to-human spread.

In our Perspective, we will argue that although it seems reassuring that the novel coronavirus appears to be much less pathogenic than MERS-CoV, and SARS-CoV, the threat of epidemic (or even pandemic) spread is likely larger than that of a more pathogenic virus. Infected people are still able to go to work and travel, thereby potentially spreading the virus. This is a huge risk to vulnerable populations with underlying comorbidities and healthcare settings, especially since SARS-CoV and MERS-CoV have shown a great propensity for nosocomial spread. Even though the virus may not be very pathogenic, this could result in a huge disruption of global public health systems and economic losses. In addition, identification of chains of transmission and subsequent contact tracing will be extremely hard in asymptomatic and mildly symptomatic cases. This warrants the current aggressive response aimed at tracing and diagnosing every infected patient and thereby breaking the transmission chain of this novel virus, so we don't have to find out what its' true epidemic or pandemic potential is.

The co-authors of this perspective have extensive experience in responding to emerging viruses, from SARS-CoV in 2003, highly pathogenic avian influenza H7N7, pandemic H1N1 influenza, MERS-CoV to the West African Ebola outbreak. The perspective is still a working draft, and is currently being reviewed by a number of co-authors and would be ready in the beginning of next week.

Kind regards,

Vincent Munster, PhD
Chief, Virus Ecology Section
Laboratory of Virology
Rocky Mountain Laboratories
NIAID/NIH

This email message is a private communication. The information transmitted, including attachments, is intended only for the person or entity to which it is addressed and may contain confidential, privileged, and/or proprietary material. Any review, duplication, retransmission, distribution, or other use of, or taking of any action in reliance upon, this information by persons or entities other than the intended recipient is unauthorized by the sender and is prohibited. If you have received this message in error, please contact the sender immediately by return email and delete the original message from all computer systems. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 17:01:26 +0000
To: Feng Zhang
Cc: Conrad, Patricia (NIH/NIAID) [E];Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Greg Folkers (b) (6)
Subject: RE: Coronavirus detection

Feng:

Thanks for the note. We would be happy to work with you to test the assays that you are developing. We ourselves are waiting for isolates and further sequence data. Happy to help you when we get these. The person at NIAID who would help with the development of the assays is Dr. Cristina Cassetti. She is copied here.

Best,
Tony

From: Feng Zhang <(b) (6)>
Sent: Sunday, January 26, 2020 11:12 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus detection

Dear Dr. Fauci,

Hope you are doing well.

I have been quite concerned about the coronavirus outbreak and have been working with colleagues to develop coronavirus testing based on our SHERLOCK technology. The technology allows for paper-strip based nucleic acid detection with single nucleotide differentiation.

I was wondering if you might be able to help us, or connect us with others, to get access to virus sequences or to partner with us to test the assays that we are developing?

Thank you very much!

Feng

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 03:43:07 +0000
To: Geller, Robert D.
Subject: RE: Coronavirus

Bob:

Thanks for the note. The CDC will designate hospitals in the Chicago area where suspect cases will be funneled. If you are not one of the designated hospitals it is unlikely that you will be referred patients. If you want to prepare for a true outbreak in the USA (unlikely), you should order typical Personal Protective Equipment (PPE) and have a isolation room, which you probably already have.

Best,
Tony

From: Geller, Robert D. [redacted] (b) (6)>
Sent: Wednesday, January 22, 2020 9:38 AM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Coronavirus

Tony
Happy New Year. As I live and practice 100 miles west of O'Hare what precautions do we need to put in place relevant to coronavirus in the hospital or offices. Thank you.
Bob

Sent from Workspace ONE Boxer This e-mail message and any attached file(s) is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged and confidential. If the reader of this message is not the intended recipient or an agent or employee of the intended entity, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received the message in error, please notify the sender immediately for instructions. Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 15:53:47 +0000
To: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNN international interview request for Fauci- clearance ASAP

Thanks, Greg.

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, January 19, 2020 10:53 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: CNN international interview request for Fauci- clearance ASAP

Today's report from Wuhan has not yet hit.
I suspect there will be more cases
I will pull it and translate it when I get it –hopefully by hit time

---

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, January 19, 2020 9:38 AM
To: ODOCPL Interviews (NIH/OD OCPL) <ODOCPLInterviews@mail.nih.gov>; OCPLPressTeam <OCPLPressTeam@od.nih.gov>; Oplinger, Anne (NIH/NIAID) [E] <[redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] <[redacted] (b) (6)>; Billet, Courtney (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Myles, Renate (NIH/OD) [E] <[redacted] (b) (6)>
Subject: CNN international interview request for Fauci- clearance ASAP

Hannah Lovejoy
Planning Producer, **CNN International**
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: [redacted] (b) (6)

Dr Fauci will pretape at cnn studio at 1130 am ET today

Topic: discuss the new coronavirus pneumonia which is now known as the Wuhan virus.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:01:09 +0000
To: Jon LaPook
Subject: RE: TIME SENSITIVE: Wife to husband spread in Illinois.

Jon:

I am very sorry that I did not get to this in time. I was frozen in the Situation Room for hours. They do not allow iPhones in the Sit Room. I would nuance your statement a little bit. There are some who say that there is evidence of asymptomatic spread and so if you say there "is no evidence that people are contagious..." some compulsive person might call you on this. I would nuance it by saying that: "it is uncertain whether asymptomatic spread occurs". You are correct that we still do not know whether someone is contagious after their symptoms have resolved.

Best regards,
Tony

-----Original Message-----
From: Jon LaPook (b) (6)
Sent: Thursday, January 30, 2020 3:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: TIME SENSITIVE: Wife to husband spread in Illinois.

Hi Tony,

I'm about to be interviewed for tonight's segment. I plan to say that the math makes sense in terms of known incubation period (either 11 or 12 days assuming she wasn't contagious before symptoms). I also will say there's no evidence that people are contagious before they get symptoms, but we still do not know whether they might be contagious after their symptoms have resolved. Do I have this right?

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 28, 2020, at 6:28 AM, Fauci, Anthony (NIH/NIAID) [E] < (b) (6)> wrote:

No one knows right now since there are no studies examining viral shedding after clinical recovery. Another reason why I want our people on site. Having said that, we will know more with studies on the 5 patients who are here in the USA

-----Original Message-----
From: Jon LaPook < (b) (6)>
Sent: Monday, January 27, 2020 11:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: Thanks, and one more question.

Any idea how long people are contagious once they stop having symptoms?

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 27, 2020, at 10:35 PM, Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)> wrote:

My pleasure!

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Monday, January 27, 2020 10:15 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: Thanks, and one more question.

I will be on CBS This Morning at 8:15A tomorrow talking about coronavirus. We will use a bite from you to start it off. Thanks again, Tony.

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 27, 2020, at 8:47 PM, Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) wrote:

Jon:
A surgical mask that one can purchase in a store and that you see so many Chinese people wearing in shots from China are certainly not perfect protectors against viral infections. They may be able to be of some benefit to block droplets from someone's sneeze or cough. These droplets contain virus, and so there may be of some benefit. They also serve to prevent people from touching their nose and mouth, which is a way of spreading virus from your hand to your mucosal surfaces. I agree that people in the USA should not feel the need to wear masks on the subway right now.
Best,
Tony

-----Original Message-----
From: Jon LaPook [redacted] (b) (6)>
Sent: Monday, January 27, 2020 8:07 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: amb@cbsnews.com
Subject: Re: Thanks, and one more question.

Hi Tony,
I'm sure you've had a long, tough day (as usual). Would you mind taking a swing at the below question about the efficacy of wearing a surgical mask? And, believe it or not. They want me to address the question of whether people should wear a surgical mask on, say, the subway right now. My answer would be no. I would love you to back me up on that!

Thanks,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

On Jan 27, 2020, at 2:51 PM, Jon LaPook [redacted] (b) (6)> wrote:

Tony,
As always, I am so grateful for the terrific access we have to you and, more importantly, to your brain. One more question: how effective do you think these regular masks are – not the N95 ones but the masks you see people wearing on the street. On the one hand, the virus is so small it could go right through the mask. On the other hand, it might be effective in stopping droplets that contain virus. And in the Lancet article about the family cluster, the girl who wore the mask did not get sick whereas the 10-year-old boy who did not wear the mask did get sick.

Please keep us in the loop about new developments!

Best,
Jon

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 16:27:38 +0000
To: carlschiller
Subject: RE: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Carl:

Thanks for the note. I hope that all is well with you. All good here. I anticipate that this new coronavirus from Wuhan will keep me busy for a while. If I get invited to the Aspen Ideas Festival this summer, I will shoot you an e-mail to see if we can connect.

Best regards,
Tony

From: carlschiller [redacted] (b) (6)
Sent: Saturday, January 18, 2020 10:29 PM
To: Jim Stratton <[redacted] (b) (6)>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Pretty much what happens when you kill and eat anything that moves.

Calling on Tony Fauci (again) .
I had lunch with Tony last year and told him he deserves the Nobel award.
He laughed and said, No it was the other Italian kid Gallo who discovered the HIV virus, not him.
Kind of reminded me of when Churchill was told that during the war he was the Lion for Britain.
Churchill replied, the British people were the Lion,
I was just privileged to deliver the roar.

On Jan 18, 2020, at 11:52 AM, James Stratton [redacted] (b) (6) wrote:

Another bad coronavirus from China:

Begin forwarded message:

From: Centers for Disease Control and Prevention <no-reply@emailupdates.cdc.gov>
Date: January 17, 2020 at 19:38:10 PST
To: [redacted] (b) (6)
Subject: CDC Health Alert Network (HAN) Health Update: Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China
Reply-To: "Centers for Disease Control and Prevention" <subscriptions@cdc.gov>

CDC issued the following Health Alert Network (HAN) Health Update on January 17, 2020. You are receiving this information because you subscribe to COCA email updates. If a colleague forwarded this email to you, yet you would like to receive future updates directly from COCA, click here.

If you have any questions about this or other clinical issues, please e-mail coca@cdc.gov
On behalf of the Clinician Outreach and Communication Activity (COCA)
Centers for Disease Control and Prevention (CDC)
Join us on Facebook

HAN
This is an official
CDC
HEALTH UPDATE

Distributed via the CDC Health Alert Network
January 17, 2020, 2030 ET (8:30 PM ET)
CDCHAN-00426

Update and Interim Guidance on Outbreak of 2019 Novel Coronavirus (2019-nCoV) in Wuhan, China

Summary

The Centers for Disease Control and Prevention (CDC) continues to closely monitor an outbreak of a 2019 novel coronavirus (2019-nCoV) in Wuhan City, Hubei Province, China that began in December 2019. CDC has established an Incident Management System to coordinate a domestic and international public health response.

Coronaviruses are a large family of viruses. Some cause illness in people; numerous other coronaviruses circulate among animals, including camels, cats, and bats. Rarely, animal coronaviruses can evolve and infect people and then spread between people such as has been seen with Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) (https://www.cdc.gov/coronavirus/mers/index.html) and Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) (https://www.cdc.gov/sars/index.html).

Chinese authorities report most patients in the Wuhan City outbreak have been epidemiologically linked to a large seafood and animal market, suggesting a possible zoonotic origin to the outbreak. Chinese authorities additionally report that they are monitoring several hundred healthcare workers who are caring for outbreak patients; no spread of this virus from patients to healthcare personnel has been reported to date. Chinese authorities are reporting no ongoing spread of this virus in the community, but they cannot rule out that some limited person-to-person spread may be occurring. China has reported that two of the patients have died, including one with pre-existing medical

conditions. Chinese health officials publicly posted the genetic sequence of the 2019-nCoV on January 12, 2020. This will facilitate identification of infections with this virus and development of specific diagnostic tests.

Thailand and Japan have confirmed additional cases of 2019-nCoV in travelers from Wuhan, China. It is possible that more cases will be identified in the coming days. This is an ongoing investigation and given previous experience with MERS-CoV and SARS-CoV, it is possible that person-person spread may occur. There is much more to learn about the transmissibility, severity, and other features associated with 2019-nCoV as the investigations in China, Thailand, and Japan continue. Additional information about this novel virus is needed to better inform population risk.

This HAN Update provides a situational update and guidance to state and local health departments and healthcare providers that supersedes guidance in CDC's HAN Advisory 424 distributed on January 8, 2020. This HAN Update adds guidance for evaluation of patients under investigation (PUI) for 2019-nCoV, prevention and infection control guidance, including the addition of an eye protection recommendation, and additional information on specimen collection.

Background

An outbreak of pneumonia of unknown etiology in Wuhan City was initially reported to WHO on December 31, 2019. Chinese health authorities have confirmed more than 40 infections with a novel coronavirus as the cause of the outbreak. Reportedly, most patients had epidemiological links to a large seafood and animal market. The market was closed on January 1, 2020. Currently, Chinese health authorities report no community spread of this virus, and no transmission among healthcare personnel caring for outbreak patients. No additional cases of infection with 2019-nCoV have been identified in China since January 3, 2020.

On January 13, 2020 public health officials in Thailand confirmed detection of a human infection with 2019-nCoV in a traveler from Wuhan, China. This was the first confirmed case of 2019-nCoV documented outside China. On January 17, 2020 a second case was confirmed in Thailand, also in a returned traveler from Wuhan City. On January 15, 2020 health officials in Japan confirmed 2019-nCoV infection in a returned traveler from Wuhan City. These persons had onset dates after January 3, 2020. These cases did not report visiting the large seafood and animal market to which many cases in China have been linked.

On January 11, 2020, CDC updated the level 1 travel health notice ("practice usual precautions") for Wuhan City, Hubei Province, China with additional information (originally issued on January 6, 2020): https://wwwnc.cdc.gov/travel/notices/watch/novel-coronavirus-china.

Recommendations for Healthcare Providers

Limited information is available to characterize the spectrum of clinical illness associated with 2019-nCoV. No vaccine or specific treatment for 2019-nCoV infection is available; care is supportive.

The CDC clinical criteria for a 2019-nCoV patient under investigation (PUI) have been developed based on what is known about MERS-CoV and SARS-CoV and are subject to change as additional information becomes available.

Healthcare providers should obtain a detailed travel history for patients being evaluated with fever and acute respiratory illness. CDC guidance for evaluating and reporting a PUI for MERS-CoV remains unchanged.

Criteria to Guide Evaluation of Patients Under Investigation (PUI) for 2019-nCoV

Patients in the United States who meet the following criteria should be evaluated as a PUI in association with the outbreak of 2019-nCoV in Wuhan City, China.

1) Fever[1] AND symptoms of lower respiratory illness (e.g., cough, shortness of breath)

–and in the last 14 days before symptom onset,

- **History of travel from Wuhan City, China**

-or-

- **Close contact[2] with a person who is under investigation for 2019-nCOV while that person was ill.**

2) Fever1 OR symptoms of lower respiratory illness (e.g., cough, shortness of breath)
–and in the last 14 days before symptom onset,

- **Close contact[2] with an ill laboratory-confirmed 2019-nCoV patient.**

The above criteria are also available at https://www.cdc.gov/coronavirus/2019-nCoV/clinical-criteria.html. The criteria are intended to serve as guidance for evaluation. Patients should be evaluated and discussed with public health departments on a case-by-case basis if their clinical presentation or exposure history is equivocal (e.g., uncertain travel or exposure).

Recommendations for Reporting, Testing, and Specimen Collection

Healthcare providers should immediately notify both infection control personnel at their healthcare facility and their local or state health department in the event of a PUI for 2019-nCoV. State health departments that have identified a PUI should immediately contact CDC's Emergency Operations Center (EOC) at 770-488-7100 and complete a 2019-nCoV PUI case investigation form available at https://www.cdc.gov/coronavirus/2019-ncov/downloads/pui-form.pdf. CDC's EOC will assist local/state health departments to collect, store, and ship specimens appropriately to CDC, including during afterhours or on weekends/holidays. At this time, diagnostic testing for 2019-nCoV can be conducted only at CDC. Testing for other respiratory pathogens should not delay specimen shipping to CDC. If a PUI tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a PUI. This may evolve as more information becomes available on possible 2019 nCoV co-infections.

For biosafety reasons, it is not recommended to perform virus isolation in cell culture or initial characterization of viral agents recovered in cultures of specimens from a PUI for 2019-nCoV. To increase the likelihood of detecting 2019-nCoV infection, CDC recommends collecting and testing multiple clinical specimens from different sites, including all three specimen types—lower respiratory, upper respiratory, and serum specimens. Additional specimen types (e.g., stool, urine) may be collected and stored. Specimens should be collected as soon as possible once a PUI is identified regardless of time of symptom onset. Additional guidance for collection, handling, and testing of clinical specimens is available at https://www.cdc.gov/coronavirus/2019-nCoV/.

Interim Healthcare Infection Prevention and Control Recommendations for Patients Under Investigation for 2019-nCoV

Although the transmission dynamics have yet to be determined, CDC currently recommends a cautious approach to patients under investigation for 2019-nCoV (https://www.cdc.gov/coronavirus/2019-nCoV/clinical-criteria.html). Such patients should be asked to wear a surgical mask as soon as they are identified and be evaluated in a private room with the door closed, ideally an airborne infection isolation room if available. Healthcare personnel entering the room should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield). Immediately notify your healthcare facility's infection

control personnel and local health department.

Additional Infection Control Practices Resources

- **Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings (https://www.cdc.gov/infectioncontrol/guidelines/isolation/index.html)**

Notes

[1] Fever may not be present in some patients, such as those who are very young, elderly, immunosuppressed, or taking certain fever-lowering medications. Clinical judgment should be used to guide testing of patients in such situations.

[2] Close contact with a person who is under investigation for 2019-nCOV.

Close contact is defined as—

a) being within approximately 6 feet (2 meters), or within the room or care area, of a novel coronavirus case for a prolonged period of time while not wearing recommended personal protective equipment or PPE (e.g., gowns, gloves, NIOSH-certified disposable N95 respirator, eye protection); close contact can include caring for, living with, visiting, or sharing a healthcare waiting area or room with a novel coronavirus case.

– or –

b) having direct contact with infectious secretions of a novel coronavirus case (e.g., being coughed on) while not wearing recommended personal protective equipment.

See CDC's Interim Healthcare Infection Prevention and Control Recommendations for Patients Under Investigation for 2019 Novel Coronavirus (https://www.cdc.gov/coronavirus/2019-nCoV/infection-control.html).

Data to inform the definition of close contact are limited. Considerations when assessing close contact include the duration of exposure (e.g., longer exposure time likely increases exposure risk) and the clinical symptoms of the person with novel coronavirus (e.g., coughing likely increases exposure risk as does exposure to a severely ill patient). Special consideration should be given to those exposed in healthcare settings.

For More Information

More information is available at at https://www.cdc.gov/coronavirus/2019-nCoV/index.html or by calling 800-CDC-INFO | (800-232-4636) | TTY: (888) 232-6348

The Centers for Disease Control and Prevention (CDC) protects people's health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national, and international organizations.

Categories of Health Alert Network messages:

Health Alert - Requires immediate action or attention; highest level of importance

Health Advisory - May not require immediate action; provides important information for a specific incident or situation

Health Update - Unlikely to require immediate action; provides updated information regarding an incident or situation

HAN Info Service - Does not require immediate action; provides general public health information

---

##This message was distributed to state and local health officers, state and local epidemiologists, state and local laboratory directors, public information officers, HAN coordinators, and clinician organizations##

You have received this message based upon the information contained within our emergency notification data base. If you have a different or additional e-mail or fax address that you would like us to use please contact your State-based Health Alert Network program at your State or local health department.

Centers for Disease Control and Prevention

1600 Clifton Rd Atlanta, GA 30329 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348

Questions or Problems | Unsubscribe

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 17:25:11 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: CNNi interview request - TODAY (Sunday 19th January)

I will let you continue to deal directly with Hannah and so I will not reply to her. However, if they want to do Skype, David could get on the phone with me and school me on how to do skype from my iPhone at home, which I have already done before with his help in my office. And so, you can tell Hannah that we are OK with Skype if the DC bureau cannot accommodate.

From: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Sent: Sunday, January 19, 2020 12:18 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10pET.

If it isn't, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 15:34
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

He will not need a car.

Also-to clarify-this will be a pre tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That's great – thank you Patricia.

Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: 19 January 2020 15:12
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I've spoken to show producers and they need Dr Fauci this evening for a pre-tape – sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: 19 January 2020 14:59
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Washington DC.

Sent from my iPhone

On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci's availability – what CNN studio will he be available from?

I will speak to my producers and confirm availability ASAP.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 14:39
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 13:57
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>

Cc: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Hannah what is the exact live hit time?

Sent from my iPhone

On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you're well.

I wanted to introduce myself, I'm Hannah Lovejoy and I'm a planning producer for **CNN International**.

We were hoping that you would be available to **join us for a one-on-one interview today (Sunday 19th January)?**

We'd like you to **discuss the new coronavirus pneumonia which is now known as the Wuhan virus**.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you're available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, **CNN International**
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: (b) (6) |

<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and

delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:09:14 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavirus vaccine monitoring

Please handle.

From: Prabhala, Rao [redacted] (b) (6) >
Sent: Thursday, January 30, 2020 9:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6) >
Subject: coronavirus vaccine monitoring

Dear Dr. Fauci,

[redacted] (b) (4)

Best,
Dr. Rao Prabhala
DFCI/BWH/HMS
[redacted] (b) (6)

The information in this e-mail is intended only for the person to whom it is addressed. If you believe this e-mail was sent to you in error and the e-mail contains patient information, please contact the Partners Compliance HelpLine at http://www.partners.org/complianceline . If the e-mail was sent to you in error but does not contain patient information, please contact the sender and properly dispose of the e-mail.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 02:18:17 +0000
To: Jon LaPook
Subject: RE: Link to tonight's segment. Thanks again, Tony.

Jon:
Very nice segment. Sorry that I did not get back to you myself today. As patty probably told you, I was completely tied up with meetings.
Best regards,
Tony

-----Original Message-----
From: Jon LaPook (b) (6)>
Sent: Tuesday, January 28, 2020 7:52 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Link to tonight's segment. Thanks again, Tony.

https://www.cbsnews.com/video/health-officials-expand-screenings-for-deadly-coronavirus/

Jonathan LaPook, M.D.
Chief Medical Correspondent, CBS News
Professor of Medicine
NYU Langone Health
Twitter @DrLaPook

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 18:23:37 +0000
To: Doepel, Laurie (NIH/NIAID) [E]
Cc: Folkers, Greg (NIH/NIAID) [E];Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: Ready for review in G:OD: Council Remarks and Council Slide DRAFTS for 01-27-2020

I have gone over the script remarks and the Council slides. The remarks are now marked as "FINAL" in the OD folder. However, I have kept the tracked changes showing so that you can see what I have done. Please accept these changes and then give it a spell and grammar check and it will be "FINAL". I have labelled the Council slides as "1st FINAL" since there are a few slides which I have indicated that will need to be updated (one of the influenza slides and the coronavirus slides) at the end of the coming week. After we do that, it will be "FINAL".
Thanks.

From: Doepel, Laurie (NIH/NIAID) [E] (b) (6)>
Sent: Friday, January 17, 2020 6:38 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Doepel, Laurie (NIH/NIAID) [E] (b) (6); Folkers, Greg (NIH/NIAID) [E] (b) (6); Conrad, Patricia (NIH/NIAID) [E] < (b) (6)
Subject: Ready for review in G:OD: Council Remarks and Council Slide DRAFTS for 01-27-2020

Dr. Fauci,

The Council Remarks and Council Slide DRAFTS for 01-27-2020 are ready for your review in G:OD. There are likely more slides than you need, but I tried to group them for potential culling.

Just as a reminder, we have no second speaker for Council this time.

Thank you,

Laurie

Laurie K. Doepel
Senior Advisor for Science Communications
Immediate Office of the Director
National Institute of Allergy and Infectious Diseases
National Institutes of Health
9000 Rockville Pike
Building 31, Suite 7A03
Bethesda, MD 20892-2520
(b) (6)

(b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:16:39 +0000
To: Aaron Weddle
Cc: 'john@vsbassociates.com';Greg Folkers [redacted] (b) (6));Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: POTUS briefing

Aaron:

Please make the usual 5 X 7 black framed photo of this with Legend: Briefing President trump on the 2019-nCoV (coronavirus) outbreak – The White House Situation Room – Jan. 29, 2020. Also, make a power point of this with the same title and Greg: please put th4 slide with our accumulating set of coronavirus slides.

Thanks,

Tony

From: Hall, Bill (HHS/ASPA) [redacted] (b) (6)>
Sent: Thursday, January 30, 2020 10:08 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: POTUS briefing

Hi Tony…came across this shot from the collection from yesterday's briefing. Thought you'd like to have a copy. Best, Bill

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 02:45:04 +0000
To: Wendy Holman
Subject: RE: Recent events

Wendy:
Thank you for your kind note. I hope that all is well with you.
Best regards,
Tony

-----Original Message-----
From: Wendy Holman <[redacted] (b) (6)>
Sent: Tuesday, January 28, 2020 9:27 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Recent events

Hi there,

I continue to be endlessly impressed with the level of poise and sophistication coming from you and your NIAID staff regarding all of the questions and concerns relating to this recent coronavirus outbreak. I admire your level headed straight shooter approach to questions. While we don't know what the next days and weeks will bring, I believe the American people derive comfort from your honest no nonsense approach with them.

Proud to be your partner,
Wendy

Wendy Holman
CEO & Co-Founder
Ridgeback Biotherapeutics
www.ridgebackbio.com
[redacted] (b) (6)

DISCLAIMER: This e-mail message and any attachments are intended solely for the use of the individual or entity to which it is addressed and may contain information that is confidential or legally privileged. If you are not the intended recipient, you are hereby notified that any dissemination, distribution, copying or other use of this message or its attachments is strictly prohibited. If you have received this message in error, please notify the sender immediately and permanently delete this message and any attachments.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 21:50:08 +0000
To: Skip Virgin
Cc: Cassetti, Cristina (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E];Mascola, John (NIH/VRC) [E];Conrad, Patricia (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];Greg Folkers [redacted] (b) (6)
Subject: RE: Collaboration with NIH? Worth talking?

Skip:

Thanks for the note. This definitely resonates with me. Such a collaboration could go through DMID (Cassetti and Erbelding) and/or VRC (Mascola). I have copied everyone of this e-mail. We can talk about specifics after we get them involved.

Best,

Tony

From: Skip Virgin [redacted] (b) (6)
Sent: Sunday, January 26, 2020 11:47 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Collaboration with NIH? Worth talking?

Tony

[redacted] (b) (4)

Skip

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue
San Francisco CA 94158
he/him/his

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 15:23:58 +0000
To: Collins, Francis (NIH/OD) [E]
Subject: RE: Coronavirus and Davos

It is about 9 to 10% Around 8000 cases and 774 deaths.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] (b) (6)>
Sent: Thursday, January 23, 2020 8:54 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Cc: Burklow, John (NIH/OD) [E] (b) (6)
Subject: RE: Coronavirus and Davos

P.S. what was the mortality rate for SARS? I've heard claims of 60% but I thought it was a lot lower than that.

FC

-----Original Message-----
From: Collins, Francis (NIH/OD) [E]
Sent: Thursday, January 23, 2020 8:52 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: Burklow, John (NIH/OD) [E] < (b) (6)
Subject: RE: Coronavirus and Davos

Thanks for all this updated info, Tony. I had a premonition that Lally Weymouth would call on me at the Washington Post luncheon (in front of numerous US Cabinet members, Ivanka, and several heads of state). Sure enough, she did. I think I did a decent job of relating what we currently know about coronavirus, and what we don't know yet.

If there are press calls about what the US is doing, I will refer them to you. I'm ccing John.

FC

-----Original Message-----
From: Fauci, Anthony (NIH/NIAID) [E] < (b) (6)>
Sent: Thursday, January 23, 2020 6:56 AM
To: Collins, Francis (NIH/OD) [E] (b) (6)

Subject: RE: Coronavirus and Davos

Anecdotal data suggest that most transmissions occur when transmitter is late in the infection, i.e. clinically ill. However, some anecdotal data suggest that early transmission does occur to some degree. The man in Seattle who travelled to Wuhan cannot remember coming into contact with anyone who appeared ill. Regarding mAbs, we have them against SARS and MERS and are hoping that there is some cross-reactivity of the anti-SARS Abs with nCov. However, it is difficult at this time to test since we do not yet have isolates of nCov; we only have sequence. As soon as we get isolated we can test.

-----Original Message-----
From: Collins, Francis (NIH/OD) [E] <(b) (6)>
Sent: Thursday, January 23, 2020 5:50 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Coronavirus and Davos

Hi again,
Was just part of a discussion with Hatchett, Farrar, WHO rep (Tedros not here), Berkley, Stoffels. Big issue seems to be whether transmissibility happens early or late in the course of infection. Obviously late would be much better for public health measures. Your read on current data?
Any effort on developing MAb at NIH?
FC

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 19 Jan 2020 18:42:24 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Tedros chapter
Attachments: 011720 PPERR Intro with Tedros Edits HM RAS.docx

I have gone over this. Please see me about it early next week wo that we can finalize it and get it out. Thanks.

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Saturday, January 18, 2020 10:11 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] <[redacted] (b) (6)>
Subject: Tedros chapter

[redacted] (b) (5)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 02:46:04 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: coronavaccine

Please handle.. Thanks.

-----Original Message-----
From: Mark Pasek (b) (6)>
Sent: Tuesday, January 28, 2020 9:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: coronavaccine

I am wondering if the complexity of the coronavirus genome invites developing a full-length dsDNA immunogen.

Mark Paul Pasek, PhD
Houston, TX
Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 16:24:23 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Personal Protective Equipment and coronavirus

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Frank Diamond <fdiamond@mjhlifesciences.com>
Sent: Thursday, January 23, 2020 11:22 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Personal Protective Equipment and coronavirus

Dear Doctor,

I would like to your input (if even just a single quote?) about the importance of PPE in light of the coronavirus outbreak for a story that I hope to post to our website today. What are the protocols? Should extra precautions be taken and, if so, what? What's the best sort of equipment? Thanks for any help.

Cordially,

Frank Diamond
Managing Editor
Infection Control Today

Disclaimer

The information contained in this communication from the sender is confidential. It is intended solely for use by the recipient and others authorized to receive it. If you are not the recipient, you are hereby notified that any disclosure, copying, distribution or taking action in relation of the contents of this information is strictly prohibited and may be unlawful.

This email has been scanned for viruses and malware, and may have been automatically archived by **Mimecast Ltd**, an innovator in Software as a Service (SaaS) for business. Providing a **safer** and **more useful** place for your human generated data. Specializing in; Security, archiving and compliance. To find out more Click Here.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 02:23:02 +0000
To: Awwad, David (NIH/NIAID) [C];Blanco Munoz, Begona
Cc: Conrad, Patricia (NIH/NIAID) [E];Ali, Dalal;Lovejoy, Hannah (NE)
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Incorrect. My home phone is (b) (6) NOT (b) (6)

From: Awwad, David (NIH/NIAID) [C] <(b) (6)>
Sent: Sunday, January 19, 2020 9:08 PM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Ali, Dalal <Dalal.Ali@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

I don't see the invite. Please send to live:niaidithelp or niaidithelp@outlook.com.

Dr. Fauci home number is (b) (6)

My cell is (b) (6)

Sent from my iPhone

On Jan 19, 2020, at 9:02 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi David,

These are the numbers we have to call Dr. Fauci. Please, confirm which one should we use:

(b) (6) and (b) (6)

I'm ready now if you prefer to test now. I can see that the invitation I sent you on Skype is still pending. Please, could you confirm you got it?

Please, let me know.

Thanks!

Begoña

From: Awwad, David (NIH/NIAID) [C] (b) (6)>
Sent: Monday, January 20, 2020 9:59 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>

Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

If you call my cell, I can conference Dr. Fauci in for a test call.

Sent from my iPhone

On Jan 19, 2020, at 8:32 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Thanks so much, Patricia!

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, January 20, 2020 9:31 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

David Awwad is the POC for the connection. He will respond.

Sent from my iPhone

On Jan 19, 2020, at 8:29 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi Patricia,

I've now taken over from Dalal and will be testing your Skype connection at 9.30 pm ET. I've sent a Skype contact request to Niadithelp from my personal Skype account [redacted] (b) (6)

Please, let me know if you didn't get it.

Thanks and regards,

Begoña

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, January 20, 2020 2:08 AM

To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ok thanks

Sent from my iPhone

On Jan 19, 2020, at 1:06 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Got it – let's test around 9:30pm then.

Adding Begona who will be the one conducting the Skype test.

Thank you all.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, January 19, 2020 1:04 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Since this is Skype he will do this from his residence in [redacted] (b) (6)

Sent from my iPhone

On Jan 19, 2020, at 1:01 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hi Patricia,

Thank you for the below.
The exact taping time is 10pmET.

We can test any time ahead of that. Since he is heading to NIH then we can test shortly before – as I'm sure the connection there is great and it wont take too long. Around 9:45pm?

I have received David's information – thanks again.

Regards,

Dalal

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, January 19, 2020 12:58 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ali- pls confirm exact interview time. Dr Fauci will be doing the interview from [redacted] (b) (6) but he works at the national institutes of Health in Bethesda Maryland. Again he will physically be in [redacted] (b) (6) for this interview.

Backup numbers for him are
[redacted] (b) (6)and cell [redacted] (b) (6)

David pls provide your cell number as well. My cell is [redacted] (b) (6)

Please provide cnn studio Number as well.

Please note pronunciation for Dr Fauci is Fow-Chee and it rhymes with grouchy.

Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:41 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hello David,

Thank you. I have attached our Skype instructions to this email.

Can you provide the following:

Location: Bethesda?
Time to Test the Skype:
Phone number for set-up:

We appreciate your flexibility and do let me know if you have any further questions.

Regards,

Ms. Dalal Ali
Planning Producer- CNN International
[redacted] (b) (6)

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Sunday, January 19, 2020 12:37 PM
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Skype handle:

Niaidithelp or niaidithelp@outlook.com

Sent from my iPhone

On Jan 19, 2020, at 12:35 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thank you for confirming Dr. Fauci's availability to do the interview via Skype.

My colleague Dalal will be in touch shortly to confirm all the logistics.

Thank you again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 17:29
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can do this by Skype on his phone. I have added David Awwad here who can give you the Skype connection info. Please include him on all future correspondence. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:18 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10pET.

If it isn't, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 19 January 2020 15:34
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6) Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

He will not need a car.

Also-to clarify-this will be a pre tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That's great – thank you Patricia.

Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 19 January 2020 15:12
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I've spoken to show producers and they need Dr Fauci this evening for a pre-tape – sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 14:59
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Washington DC.

Sent from my iPhone

On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci's availability – what CNN studio will he be available from?

I will speak to my producers and confirm availability ASAP.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: 19 January 2020 14:39
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 19 January 2020 13:57
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Hannah what is the exact live hit time?

Sent from my iPhone

On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you're well.

I wanted to introduce myself, I'm Hannah Lovejoy and I'm a planning producer for **CNN International**.

We were hoping that you would be available to **join us for a one-on-one interview today (Sunday 19th January)?**

We'd like you to **discuss the new coronavirus pneumonia which is now known as the Wuhan virus**.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you're available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, **CNN International**
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK

Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: (b) (6) |

<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting

System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.
<How to conduct a Skype interview with CNN.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:30:13 +0000
To: Emanuel, Ezekiel J
Subject: FW: CNBC: Ex-Obama health advisor: US needs to 'stop panicking and being hysterical' about coronavirus

Zeke:

Good job on this. Sorry I did not get back to you on your e-mail that I am just seeing now. I have been 'locked" in the Situation Room for hours over the past 2 days.

Best,
Tony

From: Folkers, Greg (NIH/NIAID) [E] [redacted] (b)(6)
Sent: Thursday, January 30, 2020 11:06 AM
Subject: CNBC: Ex-Obama health advisor: US needs to 'stop panicking and being hysterical' about coronavirus

Ex-Obama health advisor: US needs to 'stop panicking and being hysterical' about coronavirus

Published Thu, Jan 30 202010:17 AM EST
Jessica Bursztynsky@jbursz

- Americans are too worried about the new coronavirus that's spreading rapidly across China, former White House health advisor Ezekiel Emanuel told CNBC on Thursday
- "Everyone in America should take a very big breath, slow down and stop panicking and being hysterical," said Dr. Emanuel.
- "I think we need to put it into context, the death rate is much lower than for SARS," he added.

watch now
VIDEO03:19

US should 'stop panicking' about coronavirus, says former Obama health advisor

Americans are too worried about the new coronavirus that's spreading rapidly across China, former White House health advisor Ezekiel Emanuel told CNBC on Thursday

"Everyone in America should take a very big breath, slow down and stop panicking and being hysterical," said Dr. Emanuel, who served during Barack Obama's presidency. "We are having a little too much histrionics on this."

Alex Azar, the current secretary of Health and Human Services under President Donald Trump, also said later on CNBC on Thursday that the risk to Americans remains low.

Chinese officials on Thursday increased their confirmed coronavirus cases to nearly 8,000, though some experts believe the number to be much larger. The death roll rose to 170.

Health officials across the world having been putting efforts in place, such as travel restrictions and isolation, to stop the virus from spreading. It was first discovered in the Chinese city of Wuhan in Hubei province in December.

The Centers for Disease Control and Prevention has confirmed five cases of the coronavirus in the United States, with 92 pending tests, as of Wednesday. Other countries around the world are also reporting isolated cases.

"I'm actually pretty confident that we're going to restrict the spread in the United States and people should remember not to panic," said Emanuel, University of Pennsylvania's vice provost for global initiatives. "We need to be a little sober about it, even in China."

The Wuhan virus, which causes flu-like symptoms, is not spreading through human-to-human contact in America, Dr. Nancy Messonnier, director of the National Center for Immunization and Respiratory Diseases, said on Monday.

But Dr. Mike Ryan, executive director of the World Health Organization's health emergencies program, said Wednesday that the coronavirus has spread to a handful of people through human-to-human contact outside of China.

The WHO is set to reconvene this week to decide whether to declare the coronavirus a global health emergency.

The new virus has now infected more people in China than were sickened there during the 2002-2003 SARS epidemic. That severe acute respiratory syndrome outbreak, which also originated in China, killed 774 people.

“I think we need to put it into context, the death rate is much lower than for SARS,” Emanuel said.

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 22:05:35 +0000
To: Ayesha Khan
Cc: Conrad, Patricia (NIH/NIAID) [E];Greg Folkers ([redacted] (b) (6))
Subject: RE: Ayesha from FOX 5

Ayesha:
Thanks for the note. I have not heard anything about these people and so it would be premature to discuss them. Are they from Wuhan and travelled here? Are they being investigated by the CDC?
Thanks,
Tony

-----Original Message-----
From: Ayesha Khan <Aisha.Khan@FOXTV.COM>
Sent: Sunday, January 26, 2020 4:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Ayesha from FOX 5

Hello Dr. Fauci,

Reporter Ayesha Khan from FOX 5. Are you by any chance available for another on camera interview regarding three people who are currently being investigated for possibly showing signs of the Coronavirus in Virginia? Two in Central and one in No. Va.

I can be reached on my cell at [redacted] (b) (6)
Thanks so much!
Ayesha

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:09:45 +0000
To: Marston, Hilary (NIH/NIAID) [E]
Subject: RE: Invitation to join AAPM corona virus task-force

No. I have never heard of this organization.

From: Marston, Hilary (NIH/NIAID) [E] (b) (6)>
Sent: Tuesday, January 28, 2020 7:20 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Fwd: Invitation to join AAPM corona virus task-force

Do you think this is a good use of my time?

Begin forwarded message:

From: Prasun Mishra < (b) (6)>
Date: January 28, 2020 at 5:17:25 PM EST
To: "Marston, Hilary (NIH/NIAID) [E]" (b) (6)>
Cc: "Eisinger, Robert (NIH/NIAID) [E]" (b) (6)
Subject: Invitation to join AAPM corona virus task-force

Dear Hillary,

I was referred to you by Dr Robert Eisinger. I lead AAPM- American Association for Precision Medicine and we are in a process of creating a coronavirus task force consisting of volunteer physicians, scientists, technologists and innovators. I would like to extend my personal invitation to you to join the task-force or be an advisor to AAPM on this initiative. The task-force consists of experts who have prior experience in dealing with anti-viral drugs, diagnostics and/or have experience in handling disease outbreak.

It is concerning that coronavirus that is creating a chaos in China has now reached Europe and the US. The virus has also been reported in Australia, Thailand, France, Japan, South Korea, Taiwan, Vietnam, Singapore, and Saudi Arabia. As of Monday night, there were nearly 4,500 confirmed cases and 107 deaths. The AAPM coronavirus taskforce will work together to come-up with strategies to contain the disease, new ways to diagnose, and explore opportunities to re-purpose existing drugs to help the community in this global crisis. Also, we are taking this outbreak as an opportunity to learn, to prevent and deal with any future outbreaks.

We would love to have you as a part of this task force. Looking forward to hearing from you.

Sincerely

Prasun

Prasun J Mishra, PhD
President, American Association for Precision Medicine

640 Masonic Way, MS 150,
Belmont, California, 94002, USA
Office: 650.453.8087
E-mail: (b) (6)
www.linkedin.com/in/prasunjmishra
www.aapm.health; www.a2pm.org

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 13:18:12 +0000
To: Blanco Munoz, Begona
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Begoña:

Thanks for the note. It was great working with you last night. The precautionary measures that you should take if you go to the higher risk areas are the same as for any other respiratory borne infection such as influenza. You should wash you hands as frequently as possible. If this is not feasible then the alcohol wipes or liquid that are sold in pharmacy would be good to frequently wipe your hands with. You should stay away from "wet" animal markets where they sell live animals and you should make sure that you only eat well-cooked food. In addition, you should avoid very crowded places where there are people who are coughing or who appear ill. Finally, you can wear a mask as you will see many Chinese people wearing.

We get information from the Wuhan authorities on a daily basis. Sometimes it is difficult to know if we are receiving all of the important information on a timely basis, but I believe that the Chinese have been very good in keeping us informed. I hope that this is helpful to you.

Best regards,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Sent: Monday, January 20, 2020 4:16 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Turner, Robyn (ATL) <Robyn.Turner@turner.com>; Ali, Dalal <Dalal.Ali@turner.com>; Bloom, Deborah <Deborah.Bloom@turner.com>; Sidhu, Sandi <Sandi.Sidhu@cnn.com>
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Hi Anthony,

Thanks so much for your time today for the interview.

I just wanted to check if you could help us with some information. What are the precautionary measures we should take if we were to go to higher risk areas, like Wuhan to cover the story? How should we prepare for that? What protection should we wear?

How often are you getting information from the Wuhan authorities and is this information enough for you to do investigation on the virus?

Thanks so much in advance!

Best regards,

Begoña

From: Blanco Munoz, Begona
Sent: Monday, January 20, 2020 10:30 AM
To: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Subject: RE: CNNi interview request - TODAY (Sunday 19th January)

Hi Patricia,

The interview will air at some point after 2 am ET, in our show Newsroom.

Thanks and regards,

Begoña

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, January 20, 2020 10:27 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Can you also please let me know what time the piece will air? Thank you

Sent from my iPhone

On Jan 19, 2020, at 9:13 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

we'll test out of my personal ID, [redacted] (b) (6)

I'll talk to you at 9.30 pm ET then

Sent from my Samsung Galaxy smartphone.

-------- Original message --------
From: "Awwad, David (NIH/NIAID) [C]" [redacted] (b) (6)
Date: 20/01/2020 10:09 (GMT+08:00)
To: "Blanco Munoz, Begona" <Begona.BlancoMunoz@turner.com>
Cc: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>, "Ali, Dalal" <Dalal.Ali@turner.com>, "Lovejoy, Hannah (NE)" <Hannah.Lovejoy@turner.com>, "Fauci, Anthony (NIH/NIAID) [E]" [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

I sent a request to live guest. My request is still pending as well.

Sent from my iPhone

On Jan 19, 2020, at 9:02 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi David,

These are the numbers we have to call Dr. Fauci. Please, confirm which one should we use:

[redacted] (b) (6) and [redacted] (b) (6)

I'm ready now if you prefer to test now. I can see that the invitation I sent you on Skype is still pending. Please, could you confirm you got it?

Please, let me know.

Thanks!

Begoña

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Monday, January 20, 2020 9:59 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

If you call my cell, I can conference Dr. Fauci in for a test call.

Sent from my iPhone

On Jan 19, 2020, at 8:32 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Thanks so much, Patricia!

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Monday, January 20, 2020 9:31 AM
To: Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Cc: Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

David Awwad is the POC for the connection. He will respond.

Sent from my iPhone

On Jan 19, 2020, at 8:29 PM, Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com> wrote:

Hi Patricia,

I've now taken over from Dalal and will be testing your Skype connection at 9.30 pm ET. I've sent a Skype contact request to Niadithelp from my personal Skype account [redacted] (b) (6)

Please, let me know if you didn't get it.

Thanks and regards,

Begoña

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Monday, January 20, 2020 2:08 AM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Blanco Munoz, Begona <Begona.BlancoMunoz@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ok thanks

Sent from my iPhone

On Jan 19, 2020, at 1:06 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Got it – let's test around 9:30pm then.

Adding Begona who will be the one conducting the Skype test.

Thank you all.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, January 19, 2020 1:04 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6); Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Since this is Skype he will do this from his residence in [redacted] (b) (6)

Sent from my iPhone

On Jan 19, 2020, at 1:01 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hi Patricia,

Thank you for the below.
The exact taping time is 10pmET.

We can test any time ahead of that. Since he is heading to NIH then we can test shortly before – as I'm sure the connection there is great and it wont take too long. Around 9:45pm?

I have received David's information – thanks again.

Regards,

Dalal

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, January 19, 2020 12:58 PM
To: Ali, Dalal <Dalal.Ali@turner.com>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Ali- pls confirm exact interview time. Dr Fauci will be doing the interview from [redacted] (b) (6) but he works at the national institutes of Health in Bethesda Maryland. Again he will physically be in [redacted] (b) (6) for this interview.

Backup numbers for him are
(b) (6) and cel (b) (6).

David pls provide your cell number as well. My cell is (b) (6)

Please provide cnn studio Number as well.

Please note pronunciation for Dr Fauci is Fow-Chee and it rhymes with grouchy.

Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:41 PM, Ali, Dalal <Dalal.Ali@turner.com> wrote:

Hello David,

Thank you. I have attached our Skype instructions to this email.

Can you provide the following:

Location: Bethesda?
Time to Test the Skype:
Phone number for set-up:

We appreciate your flexibility and do let me know if you have any further questions.

Regards,

Ms. Dalal Ali
Planning Producer- CNN International
(b) (6)

From: Awwad, David (NIH/NIAID) [C] <(b) (6)
Sent: Sunday, January 19, 2020 12:37 PM
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6); Fauci, Anthony (NIH/NIAID) [E] (b) (6) Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Skype handle:

Niaidithelp or niaidithelp@outlook.com

Sent from my iPhone

On Jan 19, 2020, at 12:35 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thank you for confirming Dr. Fauci's availability to do the interview via Skype.

My colleague Dalal will be in touch shortly to confirm all the logistics.

Thank you again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>
Sent: 19 January 2020 17:29
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>; Awwad, David (NIH/NIAID) [C] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can do this by Skype on his phone. I have added David Awwad here who can give you the Skype connection info. Please include him on all future correspondence. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 12:18 PM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I am currently waiting on a reply from the DC bureau to see if it is staffed at 10pET.

If it isn't, would Dr. Fauci be interested in doing the interview with us via Skype?

Thank you again for helping to accommodate our request.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: 19 January 2020 15:34
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Ali, Dalal <Dalal.Ali@turner.com>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

He will not need a car.

Also-to clarify-this will be a pre tape so please let us know the exact hit time for the interview and Dr Fauci will be at the studio 15-20 minutes prior to the exact hit time. We would appreciate the hit time being as close to 10 pm ET as possible. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:27 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

That's great – thank you Patricia.

Does Dr Fauci need a car to and from the studio?

If so, please let me know an address and I will book it ASAP.

I will email an onsite contact as soon as all of our logistics are confirmed.

Thanks again,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: 19 January 2020 15:12
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio in Washington DC at 10 pm ET tonight. Pls confirm to am ccd here and pls send onsite contact name, number and cell number. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 10:01 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

I've spoken to show producers and they need Dr Fauci this evening for a pre-tape – sorry for any inconvenience this may have caused.

If Dr Fauci is available this evening after 10pET for a pre-tape, can you let me know?

Thank you in advance.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: 19 January 2020 14:59
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Washington DC.

Sent from my iPhone

On Jan 19, 2020, at 9:42 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Thank you for confirming Dr Fauci's availability – what CNN studio will he be available from?

I will speak to my producers and confirm availability ASAP.

Best,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 14:39
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Dr Fauci can be at the CNN studio today at 1130 am ET. Please send onsite contact name and number ASAP. Thank you.

Sent from my iPhone

On Jan 19, 2020, at 9:04 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Patricia,

Thanks for getting back to me – I believe we can pre-tape from 11aET today.

The interview would go out during CNN Newsroom tonight in the 2a or 3a hour.

Please do let me know if this is a possibility.

Thank you,
Hannah

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: 19 January 2020 13:57
To: Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com>
Cc: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: CNNi interview request - TODAY (Sunday 19th January)

Hannah what is the exact live hit time?

Sent from my iPhone

On Jan 19, 2020, at 8:31 AM, Lovejoy, Hannah (NE) <Hannah.Lovejoy@turner.com> wrote:

Hi Dr. Fauci,

I hope you're well.

I wanted to introduce myself, I'm Hannah Lovejoy and I'm a planning producer for **CNN International**.

We were hoping that you would be available to **join us for a one-on-one interview today (Sunday 19th January)?**

We'd like you to **discuss the new coronavirus pneumonia which is now known as the Wuhan virus**.

More specifically, we'd like to find out what we know about the virus, what we learned from the spread of SARS, and what sort of precautions the traveling public should be taking.

Can you kindly let me know if you're available to join us?

Thank you in advance.

Best,
Hannah

Hannah Lovejoy
Planning Producer, **CNN International**
Turner House, 16 Great Marlborough Street,
London W1F 7HS, UK
Email: Hannah.Lovejoy@turner.com
Phone: +44 207 693 1777 | Cell: +[redacted] (b) (6) |

<image001.png>

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of

the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.

Information in this email including any attachments may be privileged or confidential and is intended exclusively for the addressee. The views expressed may not be official policy, but the personal views of the originator. If you have received this email in error, please notify the sender by return e-mail and delete it from your system. You should not reproduce, distribute, store, retransmit, use or disclose its contents to anyone. Please note we reserve the right to monitor all e-mail communication through our internal and external networks. Turner and the Turner marks are trade marks of Turner Broadcasting System Inc and are used under licence.

Turner Broadcasting System Europe Limited (Company No. 1927955), Turner Entertainment Networks International Limited (Company No. 2803512), Turner Broadcasting System Holdings (Europe) Limited (Company Number 2802926) and Cable News International Limited (Company No. 5001368) are incorporated in England and Wales and share the same registered office at Turner House, 16 Great Marlborough Street, London W1F 7HS.
<How to conduct a Skype interview with CNN.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 03:45:27 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Cc: Greg Folkers (b) (6);Barasch, Kimberly (NIH/NIAID) [C]
Subject: FW: Guest for Coronavirus podcast episode

Let us try to do this.

From: Tamera Coleman <tcoleman@gingrich360.com>
Sent: Thursday, January 30, 2020 1:57 PM
To: Fauci, Anthony (NIH/NIAID) [E] <(b) (6)>
Subject: Guest for Coronavirus podcast episode

Hello Dr. Fauci -- My name is Tamera, I handle the booking for Newt Gingrich's Podcast, Newt's World. It is a non-partisan show where Newt gives historical context behind people and events. We launched last February and have 2.5 millions downloads to date with new episodes each Sunday. We are working on an episode of the podcast centered around "The Coronavirus" where you might discuss **The Global viruses** [Novel Coronavirus 2019 (nCoV-2019),SARS,MERS,Bird Flu] and **What Can Be Done to Prevent the Next Epidemic?**

If interested, Newt would interview you on Thursday, February 6th, where you would call in to the studio. The podcast would air Sunday, February 9th.

Interview Times:
8:30-9:30; 9:30-10:30; 10:30-11:30 (EST)

Looking forward to hearing back soonest, as we would like to confirm booking as much in advance as possible.

Thanks much
Tamera

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 22:07:22 +0000
To: Collins, Francis (NIH/OD) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C]
Subject: RE: Our 1:1 tomorrow

Francis:

Thanks for the note. I am swamped with coronavirus issues. Let us do the debrief about the IC meeting at a later time.

Thanks,
Tony

From: Collins, Francis (NIH/OD) [E] <[redacted] (b) (6)>
Sent: Sunday, January 26, 2020 5:05 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Our 1:1 tomorrow

Hi Tony,

We are scheduled to meet for a half hour tomorrow, and there are lots of things to discuss – like coronavirus. You must be running in ten directions at once. I will be glad to go over a list of current issues, but I will leave it to you whether this is a good day for you to give me the feedback about the review of the NIH Director's performance, or whether it's better to wait until a later day for that.

Francis

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:11:29 +0000
To: Hotez, Peter Jay
Cc: Soriano Osejo, Douglas;Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: [redacted] (b) (6)

I would be happy to. I am really tied up with coronavirus and the deadline is Friday. What do I need to do? Please work with my Special Assistant, Patty Conrad on this

---

From: Hotez, Peter Jay [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 7:06 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Cc: Soriano Osejo, Douglas [redacted] (b) (6)>
Subject: NAM nomination for Alison Galvani

Dear Tony, I'm [redacted] (b) (6)
Thanks! Peter

Peter Hotez, MD, PhD, FASTMH, FAAP
Dean, National School of Tropical Medicine
Professor, Departments of Pediatrics, Molecular Virology & Microbiology
Co-Head, Section of Pediatric Tropical Medicine
Health Policy Scholar
Baylor College of Medicine

Texas Children's Hospital Endowed Chair of Tropical Pediatrics
Co-Director, Texas Children's Hospital Center for Vaccine Development

University Professor
Department of Biology, Baylor University

Faculty Fellow, Hagler Institute for Advanced Study
Senior Fellow, Scowcroft Institute of International Affairs
Texas A&M University

Baker Institute Fellow in Disease & Poverty and Adjunct Professor of Bioengineering, Rice University
Adjunct Professor, University of Texas, School of Public Health

Founding Editor-in-Chief, PLoS Neglected Tropical Diseases

E-mail: [redacted] (b) (6)
Twitter: [redacted] (b) (6)
Skype: [redacted] (b) (6)
Website: https://peterhotez.org/
Amazon Author Center: https://www.amazon.com/Peter-J.-Hotez/e/B001HPIC48
Like us on Facebook https://www.facebook.com/BCMNationalSchoolOfTropicalMedicine/

Executive Assistant: (b) (6)
(b) (6)

Phone: (b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 22:10:27 +0000
To: Paules, Catharine
Subject: FW: Coronavirus - January 2019 Overview - Penn State Health video with Cat Paules http://bit.ly/2tzt4aB

Very nicely done! ☺

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Folkers, Greg (NIH/NIAID) [E] (b) (6)>
Sent: Thursday, January 23, 2020 4:41 PM
Subject: Coronavirus - January 2019 Overview - Penn State Health video with Cat Paules http://bit.ly/2tzt4aB

Coronavirus - January 2019 Overview - Penn State Health

Disclaimer: Any third-party material in this email has been shared for internal use under fair use provisions of U.S. copyright law, without further verification of its accuracy/veracity. It does not necessarily represent my views nor those of NIAID, NIH, HHS, or the U.S. government.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 17:59:32 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: China Coronavirus Story - CBS News request

Let us discuss.

From: Finnegan, Kevin P. <KPF@cbsnews.com>
Sent: Monday, January 20, 2020 12:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)
Subject: China Coronavirus Story - CBS News request

Dr. Fauci….

Sorry to bother you on a holiday. Dr. LaPook is off today, but I'm trying to help our team in China covering the Coronavirus story. As you I know, Chinese epidemiologist Zhong Nanshan, said two cases in Guangdong Province were confirmed to be people-to-people transmission. He also said 14 medical workers were infected. I'm reaching out to see if there is any possibility at all of a brief interview with you today. We're looking for some context as to why person to person spread is significant.

We could send a crew to you or we would also do it as a Skype interview if that works for you. Alternately, if you can give us your thoughts on this development in an e-mail, we would quote you in our story..

Again, my apologies for reaching out on a holiday, thanks for your consideration.

Kevin

Kevin Finnegan
Medical Producer

CBS Evening News with Norah O'Donnell

P. 212.975.7486
C. [redacted] (b) (6)

kpf@cbsnews.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 04:34:53 +0000
To: [redacted] (b) (6)
Subject: FW: Clip of Dr. Fauci on PBS NewsHour

FYI

From: Megan Schartner <MSchartner@scgcorp.com>
Sent: Thursday, January 30, 2020 9:46 PM
To: Deatrick, Elizabeth (NIH/NIAID) [C] [redacted] (b) (6)>; Pekoc, Ken (NIH/NIAID) [E] [redacted] (b) (6); Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Doepel, Laurie (NIH/NIAID) [E] [redacted] (b) (6) Folkers, Greg (NIH/NIAID) [E] [redacted] (b) (6)>; Hoffman, Hillary (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Rancourt, Anne (NIH/NIAID) [E] [redacted] (b) (6); Lavelle, Judith (NIH/NIAID) [E] [redacted] (b) (6); Leifman, Laura (NIH/NIAID) [E] [redacted] (b) (6); Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); NIAID OD AM <NIAIDODAM@niaid.nih.gov>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Cc: Osvald, Maria <mosvald@scgcorp.com>; Fabry, Cynthia (NIH/NIAID) [E] [redacted] (b) (6)>; Meylin Correa <mcorrea@scgcorp.com>; Lindsey Beall <lbeall@scgcorp.com>; Marcia Bache <mbache@scgcorp.com>
Subject: Clip of Dr. Fauci on PBS NewsHour

Good evening,

Below is a clip of Dr. Fauci on PBS NewsHour this evening discussing the coronavirus.

https://app.criticalmention.com/app/#/clip/public/5a05811b-ad42-4d4c-a5b3-ae46560a46bf?show_sentiment=false

Thank you,

Megan

From: Critical Mention <do-not-reply@criticalmention.com>
Sent: Thursday, January 30, 2020 9:42 PM

To: Megan Schartner
Subject: Critical Mention: Megan Schartner has shared a TV Mention with you

critical mention

You're always on it with Critical Mention.

Megan Schartner has shared a TV Mention with you!

From Megan Schartner (mschartner@scgcorp.com)

View Mention

PBS NewsHour

Genre News

Program Name PBS NewsHour
Source KETA - Network
Market DMA: 43 Oklahoma City, OK
Time Jan 30, 2020 7:29 PM EST
Clip Length 06:19.947

>> woodruff: we return now to the latest on the coronavirus outbreak. william brangham has a closer look at today's developments. >> brangham: that's right, judy, we've seen this past week the rapid spread of this virus in china, and its escape to at least 14 other nations. as we reported before, the w.h.o. has declared this a global public health emergency, and we've now seen the first confirmed person-to-person transmission here in the u.s. for a closer look at what this all means, we turn to dr. anthony **fauci**. he's the director of the national institute of allergy and infectious diseases at the n.i.h. dr. **fauci**, welcome back to the news hour. we've seen this first case, a 6 60-something year old woman who went to china, got the virus, came home and apparently infected her husband once she was back here. we know how viruses operate, especially among people who are living together. on some level this is to be expected, but people seeing this news, what would you say to them for their alarm and their concern about this? >> you know, i think you just said it. this is something to be expected when you have someone whs in very close contact with another individual that is infected. it is not surprising that there's transmission. the thing that would be of concern and that we're watching very carefully is what you call sustained transmission from one person to another to another to another. the system here right now is that that individual who was just recently infected from a person who was actually infected in china, came here, and then infected a close partner, that individual is now under isolation, and the contacts with whom that person came into, those individuals are now being traced. so the public health system is now on

top of that. what the concern globally is, the rapid sustained person-to-person-to-person transmission, which is going on right now, certain to a great degree in china, and the reason the w.h.o. declared this a public health emergency of international concern is because in other countries outside of china, we're starting to see that sustained transmission from person to person to person to person. that's the thing you need to be concerned about. but right now the risk in the united states is still low. but with the same breath i say that, i say we are taking this very, very seriously as public health officials and scientists. >> brangham: in your press conference earlier this week, you kept stressing the need for more information, for more data, for more samples to come out of china. are you getting the cooperation and the information and the sharing you need from chinese officials to best do your job? >> you know, the answer is yes, but i think we can do better. if you compare the transparency during the sars outbreak in 2002, everyone realized that they were egregiously non-transparent and that delayed things a long time. that's different now. they really are being open, but what we would like to see is the actual data and the patterns of disease that are going on there ourselves, because what happens there will inform us better as to what our policies will be here. so it looks like we're getting many that direction. the w.hmm o. -- w.h.o. is getting a group put together to go there, hopefully including us, that would actually take a first hand, on-the-ground look at the data. >> brangham: there is a fair amount of modeling coming out of hong kong and other parts of the world looking at the current spread and indicating that this may turn into a real global pandemic. do you weave that's true, or do you still think it's too early to make that call? >> no, i think you have to be realistic and say it is possible that it could turn into a global pandemic. that's the reason why we're doing everything we can to prevent that. i think to deny the possibility would be unrealistic. and that's the reason why we're preparing for the worst. whether it's going to happen, we have no way of predicting what the odds of that are. the chinese are doing rather dramatic things to try and contain that within their own country. the idea of locking down 50 million people to prevent their from going in and out of certain areas is a very, very dramatic way to try and containq-that. what we're doing here is the typical, classical public health measure, trying the keep people who arenfected out of the country, and then if someone does get in, to isolate them and to prevent them from infecting others. hopefully those public health measures will work. but we still need to prepare for the worst and we know we are taking this and the general public of the united states and the world should know that we are taking this very, very seriously. >> brangham: in just the short bit of time we have left, i imagine that this has got to be difficult for you, dealing with these fears about handful of virus cases here in the u.s. when we have another virus, the influenza virus, that has already sickened millions of americans. that's taken 8,000 temperature's lives here in this country alone. how do you help americans balance those concerns and risks over the fear of a virus coming here versus the one we already have? >> well, i think we have been through this many times in so many other situations. the fear of the unknown and what might happen almost always supersedes the concern of something that actually is happening and causing a lot of damage. and you're absolutely correct. we are in the middle of a flu season, an we have more disease and death from flu than even, you know new york some countries even have with this outbreak. so the issue is we should concentrate on protecting ourselves from influenza, which we know is patterned at the same time as we prepare for something that we're in the familiar with, because it's a brand-new infection. it's a balance. >> brangham: anthony **fauci**, thank you

---

Critical Mention allows users to search global TV, Radio, Online News & Social from the United States, Canada, and Europe, watch video, edit and share coverage, receive real-time email alerts, build reports, and analyze coverage through word clouds and graphs.

Want to learn more about Critical Mention? Sign up for a demo here.

Copyright © 2020 Critical Mention, All rights reserved.

Our mailing address is:
Critical Mention
521 5th Avenue
16th Fl
New York, NY 10175

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 22:16:32 +0000
To: Cohen, Elizabeth
Cc: Conrad, Patricia (NIH/NIAID) [E];Billet, Courtney (NIH/NIAID) [E]
Subject: RE: A question from a colleague

Elizabeth:

Aluvia is also known as Kaletra. It is a combination of two anti-HIV drugs: lopinavir and ritonavir. It was observed in non-controlled trials (historical control) in SARS to have some degree of benefit. Given the fact that there are no proven effective drugs to treat this coronavirus, it is understandable that they are using Aluvia/Kaletra on a compassionate basis. If someone is seriously ill with the virus, there is little down-side to using it. It may not help, but it unlikely will hurt.

Best,
Tony

-----Original Message-----
From: Cohen, Elizabeth <Elizabeth.Cohen@turner.com>
Sent: Sunday, January 26, 2020 5:04 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: A question from a colleague

Tony – thanks so much for chatting earlier today… a colleague of mine would love your thoughts on this… Thanks Elizabeth

https://www.reuters.com/article/us-china-health-abbvie-hiv-idUSKBN1ZP0QK

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 22:11:24 +0000
To: DLGDESK (HHS/ASPR/OPP)
Subject: RE: Attendance Confirmation Reminder: 2020 Novel Coronavirus Disaster Leadership Group Meeting

I attended the DLG meeting via telephone.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: DLGDESK (HHS/ASPR/OPP) <DLGDESK@hhs.gov>
Sent: Thursday, January 23, 2020 4:41 PM
To: Stannard, Paula (HHS/IOS) [redacted] (b) (6)>; Agnew, Ann (HHS/IOS) [redacted] (b) (6)>; Trueman, Laura (HHS/IEA) [redacted] (b) (6)>; Kadlec, Robert (OS/ASPR/IO) [redacted] (b) (6)>; Rowell, Scott (OS/ASA) < [redacted] (b) (6)>; Moughalian, Jen (HHS/ASFR) [redacted] (b) (6)>; Arbes, Sarah (HHS/ASL) [redacted] (b) (6); Murphy, Ryan (OS/ASPA) [redacted] (b) (6)>; Destro, Brenda (HHS/ASPE) [redacted] (b) (6)>; Tobias, Constance (HHS/DAB) [redacted] (b) (6)>; Giroir, Brett (HHS/OASH) < [redacted] (b) (6)>; Severino, Roger (HHS/OCR) [redacted] (b) (6)>; Grigsby, Garrett (HHS/OS/OGA) [redacted] (b) (6); Charrow, Robert (HHS/OGC) [redacted] (b) (6)>; Griswold, Nancy (HHS/OMHA HQ) [redacted] (b) (6)>; Rucker, Donald (OS/ONC) [redacted] (b) (6); Johnson, Lynn (ACF) [redacted] (b) (6)>; Robertson, Lance (ACL) [redacted] (b) (6); Khanna, Gopal (AHRQ/IOD) [redacted] (b) (6) Redfield, Robert R. (CDC/OD) [redacted] (b) (6); Verma, Seema (CMS/OA) [redacted] (b) (6)>; Engels, Thomas (HRSA) [redacted] (b) (6) Weahkee, Michael (IHS/HQ) [redacted] (b) (6) Collins, Francis (NIH/OD) [E] [redacted] (b) (6); McCance-Katz, Elinore (SAMHSA/OAS) < [redacted] (b) (6)-

(b)(6); Hall, Bill (HHS/ASPA) (b)(6)>; Schuchat, Anne MD (CDC/OD) (b)(6); Messonnier, Nancy (CDC/DDID/NCIRD/OD) < (b)(6); Cetron, Marty (CDC/DDID/NCEZID/DGMQ) (b)(6)>; Abram, Anna (FDA/OC) (b)(6)>; Shuren, Jeff (FDA/CDRH) (b)(6)>; Fauci, Anthony (NIH/NIAID) [E] (b)(6); Marston, Hilary (NIH/NIAID) [E] (b)(6); Sherman, Susan (HHS/OGC) (b)(6); Elvander, Erika (OS/OGA) (b)(6); Kerr, Lawrence (HHS/OS/OGA) (b)(6); Shuy, Bryan (OS/ASPR/IO) < (b)(6); Hassell, David (Chris) (OS/ASPR/IO) < (b)(6); Yeskey, Kevin (OS/ASPR/IO) (b)(6) Bright, Rick (OS/ASPR/BARDA) < (b)(6)>; Phillips, Sally (OS/ASPR/SPPR) (b)(6); Disbrow, Gary (OS/ASPR/BARDA) (b)(6); Humes, Rosemary (OS/ASPR/BARDA) (b)(6); Donis, Ruben (OS/ASPR/BARDA) (b)(6); Johnson, Robert (OS/ASPR/BARDA) (b)(6); DeBord, Kristin (OS/ASPR/SPPR) (b)(6); Moudy, Robin (OS/ASPR/SPPR) (b)(6); Lawrence, Theresa (OS/ASPR/SPPR) (b)(6)>; Waters, Cicely (OS/ASPR/OEA) (b)(6)>; Michael, Gretchen (OS/ASPR/OEA) (b)(6); Ford-Barnes, Arwenthia (OS/ASPR/IO) (b)(6) Callahan, Victoria (OS/ASPR/IO) (CTR) (b)(6)>; Johnson, Kelly J. (OS/ASPR/SPPR) (b)(6); Donnelly, Kelsey (OS/ASPR/SPPR) (CTR) (b)(6)>; Chang, William (HHS/OGC) (b)(6) Grimm, Christi A (OIG/IO) (b)(6); Jernigan, Daniel B. (CDC/DDID/NCIRD/ID) (b)(6)>; Patel, Anita (CDC/DDID/NCIRD/OD) (b)(6)>; Marks, Peter (FDA/CBER) (b)(6)>; (b)(6); Taitsman, Julie K (OIG/IO) (b)(6)>; Cochran, Norris (HHS/ASFR) (b)(6)>; Toedt, Michael (IHS/HQ) (b)(6)>; Vineyard, Michael (OS/ASPR/IO) (b)(6)>; Imbriale, Samuel (OS/ASPR/SIIM) (b)(6); Roman-Stolte, Claudia (OS/ASPR/SPPR) (CTR) (b)(6)>; Thornton, Cody R. (OS/ASPR/SIIM) (b)(6); Debarros, Jean-pierre (MIL) (b)(6); Debarros, Jeanpierre (OS/ASPR/EMMO) (b)(6); Monahan, Kenneth (MAIL.MIL) (b)(6)>; Monahan, Kenneth (OS/ASPR/EMMO) (b)(6); Sakris, Derek (OS/ASPR/EMMO) (b)(6)>; Sims, Andrew (OS/ASPR/EMMO) (b)(6); Soza, Liza (MIL) (b)(6); Vincent, Erik (OS/ASPR/EMMO) (b)(6)>; Weir, Charles (OS/ASPR/IO) < (b)(6)>; Bonds, Michelle E. (CDC/OD/OADC) (b)(6)

Cc: Lepore, Loretta (CDC/OD/OCS) (b)(6)>; Mciff, Colin (HHS/OS/OGA) (b)(6); Nevel, Amy (HHS/ASPE) (b)(6)>; Gregg, William (Joe) (CDC/DDID/NCIRD/OD) (b)(6); DLGDESK (HHS/ASPR/OPP) <DLGDESK@hhs.gov>

Subject: Attendance Confirmation Reminder: 2020 Novel Coronavirus Disaster Leadership Group Meeting

Dear Disaster Leadership Group (DLG) Members, Thank you to everyone who participated in today's 2020 Novel Coronavirus DLG meeting. Please remember to confirm your attendance, whether in the room or on the call, by emailing the DLGDESK resource mailbox at DLGDESK@hhs.gov.

Respectfully,

Kelsey Donnelly (CTR)
Jr. Management Analyst, Aveshka Inc.
Office of the Assistant Secretary for Preparedness and Response
Office of Strategy, Policy, Planning, and Requirements

HEALTH AND HUMAN SERVICES (DHHS) | O'Neill House Office Building | 200 C Street SW | Washington, DC
o: (b) (6) m: (b) (6)
(b) (6) | www.phe.gov

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Fri, 31 Jan 2020 10:53:30 +0000
To:	Conrad, Patricia (NIH/NIAID) [E]
Subject:	FW: Radio Interview Request_tbs eFM, Seoul, South Korea

Let us discuss

From: This Morning <efmthismorning@gmail.com>
Sent: Friday, January 31, 2020 4:03 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Radio Interview Request_tbs eFM, Seoul, South Korea

Dear Dr. Anthony Fauci,

Hello, my name is Ajin Oh, and I am a writer for TBS eFM's "This Morning" English radio program in Seoul, Korea.

We would like to request a phone interview to hear about how Gilead is assessing the potential use of Ebola drug as treatment for the novel coronavirus

We are hoping to do this interview at **8:00 PM local time in Maryland on Saturday February 1st.**

The interview will last for about 10 minutes, and we will send you a list of potential questions after receiving your confirmation.

If you're available for the interview, please kindly provide us with the phone number we'll be using to call you for the interview and a back-up number.

I look forward to hearing from you soon. Thank you in advance for your time.

Best Regards,
Ajin Oh

--
This Morning with Alex Jensen
tbs eFM 101.3 MHz, Seoul
https://tbs.seoul.kr/cont/eFM/ThisMorning/introduction/introduction.do
http://twitter.com/efmthismorning
http://www.facebook.com/efmthismorning
M : [redacted] (b) (6) (Kyungmi Choi)
[redacted] (b) (6) (Myungju Lee)
[redacted] (b) (6) (Ajin Oh)
============================

tbs eFM (101.3 MHz) is the first all-English radio station in Seoul, and "This Morning" is a current affairs program that airs live from 7:00-9:00 AM (GMT+9) five days a week.

We have had numerous outstanding guests on our program, including Richard Thaler (Economist, Winner of 2017 Nobel Economics Prize), Slavoj Žižek (Philosopher & Cultural Critic), Noam Chomsky(MIT Linguist & Philosopher), Angus Deaton (leading microeconomist), Julian Assange (founder of Wikileaks), Malcolm Gladwell (Author of Tipping Point & Outliers), Jeremy Rifkin (Economic and social theorist), Ruud Lubbers (former Prime Minister of the Netherlands), John Bolton (former US Ambassador to the UN), Joseph S. Nye (former US Assistant Secretary of Defense), Francis Fukuyama (Political Scientist & Author), Jared Diamond (Author of "Guns, Germs, and Steel), Richard Jones (Deputy Executive Director of IEA), Achim Steiner (Executive Director of the UN Environment Program), Yvo de Boer (former executive secretary of UN Framework Convention on Climate Change), John Naisbitt (Futurologist & Author of "Megatrends"), George Whitesides (CEO of Virgin Galactic), Yao Ming (Former NBA player), Park Ji-Sung (Football player), Michelle Rhee (former Chancellor of the District of Columbia Public Schools system), Chang-rae Lee (Author of "The Surrendered" & Professor of creative writing at Princeton University) and many others.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 22:41:36 +0000
To: Conrad, Patricia (NIH/NIAID) [E]
Subject: RE: NPR HIT TOMORROW MOVED FROM 5:35 AM TO 7:05 AM ET

OK

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, January 26, 2020 5:40 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: NPR HIT TOMORROW MOVED FROM 5:35 AM TO 7:05 AM ET

TEST WILL BE AT 6:55 AM ET WITH DAVID AWWAD

From: Clare Lombardo <CLombardo@npr.org>
Sent: Sunday, January 26, 2020 4:56 PM
To: Awwad, David (NIH/NIAID) [C] < [redacted] (b) (6)>
Cc: Simone Popperl <SPopperl@npr.org>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>; Matt Kwong <MKwong@npr.org>; Miranda Kennedy <MKennedy@npr.org>; Jacob Conrad <JConrad@npr.org>; Vince Pearson <vpearson@npr.org>; Alicia Montgomery <AMontgomery@npr.org>; Barry Gordemer <BGordemer@npr.org>; Barasch, Kimberly (NIH/NIAID) [C] < [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: RE: interview with Dr Fauci

Great.

Then, as you know, the sign-in is [redacted] (b) (4) and the password is [redacted] (b) (4)'. Dr. Fauci will start a recording with the app and hold the phone up to his ear as he speaks on his landline during his live interview.

As Simone said below, our 24/7 phone is 202-513-2158 if any issues come up. Otherwise, our team will reach you and Dr. Fauci at 6:55 a.m. tomorrow on his work landline.

Thanks again for taking the time and your help coordinating.

Best,
Clare

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Sunday, January 26, 2020 4:44 PM
To: Clare Lombardo <CLombardo@npr.org>
Cc: Simone Popperl <SPopperl@npr.org>; Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>;

Matt Kwong <MKwong@npr.org>; Miranda Kennedy <MKennedy@npr.org>; Jacob Conrad <JConrad@npr.org>; Vince Pearson <vpearson@npr.org>; Alicia Montgomery <AMontgomery@npr.org>; Barry Gordemer <BGordemer@npr.org>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Re: interview with Dr Fauci

I have done this many times before.

Sent from my iPhone

On Jan 26, 2020, at 4:37 PM, Clare Lombardo <CLombardo@npr.org> wrote:

Thanks for confirming, David. Has one of our producers already walked you through it? If not, I'll give you a call and give you a rundown so that you're all set up tomorrow. I'm attaching instructions for the app to this email, which would be good to have handy just in case. Let me know if there's a good number to reach you.

Thanks!

Clare
<image001.gif>
Clare Lombardo | NPR | clombardo@npr.org | **P** 202.513.2608

From: Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Sent: Sunday, January 26, 2020 4:33 PM
To: Simone Popperl <SPopperl@npr.org>
Cc: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Matt Kwong <MKwong@npr.org>; Clare Lombardo <CLombardo@npr.org>; Miranda Kennedy <MKennedy@npr.org>; Jacob Conrad <JConrad@npr.org>; Vince Pearson <vpearson@npr.org>; Alicia Montgomery <AMontgomery@npr.org>; Barry Gordemer <BGordemer@npr.org>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] <[redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: interview with Dr Fauci

The app is already installed.

Sent from my iPhone

On Jan 26, 2020, at 4:29 PM, Simone Popperl <SPopperl@npr.org> wrote:

Thanks very much. Per below, the live hit will be at 7:07 AM ET and last for 5 minutes. We would need to get Dr. Fauci on the line by 6:55 AM ET to confirm the connection is stable.

One of my colleagues will be in touch with David Awwad shortly to set up the app.

Our 24-hour line is 202-513-2158 – that will allow us to transfer you directly into the booth if there are any issues.

Simone

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Sunday, January 26, 2020 4:25 PM
To: Simone Popperl <SPopperl@npr.org>
Cc: Matt Kwong <MKwong@npr.org>; Clare Lombardo <CLombardo@npr.org>; Miranda Kennedy <MKennedy@npr.org>; Jacob Conrad <JConrad@npr.org>; Vince Pearson <vpearson@npr.org>; Alicia Montgomery <AMontgomery@npr.org>; Barry Gordemer <BGordemer@npr.org>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6); Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6) Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>; Awwad, David (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: Re: interview with Dr Fauci

Yes we can do app for 7 am ET live hit. Pls confirm that the live hit will be right at 7:00 am ET.

David Awwad cc'd here will handle the connection and app. Pls feel free to coordinate with him directly and pls cc all of us.

Pls also provide your control room number for any issues. Thank you

Sent from my iPhone

On Jan 26, 2020, at 4:20 PM, Simone Popperl <SPopperl@npr.org> wrote:

Confirmed. I am looping in our swing and overnight teams so you will be able to easily be in touch with them if anything changes.

Did Nina review the possibility of having Dr. Fauci download NPR's propriety app Report-It on his cell phone to record a high quality version of his site of the conversation for us to use in subsequent feeds? One of our producers could walk your team through it this evening. It will take less than 5 minutes of your time.

Feel free to reply all to this message or give us a call anytime on 202-513-2158 with questions.

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Sunday, January 26, 2020 3:43 PM
To: Simone Popperl <SPopperl@npr.org>
Cc: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>; Routh, Jennifer (NIH/NIAID) [E] [redacted] (b) (6)>; Oplinger, Anne (NIH/NIAID) [E] [redacted] (b) (6)>; Stover, Kathy (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Re: interview with Dr Fauci

Hi and yes we can move the hit to 7:00 am ET. But we need to change the number- he will now do from his landline number at work - please call us at 7:00 am at [redacted] (b) (6). Thank you.

Sent from my iPhone

On Jan 26, 2020, at 2:42 PM, Simone Popperl <SPopperl@npr.org> wrote:

Yes, Nina was coordinating on Friday for the 5:35 am time, but with news we want to move him to 7 AM ET. Nina is not on shift today, so I have taken over all of her bookings.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Sunday, January 26, 2020 2:41 PM
To: Simone Popperl <SPopperl@npr.org>
Subject: Re: interview with Dr Fauci

I was working with Nina Kravinsky for the 535 am ET hit. Pls advise

Sent from my iPhone

On Jan 26, 2020, at 2:29 PM, Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)> wrote:

Is your request in addition to the morning edition request we have for 535 am tomorrow? Or are you asking for us to move the 525 am to 7:00 am ET?

Sent from my iPhone

On Jan 26, 2020, at 2:23 PM, Simone Popperl <SPopperl@npr.org> wrote:

Hi Patricia,

Thanks so much for the quick chat by phone just now – following up by email as you suggested.

We would love it if Dr. Fauci could join Morning Edition tomorrow at 7 AM ET. He would be speaking with Rachel Martin. The exact hit time would be 7:07 AM, but we'd want to have him on the line by 6:55 AM ET just to make sure the connection is stable. Our line desk number is 202-513-2158. We would plan to call him on his landline, with the cell as a backup.

He can give us a call anytime at 202-513-2158 – that's our 24 hour line.

Looking forward to hearing from you when you are able to confirm!

Simone

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)>
Sent: Friday, January 24, 2020 4:27 PM
To: Nina Kravinsky <NKravinsky@npr.org>
Cc: Denise Couture <DCouture@npr.org>; Gail Austin <GAustin@npr.org>; Simone Popperl <SPopperl@npr.org>; Matt Kwong <MKwong@npr.org>; Clare Lombardo <CLombardo@npr.org>; Jacob Conrad <JConrad@npr.org>; Vince Pearson <vpearson@npr.org>
Subject: Re: interview with Dr Fauci

That is a landline. Backup would be his cell at [redacted] (b) (6)

And we would want your control room number for him to call you Thanks.

Sent from my iPhone

On Jan 24, 2020, at 4:21 PM, Nina Kravinsky <NKravinsky@npr.org> wrote:

Thanks again for helping us coordinate! Just want to confirm that the [redacted] (b) (6) is a landline. If it's a cell, the Sunday team will likely coordinate with you all about downloading an app to assure good audio quality.

If it's a landline, we should be good to go.

Nina

From: Conrad, Patricia (NIH/NIAID) [E] <[redacted] (b) (6)
Sent: Friday, January 24, 2020 3:45 PM
To: Denise Couture <DCouture@npr.org>; Nina Kravinsky <NKravinsky@npr.org>
Cc: ME-DC <ME-DC@npr.org>
Subject: RE: interview with Dr Fauci

Perfect- I will be on email and my cell is [redacted] (b) (6)

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Denise Couture <DCouture@npr.org>
Sent: Friday, January 24, 2020 3:41 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6); Nina Kravinsky <NKravinsky@npr.org>
Cc: ME-DC <ME-DC@npr.org>
Subject: RE: interview with Dr Fauci

Hi Pat,

I hope all's well with you. I'm at Morning Edition now. Glad to see you and Dr. Fauci are still a team!

As for Monday, we are confirmed for Monday, but as for "firm" (as in 100 percent), we're as firm as we (NPR daily news programs) ever are with any guest on a Friday afternoon for a Monday show. If something huge happens over the weekend, the schedule could get scrambled.

If anything changes over the weekend, our Sunday team will reach out.

Have a terrific weekend,

Denise
(formerly Diane Rehm Show and 1A)

<image001.jpg>
Denise Couture | Senior Editor | **morning edition** | dcouture@npr.org | desk 202-513-2517 | cell [redacted] (b) (6)
NPR reaches almost 40 million listeners on more than 1,000 radio stations across the United States.

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, January 24, 2020 3:26 PM
To: Nina Kravinsky <NKravinsky@npr.org>
Cc: ME-DC <ME-DC@npr.org>
Subject: RE: interview with Dr Fauci

Just to be clear – we are firm for this right? You will call him at [redacted] (b) (6) a few minutes before 5:34 am ET?

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Nina Kravinsky <NKravinsky@npr.org>
Sent: Friday, January 24, 2020 11:50 AM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6); Pekoc, Ken (NIH/NIAID) [E] [redacted] (b) (6)>; ME-DC <ME-DC@npr.org>
Subject: RE: interview with Dr Fauci

Hi Patricia,

Thanks so much. I'm looping in my colleagues who will be handling this over the weekend. Please **reply all** with any updates. Someone from the team will be in touch either this afternoon or on Sunday to confirm details.

Thanks again,
Nina

From: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Sent: Friday, January 24, 2020 11:41 AM
To: Nina Kravinsky <NKravinsky@npr.org>
Cc: Barasch, Kimberly (NIH/NIAID) [C] (b) (6); Pekoc, Ken (NIH/NIAID) [E] <(b) (6)
Subject: interview with Dr Fauci

Dr. Fauci can be available for your interview as per below - LIVE HIT at 5:34 am ET

Dr. Fauci would do this by phone – please call him at (b) (6) with back cell (b) (6)

Please confirm hit time and please send us your Monday morning control room number and contact info as well. Thank you

Organization: NPR's Morning Edition
Producer: Nina Kravinsky
Phone #(s): (b) (6), nkravinsky@npr.org
Subject: Wuhan coronavirus
Deadline: today for coordination
Spokesperson: NIAID Director Anthony S. Fauci, by phone
Expected place of publication: radio, online
Expected date of publication/airing: Monday, Jan. 27
Expected prominence: Morning Edition

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

<Report_IT_FTP.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 20:11:26 +0000
To: Routh, Jennifer (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: Dr. Fauci & novel coronavirus

Jennifer:
Thanks for the note. Please thank Kristen Nordlund for her note. My discussion in the CBS interview was very much in line with the CDC talking points. It was the kind of interview where they will probably use less than30 seconds of a discussions that took 5 minutes. Please get the clip when it is available.
Best,
Tony

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Monday, January 20, 2020 2:03 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Fwd: Dr. Fauci & novel coronavirus

Sent from my iPhone

Begin forwarded message:

From: "Routh, Jennifer (NIH/NIAID) [E]" [redacted] (b) (6)>
Date: January 20, 2020 at 2:02:39 PM EST
To: "Nordlund, Kristen (CDC/DDID/NCIRD/OD)" [redacted] (b) (6), "Stover, Kathy (NIH/NIAID) [E]" [redacted] (b) (6) "Fritz, Craig (NIH/OD) [E]" [redacted] (b) (6)>
Cc: "Billet, Courtney (NIH/NIAID) [E]" [redacted] (b) (6), "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: Re: Dr. Fauci & novel coronavirus

Thanks, Kristen. I am cc'ing other colleagues for awareness, and we will pass these along to Dr. Fauci.

From: Nordlund, Kristen (CDC/DDID/NCIRD/OD) [redacted] (b) (6)>
Sent: Monday, January 20, 2020 1:54 PM
To: Stover, Kathy (NIH/NIAID) [E]; Routh, Jennifer (NIH/NIAID) [E]; Fritz, Craig (NIH/OD) [E]
Subject: Dr. Fauci & novel coronavirus

Hi Kathy, Jennifer, and Craig,

Apologies for casting a wide net – especially on a holiday. I work in the communications office at CDC handling the response to the 2019 novel coronavirus outbreak. I understand Dr. Fauci is doing some on camera interviews this afternoon – CBS reached out to us a few hours ago and then just said they'd gotten

Dr. Fauci. I just wanted to make sure he has out latest talking points and reinforced our position to lean forward on this issue. I've included some main points below:

- This is a rapidly evolving situation and new information is coming in each day. Our recommendations will evolve as the situation changes.
- We are preparing across the public health and health care system to prevent, detect, and respond to this novel coronavirus. The earlier we detect a case, the better we can protect the public and the more we can understand about this virus, and its risk for spread.
- At this point, early detection provides an important strategy for prevention. Whether or not a case is discovered , the risks and efforts of leaning forward are far less than the consequences of deploying these strategies too late.
- As we learn more about the newly emerging virus, the federal government will adjust its screening and response procedures appropriately. However, based on the information we have today, we believe the current risk from this virus to the general public is low.

Additionally, if he would like to speak with our team working on this or Dr. Messonnier, who is helping lead out response, I'm happy to help set that up.

Thanks,
Kristen

Kristen Nordlund
CDC Public Affairs
p. (b) (6) | c. (b) (6) | e. (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:30:48 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Interferons for coronaviruses?
Attachments: JAMA-SARS-IFN.pdf, Clinical protocol for treatment of SARS with IFN.pdf, AVT-05-OA-0505-SARS-Fish.pdf

Please take a look at this and handle.

From: Young, Howard (NIH/NCI) [E] [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 12:43 PM
To: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>; Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: RE: Interferons for coronaviruses?

Thank you, they are attached. I also know the lead investigator, Dr. Fish so I can arrange contact if that is needed. Here is an additional paper as well.

Howard

From: Cassetti, Cristina (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Tuesday, January 28, 2020 12:32 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>; Young, Howard (NIH/NCI) [E] [redacted] (b) (6)
Subject: RE: Interferons for coronaviruses?

Dear Dr. Young,

Can you please send me the attachments? I will pass them along to our staff involved in the response.

Thank you,

Cristina

Cristina Cassetti, Ph.D.
Deputy Director
Division of Microbiology and Infectious Diseases
National Institute of Allergy and Infectious Diseases, NIH
5601 Fishers Lane, Room 7G51
Rockville, MD 20852

Tel: [redacted] (b) (6)
[redacted] (b) (6)

Administrative Assistant:
Ms. Roshawn Treadwell-Hyde
Tel: [redacted] (b) (6)
[redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 12:29 PM
To: Young, Howard (NIH/NCI) [E] [redacted] (b) (6)>
Cc: Cassetti, Cristina (NIH/NIAID) [E] <[redacted] (b) (6)>
Subject: Re: Interferons for coronaviruses?
Importance: High

Howard:
Thanks for sending this.
Best,
Tony

On Jan 28, 2020, at 12:08 PM, Young, Howard (NIH/NCI) [E] [redacted] (b) (6)> wrote:

Dear Dr. Fauci,

I just wanted to pass along a clinical protocol approved in Canada for the use of interferon in the treatment of SARS. I have also attached the JAMA paper describing the trial. Perhaps it might be considered in this new outbreak?

Sincerely,
Howard Young

Howard A. Young, Ph.D.
Center for Cancer Research
NCI at Frederick
Frederick, MD 21702
Tel: [redacted] (b) (6)
Email: [redacted] (b) (6)

<Clinical protocol for treatment of SARS with IFN.pdf>
<JAMA-SARS-IFN.pdf>

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 22:13:39 +0000
To: [redacted] (b) (6) (NIH/CC/BEP) [E]
Subject: RE: Online First: Fauci on Coronavirus, Improving the Residency Match, and more

I worked on it all day Monday, and remember that I almost erased it and David saved the day. And I also am good friends with the Editor of JAMA.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: [redacted] (b) (6) (NIH/CC/BEP) [E] [redacted] (b) (6)
Sent: Thursday, January 23, 2020 3:39 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: FW: Online First: Fauci on Coronavirus, Improving the Residency Match, and more

How were you so timely in getting this written and published?

[redacted] (b) (6)
[redacted]
NIH Clinical Center
(b) (6) [redacted]

From: JAMA <updates@jamanetwork.org>
Sent: Thursday, January 23, 2020 3:36 PM
To: [redacted] (b) (6) (NIH/CC/BEP) [E] [redacted] (b) (6)>
Subject: Online First: Fauci on Coronavirus, Improving the Residency Match, and more

Trouble viewing this email? Read it Online

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 22:50:42 +0000
To: John Timmer
Subject: RE: Delta, American, United to suspend all China mainland flights as coronavirus crisis grows

Thanks John. Watch the news and you will see what I have been doing over the past 5 days.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: John Timmer (b) (6)
Sent: Friday, January 31, 2020 5:49 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Delta, American, United to suspend all China mainland flights as coronavirus crisis grows

You probably have already seen this. American, Delta and United canceling flights to China until March 27. A week ago Sunday at Starbucks when you mentioned this virus I had hardly heard anything about it. Now there's a full blown panic.
I'm glad you're on it! John

https://www.usatoday.com/story/travel/2020/01/31/coronavirus-china-flight-ban-delta-cuts-all-flights-white-house/4620989002/

John Timmer
(b) (6)

Sent from my iPhone

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 20 Jan 2020 21:10:26 +0000
To: Mascola, John (NIH/VRC) [E]
Cc: Graham, Barney (NIH/VRC) [E]
Subject: FW: Wuhan, 2019-nCoV

John/Barney:

Before I call up Skip, [redacted] (b) (5)

Thanks,
Tony

From: Skip Virgin [redacted] (b) (6)
Sent: Monday, January 20, 2020 3:51 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Wuhan, 2019-nCoV

Tony

[redacted] (b) (4)

(b) (4), (b) (6)

[redacted]

Skip

Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):10473-8. doi: 10.1073/pnas.1510199112. Epub 2015 Jul 27.

Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus.

Corti D[1], Zhao J[2], Pedotti M[3], Simonelli L[3], Agnihothram S[4], Fett C[4], Fernandez-Rodriguez B[3], Foglierini M[3], Agatic G[5], Vanzetta F[5], Gopal R[6], Langrish CJ[7], Barrett NA[8], Sallusto F[3], Baric RS[9], Varani L[3], Zambon M[6], Perlman S[10], Lanzavecchia A[11].

Author information

Abstract

Middle East Respiratory Syndrome (MERS) is a highly lethal pulmonary infection caused by a previously unidentified coronavirus (CoV), likely transmitted to humans by infected camels. There is no licensed vaccine or antiviral for MERS, therefore new prophylactic and therapeutic strategies to combat human infections are needed. In this study, we describe, for the first time, to our knowledge, the isolation of a potent MERS-CoV-neutralizing antibody from memory B cells of an infected individual. The antibody, named LCA60, binds to a novel site on the spike protein and potently neutralizes infection of multiple MERS-CoV isolates by interfering with the binding to the cellular receptor CD26. Importantly, using mice transduced with adenovirus expressing human CD26 and infected with MERS-CoV, we show that LCA60 can effectively protect in both prophylactic and postexposure settings. This antibody can be used for prophylaxis, for postexposure prophylaxis of individuals at risk, or for the treatment of human cases of MERS-CoV infection. The fact that it took only 4 mo from the initial screening of B cells derived from a convalescent patient for the development of a stable chinese hamster ovary (CHO) cell line producing neutralizing antibodies at more than 5 g/L provides an example of a rapid pathway toward the generation of effective antiviral therapies against emerging viruses.

J Virol. 2008 Apr;82(7):3220-35. doi: 10.1128/JVI.02377-07. Epub 2008 Jan 16.

Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.

Rockx B[1], Corti D, Donaldson E, Sheahan T, Stadler K, Lanzavecchia A, Baric R.
Author information

Abstract

Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002, and detailed phylogenetic and epidemiological analyses have suggested that it originated from animals. The spike (S) glycoprotein has been identified as a major component of protective immunity, and 23 different amino acid changes were noted during the expanding epidemic. Using a panel of SARS-CoV recombinants bearing the S glycoproteins from isolates representing the zoonotic and human early, middle, and late phases of the epidemic, we identified 23 monoclonal antibodies (MAbs) with neutralizing activity against one or multiple SARS-CoV spike variants and determined the presence of at least six distinct neutralizing profiles in the SARS-CoV S glycoprotein. Four of these MAbs showed cross-neutralizing activity against all human and zoonotic S variants in vitro, and at least three of these were mapped in distinct epitopes using escape mutants, structure analyses, and competition assays. These three MAbs (S109.8, S227.14, and S230.15) were tested for use in passive vaccination studies using lethal SARS-CoV challenge models for young and senescent mice with four different homologous and heterologous SARS-CoV S variants. Both S227.14 and S230.15 completely protected young and old mice from weight loss and virus replication in the lungs for all viruses tested, while S109.8 completely protected mice from weight loss and clinical signs in the presence of viral titers. We conclude that a single human MAb can confer broad protection against lethal challenge with multiple zoonotic and human SARS-CoV isolates, and we identify a robust cocktail formulation that targets distinct epitopes and minimizes the likely generation of escape mutants.

Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12123-8. Epub 2007 Jul 9.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.

Zhu Z[1], Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley LE, Prabakaran P, Rockx B, Sidorov IA, Corti D, Vogel L, Feng Y, Kim JO, Wang LF, Baric R, Lanzavecchia A, Curtis KM, Nabel GJ, Subbarao K, Jiang S, Dimitrov DS.
Author information

Abstract

The severe acute respiratory syndrome coronavirus (SARS-CoV) caused a worldwide epidemic in late 2002/early 2003 and a second outbreak in the winter of 2003/2004 by an independent animal-to-human transmission. The GD03 strain, which was isolated from an index patient of the second outbreak, was reported to resist neutralization by the human monoclonal antibodies (hmAbs) 80R and S3.1, which can potently neutralize isolates from the first outbreak. Here we report that two hmAbs, m396 and S230.15, potently neutralized GD03 and representative isolates from the first SARS outbreak (Urbani, Tor2) and from palm civets (SZ3, SZ16). These antibodies also protected mice challenged with the Urbani or recombinant viruses bearing the GD03 and SZ16 spike (S) glycoproteins. Both antibodies competed with the SARS-CoV receptor, ACE2, for binding to the receptor-binding domain (RBD), suggesting a mechanism of neutralization that involves interference with the SARS-CoV-ACE2 interaction. Two putative hot-spot residues in the RBD (Ile-489 and Tyr-491) were identified within the SARS-CoV spike that likely contribute to most of the m396-binding energy. Residues Ile-489 and Tyr-491 are highly conserved within the SARS-CoV spike, indicating a possible mechanism of the m396 cross-reactivity. Sequence analysis and mutagenesis data show that m396 might neutralize all zoonotic and epidemic SARS-CoV isolates with known sequences, except strains derived from bats. These antibodies exhibit cross-reactivity against isolates from the two SARS outbreaks and palm civets and could have potential applications for diagnosis, prophylaxis, and treatment of SARS-CoV infections.

Science. 2016 Aug 26;353(6302):933-6. doi: 10.1126/science.aaf1220. Epub 2016 Aug 18.

Discovery of a proteinaceous cellular receptor for a norovirus.

Orchard RC[1], Wilen CB[1], Doench JG[2], Baldridge MT[1], McCune BT[1], Lee YC[1], Lee S[1], Pruett-Miller SM[3], Nelson CA[1], Fremont DH[1], Virgin HW[4].
Author information

Abstract

Noroviruses (NoVs) are a leading cause of gastroenteritis globally, yet the host factors required for NoV infection are poorly understood. We identified host molecules that are essential for murine NoV (MNoV)-induced cell death, including CD300lf as a proteinaceous receptor. We found that CD300lf is essential for MNoV binding and replication in cell lines and primary cells. Additionally, Cd300lf(-/-) mice are resistant to MNoV infection. Expression of CD300lf in human cells breaks the species barrier that would otherwise restrict MNoV replication. The crystal structure of the CD300lf ectodomain reveals a potential ligand-binding cleft composed of residues that are critical for MNoV infection. Therefore, the presence of a proteinaceous receptor is the primary determinant of MNoV species tropism, whereas other components of cellular machinery required for NoV replication are conserved between humans and mice.

Herbert W. 'Skip' Virgin M.D., Ph.D.
Executive Vice President, Research
Chief Scientific Officer
Vir Biotechnology
499 Illinois Avenue

San Francisco CA 94158
he/him/his

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 29 Jan 2020 03:36:57 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Coronavirus Detection

Please handle. Thanks.

From: [redacted] (b) (6)
Sent: Tuesday, January 28, 2020 10:56 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)
Subject: Coronavirus Detection

Dear Dr. Fauci,

I am a microbiologist and also write oil and climate change thrillers. My books can be seen on Google (oil thrillers) and my story ROUND AND ROUND is a climate adventure. Soon to be followed by WE'RE BACK (Old Life forms arise as the planet warms).

With regard to Corona virus I should suggest a small hand held screen at AIRPORTS AND OTHER SITES coated with immobilized corona virus antibody. The traveler will breath onto the plate . Live traveler carried virus (antigen) will bind with the antibody immediately and this can be tied into an electric signal or alarm on the small hand held device. The traveler, if positive as a possible carrier, is then detained for further examination. The screen is subsequently "hit" to heat the surface or inactivate the antigen or some other method to prepare for the the next traveler in the plane, train or ship screening process. We have the technology to do this and come up with hand devices at all major ports of entry. Cruise ship passengers and other travelers worldwide can also be screened by this device.

Suggested Name: CORONATEK

Gary Kraidman
[redacted] (b) (6)
Bachelor of Science Brooklyn College
Master of Science cum laude Long Island University (Microbiology)
Rolex Award for oyster conchiolin protein in medicine and industry.
Member Mystery writers of America (political thrillers as well as climate change sci fi).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 22:59:12 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: interesting information to share

Please respond to this person. Be nice to him. He used to be in NIAID.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: James Mond [redacted] (b) (6)
Sent: Thursday, January 23, 2020 11:48 AM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: interesting information to share

Hi Tony, long time no speak and I hope all is well. I am currently the chief medical officer of a company that manufacture immune globulin and hyperimmune globulins. One of the hyperimmune globulins that was recently FDA approved was manufactured from the plasma of donors who were tested to have high titer neutralizing antibodies to RSV and the IG that was made was also found to have high titer binding antibodies to multiple other respiratory viruses including Coronavirus. [redacted] (b) (4)

[redacted] (b) (4)

Thanks very much

Best wishes,

Jimmy

Jimmy Mond MD,PhD
Chief Scientific Officer/Chief Medical Officer

Corporate Headquarters
465 Route 17 S
Ramsey, NJ 07446

Florida Campus
5800 Park of Commerce Blvd NW
Boca Raton, FL 33487

Direct [redacted] (b) (6)
Tel: 201 478-5552
Fax: 201 478-5553
[redacted] (b) (6)
www.admabiologics.com

The information contained in this e-mail is confidential and/or proprietary to ADMA Biologics, Inc. and/or its subsidiaries and affiliates, and is intended to be received by the individual or entity named above for limited use, without copying, forwarding, disclosing or otherwise transmitting this message to any other party. Please return this email if you received this message in error or are unable to acknowledge and protect the confidential/proprietary nature of its contents.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 26 Jan 2020 23:21:36 +0000
To: Rotrosen, Daniel (NIH/NIAID) [E];Abbey, Lillian (NIH/NIAID) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Barasch, Kimberly (NIH/NIAID) [C];Breen, Joseph (NIH/NIAID) [E];Erbelding, Emily (NIH/NIAID) [E]
Subject: RE: Lyme responses for Todd Slotkin

Someone send the material to Dan.

From: Rotrosen, Daniel (NIH/NIAID) [E] (b) (6)>
Sent: Sunday, January 26, 2020 6:09 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6); Abbey, Lillian (NIH/NIAID) [E] (b) (6)>
Cc: Conrad, Patricia (NIH/NIAID) [E] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] (b) (6)>; Breen, Joseph (NIH/NIAID) [E] (b) (6)>; Erbelding, Emily (NIH/NIAID) [E] (b) (6)>
Subject: Re: Lyme responses for Todd Slotkin

Tony,

Todd Slotkin contacted you about Lyme Disease, I gather about establishing some coalition. His connection with us on food allergy was short lived and long ago.

Glad to help in any way I can though I think DMID is working on this. I didn't receive the attachment, but gather it's something Lillian Abbey prepared and have copied her.

Dan

On Jan 26, 2020, at 5:43 PM, Fauci, Anthony (NIH/NIAID) [E] <(b) (6)> wrote:

Someone else MUST do this. I cannot do food allergy at all right now. I am drowning with coronavirus stuff. Please take me off this grid. Give it to Dan.

From: Conrad, Patricia (NIH/NIAID) [E] (b) (6)
Sent: Sunday, January 26, 2020 6:18 AM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Subject: Lyme responses for Todd Slotkin

This is not urgent but we said we would respond to Todd slotkin this week

To refresh your memory Todd Slotkin - a big financial guy in NYC wrote dan Rotrosen to connect with you on Lyme. He was involved in food allergy in the past. He is now interested in Lyme and sent questions. Joe Breen said we should respond in writing so the attached drafts are for your approval/editing. Email chain below explains

We said we would send these and offer a follow up call with you if needed.

Happy to discuss.

Sent from my iPhone

Begin forwarded message:

From: "Abbey, Lillian (NIH/NIAID) [E]" <[redacted] (b) (6)>
Date: January 21, 2020 at 4:04:07 PM EST
To: "Conrad, Patricia (NIH/NIAID) [E]" [redacted] (b) (6)>
Cc: "Erbelding, Emily (NIH/NIAID) [E]" <[redacted] (b) (6)>, "Marques, Adriana (NIH/NIAID) [E]" [redacted] (b) (6)>, NIAID BUGS <BUGS@niaid.nih.gov>, "Miller, Katherine (NIH/NIAID) [E]" [redacted] (b) (6)>
Subject: RE: on behalf of Dr. Fauci

Dear Patty,
Here is a proposed email response (first attachment) and responses to their Qs (second attachment). We've already secured input from Adriana, copied here, on the Qs and As. Please let us know if you need anything else.
Sincerely,
Lillian

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, January 17, 2020 2:11 PM
To: Abbey, Lillian (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6); Breen, Joseph (NIH/NIAID) [E] [redacted] (b) (6); NIAID BUGS <BUGS@niaid.nih.gov>
Subject: RE: on behalf of Dr. Fauci

Per ASF - can get the draft by COB Tuesday Jan 21? Good to know about Dr. Marques.

Thanks to all for your help with this request.

Patricia L. Conrad
Public Health Analyst and
Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03

Bethesda, Maryland 20892
[redacted] (b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Abbey, Lillian (NIH/NIAID) [E] [redacted] (b) (6)>
Sent: Friday, January 17, 2020 1:52 PM
To: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Breen, Joseph (NIH/NIAID) [E] [redacted] (b) (6)>; NIAID BUGS <BUGS@niaid.nih.gov>
Subject: FW: on behalf of Dr. Fauci

Dear Patty,
We just spoke with Joe and I wanted to confirm that we are developing a response to the questions, per Joe's discussion with Dr. Fauci. When do you want the response? Assume ASAP but please advise. Also, can you please let Dr. Fauci know that Adriana Marques in our intramural program serves on the GLA Board. We will be sure to secure her input on the draft response, and may want to note this fact in the letter.
Thank you,
Lillian

From: Conrad, Patricia (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Friday, January 17, 2020 10:53 AM
To: Breen, Joseph (NIH/NIAID) [E] [redacted] (b) (6)>
Cc: Erbelding, Emily (NIH/NIAID) [E] [redacted] (b) (6)>; Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)>
Subject: on behalf of Dr. Fauci

Hi Joe:

Todd Slotkin contacted Dr Fauci (thru Dan Rotrosen and FARE) – please see below and attached. Dr Fauci would like to speak with you about this request. Can you please give him a call today if you can at [redacted] (b) (6). He is available between 12:30 pm – 3:00 pm ET and then again between 330 pm – 5 pm ET.

Thanks..

Patricia L. Conrad
Public Health Analyst and

Special Assistant to the Director
National Institute of Allergy and Infectious Diseases
The National Institutes of Health
31 Center Drive, MSC 2520 - Room 7A03
Bethesda, Maryland 20892
(b) (6)
301-496-4409 fax

Disclaimer:
The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statement made that are sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Todd Slotkin (b) (6)
Sent: Thursday, January 16, 2020 11:47 AM
To: Conrad, Patricia (NIH/NIAID) [E] <(b) (6)>
Cc: Robert A. Kobre <robert.kobre@credit-suisse.com>
Subject: Fauci - Lyme Disease

Patty,

Happy and healthy New Year to you and your family.

I am following up on your kind offer to assist us on Lyme Disease with Dr. Fauci. As you requested.
I have attached the specific topics that we are seeking advice on.

As way of background, I worked with Dr. Fauci on Food Allergies from 2004-15 and we made some great advancements on the strategy as well as the approach to the science. In the last few years I have been working with Robert Kobre, Chairman of the Global Lyme Alliance (GLA)- the largest not for profit dedicated to Lyme research, education and awareness. We would appreciate the time to meet with Dr. Fauci to discuss how we can help break the bottleneck that has been holding back public and private funding of Lyme disease research. GLA has funded $10 million in research over the last five years alone and sponsored a conference at Cold Spring Harbor that included the NIH, CDC, FDA, and leading academic researchers who published a paper concluding that the current Lyme diagnostic tools as inadequate. We believe that GLA has a unique insight into Lyme disease research. Long held beliefs on the limited prevalence of the disease, limited ability for the bacteria to evade detection and limited ability for the bacteria to survive anti-biotic eradication are a few of the cornerstones that has hampered progress in the diagnosis and treatment of Lyme disease. The result is escalating incurrence rates (430,000 new cases a year in the US), and long term impact to the patients, their families and medical system; thus, we need your advice. Attached are some of the topics we would like to cover in an informal meeting with Rob Kobre, the GLA CEO, GLA Chief Science Officer and me.

Thank you again for your time on this matter and look forward to hearing from you and Dr. Fauci.

Best,
Todd

[redacted] (b) (6) (m)
212-763-1901 (o)

P.S. Robert Kobre's contact information is [redacted] (b) (6) (m) and 212-325-2567 (o). His email address is robert.kobre@credit-suisse.com

Hi Todd,

Best wishes to you too. Simplest and fastest will be to connect with Tony's assistant, Patty Conrad, whom I've copied above.

If for a Lyme Disease referral best to let Patty know the patient's approximate age and location, or where easy to travel.

It's been nice to see how much FARE has grown over the years.

Best, Dan

On Dec 3, 2019, at 8:58 PM, Todd Slotkin [redacted] (b) (6)> wrote:

Dan,

Hope you and your family had a great thanksgiving.

We had worked together on Food Allergies about 5-6 years ago. I need some advice from Tony Fauci on Lyme Disease. Would you have his contact information?

thanks so much,
Todd

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 20:41:33 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - CNN International LIVE HIT: 7:00 pm ET)
Attachments: RE: Hi Patricia, CNN International looking to interview NIAID at 6pET?

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 19:50:07 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: CNN International Corona Interview via Skype with David
Attachments: RE: Request CNN International Dr. Anthony Fauci 5pmET TAPING (SKYPE)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 27 Jan 2020 23:24:15 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: WTOP - live hit 6:50 pm ET via Facetime
Attachments: RE: WTOP

Mike Murillo | News Anchor & Reporter
mmurillo@wtop.com | 202-895-5253 direct
Twitter: @mikemurillowtop

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 17:08:13 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: CGTN Interview Live hit via skype
Attachments: RE: Interview request: Wuhan coronavirus, CGTN TV, RE: Interview request: Wuhan coronavirus, CGTN TV

Delal Pektas
Delal.Pektas@CGTNAmerica.com
Work cell phone: (b) (6)
Personal cell phone: (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 17:36:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: NPR On Point Radio SHow (LIVE HIT: 11:00 am - 11:20 am ET)
Attachments: FW: Interview request: On Point, Wuhan coronavirus, RE: Interview request: On Point, Wuhan coronavirus

Anna Bauman
On Point
asbauman@bu.edu
Phone: Will update
Topic: Wuhan coronavirus
Deadline: 11:00-noon 1/29

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Mon, 16 Dec 2019 21:21:16 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Bill Paul Lecture - Nussenzweig
Attachments: Re: oct 7 bill paul lecture

ASF may introduce per Auch

Dr. Michel Nussenzweig will deliver the annual Bill Paul lecture on Wednesday, October 7. The lecture will be held from 3:00 pm – 4:00 pm. Please let me know if Dr. Fauci can provide the introductory remarks at the beginning of the lecture. If so, please let me know what materials he needs and I will send to you in advance along with the Zoom link. I will share the Zoom link with the Paul family as well. Additional attendees will join via videocast.nih.gov.

I will ask Dr. Germain or Dr. Sen to moderate the Q&A at the end of the presentation.

Here's the WALS website with Dr. Nussenzweig's lecture title and summary:
https://oir.nih.gov/wals/2020-2021/human-antibody-responses-sars-covid-2

Thank you,
Jackie

Jacqueline Roberts
NIH WALS Coordinator

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 8 Jan 2020 13:47:13 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Marston, Hilary (NIH/NIAID) [E];'Catharine Paules'
Subject: Corona Editorial Discussion
Attachments: RE: Corona editorial, FW: Corona editorial

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 18:26:07 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CNN LIVE HIT: 5:40 pm ET on Truck at 5:30 pm ET
Attachments: RE: CNN / Sat: Dr. Fauci (5-7P)

Studio truck will arrive fauci residence at 5:15 pm

CNN DC
820 First St, NE

I will be your on-site POC:
Melissa Giaimo
(b) (6)

Hi Patty,

We just got off the phone. We are producing a special edition of Sit Room on Sat. With the CDC confirming the first human-to-human case in the US, we expect coverage of coronavirus to grow.

Can Dr. Fauci join us Sat on Sit Room? Brianna Keilar will be in for Wolf.

Best,
Melissa

MELISSA GIAIMO
Senior Editorial Producer ***"Situation Room with Wolf Blitzer"***
(b) (6) cell
+1-202-351-4406 work
melissa.giaimo@turner.com

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 20:16:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD- WTOP (LIVE HIT: 7:10 pm ET)
Attachments: RE: dr fauci

Mike Jakitis 202-895-5060

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 18:25:27 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Skype interview with Voa NEWS - Corona virus
Attachments: RE: Interview request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Jan 2020 23:13:15 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: PBS News Hour Live Hit: 6:30 pm ET
Attachments: Re: **Can we do a studio hit around 6:30 or 6:40 for PBS NewsHour

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 17:11:30 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Interview with The Economist (print)
Attachments: Interview request (print): coronavirus vaccine development | Economist, interview with Dr. Fauci, RE: interview with Dr. Fauci

Slavea Chankova
The Economist
[redacted] (b) (6) | slaveachankova@economist.com
Subject: coronavirus vaccine development
Deadline: EOB Mon, Feb 3

Hi Patty,

This reporter hopes to speak with an expert to learn more about NIH's coronavirus vaccine development plan. She specifically wants to know what improvements are being made over the vaccine development program for SARS and other coronaviruses. She has time to speak today until 1:30pm ET. She is available anytime Monday.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 18:47:24 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: HOLD TRT News - by skype taped
Attachments: RE: Urgent Interview Request Dr Fauci, image001.jpg

---

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 20:54:07 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: HOLD - NBC interview corona (LIVE HIT: TBD
Attachments: Re: [EXTERNAL] RE: TODAY Request Tomorrow 1/31

Clare Hiler | (b) (6)

CLARE E. HILER |
<image001.png>
NBC NEWS | 212-664-3639 | (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 31 Jan 2020 23:22:10 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: WH TASK FORCE Conf Call The requested participation is Task Force Member ONLY.
Attachments: DO NOT FORWARD White House Task Force on Coronavirus CONFERENCE CALL, TOMORROW, Saturday, February 1, 2020 from 4:00 - 4:30 p.m.

(U//FOUO) There will be a **White House Task Force on Coronavirus UNCLASSIFIED CONFERENCE CALL TOMORROW, Saturday, February 1, 2020,** from **4:00 – 4:30 p.m.** The requested participation is **Task Force Member ONLY.** Please confirm receipt and contact Ryan Shellooe with any additional questions at (b) (6).

In order to access the conference as a participant, dial the number below and enter the Participant Code:

Participant Dial-In: (b) (4)
Participant Code: (b) (4)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 20:33:28 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: WCBS Interview re Wuhan Coronavirus (5-10 minutes)
Attachments: Interview request: Wuhan coronavirus, WCBS radio, Re: Interview request: Wuhan coronavirus, WCBS radio, Re: Interview request: Wuhan coronavirus, WCBS radio

Angel Saborido
WCBS Radio
Phone: 212-524-2910
Email: asaborido@wcbs880.com
Subject: Wuhan coronavirus
Deadline: This evening (could do tomorrow if necessary)

Hi Laurie,

This radio producer would like to have Dr. Fauci call in for a live radio interview at one of the following times this evening: 4:45, 5:15, 5:45, or 6:15. If none of those times work, he'd like to do it tomorrow instead. The conversation would last between 5-10 minutes.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 21:00:22 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: The Morning Goods with Madelyn Woods Radio Show (LIVE HIT: 7:15 am - 7:30 am)
Attachments: FW: Interview request: Wuhan coronavirus, The Morning Goods with Madelyn Woods, RE: Wuhan interview with Dr. Fauci

Senita Brooks
The Morning Goods with Madelyne Woods (talk radio)
(b) (6)
Topic: Wuhan coronavirus
Deadline: 7:30 tomorrow morning

Hi Patty and Laurie,

This producer would like Dr. Fauci to participate in a live talk radio show for a 15-minute interview tomorrow morning, ideally between 7:00 and 7:30. The conversation would be general, layperson-friendly questions on the Wuhan coronavirus. Their studios are in Silver Spring, and they'd like to have Dr. Fauci come in to participate in person, but they'd be fine with a phone call instead. This would be broadcast live.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 22:11:25 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: TRT World Turkish TV Corona Virus - Live Hit
Attachments: RE: interview request

I am reaching out to ask if Doctor Fauci can comment on First U.S. case of potentially deadly coronavirus confirmed in Washington state.
This is a request for the news hour at 7 PM or 9 PM.
Show is hosted by Sally Ayhan in our DC studio.
Waiting

STORY DETAILS:
A man in Washington state has been diagnosed with the mysterious virus, the first case reported in the United States since the pneumonia-like illness first appeared last month in the central Chinese city of Wuhan, people familiar with the investigation said.
https://www.washingtonpost.com/health/2020/01/21/coronavirus-us-case/

Serra KARACAM
Interview Producer

<image007.jpg>

TRT WORLD Channel,
1819 L Street, Suite 700
NW Washington DC, 20036
T. +1 202 800 88 04
M. [redacted] (b) (6)

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Jan 2020 23:04:01 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: FOX Business News Coronoa virus (LIVE HIT:12:25 pm ET)
Attachments: RE: FOX BUSINESS NETWORK GUEST REQUEST, FW: FOX BUSINESS NETWORK GUEST REQUEST

Firm for 12:25 pm Live hit

I am reaching out to see if Dr. Fauci is available to join us tomorrow between 12-1pmET on *Cavuto: Coast to Coast* on Fox Business with Neil Cavuto. We are looking to discuss drug pricing, and would love to have Dr. Fauci join us.

Please let me know if this is something we can arrange.

Best,
Kevin Fitzgerald

Kevin Fitzgerald
Booker
Fox Business - Cavuto: Coast to Coast
1211 Avenue of the Americas – 12th Floor
O: 212.601.2902
C: (b) (6)
Kevin.Fitzgerald@FoxNews.com

From:	Fauci, Anthony (NIH/NIAID) [E]
Sent:	Wed, 22 Jan 2020 13:43:44 +0000
To:	Fauci, Anthony (NIH/NIAID) [E]
Subject:	Coronavirus interview with John Catsimatidis Radio Show (taped at 5:15 pm ET)
Attachments:	FW: John Catsimatidis office. , RE: John Catsimatidis office.

From: Matt [redacted] (b) (6)>
Sent: Tuesday, January 21, 2020 6:47 PM
To: Barasch, Kimberly (NIH/NIAID) [C] [redacted] (b) (6)
Subject: Re: John Catsimatidis office.

Kim. I'm back. Would Dr. Fauci have a few minutes this week to talk about the flu from China. Same as always 8-10 minutes on phone.
Matt Wanning
[redacted] (b) (6)
New York

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:19:39 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Assoc Press on Camera Coronavirus (taped at 11:10 am ET)
Attachments: Re: AP REQUEST: FAUCI INTERVIEW, RE: AP REQUEST: FAUCI INTERVIEW

Greetings Patricia,

Would Dr. Fauci be available before noon today to discuss the coronavirus? I heard him on WTOP this morning addressing a vaccine that is in the works for the virus.

Please let me know if you can you fit AP into his schedule today. Happy to book a studio link.

We appreciate the consideration.

Best,

Lisa

<image001.jpg>
Lisa Nicole Matthews
Assignment Manager, U.S. Video
Associated Press | Washington

Broadcast News Center
1100 13th Street NW
Washington, DC 20005
Office 202-641-9700
Cell (b) (6)
@lisanmatthews

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:47:21 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: VRC with CNN - Corona Virus
Attachments: FW: request to visit VRC re novel coronavirus

Jen Routh coordinating

Hello – CNN has confirmed they would like to visit today. 3:30-4 laboratory filming with hand-held model and visuals (with Dr. Graham, Dr. Corbett and Dr. Fauci), then 4-4:30 conversation with Dr. Fauci.

The producer can't make it up from Atlanta so they are sending a camera person and he and potentially Elizabeth Cohen will ask Dr. Fauci questions via phone. They might be able to send a local producer. It is not ideal, but they are trying to get what they can as quickly as possible. They would still like for us to explain the vaccine design using the hand-held model and computer images, which will be filmed. They said they would potentially like to return just for b-roll in the next week or so once VRC has received Wuhan reagents.

I will get to the VRC around 3 and will be there for the full visit. My cell is (b) (6).

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 14:40:18 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Italian TV taped hit Coronoavirus
Attachments: RE: Wuhan coronavirus, MediaSet

Maria Louisa Rossi Hawkins
Mediaset (large Italian TV media conglomerate)
(b) (6)
(b) (6)
Topic: Wuhan coronavirus
Deadline: After 3:00 today

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 17:22:04 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Univision Corona virus interview by skype
Attachments: RE: corona virus interview with Dr. Fauci

Paola Bayron
Univision
(b) (6), pbayron@univision.com
Seeking: video Skype interview, for live broadcast
Topic: coronavirus
Deadline: 2:00 today

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 19:30:05 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Interview with Greta Van Sustern VOA re Coronavirus
Attachments: RE: Voice of America - Plugged In with Greta Van Susteren show - TV Interview Request - Weds. Jan 29, 2019, RE: Voice of America - Plugged In with Greta Van Susteren show - TV Interview Request - Weds. Jan 29, 2019

Firm For Monday.

VOA has confirmed everything below with VideoLink.
Our control room name is VOA Control Room 53 – the number is 202-382-8053.
Elizabeth Cherneff is (b) (6) for any concerns between now and Monday.

Elizabeth here, Voice of America producer with Greta Van Susteren's show here in DC.
I am writing to extend an invitation to Dr. Anthony Fauci to join Greta for a live 1-on-1 interview on our show **next Wednesday January 29, 2019 at 10:30a EST.**
We plan to ask Dr. Fauci about the coronavirus outbreak originating in China– what do we know about it and what are the concerns about its potential threat to humans?
This interview would run about 6-8 minutes in length.
We are happy to accommodate Dr. Fauci at VOA's studios, or remotely via NIH's ReadyCam Studio, as we have in the past.

"Plugged In" is a 30-minute news magazine that airs in more than a dozen affiliates across Africa and Europe, including VOA Persian Service's 24-hour channel. The Voice of America (VOA) is a dynamic international multimedia broadcaster with service in more than 40 languages. Serving an estimated weekly global audience of more than 275 million, VOA provides news, information, and cultural programming through the Internet, mobile and social media, radio, and television. VOA is funded by the U.S. Government through the U.S. Agency for Global Media.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Jan 2020 21:07:54 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Lou Dobbs Fox Business News - Live Hit: 7:25 pm ET - Corona virus
Attachments: RE: [EXTERNAL] RE: fbn inquiry

Anne.McCarton@FOXNEWS.COM

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 16:09:48 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: FOX news radio Live hit 1:10 pm
Attachments: RE: FOX News Radio Interview Request

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 16:51:58 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: CNBC Squawk Box Corona virus - (LIVE HIT: 7:30 am)
Attachments: RE: CNBC Squawk Box request, FW: CNBC Squawk Box request

Control room number is 201-735-4112.

LIVE HIT: 7:30 am et – 7:40 am ET

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 17:00:35 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: Cox Media Group Interview re Coronavirus (taped 2:15 pm ET)
Attachments: Re: interview request: Cox media group/ CoV

Katie Suiters
Producer
Cox Media Group Washington Bureau
Direct: (202)777-7052 | Cell: [redacted] (b) (6)
katie.suiters@coxinc.com

Cox would like to send a crew to campus today around 11 a.m. for a quick on-camera interview on CoV. They would ask how concerned traveling Americans should be.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Jan 2020 20:27:12 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Corona virus briefing to Hill (w/Redfield)
Attachments: RE: URGENT: please advise - request for Member briefings on coronavirus, Update. Fwd: full bipar senate briefing tomorrow at 10:30 re: coronavirus

Friday, Jan. 24 – before 1pm

- Request from Sen. Lamar Alexander (R-TN; Chair, Senate HELP Committee) – may include other HELP Members or other Senators
- CDC and NIH participation requested; may also include NSC
- We were initially told it would be classified but now appears they will do unclassified to facilitate HHS participation

Senator Alexander is hosting a **full senate (bipar) briefing tomorrow at 10:30AM** on coronavirus in the HELP hearing room. We just go the request a few minutes ago so please help us coordinate quickly. They would like the briefers to be (1) CDC, (2) NIAID, (3) ASPR, and (4) State. I suggest that they speak in that order. Can someone from NSC/WH please loop in relevant State colleagues. This briefing will be unclassified.

Below is my suggested run of show (the topics listed below by each speaker are what they have specifically asked to hear about):

1. Senators arrive, mingle with principals and sit down
2. Dr. Redfield, 10 mins (+one SME) to provide the "here is what we know," "here is where it started," here is what it is," "here is where it is in the US," "here is what the US resources and protocols are to detect and treat," "what can we do domestically given we can't shut off a city like Wuhan"
3. Dr. Fauci, 5 mins—provide info on what NIAID is doing
4. Dr. Kadlec, 5 mins—provide info on what ASPR is doing
5. State, 5 mins—here is what China is doing that we know of
6. Approx. 30 mins of Q&A

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 16:41:18 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: NPR Morning Edition (LIVE HIT:7:05 AM WITH AWWAD AT OFFICE)
Attachments: RE: Morning edition Monday, interview with Dr Fauci, RE: interview with Dr Fauci

As Simone said below, our 24/7 phone is 202-513-2158

Reporter: Rachel Martin / Steve Inskeep
Organization: NPR's Morning Edition
Producer: Nina Kravinsky
Phone #(s): [redacted] (b) (6) nkravinsky@npr.org
Subject: Wuhan coronavirus
Deadline: today for coordination
Spokesperson: NIAID Director Anthony S. Fauci, by phone
Expected place of publication: radio, online
Expected date of publication/airing: Monday, Jan. 27
Expected prominence: Morning Edition

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 18:21:11 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Senate Approps Clerks visit to NIH
Attachments: Please advise: House Clerk Visit Feb 4 and Senate Clerk Visit Feb 21- Availability Check, RE: pelase read, RE: Confirmed 1:15pm start: Feb 21st Senate Appropriations Staff Visit, FW: senate clerks at nih tomorrow

NIH OLPA has confirmed that Dr. Fauci's slot for the Feb. 21st visit of the Senate appropriations clerks will be 1:15pm – 1:55pm (40 minutes).

National Institutes of Health

Senate Clerk Briefings

Friday, February 21st

Building 31, Conference Room 31 A, 4A53

10:00 am – 4:00 pm

Times	Event
10:00	**Clerks Arrive on Campus**
10:00 – 10:10	**Welcome** • NIH Director Francis Collins
10:10 – 10:50	**CSR Director Meet and Greet** • CSR Director Noni Byrnes
10:50 – 11:30	**NCI Update** • NCI Director Ned Sharpless
11:30 – 12:10	**NIDA Update** • NIDA Director Nora Volkow
12:10 – 12:40	**Break – Lunch**
12:40 – 1:15	**NIMHD Update** • NIMHD Director Eliseo Pérez-Stable
1:15 – 1:55	**NIAID Update** • NIAID Director Anthony Fauci
1:55 – 2:00	**Break**
2:00 – 2:20	**Non-human Primate Discussion** • Associate Director for Science Policy & Acting Chief of Staff Carrie Wolinetz
2:20 – 2:40	**Human Fetal Tissue Update** • Associate Director for Science Policy & Acting Chief of Staff Carrie Wolinetz
2:40 – 2:55	**Harassment Update** • Associate Director for Science Policy & Acting Chief of Staff Carrie Wolinetz
2:55 – 3:15	**IC Performance Assessments**

	• Principal Deputy Director Lawrence Tabak
3:15 – 3:50	**Buildings and Facilities** • Principal Deputy Director Lawrence Tabak • Deputy Director for Management Alfred Johnson • Associate Director for Budget Neil Shapiro • Associate Director for Research Facilities Dan Wheeland
3:50 – 4:00	**Clerks Depart**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 18:24:48 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: House Approps Clerks Visit to NIH - Working Lunch 1:20 pm - 2:00 pm
Attachments: Please advise: House Clerk Visit Feb 4 and Senate Clerk Visit Feb 21- Availability Check, FW: Draft agenda for House L-HHS Clerks visit on 2.4.2020

National Institutes of Health

House Appropriations Staff Briefings
Tuesday, February 4th
Medical Board Room
11:00 am – 4:00 pm

Times	Event
11:00	**Staff arrive on campus**
11:00 – 11:10	**Welcome**
11:10 – 11:40	***All of Us* Research Program Updates** • *All of Us* Research Program COO Stephanie Devaney
11:40 – 12:20	**Buildings and Facilities Tour** • Clinical Center CEO James Gilman • Associate Director for Research Facilities Daniel Wheeland • Associate Director for Budget Neil Shapiro
12:20 – 12:55	**Sexual Harassment/Clinical Trials** • Associate Director for Science Policy & Acting Chief of Staff Carrie Wolinetz
12:55 – 1:20	**Break/Get lunch and bring back to room**
1:20 – 2:00	**NIAID Update (Working Lunch)** • NIAID Director Anthony Fauci
2:00 – 2:30	**B&F Discussion** • Principal Deputy Director Lawrence Tabak • Associate Director for Budget Neil Shapiro • Deputy Director for Management Alfred Johnson • Associate Director for Research Facilities Daniel Wheeland • Clinical Center CEO James Gilman
2:30 – 2:50	**INCLUDE Update** • NICHD Director Diana Bianchi
2:50 – 3:20	**Foreign Influence/Conflicts of Interest** • Deputy Director for Extramural Research Michael Lauer
3:20 – 4:00	**NCI Update** • NCI Director Ned Sharpless
4:00	**Staff depart**

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Fri, 24 Jan 2020 18:57:38 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: WCBS Radio interview - Corona - LIVE HIT 6:15 pm ET
Attachments: FW: WCBS INTERVIEW REQUEST

Angel Saborido
Producer, WCBS880
212-524-2910

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 28 Jan 2020 13:39:50 +0000
To: Fauci, Anthony (NIH/NIAID) [E]
Subject: Call with Tim Kingston re: 30th Anniversary of SF AIDS Conf
Attachments: RE: 30th Anniversary of SF AIDS Conf Exhibit at SF Library organizers Rick Gerharter, Liz Highleyman and Tim Kingston, RE: 30th Anniversary of SF AIDS Conf Exhibit at SF Library organizers Rick Gerharter, Liz Highleyman and Tim Kingston, RE: PLEASE READ: 30th Anniversary of SF AIDS Conf Exhibit at SF Library organizers Rick Gerharter, Liz Highleyman and Tim Kingston, RE: PLEASE READ: 30th Anniversary of SF AIDS Conf Exhibit at SF Library organizers Rick Gerharter, Liz Highleyman and Tim Kingston

This would come under the heading of a blast from the past. I think you might remember me as that pesky reporter from SF Bay Times and SF Frontiers who did a fair bit of writing about the epidemic back in the day. Well I am currently at work on a photo exhibit being organized by photographer Rick Gerharter at the SF Library and I have been tasked with writing some of the blurbs accompanying the photos. I was hoping that we might have a chat about those days, because I want a quote from you about what the situation was at the SF AIDS conf in terms of hopefulness and lack thereof at that time and how things have changed since then. Is there a chance we could have a conversation about this at your convenience?

Ah, and the sfgov.org address, I found a different line of work than reporting (wherein I would have been on the dogfood retirement plan) and I am now a Public Defender investigator.

Looking forward to hearing from you.

All the Best, Thanks,
Tim

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 21 Nov 2019 16:05:56 +0000
To: Fauci, Anthony (NIH/NIAID) [E];Awwad, David (NIH/NIAID) [C]
Subject: NAS meeting - Washington dc - virtual
Attachments: FW: NAS 157th Annual Meeting: April 25-28, 2020, FW: Registration Confirmed - 2020 NAS Annual Meeting, FW: NAS Annual Meeting now entirely online

TBD timing

Dear Dr. Fauci,

Based on evolving guidance from public health experts regarding the COVID-19 pandemic, the NAS Annual Meeting will now take place entirely online via webcast, webinars, and Zoom meetings. Because you had planned to attend the annual meeting in person, we are writing to let you know about the changes in plans. Please remember to cancel your hotel reservation if applicable.

Details about the online sessions and how to connect will be provided on our website and by email in the coming weeks. In the meantime, please contact us at annual@nas.edu if you have any questions. We hope to see you again in person at the 2021 annual meeting and look forward to your online participation this year.

Sincerely,
NAS Membership Office

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 3 May 2020 17:55:14 +0000
To: 'Sharpless, Ned [redacted] (b) (6)';Tromberg, Bruce (NIH/NIBIB) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E]
Subject: FW: 2 quick points
Attachments: covid contact tracing.pdf

Ned/Bruce:

I thought that I would pass this on to you in case you have interest. Thanks.

Best,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Eric Ottesen [redacted] (b) (6)
Sent: Saturday, May 2, 2020 8:23 AM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: 2 quick points

Dear Tony,

1. I had planned to write to thank you for giving an interview [redacted] (b) (6) for the Washington Post last month. Your generosity with time was 'all Tony,' and I did appreciate it. I was waiting for the chaos around you to subside before writing but.....
2. Last evening I was asked to forward the message below to you. You might already know Jack Warren, Professor of Medicine and Infectious Diseases at U. Maryland [redacted] (b) (6) [redacted] As his email says, [redacted] (b) (6) Samsung's venture capital group, which has an idea for a future, comprehensive surveillance system for COVID-19 [redacted] (b) (4) [redacted]. It is interesting, but all I know is what I read in the power-point attached. I cannot imagine you would have time

to look at it yourself, but perhaps it could be shared with other systems-oriented individuals working towards 'opening up' responsibly.

Pardon me for stepping out of my normal NTD 'swim lane' but I did want to help out [redacted] (b) (6) and certainly nothing is more important these days than COVID-19 and the outstanding work you are doing to manage it.

All the very best,

-Eric

From: Warren, John [mailto [redacted] (b) (6)
Sent: Thursday, April 30, 2020 6:52 PM
To: [redacted] (b) (6)
Subject: Jack Warren

Eric

A voice from the past. Covid-19 prevented us from meeting up [redacted] (b) (6) but I'm writing because it might yet bring at least the two of us together.

[redacted] (b) (6) Samsung's venture capital group and his team has what I think is an incredibly useful idea for contact tracing for covid-19 as well as actually opening the economy up again. The idea is contained within the attachment.

I wonder if you still have any contacts with Anthony Fauci. Is so, could you see your way clear to forwarding the attachment to him? The group has identified some appropriate test manufacturers but is at the point where they need to know the spectrum so as to focus on the optimal ones. The thought was that Tony Fauci might be the best person to know what tests are in development stage.

What are your thoughts?

Don't worry about confidentiality; they want to widely share this idea so as to get it out as quickly as possible.

Thanks

Jack Warren MD
Professor of Medicine
Division of Infectious Diseases
University of Maryland School of Medicine
Baltimore MD 21201
[redacted] (b) (6)

Product Concept
“Covid Clear”
Digital Proof of No Infection

April 2020

Masks, Contact Tracing & Immunity Passports Won't Bring the US Economy Back

- A return to normal economic activity requires **confidence that those around us are not infectious**
- A widely available vaccine and/or herd immunity could take up to **18 months, possibly longer**
- In the interim, **existing proposals will not provide the level of confidence required**
    - Masks are necessary but not sufficient
    - Contact tracing, while critical, is retrospective and does not prevent us from being exposed
    - The usefulness of immunity/antibody tests is limited
        - Only useful for those already infected (<10% in the US)
        - Not yet clear that having antibodies eliminates possibility of being infectious
    - Temp checks are helpful, but 25-50% of infectious people are asymptomatic (i.e., no fever)
- Instead, we need a **widely recognized way to certify that each of us is not currently infectious** and to use this certification as a way to safely, and confidently, go into shared spaces again.
- **We call this idea "Covid Clear"** - a portable and irrefutable proof of no infection

This is Not Complicated to Assemble - Here's What's Needed

- A **rapid, low-cost, home test** for infectiousness (testing for the virus, not antibodies)
    - High sensitivity (low percentage chance of false negatives)
    - Under 15 minutes
    - Under $20 per test
    - Self-administered twice per week via saliva or anterior nasal swab

- **Integration of the test results with a portable digital device** to irrefutably prove:
    - the test was taken by the person whose biometrics are tied to the device
    - the results have not been tampered with
    - the test was taken within the allotted timeline before the results expire and become invalid
    - the person claiming to be "safe/not infectious" is indeed who they say they are

- This is plausible **TODAY!**

First Test to be Approved in May; More to Follow

- Company 1:
    - Antigen test
    - Likely to be FDA-approved in May
    - Single-digit $ bill of materials, results in under 15 mins, 92% sensitivity
    - Results appear like a pregnancy test (colors/patterns on a test strip)
    - Currently a nasal swab but clear visibility to saliva and self administration within 6-8 weeks
- Company 2:
    - Similar technical approach as above but currently focused on antibody/immunity test
    - Would consider pursuing virus test in parallel with the right partner
    - Results appear like a pregnancy test (colors/patterns on a test strip)
    - Currently a nasal swab but clear visibility to saliva
- Investigating several others:
    - Jonathan Rothberg/Homodeus approach
    - Rutgers saliva test recently approved by FDA (not currently designed for home)
    - CRISPR approach out of UCSF
    - Initial immune response proteins at University of Colorado
    - Spectroscopy with dyes at Albany Medical Center
    - Many more in development - the US will have several viable home tests in market by Sept 1

The Missing Piece: Calling Apple, Samsung, and Google!

- Assuming one or more of these tests is FDA-approved and deployed at scale, integration of the results with a portable digital device will be critical, and we believe it is possible:
  - **Phone optical sensors** to "read" the strip test results
  - **Biometrics** to ensure the test-taker is the person whose biometrics are tied to the phone
  - **Secure enclave** to encrypt and store the results
  - **Integration with contact tracing** for further confidence: not only was the person not infected when they took the test 3 days ago, they have not been near an infectious person since

- The app would then be used to show the most recent, valid test result in order to gain access to:
    - Hospitals, Schools, Warehouses/Factories, Offices, Airplanes, Restaurants, Malls, Stadiums/Arenas, Amusement Parks, etc

- Depending on the level of confidence required in a given shared space, and the level of outbreak risk, the "scanning" may be different by venue: i.e., a visual check at a small restaurant, a QR code scan for a warehouse/office, integration with TSA Pre for flights, and a CLEAR kiosk at a stadium.

Decreases Burden on Contact Tracing; Works with Immunity Tests and Vaccines

- Contact Tracing
    - Covid Clear test results could be automatically and anonymously shared with the various contact tracing systems in development, thereby improving their accuracy and coverage

    - Also, Covid Clear should **significantly decrease the resources and time required to contact trace**, since the platform would be able to inform the contact tracers which of the people on their checklists have already tested negative

- Immunity Tests
    - As reliable immunity tests become available, **we envision integrating those test results as well**, thereby allowing people to prove that they a) have the antibodies and b) are not infectious

- Vaccines
    - Similarly, we envision a **“proof of vaccination”** to be integrated into the app

How It Works & Where it Fits

- Open Source
- Published SDKs and APIs
- Self-Sovereign Identity
- Private-by-Design
- No Infection "Confidence Score" (0-100)


Rapid Virus Tests
(Home, Office, Point of Care)
Covid Clear
Contact Tracing Platforms (US States, GOOG/APPL)
Access Systems & Apps (Delta. Uber, Ticketmaster, Airbnb, Opentable, Clear)

Who Pays? Employers & Govts Will Fund Deployment, Possibly B2C F500 Too

- Multiple types of organizations have an incentive to pay for Covid Clear
  - **Employers** who manage warehouses, factories, food processing plants, and large offices
  - **State and County Govts** who want to jumpstart their economies and need a better way to give their citizens the confidence to leave quarantine
  - Businesses whose revenue is **dependent on large public gatherings**
    - Sports leagues, mall owners/REITs, amusement park operators, etc
  - Businesses whose revenue is **dependent on people gathering in small, close quarters**
    - Airlines, restaurant chains, retail chains, etc
  - Other
    - One could even imagine a family giving Covid Clear as a gift so that a nanny or housekeeper (and their families) could be regularly tested, or grandparents buying the system for their grandchildren to feel more comfortable about family visits.

This Does Not Have to be Ubiquitous to Work. We Can Start Small.

- A school
- A hospital
- A fire station
- A police district
- A food processing plant
- A warehouse
- A factory
- A stadium
- A town

- One-off consumer use cases could also develop:
    - The Patriots (or Taylor Swift) include a test kit with every ticket they sell
    - Grandparents buy a test kit on Amazon for their son, daughter-in-law, and grandchildren
    - Delta Airlines reopens NYC-SF leg and includes a test with every itinerary
    - Marriott reopens in certain cities and includes a test kit with every reservation confirmation

- If enough of the above use cases prove successful, local and state governments would likely then subsidize the tests so that ALL businesses and organizations benefit and ALL citizens are safe.

Does the Math Work? Yes.

- Especially as costs come down with scale
- The cost of the tests today is \$20-\$40 per week, or roughly \$1000-\$2000 per year per person
- **While this is a significant amount of \$, it pales in comparison to the costs of a "scared economy"**:
    - US government already sending \$1200 checks to many citizens, with more to come
    - Employers actively looking to provide a safe work environment for their employees
    - The collective lost revenue per person of a "scared economy" to:
        - Airlines
        - Retail
        - Restaurants
        - Sports Leagues
        - Malls
        - Amusement Parks
        - etc.
- At scale, costs could decrease to \$10-\$20 per week, or roughly \$500-\$1000 per year per person

And the Math is Even More Compelling from a Macroeconomic Perspective

- The current "closed economy" is costing the United States between **$100B-$350B per month*** as compared to the economy before the pandemic.
- As states begin to reopen, no one knows how much the economy will improve, but a recent survey showed that 57% of US citizens are still "very" or "somewhat" concerned about being infected.**
- Optimistically, even if the "scared economy" is 50% better than the "closed economy", that's still costing the US between **$50B-$175B per month**.
- By contrast, if deployed to every single US citizen, **Covid Clear would cost roughly $27B per month.**

*"Roadmap to Pandemic Resilience" - Edmond J. Safra Center For Ethics At Harvard University 04/20/2020
**Washington Post-University of Maryland Poll, reported 04/21/2020

Another Important Consideration: Future Proofing & Pandemic Resilience

- Unfortunately, the scientific consensus is that this will not be the last pandemic of our lifetimes (whether natural or synthesized), and possibly not even the last pandemic of this decade.
- Given this, one could make the argument that the cost of **Covid Clear is also a down payment** on being prepared for those future crises:
    - Citizens will be comfortable with the idea that they will have to temporarily self-isolate until home tests become available and then will need to carry around a "proof of no infection".
    - **The infrastructure will be in place** to certify that people are not infectious throughout the country: at airports, offices, factories, warehouses, stadiums, amusement parks, etc.
- Psychologically and economically, this is critical: when the next pandemic hits, we will know we have a "proof of no infection" system already in place. This in turn will provide us with the comfort that future pandemic economic crises will not last until we develop a vaccine but instead until we have a rapid, low-cost, and high sensitivity home test - **a far easier medical problem to solve**.

Challenges and Mitigants

- Challenge: In the US, only 85% of the population has a smartphone; what about the other 15%?
  - Mitigants: The government, or businesses, may be willing to subsidize device costs. Or a cheaper, perhaps even non-digital, portable device could hold the test results.
- Challenge: The privacy implications here are enormous; people don't want their healthcare tracked
  - Mitigants: Test result data tied to identity is stored and encrypted on the phone and never leaves the phone. And any data shared with contact tracing systems is fully anonymized.
- Challenge: This is overkill - only the most vulnerable will be too scared to get back to work/life
  - Mitigants: In the US, over 50% of the population have conditions comorbid with Covid-19. And this figure does not include all of the people that they live with.
- Challenge: Liability for false negatives
  - Mitigants: Currently, test companies bear all liability. We also believe we can work with governments and employers to fully indemnify all companies involved in the product, much as the government does for vaccine manufacturers.

Next Steps / How You Can Help

- If you believe in this concept, please forward this deck onto anyone who could help refine the idea and/or help make it a reality:
  - Potential contributors to the software and app (developers, designers, etc)
  - Other manufacturers of rapid, low cost home tests for the presence of SARS-CoV-2
  - Developers of contact tracing platforms
  - Potential early customers:
    - Employers
    - Local and State Governments
    - Businesses whose revenue is dependent on large public gatherings
    - Businesses whose revenue is dependent on people gathering in small, close quarters
  - Potential advocates
    - Public health experts, epidemiologists, and medical ethicists
    - Economists
    - Healthcare, business, and political leaders on “how to reopen our economy” task forces
- Please also reach out to me directly with any thoughts/questions/concerns: guswarren@gmail.com

Thank you.

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 30 Apr 2020 21:47:05 +0000
To: [redacted] (b) (6)
Subject: FW: Autopsy data supporting Remdesivir trial
Attachments: [redacted] (b) (4)
[redacted]

Take a look at the Figures in the manuscript. [redacted] (b) (5)

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Timothy Schacker [redacted] (b) (6)
Sent: Thursday, April 30, 2020 1:10 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6)>
Subject: Autopsy data supporting Remdesivir trial

Tony,

[redacted] (b) (4)

Stay well (please) and thank you for all you are doing!

Tim

Timothy Schacker, M.D.
Vice Dean for Research, Medical School
Director, Program in HIV Medicine
University of Minnesota

Mail:
MMC 250
420 Delaware Street SE
Minneapolis, MN 55455

FedEx/UPS:
Mayo C688
420 Delaware Street SE
Minneapolis, MN 55455

Phone: (b) (6)
Fax: 612-626-5599
email: (b) (6)

A final version of this draft article can be found at https://arxiv.org/ftp/arxiv/papers/2005/2005.00004.pdf

(b) (4)

[redacted]

(b)(4)

[redacted]

(b)(4)

[redacted]

(b) (4)

[redacted]

(b)(4)

[redacted]

(b)(4)

[redacted]

(b)(6)

[redacted]

(b)(4)

[redacted]

(b) (4)

[redacted]

(b)(4)

[redacted]

(b) (4)

[redacted]

(b)(4)

[redacted]

(b)(4)

[redacted]

(b)(4)

[redacted]

(b)(4)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Thu, 23 Apr 2020 11:54:41 +0000
To: Corey MD, Larry [redacted] (b) (6);Mascola, John (NIH/VRC) [E]
Cc: Conrad, Patricia (NIH/NIAID) [E];Fauci, Anthony (NIH/NIAID) [E]
Subject: NEJM manuscript
Attachments: COVID vaccine editorial_prefinal April21_7pm fsc - with minor Fauci edits.docx

Larry/John:

I have gone over the changes that Francis has inserted and I have edited some of them. Please accept his changes and my edits of them (or any additional edits that you have) and then it is OK to send in. Please let me know if you have any questions.

Thanks,

Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: [redacted] (b) (6)
FAX: (301) 496-4409
E-mail: [redacted] (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

A final version of this draft article can be found at https://pubmed ncbi.nlm.nih.gov/32393526/

(b) (5)

[redacted]

(b) (5)

[redacted]

(b)(3)

[redacted]

(b) (5)

[redacted]

(b) (5)

[redacted]

(b) (5)

[redacted]

(b)(5)

[redacted]

(b) (5)

[redacted]

(b) (5)

[redacted]

(b)(5)

[redacted]

(b)(5)

[redacted]

(b) (5)

[redacted]

(b)(5)

[redacted]

(b)(3)

[redacted]

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Wed, 22 Apr 2020 00:16:44 +0000
To: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Subject: FW: For your attention
Attachments: COVAX2020 - A GLOBAL EFFORT for the ACCELERATED DEVELOPMENT, PRODUCTION and EQUITABLE ACCESS to COVID-19 VACCINES_16Apr2020_DRAFT.docx

See attachment that Hilary sent me. [redacted] (b) (5)

From: Marston, Hilary (NIH/NIAID) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 7:44 PM
To: Fauci, Anthony (NIH/NIAID) [E] < [redacted] (b) (6)
Subject: Re: For your attention

[redacted] (b) (5)

From: Anthony Fauci [redacted] (b) (6)>
Date: Tuesday, April 21, 2020 at 7:30 PM
To: Hilary Marston < [redacted] (b) (6)v>
Subject: FW: For your attention

Have you heard of this on any of the calls where you represent me??

From: Collins, Francis (NIH/OD) [E] [redacted] (b) (6)
Sent: Tuesday, April 21, 2020 7:28 PM
To: Fauci, Anthony (NIH/NIAID) [E] [redacted] (b) (6); Lane, Cliff (NIH/NIAID) [E] [redacted] (b) (6); Tabak, Lawrence (NIH/OD) [E] [redacted] (b) (6)>; Freire, Maria (FNIH) [T] <mfreire@fnih.org>; Wholley, David (FNIH) [T] <dwholley@fnih.org>
Subject: FW: For your attention

Hi all,

See note below from Victor Dzau about a global effort on COVID-19. I can't tell if this is more than a fund-raising effort. I know we have Gates reps on our ACTIV working groups – has any of this plan come up, David?

Francis

From: Dzau, Victor J. <VDzau@nas.edu>
Sent: Tuesday, April 21, 2020 4:10 PM
To: Collins, Francis (NIH/OD) [E] < [redacted] (b) (6)
Cc: Kanarek, Morgan <MKanarek@nas.edu>
Subject: For your attention

Dear Francis,

Congratulations on your launch of Public Private Partnership to speed COVID 19 vaccine and treatment options. This is very timely and much needed. Kudos to your leadership.

I am sure you are aware of a global coordinating effort to accelerate vaccines, diagnostics and therapeutics. I have been part of the conversation and planning along with Jeremy Farrar, Richard Hatchett, Seth Berkley, Chris Elias, Paul Stoffels etc. Recently WHO, Gates Foundation and European Commission have been leading the planning. This has advanced rapidly and is in the final stages in development that will be soon announced. It has involved European Commission, Germany, Japan, UK, Norway, France, Saudi as well as Gates Foundation, WHO, World Bank, Wellcome Trust, GAVI, Global Fund, CEPI, GPMB and private sector industry. The initiative will begin with a Pledge conference for $8B as a starting point. This will be led by President von der Leyen and is co-chaired by the above country leaders. This will occur on May 4. In addition by the end of this week or early next week there will be an announcement on the global coordinating structure with will involve Gates, WHO etc.

I am writing to be sure that you and the White House are aware of these upcoming events. Can you share this information with the White House? Besides you, who else should I share this information with? I will be happy to send you background documents if you wish.

Please call me anytime.

Best,

Victor

16 April 2020

COVAX2020 - A GLOBAL PARTNERSHIP for the ACCELERATED DEVELOPMENT, PRODUCTION and EQUITABLE ACCESS to COVID-19 VACCINES

(b) (4)

[redacted]

(b)(4)

[redacted]

(b) (4)

[redacted]

DRAFT

(b) (4)

[redacted]

(b) (4)

[redacted]

DRAFT

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Tue, 21 Apr 2020 17:43:21 +0000
To: EDWARD SCOLNICK
Cc: Mascola, John (NIH/VRC) [E];Cassetti, Cristina (NIH/NIAID) [E];Marston, Hilary
(NIH/NIAID) [E]
Subject: RE: for your consideration
Attachments: Scientists_to_Stop_COVID19_2020_04_15_FINAL.pdf

Ed:

Thank you for your note and for sending this. The outline that you provide is exactly in sync with what we are already doing and have definitive plans to do with regard to classic antivirals, monoclonal antibodies, and a variety of vaccine candidates. As you know, the candidate developed here at NIH in collaboration with Moderna is well into phase 1 trials and at least 2 others are entering into phase 1 trials.
Best regards,
Tony

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----
From: EDWARD SCOLNICK (b) (6)
Sent: Sunday, April 19, 2020 5:18 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)>
Cc: David R. Liu (b) (6); Schreiber, Stuart (b) (6); Michael Rosbash (b) (6)>; Ramnik Xavier (b) (6)
Subject: for your consideration

Tony . I hope your mail box is not so full that there is room for this. A group of concerned scientists from different parts of the country was organized to try to encapsulate and focus the national effort against Covid. This document has been shared with the White House although we are not sure if it has had any effect on their plans. It has also been shared with The Gates Foundation and a few other business and academic leaders. We think we have been fairly comprehensive in our considerations and recommendations. I hope you will find this helpful. We would greatly appreciate a conversation with you after you have had an opportunity to digest the content of the proposal. If there is anything else we can do to help you in this National emergency, we stand ready to help. When I was at Merck ,we led the successful effort to make HIV a manageable disease and we dramatically lowered the death rate as a result of the drugs we made ,and the first triple therapy trial during the HIV pandemic. We hope we can help do the same for The Covid Pandemic Best wishes Ed scolnick

SCIENTISTS
TO STOP
COVID-19

April 15, 2020

We are a group of passionate citizen-scientists who offer four actionable, non-partisan proposals to produce safe and effective COVID-19 therapeutics and vaccines in the shortest possible timeframe, and to reopen our society in a manner that reduces the risk of future COVID-19 outbreaks. None of the contributors named in this proposal have any direct or known indirect financial interests in the referenced companies. Our only motivation is to help defeat the serious threat our nation and the world now faces.

The war against COVID-19 is being fought on multiple fronts: by our heroic healthcare workers on the front lines; by talented scientists in the laboratories of corporations and research institutions; by governments at the federal, state, and local levels; and by other citizens sacrificing their freedoms to limit the spread of the pandemic. Here we describe plans to develop therapeutics and vaccines, and to reopen our businesses and schools, that could be deployed in several waves.

We envision a **first wave of therapies using existing drugs** that will establish a beachhead in the fight against the virus (*testing in April-May 2020, use immediately afterwards*). A **second wave of potent new antibody drugs** developed specifically to neutralize COVID-19 offer a promising combination of speed, safety, and likelihood of being effective (*testing in June-August 2020, use afterwards*). A **third wave of vaccines for long-term victory over the virus** will offer seasonal or multi-year immunity to COVID-19 (*testing in March 2020-March 2021, use afterwards*). In parallel, **reopening of businesses and schools to restore our society and economy** (*implementation in May-June 2020, lasting until the threat has passed*) will use science-driven symptom reporting, virus testing, and personal protective gear to minimize future COVID-19 outbreaks and additional loss of life.

The four proposals that follow describe: (1) How to rapidly repurpose an antiviral drug to treat COVID-19 patients; (2) How to expedite the development of human antibody drugs to treat patients and to provide short-term protection for healthy individuals; (3) How to develop COVID-19 vaccines on an expedited time scale; and (4) How to reopen our businesses and schools in a manner that reduces the risk of future outbreaks and deaths.

It is critical that approaches to drugs, vaccines, and reopening our society be pursued and supported simultaneously. To defeat this novel coronavirus in the United States, and around the world, will require a massive and well-organized collaborative effort from government, industry, philanthropy, and citizens. It is vital that we establish these partnerships and take actions immediately.

We hope these proposals will be considered with the seriousness and speed required by the current circumstances.

Sincerely yours,

Scientists to Stop COVID-19

Dr. Thomas J. Cahill, MD, Ph.D.	**Dr. Michael Rosbash, Ph.D.**
Dr. Benjamin Cravatt, Ph.D.	**Dr. Stuart Schreiber, Ph.D.**
Lynn R Goldman **Dr. Lynn Goldman, M.D., M.S., M.P.H.**	**Dr. Edward Scolnick, M.D.**
Dr. Akiko Iwasaki, Ph.D.	Jonathan W. Simons **Dr. Jonathan W. Simons, M.D.**
Michael Lin **Dr. Michael Z. Lin, M.D., Ph.D.**	**Dr. Ramnik Xavier, M.D., Ph.D.**
Dr. David Liu, Ph.D.	**Dr. R. Scott Kemp, Ph.D.**

None of the named contributors is aware of any direct financial interest in the companies mentioned herein and none receives compensation of any kind for his or her participation.

Contributors

Dr. Thomas J. Cahill, MD, Ph.D. is the Founder and Managing Partner of Newpath Management, L.P. Dr. Cahill received both his M.D. and Ph.D. from Duke University. His Ph.D. work, with Professor Robert Lefkowitz (Nobel Laureate), focused on studying cellular receptors and their signaling to inform novel drug development and discovery.

Dr. Benjamin Cravatt, Ph.D. is a Professor of Chemistry at The Scripps Research Institute in La Jolla, California and a member of the National Academy of Sciences. He is a founder of Vividion Therapeutics, Abide Therapeutics, and ActiveX Biosciences. Considered a co-inventor of activity-based proteomics, Cravatt is a prominent figure in the field of chemical biology.

Dr. Lynn R. Goldman, M.D., M.S., M.P.H. is the Dean and Professor of Environmental and Occupational Health at the Milken Institute School of Public Health at the George Washington University. She is a member of the National Academy of Medicine, the National Research Council Strategic Planning Group, and the NIH National Advisory Environmental Health Sciences Council.

Dr. Akiko Iwasaki, Ph.D. is a Professor of Immunobiology at Yale University School of Medicine, and a Howard Hughes Medical Institute Investigator. She is a member of the National Academy of Sciences, and a member of the National Academy of Medicine. She has discovered molecular mechanisms underlying innate and adaptive antiviral immunity and is a pioneer of novel vaccine strategies.

Dr. R. Scott Kemp, Ph.D. is an Associate Professor and Director of the Laboratory for Nuclear Security and Policy at the Massachusetts Institute of Technology. Dr. Kemp works on the scientific foundations of U.S. national security policy.

Dr. Michael Z. Lin, M.D., Ph.D. is Associate Professor of Neurobiology, Bioengineering, and Chemical and Systems Biology at Stanford University. A NIH Pioneer Award recipient, Dr. Lin develops protein-based tools for molecular imaging and control of gene and viral therapy.

Dr. David Liu, Ph.D. is Professor of Chemistry and Chemical Biology at Harvard University, Vice-Chair of the Faculty at the Broad Institute of MIT and Harvard, and a Howard Hughes Medical Institute Investigator. He is a founder of Editas Medicine, Beam Therapeutics, Pairwise Plants, Exo Therapeutics, and Prime Medicine. Liu is a pioneer in chemical biology, protein engineering, and gene editing, and has developed technologies such as base editing and prime editing.

Dr. Michael Rosbash, Ph.D. is the 2017 Nobel laureate in Physiology or Medicine, a member of the National Academy of Sciences, a Professor of Biology at Brandeis University, and a Howard Hughes Medical Institute Investigator. Rosbash is a pioneer of chronobiology, the study of how living systems sense and respond to time.

Dr. Stuart Schreiber, Ph.D. is a Professor of Chemistry and Chemical Biology at Harvard University and co-Founder of the Broad Institute. He is a member of the National Academy of Sciences, and a founder of Vertex Pharmaceuticals, Ariad Pharmaceuticals, Infinity Pharmaceuticals, Forma Therapeutics, H3 Biomedicine and Jnana Therapeutics. Schreiber co-pioneered the field of chemical biology.

Dr. Edward Scolnick, M.D. is the former Head of Research and Development at Merck and a core investigator at the Broad Institute of MIT and Harvard. While at Merck, Scolnick oversaw the development of 28 FDA-approved drugs and vaccines, including statins, HIV protease inhibitors, and Gardasil. He also made seminal discoveries on the nature of genes that cause cancer in humans before beginning his 22-year career at Merck.

Dr. Jonathan W. Simons, M.D. is the CEO and President of the Prostate Cancer Foundation. Simons a molecular oncologist who previously was the Founding Director of the Winship NCI Cancer Center at Emory University, and currently co-directs the PCF-Veterans Administration Precision Oncology Program for Prostate Cancer.

Dr. Ramnik Xavier, M.D., Ph.D. is Professor of Medicine at Harvard Medical School, former Chief of Gastroenterology at Massachusetts General Hospital, and a core institute member of the Broad Institute of MIT and Harvard. He has discovered molecular mechanisms underlying innate and adaptive immunity, as well as causes of Crohn’s disease, ulcerative colitis, inflammatory bowel disease, and autoimmunity.

INDEX

I. **FIRST WAVE: REPURPOSED DRUGS (Pages 5-7)**
Originally included in our April 4th, 2020 proposal and restated here

II. **SECOND WAVE: ANTIBODY THERAPIES (Pages 8-9)**
Originally included in our March 27th, 2020 proposal and restated here

III. **THIRD WAVE: VACCINES (Pages 10-11)**
Newly incorporated

IV. **RESTORING OUR SOCIETY AND ECONOMY (Pages 12-16)**
Newly incorporated

Please reach out **info@newpath.partners** for more information.

I. FIRST WAVE: REPURPOSED DRUGS

Plan to prepare for immediate provisional use of a repurposed antiviral drug to treat COVID-19

In the immediate term, **remdesivir** has emerged as the leading candidate for an effective therapy in COVID-19. Here, we lay out the evidence for remdesivir's efficacy and safety and propose how to accelerate its approval and use to treat COVID-19.

COVID-19 is caused by the virus SARS-CoV-2. The genome of SARS-CoV-2—the genetic instructions required for its life cycle—is a single strand of RNA. A viral enzyme called **RNA replicase** must copy this strand of RNA in order for the virus to replicate. This enzyme does not exist in humans, and thus drugs that inhibit RNA replicase could effectively treat COVID-19 without harming patients**. A similar strategy of inhibiting a viral replicase was effectively used with HIV.**

As detailed below, given its favorable safety profile and preliminary evidence of efficacy, we believe it is essential to plan now to facilitate the use of remdesivir to treat COVID-19. We propose the following:

- **FDA should coordinate with Gilead**, the maker of remdesivir, to receive the results of their clinical trials as they come in, rather than wait for submission of a new drug application (NDA). NDA preparation often takes months after clinical trials are complete. FDA can dramatically shorten the process by examining the data themselves directly in real time without requiring NDA paperwork. If the results are clearly positive, then provisional approval can be granted.
- The government should take steps to **facilitate large-scale manufacturing of remdesivir** by **other U.S. drug companies** in addition to Gilead. For example, the government could identify companies with manufacturing capabilities suitable for remdesivir synthesis at scale and begin discussions with those companies to clear any regulatory hurdles needed to repurpose those capabilities for remdesivir production.
- Both of these steps are similar to what we have already recommended for monoclonal antibody therapy (see the proposal below).
- Remdesivir is being tested in multiple COVID-19 clinical trials. The drug is given intravenously, and the initial dose is 200 mg followed by 100 mg for 5-10 days. **We believe this dose may be too low and treatment should be administered earlier in symptomatic patients.** Whether higher doses could be given safely can be determined by examining the animal safety studies carried out by Gilead. If these studies do not reveal a potential safety issue at higher doses, then higher doses should be given as early as possible during infection. We speculate that the current dose is chosen because of limited supplies. We urge the government to determine the facts around this issue so optimal trial doses for efficacy can be determined.
- An inhaled form of remdesivir (instead of intravenous) is important so that treatment can be administered remotely. Government should help push this initiative through. GlaxoSmithKline (GSK) and AstraZeneca have experience in this area and might be helpful.

Below we present recent evidence from peer-reviewed publications that suggests remdesivir may turn out to be effective and safe for COVID-19. **Knowing how to most effectively and safely use remdesivir to treat COVID-19 will require properly designed randomized, controlled trials in actual patients**.

- A 2016 *Nature* article showed that **remdesivir inhibits viral RNA replicases and is safe and effective in monkeys infected with Ebola virus** (which, like SARS-CoV-2, is an RNA virus). At the highest dose of remdesivir, monkeys were *completely protected from death* caused by Ebola virus. Ebola virus infection is very rapid in Monkeys and the best results were observed when the drug was given early after infection. **Early treatment with remdesivir, versus later in disease course, will also likely be a key determinant for success with coronavirus.**

- A 2017 *Science Translational Medicine* article showed that remdesivir was effective against coronaviruses, the family of RNA viruses to which SARS-CoV-2 belongs. Importantly, remdesivir was shown to inhibit SARS-CoV-1, whose RNA replicase is 96% identical to that of SARS-CoV-2; SARS-CoV-1 causes SARS through a process essentially identical to severe COVID-19 cases. Indeed, from a clinical perspective, SARS and COVID-19 could be considered two forms of the same disease. Remdesivir potently inhibited SARS-CoV-1 and other pathogenic coronaviruses in human lung cells with a therapeutic index of over 100, meaning that the dose required to stop the virus was at least 100 times lower than the dose required to show any toxicity to cultured human lung cells. This study also showed that remdesivir inhibited SARS-CoV-1 replication in lungs of infected mice.
- **Remdesivir has already been shown to be safe in humans**. In a trial of Ebola patients described in 2019, remdesivir did not show any noted toxicity. Safety is the primary barrier to wide use of any experimental drug, and this trial proved remdesivir can be safely used in humans (Mulangu *et al., New England Journal of Medicine* 2019).
- Remdesivir can be dosed to sufficient concentrations to have antiviral effects. In this same 2019 study, it was effective at reducing Ebola virus levels. Ebola virus is not a coronavirus, but this result demonstrates that **remdesivir can reach concentrations in humans that have an antiviral effect.**
- **We believe too low a dose of remdesivir was used in the Ebola trial. A dose of 10-20 mg/kg should be considered in the current clinical situation. We elaborate on this point later in this memo.**
- In monkeys infected with MERS virus, which is 50% identical to SARS-CoV-2, remdesivir inhibited viral replication and reduced lung damage (de Wit *et al., PNAS* 2020). Thus, **remdesivir can inhibit disease caused by a coronavirus in primates.**
- In human cells in the lab, **remdesivir inhibits replication of SARS-CoV-2**, the virus causing COVID-19. (Wang *et al. Cell Research* 2020)
- remdesivir has already been given on a compassionate use basis to many COVID-19 patients, and a case report exists (e.g., Holshue *et al., New England Journal of Medicine* 2020). No major adverse effects have been reported, suggesting that **remdesivir is safe in COVID-19 patients.**
- **These case reports emphasize that knowing how to most effectively and safely use remdesivir to treat COVID-19 will require properly designed, randomized, and controlled trials in actual patients.**

Therefore, we await the final and most important piece of information: the results of properly designed, randomized clinical trials of remdesivir in COVID-19 patients. There are over 20 such trials currently in progress worldwide. These trials will tell us how effective remdesivir is at treating COVID-19, how early in the disease remdesivir should be given, and the best dosage. The first remdesivir trial was initiated in February 2020 in China and results are expected later this month. Given the above preliminary evidence of efficacy and safety, it will be a surprise if remdesivir does not have a positive effect.

In assessing the potential widespread use of remdesivir in infected patients, certain points are critical:

1. The proper dose of the drug needs to be determined. FDA previously limited the dose based on reversible liver function tests; an increase in dose may be possible without compromising safety.

2. If scrutiny of preclinical safety data confirms that such higher doses can be used, we are optimistic that **administering the drug early in infection will be helpful**. In the *NEJM* case report, the drug was not given until day 7 of infection and seemed to already offer clinical benefit by day 8.
3. Supply of the drug is crucial. We speculate that the low dose used in the Ebola trial was chosen based upon a limited supply. The government needs to determine how quickly millions of doses can be manufactured and whether contract companies need to bolster what Gilead can do in their own manufacturing facilities. Gilead has recently released a letter underlining the limited doses that will be available. Gilead is ramping up their production capabilities. However, their estimate of how many patients can be treated will depend upon a future determination of optimal dose.

It is important to understand both the benefits and limitations of remdesivir compared to other therapeutic options, including the neutralizing human monoclonal antibodies we recommended in our first proposal. Based on the experience with Ebola (Mulangu *et al., New England Journal of Medicine* 2019), remdesivir is unlikely to be better for COVID-19 than the best monoclonal antibodies currently under development. However, monoclonal antibodies will not be available for a few more months, and for this reason we consider them part of a **second wave** of therapies entering clinical trials in the summer. A **first wave of therapies can *only* come from repurposed drugs**. Since neutralizing monoclonal antibodies function by a distinct mechanism, it is also possible that the combination of monoclonal antibodies and remdesivir will be an even more effective second wave therapy than either single agent alone.

Finally, we recognize that other repurposed drugs and drug candidates have also garnered promising data, including other antivirals such as niclosamide, favipiravir, camostat, hydroxychloroquine, and chloroquine, as well as drugs that alleviate the excessive immune responses that can cause death (inflammation blockers such as tocilizumab). In addition, novel therapeutic modalities, such as Alnylam's use of silencing RNA molecules to destroy viral RNAs that are essential to the SARS-CoV-2 life cycle, are also promising and offer unique strengths, although most novel modalities will require additional time for validation in animals before clinical trials can begin. A fairly comprehensive list of potential COVID-19 therapies is maintained by the Milken Institute: **https://milkeninstitute.org/covid-19-tracker**. **Many of our suggestions, while presented for remdesivir, are also applicable to other drug candidates**. However, prioritization may be necessary to widely deploy any repurposed drugs on a greatly accelerated time scale.

II. SECOND WAVE: ANTIBODY THERAPIES

Plan for widespread deployment of an antibody therapy and short-term vaccine by Fall 2020

American biotechnology companies have **already cloned antibodies against COVID-19** virus from recovered patients and mice with human immune systems, and determined which antibodies are especially effective at neutralizing the virus in petri dish experiments. These **monoclonal antibodies** can now be used both to **prevent** COVID-19 like a short-term vaccine, and to **treat** COVID-19 patients.

Two American companies (Regeneron Pharmaceuticals and Vir Biotechnology) are leaders in the monoclonal antibody space. Both of these companies have (1) a proven track record of developing similar therapeutics on expedited timelines (i.e., for Ebola virus); (2) development timelines for COVID-19 therapeutic candidates that are leading the industry; and (3) manufacturing capabilities to enable 100% of their production be done in the United States. Although other COVID-19 therapeutic strategies must be advanced in parallel, we consider these monoclonal antibodies to have the highest likelihood of succeeding for the following reasons.

- Antibodies can **protect** healthy critical workers, as well as "high-risk" individuals.
- Antibodies can also **treat** those already infected, as demonstrated during the Ebola outbreak.
- Human antibodies are routinely administered, for example in cancer therapy and in travel shots, and are considered **very safe**. Indeed, the antibody-containing serum of recovered COVID-19 patients is already being used to treat small numbers of critically ill patients.
- This approach has the potential to be in human clinical trials by **June**, and if expedited with assistance from the government, to be approved by **this summer or fall**—far sooner than traditional vaccine or drug development approaches. This timeline is based on the recent experience American companies have had in producing an **effective** treatment against Ebola **in record time**.

To accelerate the testing, approval, and distribution of monoclonal antibodies against COVID-19, **there must be regulatory flexibility and focused efforts to eliminate all avoidable bottlenecks** via the following steps:

- These companies will be submitting investigational new drug ("IND") applications to initiate clinical trials to the FDA in the near future. **We suggest the WH and FDA leadership work directly with these companies on a regular or daily basis.** The WH can then ensure that the FDA asks all its questions to these companies **before** receiving the IND. Standard rules are that companies must wait 30 days after submitting an IND before initiating trials. We recommend that the FDA **allow trial initiation immediately upon IND receipt** as their questions will have already been answered. *Desired timeframe: April-June 2020.*
- The FDA should allow, encourage, and facilitate the task of scaling up production of COVID-19 treatments prior to final approval; this is, of course so that treatments can be broadly available to the public the day of approval. For example, the FDA could quickly approve new or overseas plants for the production of other medicines, so that **U.S. plant can be devoted entirely to manufacturing COVID-19 treatments**. Similar manufacturing assistance should also be offered to all U.S. companies well-positioned to pursue the monoclonal antibody approach. All other rate-limiting manufacturing issues should be addressed now. If the above steps occur expeditiously, it should be possible to manufacture antibodies for COVID-19 at a scale sufficient for widespread deployment in the late summer or early fall of 2020. *Desired timeframe: June-August 2020.*

- Engage **other large U.S. biomanufacturers to contribute their capacity** to the manufacturing effort, to further expedite broad availability upon FDA approval. *Desired timeframe: June-August 2020.*
- Clinical trials usually begin with a small safety trial in a small number of people. We suggest monoclonal antibody treatments be allowed to proceed directly to a **larger efficacy trial** (e.g., by employing dose-titration in infected individuals, etc.) with enough patients to reveal how well the antibodies work, ideally both as a treatment and as a short-term vaccine. Scientists and physicians have enough experience with other virus-neutralizing antibodies to know the dose required. Safety will be confirmed simultaneously in this efficacy trial. *Desired timeframe: June-August 2020.*
- Following a successful clinical trial, a company reports the results and formally submits a new drug application ("NDA"). FDA review of an NDA normally takes 9-12 months. Given the state of the pandemic, we recommend that the FDA communicate daily with these companies during preparation of the NDA to assure all required components are included, and then **complete the NDA review within 1 week of receipt** since its questions will have already been answered prior to submission. *Desired timeframe: August-September 2020.*
- Given the efforts outlined above to preemptively mass-produce treatment in advance of the clinical trial outcome, broad administration can begin both as a treatment (prioritizing critically ill patients) and as a short-term vaccine immediately upon FDA approval. *Desired timeframe: August-September 2020.*

Other necessary associated efforts that must be pursued in parallel:

- **Tests for viral load and for prior infection**: Ensure availability of the fastest and most reliable test for measuring the amount of virus in the blood in patients at the point of care. These tests are necessary to ascertain if the treatment is working.
- **Serological (antibody) testing:** These tests reveal if an individual was previously infected. They provide important demographic data to guide public-health policy and are especially important for determining which individuals are eligible to participate in the trials of new drug candidates.
- **Notify hospitals** where the trials will take place as soon as possible so the hospital institutional review boards ("IRBs") do not delay approval. Ensure there is no red tape at any of the above steps.

Timeline summary:

- By June 2020: investigational new drug application submitted and reviewed; efficacy clinical trials begin.
- June to August 2020: manufacturing ramp-up and antibody production for broad and nationwide administration.
- August 2020: Proof of efficacy in preventing infection and/or treating disease obtained from clinical trials; if positive, as anticipated, very rapid FDA approval of a new drug application.
- August-September 2020: widespread administration of antibodies to the American population. We believe this will make a major contribution to preventing a second wave of disease in the fall, which will impede, if not destroy, our societal and economic recovery.

III. THIRD WAVE: VACCINES

Plan for rapid development of a vaccine against COVID-19 and future pandemics

As with many other infectious disease epidemics, eventual control will require the development and implementation of an effective vaccine that can provide population-wide immunity against the pathogen. **This third wave vaccine-based approach will establish long-term victory over the virus.** Historically, the average time for new vaccine approval is six to eight years. The current unprecedented nature of the COVID-19 pandemic requires immediate and unique action. Some approaches currently being pursued include inactivated virus particles (Sinovac), recombinant proteins (Sanofi), live hybrid viruses (Janssen), and RNA-based vaccines (Moderna, CureVac, BioNTech/Pfizer, Translate/Sanofi). More examples are listed at milkeninstitute.org/covid-19-tracker. It is not known yet if vaccines will need to be seasonal, as with influenza, or will provide durable long-term immunity, as with measles. *Timeframe: testing in March 2020-March 2021, use afterwards.*

- We propose that the federal government appoint an empowered council who will work with U.S. and global stakeholders to coordinate the required development and investment actions in an efficient, time-sensitive, and non-partisan way.
- It is essential for speed, assessment of comparative clinical data and prior immunity, and manufacturing at scale that a standardized clinical assessment approach be devised and supported by key regulatory authorities.
- We propose a centralized funding source to effectively allocate resources and personnel.
- The coordination must involve the end-to-end vaccine R&D process, including the developers, regulators, funders, and global stakeholders.

The proposed centralized approach has proven effective in the past while responding to national and global emergencies. A similar approach effectively accelerated the development of a polio vaccine in the 1950s. In this celebrated case, the private National Foundation for Infantile Paralysis (later known as the March of Dimes) provided centralized funding and technical decision making to ensure the development and availability of a vaccine for what was at the time a devastating infectious disease. **The same focus is required even more acutely to confront the current pandemic.**

The effectiveness and safety of a given SARS-CoV-2 vaccine design can only be assessed by clinical study. **Given the urgency of the SARS-CoV-2 pandemic, it is essential that a standardized clinical assessment approach be devised and supported by key regulatory authorities, both for speed and to ensure the ability to assess comparative clinical data.** Such a standardized approach is intended to provide a rapid progression to clinical study in a way that will yield the relevant safety and efficacy data in as short a period as possible, allowing for potential rapid deployment.

Manufacturing investments are quite substantial and, accordingly, will likely be made by government or large funding organizations. We must focus on manufacturing an effective vaccine at a scale that will permit world-wide use. In a typical vaccine development program, investments in scale-up and manufacturing are tied to an increasing understanding of a given vaccine's clinical potential. Such a measured approach **is not viable** for SARS-CoV-2 because of the urgency. **Large at-risk development decisions will need to be made**, **for each individual promising vaccine candidate, well before significant clinical data become available**. However, given the scale of the at-risk investments, the number of vaccine approaches in which such investments can be made will necessarily be smaller than the much larger number of all SARS-CoV-2-related vaccine R&D efforts.

At present, the non-company funding sources for the large majority of SARS-CoV-2 vaccine efforts globally include the Coalition for Epidemic Preparedness (CEPI), the Biomedical Advanced Research and Development Authority of the U.S. government (BARDA), the Bill & Melinda Gates Foundation (BMGF), and an increasing number of sovereign country governments. CEPI (**www.CEPI.net**) is funded by the BMGF, the Wellcome Trust, and several European governments. BARDA is a part of HHS and is fully funded by the U.S. Government. BMGF is the world's largest private charity. An effort is ongoing for these three largest funders to coordinate their support in a way that will allow for efficient decision making and use of available funds for at-risk investment and development support.

Given the increasing number of stakeholders involved in the COVID-19 vaccine effort, we are concerned that the effort will become diffuse and will not achieve the level and degree of focus required for a sufficiently swift pandemic response. **To that end, unprecedented transparency and coordination are required. Coordination must involve the end-to-end vaccine R&D process, including the developers, regulators, funders, and global stakeholders.**

Such coordination requires centralized decision making to manage the activities across multiple individual promising approaches, and among the supporting functional and funding efforts—thus our recommendation to appoint an "empowered council". A prospective agreement must be established primarily among the regulators, the key funders, and key global stakeholders to ensure that the empowered individual has the authority to direct the overall enterprise. The empowered individual should have a strong technical/scientific background with direct experience in the previous development of infectious disease vaccines. Decisions and direction by this individual should be based on his/her technical and scientific judgment supported by a small group of similarly technical and experienced advisors. Such a central coordinating and decision mechanism can ensure alignment among regulatory requirements for clinical and pre-clinical evaluation of vaccine candidates and can effectively manage the large at-risk scale-up and manufacturing investments needed to ensure ready availability of a vaccine as soon as its safety and efficacy has been demonstrated. It can also manage the complexities of the multiple parallel technical approaches that will be required.

Over the years, vaccine R&D for other human and animal pathogens have led to the development of a number of different "vaccine platforms," most of which can potentially be adapted for the design of a potentially effective vaccine against SARS-CoV-2. Many organizations and companies are currently involved in designing various vaccine approaches using either internal funding or funding from various support sources (see later). Among these efforts, Moderna's RNA-based vaccine has already commenced clinical trials, and whether subjects create protective antibodies will be assessed in the next few months. However, whether this vaccine safely prevents disease may take longer to assess, and Moderna does not anticipate widespread implementation for at least 12 months. We recommend a centralized approach to manage the anticipated flow of clinical data as we evaluate the various vaccine candidates. Such a standardized approach is intended to provide a rapid progression to clinical study in a way that will yield the relevant comparative safety and efficacy data in as short a period as possible, allowing for potential rapid deployment.

IV. RESTORING OUR SOCIETY AND ECONOMY

A COVID-19 Risk Reduction Plan for Reopening Schools and Businesses

While drastic social-distancing and lock-down measures remain a necessary step to disrupt the exponential spread of COVID-19 in the United States, reopening our economy is increasingly urgent for the welfare of many Americans. In this document we propose a plan for returning people to schools and businesses in a manner that reduces the risk of future COVID-19 outbreaks and loss of life, for example from a "second wave" of the disease in the fall.

Once current social-distancing measures are lifted, the current policy of testing only symptomatic individuals cannot adequately curtail COVID-19 transmission. For example, a study of COVID transmission in Wuhan, China occurring between February 1 and March 12—when Chinese health officials were carrying out house-to-house temperature checks on the general population—found that even with such intrusive measures 86% of COVID cases were not identified, likely because the majority of infected persons had very mild symptoms.[1]

In this proposal, we describe a policy that requires individuals returning to schools and work to take three key steps: 1) to report symptoms daily before working; 2) to participate in frequent virus (PCR) testing; and 3) to wear certain personal protective equipment (PPE). We assess that this policy will substantially reduce the risks associated with reopening our society and restoring our economy, thereby protecting our recovery.

Daily Certification of Symptoms

All employees and students must **certify (via smartphone app), before leaving home, that they are not experiencing enough of the following COVID-19 symptoms** to exceed a calculated risk, weighted by symptom frequency, of being infected with SARS-CoV-2 (incidence frequency and standard error are shown, with data sources):

a. Fever (0.64±0.030)[2–4]
b. Sinus pain (0.50±0.18)[4]
c. Cough (0.46±0.032) [2–4]
d. Reduced or altered sense of smell or taste (4/9)[4]
e. Expectoration (0.32±0.036)[3]
f. Stuffy nose (0.25±0.15)[4]
g. Chills (0.18±.044)[2]
h. Fatigue (0.18±0.025)[2,3]
i. Sore throat (0.13±0.039)[2]
j. Headache (0.13±0.037)[2,4]
k. Difficulty breathing (0.11±0.034)[2,4]
l. Joint or muscle pain(0.099±0.023)[3,4]
m. Diarrhea (0.056±0.015)[2–4]
n. Vomiting (0.026±0.018)[2]

This certification should detect the vast majority of symptomatic cases, including mildly symptomatic ones, among those who accurately respond. None of these individual symptoms are specific to COVID-19, but in aggregate they can be used to assess an individual's risk of being infected with SARS-CoV-2, and even if caused by other pathogens are a prudent basis for staying at home. The acceptable level of calculated risk may differ among occupations (for example, nursing home caregivers could be subject to a very low risk threshold). We note that symptomatic patients are thought to be contagious prior to feeling symptoms, and that a large fraction of infected persons may remain asymptomatic for the entire course of the infection.

Estimates of the continually asymptomatic fraction have been made from several closed-cohort studies. One study using data from Japanese citizens evacuated from Wuhan estimated the asymptomatic fraction at 31%

(95%CI 7.8%–54%).[5] Another study using data from the Diamond Princess cruise ship (which had an age distribution skewed older than the general population) estimated that 18% (95%CI: 16–20%) of infected persons remain asymptomatic, subject to assumptions about the incubation period.[6] In contrast, a third study of 4,950 close contacts found that only 6.2±2.2% of infected persons were fully asymptomatic throughout the course of the disease, but that an additional 38±5.4% showed only mild symptoms and may not have considered themselves to be infected.[3]

These data emphasize the importance of respondents giving accurate answers to survey questions and using centralized algorithms, rather than individual judgment, to make decisions about who can engage in work and school activities. A variety of strategies can be used to increase compliance, including assurances of pay while at home with symptoms. The calculated risk threshold can be set by governments and adapted to respond to real-time epidemiology.[7]

We also considered the use of fever screening devices that rapidly measure the temperatures of people at the entrances to schools and businesses. However, we are concerned that questions about the accuracy of this method, the availability and cost of fever screening devices at the scale needed, and the fact that fever screening assesses only one COVID-19 symptom may limit its practical usefulness in the current situation.

Whether fully asymptomatic COVID-19 cases pose an infection risk to others remain to be seen. We are only aware of one study that examined this question, but the statistical uncertainties were too large to make a useful deduction of the asymptomatic carrier risk.[3] However, because asymptomatic case fractions may be large, and because even symptomatic cases may be contagious prior to the onset of symptoms, frequent virus testing to detect viral presence is essential, in addition to a daily survey of symptoms.

Frequent Testing for Virus

Several methods, including PCR, can detect viral RNA in specimens collected from individuals. The sampling and analysis procedures for PCR tests, however, yield a significant false-negative rate, which means that relying on only a single PCR test for each individual may be insufficient. For example, in the case of tests performed on close-contact cohorts, throat-swab PCR was found to have a false-negative rate of 28.7% after one sample, reduced to 7.8% with a second sample at a later time. Another study found that China's national PCR test had a false-negative rate of 34%.[8] Note that the sensitivities of PCR tests for asymptomatic and pre-symptomatic cohorts have not been separately established. The steps described below, coupled with the certification of symptoms described above, will provide the data needed to establish these sensitivities.

Nasopharyngeal or throat-swab PCR sampling is too invasive and demanding for regular mass testing. **As an alternative, we propose frequent—ideally, daily—virus testing of all people returning to school or businesses from samples collecting by having people spit into barcoded tubes.** In one study of SARS-CoV-2 PCR tests, saliva collected from an individual's tongue was found to have 93.3±0.5% the sensitivity of samples taken from nasopharyngeal swabs.[9] Another study not specific to SARS-CoV-2, found that saliva was generally identical in sensitivity to nasopharyngeal swabs for most respiratory pathogens, but there was a high-rate of discordance between the two sampling locations (i.e., two-location sampling would substantially reduce false negatives but with a higher sample-collection burden).[10] These data suggest the probability of a single salivary PCR detecting a typical symptomatic person is about 67%. Collecting at least two specimens (which can be pooled) from an individual each day would greatly increase overall sensitivity. In addition, increasing the number of PCR cycles performed will also greatly increase the sensitivity of PCR testing, at the expense of a higher false positive rate.[8] However, "weak positives"—those with C_t values high enough that they would not have been detected with a standard PCR test thresholds—can be re-tested immediately the next day before work, requiring only a one-day quarantine (or less) while the follow-up test is processed. PCR primer sets that amplify endogenous human RNAs known to occur in saliva[10a] can be used as positive controls to authenticate sample collection and testing procedures.

From a practical perspective, samples for mass virus testing should ideally be collected at the end of the workday, processed overnight, and reported to individuals before they decide to come to work or school the next morning. Positive virus tests result in immediate quarantine, contact tracing, and quarantine of close contacts, ideally in coordination with state and local public health officials if governments succeed in establishing urgently needed contact tracing infrastructure. For the many employers and schools that will not be able to establish such a sample collection and testing capability, governments should facilitate the ability of drug stores and other local point-of-care facilities to perform standardized virus tests. We appreciate that this second component of our proposal is a major undertaking, but we anticipate that frequent testing of all people returning to work and school is critical to restarting our society and rescuing our economy while minimizing the chance of new outbreaks that force future shutdowns and cause additional loss of life.

Required Personal Protective Equipment (PPE)

We recommend that wearing PPE throughout the work or school day become a requirement. Multiple studies have shown that the single most effective piece of PPE is a face mask or respirator. **For the general public, we recommend surgical-style masks, with simple training on their use**. Surgical masks have been shown to be effective with an odds ratio of 0.32 (95%CI: 0.25–0.4), meaning that a person reduces their risk of contracting respiratory viruses to 32% of the normal risk by wearing a surgical mask.[11] N95 respirators can be even more effective, but are more difficult to acquire in mass quantities, and too burdensome to wear for prolonged periods to expect good compliance from most individuals. N95 respirators provide an odds ratio of 0.09 (0.03-0.30), with the high variance emphasizing the importance of leak-tight fit and proper use, which is difficult to maintain outside a trained user cohort.[11] Controlled comparisons of surgical masks and N95 respirators in real-world settings of occasional exposure have found them similarly effective in reducing respiratory infections.[12] Surgical masks therefore strike an optimal balance between availability and practical effectiveness for most people.

In contrast, cloth masks were reported to be 63% as effective as surgical masks in preventing any respiratory symptoms for the wearer, and only 8% as effective in preventing influenza-like illness.[13] As such, we recommend that **wearing surgical masks (or, for high-exposure settings, N95 respirators with appropriate training), rather than cloth masks, be required for entering schools and businesses**. We note that studies on the lifetime of coronaviruses on surfaces including paper[14a] suggest that if masks are in limited supply, reusing masks that have been stored away from human contact for 5-7 days may pose minimal additional risk.

Gloves can also lower infection risk, offering an odds ratio of 0.43 (95%CI: 0.29-0.65) in a hospital setting.[11] They could also be required, although proper use habits are needed for gloves to be effective. We anticipate that many people not accustomed to the uses of gloves for biomedical purposes will contaminate themselves, surfaces, or others through improper use.

Antibody (Serological) Testing

Antibody tests are an important tool in the fight against COVID-19. Unlike PCR tests, which detect the presence of the virus's RNA genome, and thus can approximate how many virus particles are present in a patient sample, antibody tests reveal the presence of antibodies that a person's immune system has produced as a consequence of being infected with SARS-CoV-2. It is possible—perhaps even likely—that protection from future SARS-CoV-2 reinfection by a person's own antibodies can be strong and can last >1 year. This expectation is based on one preliminary study[14] of SARS-CoV-2 in monkeys, and one long-term study[15] of humans infected with the virus that caused the original SARS epidemic. Importantly, however, this critical information is not yet known with actionable certainty.

Antibody tests provide important information for guiding public-health policy. They are the best tool currently available to understand the percentage of people within a community that have been previously infected with SARS-CoV-2. Antibody tests thus reveal the extent to which transmission countermeasures have been effective, how many people may need a COVID-19 drug or vaccine in the future, and how far away we are from "herd immunity." Antibody tests can also serve a surrogate measurement of a person's immunity to reinfection, with the important caveats presented below. Therefore, they can also be used to identify especially vulnerable or less-vulnerable sub-populations (see below).

Vaccines are widely seen as part of the COVID-19 endgame. The Milken Institute currently lists 79 vaccine development efforts underway. **Antibody testing is important for vaccine development** in two ways:

1) Antibody testing is needed to identify individuals who are eligible for testing any COVID-19 drug or preventative, including vaccine candidates. People with pre-existing SARS-CoV-2 antibodies cannot be used to test the effectiveness of such candidate drugs or vaccines, because the potential ability of those antibodies to neutralize the virus could obscure the effect of the drug or vaccine candidate in people who have not been previously exposed.

2) Antibody testing is needed to assess the ability of a vaccine candidate to do its job—to elicit antibodies in the subject.

These key benefits highlight the importance of continued development and deployment of antibody testing. However, **we do not anticipate that antibody tests will have a major impact on reopening workplaces or schools in the near future** for the following reasons:

1) It seems likely that only a low fraction of the population by the late spring of 2020 will have been infected with SARS-CoV-2. This assessment is based on the number of reported and projected deaths (not reported cases, which are highly dependent on testing coverage) and current estimates of the infection-fatality rate. Therefore, it is unlikely that people with SARS-CoV-2 antibodies will represent a significant fraction of our students or workforce in the coming months. An important exception to this point is noted below.

2) It is not yet known what level of antibody titers offer what probability of re-infection resistance, or for how long, as noted above. It is even more difficult to know how this assumed correlation will vary among individuals.

3) Based on recent reports, it takes ~2 weeks from first symptoms for the substantial majority (>90%) of infected people to form robust antibody titers, with possible dependence on the level of symptoms in the patient (there are conflicting reports on the latter point).[16,17]

4) Protecting our citizens from future infection is the most important requirement for a successful restoration of our society. Virus (PCR) tests inform infectivity much more than antibody tests—indeed, antibody tests do not explicitly assess infectivity at all.

One important exception to the lack of applicability of antibody tests to reopening schools and workplaces in the near future is that some local communities have experienced outbreaks with much greater than 10% exposure. For examples, in some towns, ships, nursing homes, detention centers, shipping warehouses, and health-care settings, exposure has far exceeded the modest average fraction of infected persons nationwide. In these special cases, serological testing can be an important surrogate for identifying who is still vulnerable, and who may be at lower risk to return to work.

Finally, we note the danger of strongly associating a positive antibody test with the right to return to school or to work. Plans to reopen our workplaces and schools must **avoid the moral hazard of creating a perverse incentive to purposefully increase one's risk of exposure** to the SARS-CoV-2 virus in order to increase the chance of being able to return to their studies or professional work.

References Cited

1. Li, R. *et al.* Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* eabb3221 (2020) doi:10.1126/science.abb3221.
2. Liu, Y. *et al.* Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect. Dis.* S1473309920302322 (2020) doi:10.1016/S1473-3099(20)30232-2.
3. Luo, L. *et al. Modes of contact and risk of transmission in COVID-19 among close contacts*. http://medrxiv.org/lookup/doi/10.1101/2020.03.24.20042606 (2020) doi:10.1101/2020.03.24.20042606.
4. Wölfel, R. *et al.* Virological assessment of hospitalized patients with COVID-2019. *Nature* (2020) doi:10.1038/s41586-020-2196-x.
5. Nishiura, H. *et al.* Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *Int. J. Infect. Dis.* S1201971220301399 (2020) doi:10.1016/j.ijid.2020.03.020.
6. Mizumoto, K., Kagaya, K., Zarebski, A. & Chowell, G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **25**, (2020).
7. van de Kassteele, J., Eilers, P. H. C. & Wallinga, J. Nowcasting the Number of New Symptomatic Cases During Infectious Disease Outbreaks Using Constrained P-spline Smoothing: *Epidemiology* **30**, 737–745 (2019).
8. Vogels, C. B. F. *et al. Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays*. http://medrxiv.org/lookup/doi/10.1101/2020.03.30.20048108 (2020) doi:10.1101/2020.03.30.20048108.
9. Tu, Y.-P. *et al. Patient-collected tongue, nasal, and mid-turbinate swabs for SARS-CoV-2 yield equivalent sensitivity to health care worker collected nasopharyngeal swabs*. http://medrxiv.org/lookup/doi/10.1101/2020.04.01.20050005 (2020) doi:10.1101/2020.04.01.20050005.
10. To, K. K. *et al.* Additional molecular testing of saliva specimens improves the detection of respiratory viruses. *Emerg. Microbes Infect.* **6**, 1–7 (2017).

10a. Lin, Z. *et al.* Noncoding RNAs in human saliva and potential disease biomarkers. *Front. Genet.* **6**, 175 (2015) doi: 10.3389/fgene.2015.00175

11. Jefferson, T. *et al.* Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. *BMJ* **336**, 77–80 (2008).
12. Smith, J. D. *et al.* Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis. *Can. Med. Assoc. J.* **188**, 567–574 (2016).
13. Teunis, P. F. M., Brienen, N. & Kretzschmar, M. E. E. High infectivity and pathogenicity of influenza A virus via aerosol and droplet transmission. *Epidemics* **2**, 215–222 (2010).
14. Bao, L. *et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques*. http://biorxiv.org/lookup/doi/10.1101/2020.03.13.990226 (2020) doi:10.1101/2020.03.13.990226.

14a. Kampf, G. *et al.* Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. *J. Hosp. Infect.* **104**, 246 (2020).

15. Wu, L.-P. *et al.* Duration of Antibody Responses after Severe Acute Respiratory Syndrome. *Emerg. Infect. Dis.* **13**, 1562–1564 (2007).
16. Lou, B. *et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset*. http://medrxiv.org/lookup/doi/10.1101/2020.03.23.20041707 (2020) doi:10.1101/2020.03.23.20041707.
17. Guo, L. *et al.* Profiling Early Humoral Response to Diagnose Novel Coronavirus Disease (COVID-19). *Clin. Infect. Dis.* ciaa310 (2020) doi:10.1093/cid/ciaa310.